0001156039-24-000066.txt : 20240418 0001156039-24-000066.hdr.sgml : 20240418 20240418141619 ACCESSION NUMBER: 0001156039-24-000066 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240418 DATE AS OF CHANGE: 20240418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 24853900 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 10-Q 1 elv-20240331.htm 10-Q elv-20240331
false2024Q1000115603912/3100011560392024-01-012024-03-3100011560392024-04-10xbrli:shares00011560392024-03-31iso4217:USD00011560392023-12-31iso4217:USDxbrli:shares00011560392023-01-012023-03-310001156039us-gaap:ProductMember2024-01-012024-03-310001156039us-gaap:ProductMember2023-01-012023-03-310001156039elv:ServiceFeesMember2024-01-012024-03-310001156039elv:ServiceFeesMember2023-01-012023-03-3100011560392022-12-3100011560392023-03-310001156039us-gaap:CommonStockMember2023-12-310001156039us-gaap:AdditionalPaidInCapitalMember2023-12-310001156039us-gaap:RetainedEarningsMember2023-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001156039us-gaap:NoncontrollingInterestMember2023-12-310001156039us-gaap:RetainedEarningsMember2024-01-012024-03-310001156039us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001156039us-gaap:CommonStockMember2024-01-012024-03-310001156039us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001156039us-gaap:CommonStockMember2024-03-310001156039us-gaap:AdditionalPaidInCapitalMember2024-03-310001156039us-gaap:RetainedEarningsMember2024-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001156039us-gaap:NoncontrollingInterestMember2024-03-310001156039us-gaap:CommonStockMember2022-12-310001156039us-gaap:AdditionalPaidInCapitalMember2022-12-310001156039us-gaap:RetainedEarningsMember2022-12-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001156039us-gaap:NoncontrollingInterestMember2022-12-310001156039us-gaap:RetainedEarningsMember2023-01-012023-03-310001156039us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001156039us-gaap:CommonStockMember2023-01-012023-03-310001156039us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001156039us-gaap:CommonStockMember2023-03-310001156039us-gaap:AdditionalPaidInCapitalMember2023-03-310001156039us-gaap:RetainedEarningsMember2023-03-310001156039us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001156039us-gaap:NoncontrollingInterestMember2023-03-31elv:individualelv:countyelv:stateelv:segmentxbrli:pure0001156039elv:ParagonHealthcareInc.Member2024-03-310001156039elv:BioPlusParentLLCAndSubsidiariesMember2024-03-310001156039elv:BioPlusParentLLCAndSubsidiariesMember2024-01-012024-03-310001156039us-gaap:EmployeeSeveranceMemberelv:A20232024BusinessEfficiencyProgramMemberelv:CorporateOtherSegmentMember2024-03-310001156039us-gaap:EmployeeSeveranceMemberelv:A20232024BusinessEfficiencyProgramMemberelv:CorporateOtherSegmentMember2023-12-310001156039us-gaap:EmployeeSeveranceMemberelv:A20232024BusinessEfficiencyProgramMemberelv:CorporateOtherSegmentMember2024-01-012024-03-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2024-03-310001156039us-gaap:ForeignGovernmentDebtMember2024-03-310001156039us-gaap:USStatesAndPoliticalSubdivisionsMember2024-03-310001156039us-gaap:CorporateDebtSecuritiesMember2024-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2024-03-310001156039us-gaap:CommercialMortgageBackedSecuritiesMember2024-03-310001156039us-gaap:OtherAggregatedInvestmentsMember2024-03-310001156039us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-12-310001156039us-gaap:ForeignGovernmentDebtMember2023-12-310001156039us-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310001156039us-gaap:CorporateDebtSecuritiesMember2023-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMember2023-12-310001156039us-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310001156039us-gaap:OtherAggregatedInvestmentsMember2023-12-31elv:security0001156039us-gaap:ExchangeTradedFundsMember2024-03-310001156039us-gaap:ExchangeTradedFundsMember2023-12-310001156039elv:CommonEquitySecuritiesMember2024-03-310001156039elv:CommonEquitySecuritiesMember2023-12-310001156039us-gaap:PrivateEquityFundsMember2024-03-310001156039us-gaap:PrivateEquityFundsMember2023-12-310001156039us-gaap:FixedMaturitiesMember2024-01-012024-03-310001156039us-gaap:FixedMaturitiesMember2023-01-012023-03-310001156039us-gaap:EquitySecuritiesMember2024-01-012024-03-310001156039us-gaap:EquitySecuritiesMember2023-01-012023-03-310001156039us-gaap:OtherInvestmentsMember2024-01-012024-03-310001156039us-gaap:OtherInvestmentsMember2023-01-012023-03-310001156039us-gaap:MaturityOvernightMemberus-gaap:CashMember2024-03-310001156039us-gaap:MaturityOvernightMemberus-gaap:CashMember2023-12-310001156039us-gaap:MaturityOvernightMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001156039us-gaap:MaturityOvernightMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:MaturityOvernightMember2024-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:MaturityOvernightMember2023-12-310001156039us-gaap:CashFlowHedgingMember2024-03-310001156039us-gaap:CashFlowHedgingMember2023-12-310001156039us-gaap:FairValueInputsLevel1Member2024-03-310001156039us-gaap:FairValueInputsLevel2Member2024-03-310001156039us-gaap:FairValueInputsLevel3Member2024-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2024-03-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel1Member2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtMember2024-03-310001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel3Member2024-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-03-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-03-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2024-03-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialMortgageBackedSecuritiesMember2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialMortgageBackedSecuritiesMember2024-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialMortgageBackedSecuritiesMember2024-03-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-03-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001156039us-gaap:OtherDebtSecuritiesMember2024-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2024-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ExchangeTradedFundsMember2024-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2024-03-310001156039us-gaap:FairValueInputsLevel1Memberelv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2024-03-310001156039us-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2024-03-310001156039elv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001156039elv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2024-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2024-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PrivateEquityFundsMember2024-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2024-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2024-03-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-03-310001156039us-gaap:EquitySecuritiesMember2024-03-310001156039us-gaap:FairValueInputsLevel1Memberelv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2024-03-310001156039us-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2024-03-310001156039elv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2024-03-310001156039elv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2024-03-310001156039us-gaap:DerivativeMemberus-gaap:FairValueInputsLevel1Member2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeMember2024-03-310001156039us-gaap:DerivativeMemberus-gaap:FairValueInputsLevel3Member2024-03-310001156039us-gaap:DerivativeMember2024-03-310001156039us-gaap:FairValueInputsLevel1Member2023-12-310001156039us-gaap:FairValueInputsLevel2Member2023-12-310001156039us-gaap:FairValueInputsLevel3Member2023-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-12-310001156039us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel1Member2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtMember2023-12-310001156039us-gaap:ForeignGovernmentDebtMemberus-gaap:FairValueInputsLevel3Member2023-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001156039us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:ResidentialMortgageBackedSecuritiesMember2023-12-310001156039us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialMortgageBackedSecuritiesMember2023-12-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001156039us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001156039us-gaap:OtherDebtSecuritiesMember2023-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2023-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ExchangeTradedFundsMember2023-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:ExchangeTradedFundsMember2023-12-310001156039us-gaap:FairValueInputsLevel1Memberelv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2023-12-310001156039us-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2023-12-310001156039elv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001156039elv:CommonEquitySecuritiesMemberus-gaap:EquitySecuritiesMember2023-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2023-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:PrivateEquityFundsMember2023-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:PrivateEquityFundsMember2023-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMember2023-12-310001156039us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310001156039us-gaap:EquitySecuritiesMember2023-12-310001156039us-gaap:FairValueInputsLevel1Memberelv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2023-12-310001156039us-gaap:FairValueInputsLevel2Memberelv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2023-12-310001156039elv:CommonEquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2023-12-310001156039elv:CommonEquitySecuritiesMemberus-gaap:OtherInvestmentsMember2023-12-310001156039us-gaap:DerivativeMemberus-gaap:FairValueInputsLevel1Member2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:DerivativeMember2023-12-310001156039us-gaap:DerivativeMemberus-gaap:FairValueInputsLevel3Member2023-12-310001156039us-gaap:DerivativeMember2023-12-310001156039us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-03-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001156039us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001156039us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310001156039us-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001156039us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001156039us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001156039us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001156039us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001156039us-gaap:ShortDurationInsuranceContractAccidentYear2022Member2024-03-310001156039us-gaap:ShortDurationInsuranceContractAccidentYear2023Member2024-03-310001156039elv:ShortDurationInsuranceContractAccidentYear2024Member2024-03-310001156039elv:SeniorUnsecuredNotesMemberus-gaap:SeniorNotesMember2024-03-310001156039elv:SeniorUnsecuredNotesMemberus-gaap:SeniorNotesMember2023-12-310001156039elv:SurplusNotesMember2024-03-310001156039elv:SurplusNotesMember2023-12-310001156039elv:A5YearFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-01-012024-03-310001156039elv:A5YearFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-03-310001156039elv:A5YearFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310001156039us-gaap:CommercialPaperMember2024-03-310001156039us-gaap:CommercialPaperMember2023-12-310001156039us-gaap:FederalHomeLoanBankAdvancesMember2024-03-310001156039us-gaap:FederalHomeLoanBankAdvancesMember2023-12-3100011560392022-09-012022-09-300001156039elv:BCBSAntitrustLitigationMember2022-09-012022-09-3000011560392022-09-30elv:appeal0001156039elv:AnthemInc.v.ExpressScriptsInc.Memberelv:PharmacypricingMember2016-03-012016-03-310001156039elv:OperationalMemberelv:AnthemInc.v.ExpressScriptsInc.Member2016-03-012016-03-310001156039elv:AnthemInc.v.ExpressScriptsInc.Member2016-03-012016-03-310001156039elv:TechnologyInfrastructureAndRelatedManagementAndSupportServicesMember2024-01-012024-03-3100011560392024-03-222024-03-2200011560392023-03-242023-03-240001156039us-gaap:SubsequentEventMember2024-04-1600011560392023-01-240001156039us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember2024-01-012024-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember2023-01-012023-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310001156039us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310001156039elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001156039elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001156039elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-03-310001156039elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-03-310001156039elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310001156039elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-12-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-12-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-01-012024-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-01-012023-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-03-310001156039us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310001156039us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310001156039elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001156039elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001156039elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-03-310001156039elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-03-310001156039elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310001156039elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-01-012023-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310001156039us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310001156039us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001156039us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2022-12-310001156039us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310001156039us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310001156039us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001156039us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001156039elv:RestrictedStockUnitsContingentMember2024-01-012024-03-310001156039us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001156039elv:RestrictedStockUnitsContingentMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:HealthBenefitsSegmentMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonRxSegmentMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonServicesSegmentMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonTotalMember2024-01-012024-03-310001156039us-gaap:CorporateAndOtherMemberus-gaap:OperatingSegmentsMember2024-01-012024-03-310001156039us-gaap:IntersegmentEliminationMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberelv:HealthBenefitsSegmentMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonRxSegmentMemberus-gaap:ProductMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberelv:CarelonServicesSegmentMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberelv:CarelonTotalMember2024-01-012024-03-310001156039us-gaap:CorporateAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2024-01-012024-03-310001156039us-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:HealthBenefitsSegmentMemberelv:ServiceFeesMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonRxSegmentMemberelv:ServiceFeesMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonServicesSegmentMemberelv:ServiceFeesMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:ServiceFeesMemberelv:CarelonTotalMember2024-01-012024-03-310001156039us-gaap:CorporateAndOtherMemberus-gaap:OperatingSegmentsMemberelv:ServiceFeesMember2024-01-012024-03-310001156039us-gaap:IntersegmentEliminationMemberelv:ServiceFeesMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:HealthBenefitsSegmentMemberelv:UnaffiliatedMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonRxSegmentMemberelv:UnaffiliatedMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonServicesSegmentMemberelv:UnaffiliatedMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonTotalMemberelv:UnaffiliatedMember2024-01-012024-03-310001156039us-gaap:CorporateAndOtherMemberus-gaap:OperatingSegmentsMemberelv:UnaffiliatedMember2024-01-012024-03-310001156039us-gaap:IntersegmentEliminationMemberelv:UnaffiliatedMember2024-01-012024-03-310001156039elv:UnaffiliatedMember2024-01-012024-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMemberelv:HealthBenefitsSegmentMember2024-01-012024-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMemberelv:CarelonRxSegmentMember2024-01-012024-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMemberelv:CarelonServicesSegmentMember2024-01-012024-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMemberelv:CarelonTotalMember2024-01-012024-03-310001156039elv:AffiliatedMemberus-gaap:CorporateAndOtherMemberus-gaap:IntersegmentEliminationMember2024-01-012024-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMember2024-01-012024-03-310001156039us-gaap:OperatingSegmentsMemberelv:HealthBenefitsSegmentMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonRxSegmentMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonServicesSegmentMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonTotalMember2023-01-012023-03-310001156039us-gaap:CorporateAndOtherMemberus-gaap:OperatingSegmentsMember2023-01-012023-03-310001156039us-gaap:IntersegmentEliminationMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberelv:HealthBenefitsSegmentMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonRxSegmentMemberus-gaap:ProductMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberelv:CarelonServicesSegmentMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberelv:CarelonTotalMember2023-01-012023-03-310001156039us-gaap:CorporateAndOtherMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2023-01-012023-03-310001156039us-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:HealthBenefitsSegmentMemberelv:ServiceFeesMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonRxSegmentMemberelv:ServiceFeesMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonServicesSegmentMemberelv:ServiceFeesMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:ServiceFeesMemberelv:CarelonTotalMember2023-01-012023-03-310001156039us-gaap:CorporateAndOtherMemberus-gaap:OperatingSegmentsMemberelv:ServiceFeesMember2023-01-012023-03-310001156039us-gaap:IntersegmentEliminationMemberelv:ServiceFeesMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:HealthBenefitsSegmentMemberelv:UnaffiliatedMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonRxSegmentMemberelv:UnaffiliatedMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonServicesSegmentMemberelv:UnaffiliatedMember2023-01-012023-03-310001156039us-gaap:OperatingSegmentsMemberelv:CarelonTotalMemberelv:UnaffiliatedMember2023-01-012023-03-310001156039us-gaap:CorporateAndOtherMemberus-gaap:OperatingSegmentsMemberelv:UnaffiliatedMember2023-01-012023-03-310001156039us-gaap:IntersegmentEliminationMemberelv:UnaffiliatedMember2023-01-012023-03-310001156039elv:UnaffiliatedMember2023-01-012023-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMemberelv:HealthBenefitsSegmentMember2023-01-012023-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMemberelv:CarelonRxSegmentMember2023-01-012023-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMemberelv:CarelonServicesSegmentMember2023-01-012023-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMemberelv:CarelonTotalMember2023-01-012023-03-310001156039elv:AffiliatedMemberus-gaap:CorporateAndOtherMemberus-gaap:IntersegmentEliminationMember2023-01-012023-03-310001156039elv:AffiliatedMemberus-gaap:IntersegmentEliminationMember2023-01-012023-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                     to                     
Commission file number: 001-16751
eh_logo.jpg
ELEVANCE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Indiana 35-2145715
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification Number)
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (833) 401-1577
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueELVNew York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer☒  Accelerated filer☐
Non-accelerated filer☐  Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of April 10, 2024, 232,417,867 shares of the Registrant’s Common Stock were outstanding.


Elevance Health, Inc.
Quarterly Report on Form 10-Q
For the Period Ended March 31, 2024
Table of Contents
 
  Page
PART I. FINANCIAL INFORMATION
ITEM 1.
ITEM 2.
ITEM 3.
ITEM 4.
PART II. OTHER INFORMATION
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 3.
ITEM 4.
ITEM 5.
ITEM 6.
-1-

PART I. FINANCIAL INFORMATION
ITEM 1.    FINANCIAL STATEMENTS
Elevance Health, Inc.
Consolidated Balance Sheets
March 31,
2024		December 31,
2023
(Unaudited)

(In millions, except share and per share data)
Assets
Current assets:
Cash and cash equivalents$6,226 $6,526 
Fixed maturity securities (amortized cost of $30,427 and $30,446; allowance for credit losses of $4 and $4)
29,530 29,614 
Equity securities511 229 
Premium receivables8,931 7,902 
Self-funded receivables4,242 4,558 
Other receivables5,120 5,405 
Other current assets6,388 5,795 
Total current assets60,948 60,029 
Long-term investments:
Fixed maturity securities (amortized cost of $902 and $890; allowance for credit losses of $0 and $0)
880 876 
Other invested assets6,713 6,107 
Property and equipment, net4,451 4,359 
Goodwill25,947 25,317 
Other intangible assets10,710 10,273 
Other noncurrent assets2,245 1,967 
Total assets$111,894 $108,928 
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable$16,459 $16,111 
Other policyholder liabilities5,298 5,600 
Unearned income1,474 1,402 
Accounts payable and accrued expenses5,658 6,910 
Short-term borrowings1,575 225 
Current portion of long-term debt2,900 1,649 
Other current liabilities10,970 9,894 
Total current liabilities44,334 41,791 
Long-term debt, less current portion21,976 23,246 
Reserves for future policy benefits765 778 
Deferred tax liabilities, net2,201 1,970 
Other noncurrent liabilities1,908 1,738 
Total liabilities71,184 69,523 
Commitments and contingencies – Note 11
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none
— — 
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding –
232,544,717 and 233,071,088
2 2 
Additional paid-in capital8,883 8,868 
Retained earnings33,088 31,749 
Accumulated other comprehensive loss(1,365)(1,313)
Total shareholders’ equity40,608 39,306 
Noncontrolling interests102 99 
Total equity40,710 39,405 
Total liabilities and equity$111,894 $108,928 
See accompanying notes.
-2-

Elevance Health, Inc.
Consolidated Statements of Income
(Unaudited) 
 Three Months Ended 
 March 31
20242023
(In millions, except per share data)
Revenues
Premiums$35,696 $35,868 
Product revenue4,499 4,022 
Service fees2,078 2,008 
Total operating revenue42,273 41,898 
Net investment income465 387 
Net losses on financial instruments(161)(113)
Total revenues42,577 42,172 
Expenses
Benefit expense30,546 30,786 
Cost of products sold3,825 3,481 
Operating expense4,886 4,800 
Interest expense265 251 
Amortization of other intangible assets116 235 
Total expenses39,638 39,553 
Income before income tax expense
2,939 2,619 
Income tax expense690 615 
Net income2,249 2,004 
Net income attributable to noncontrolling interests
(3)(15)
Shareholders’ net income$2,246 $1,989 
Shareholders’ net income per share
Basic $9.65 $8.37 
Diluted $9.59 $8.30 
Dividends per share$1.63 $1.48 















See accompanying notes.

-3-

Elevance Health, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited) 
 Three Months Ended 
 March 31
20242023
(In millions)
Net income$2,249 $2,004 
Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments(56)427 
Change in non-credit component of impairment losses on investments
— (2)
Change in net unrealized gains/losses on cash flow hedges2 11 
Change in net periodic pension and postretirement costs4 2 
Change in future policy benefits (2)2 
Foreign currency translation adjustments— 2 
Other comprehensive (loss) income
(52)442 
Net income attributable to noncontrolling interests
(3)(15)
Other comprehensive income attributable to noncontrolling interests
— (2)
Total shareholders’ comprehensive income$2,194 $2,429 



















See accompanying notes.

-4-

Elevance Health, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended 
 March 31
20242023
(In millions)
Operating activities
Net income$2,249 $2,004 
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses on financial instruments161 113 
Equity in net losses of other invested assets
27 30 
Depreciation and amortization331 462 
Deferred income taxes136 (255)
Share-based compensation62 61 
Changes in operating assets and liabilities:
Receivables, net(282)(29)
Other invested assets(29)(15)
Other assets(1,104)(348)
Policy liabilities31 306 
Unearned income72 3,282 
Accounts payable and other liabilities(257)18 
Income taxes581 839 
Other, net— 1 
Net cash provided by operating activities1,978 6,469 
Investing activities
Purchases of investments(6,103)(7,443)
Proceeds from sale of investments4,898 2,489 
Maturities, calls and redemptions from investments535 3,533 
Changes in securities lending collateral(212)204 
Purchases of subsidiaries, net of cash acquired(1,120)(1,638)
Purchases of property and equipment(279)(301)
Other, net(29)(28)
Net cash used in investing activities(2,310)(3,184)
Financing activities
Proceeds from long-term borrowings— 2,574 
Repayments of long-term borrowings— (1,908)
Proceeds from short-term borrowings1,350 325 
Changes in securities lending payable212 (205)
Changes in bank overdrafts(586)(291)
Repurchase and retirement of common stock(566)(622)
Cash dividends(379)(351)
Proceeds from issuance of common stock under employee stock plans97 43 
Taxes paid through withholding of common stock under employee stock plans(100)(98)
Other, net4 2 
Net cash used in financing activities32 (531)
Effect of foreign exchange rates on cash and cash equivalents— 1 
Change in cash and cash equivalents(300)2,755 
Cash and cash equivalents at beginning of period6,526 7,387 
Cash and cash equivalents at end of period$6,226 $10,142 
See accompanying notes.

-5-

Elevance Health, Inc.
Consolidated Statements of Changes in Equity
(Unaudited)
Total Shareholders’ Equity
 Common StockAdditional
Paid-in
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss		Noncontrolling
Interests		Total
Equity
(In millions)Number of
Shares		Par
Value
December 31, 2023233.1 $2 $8,868 $31,749 $(1,313)$99 $39,405 
Net income— — — 2,246 — 3 2,249 
Other comprehensive loss
— — — — (52)— (52)
Repurchase and retirement of common stock, including excise tax(1.1)— (44)(525)— — (569)
Dividends and dividend equivalents— — — (382)— — (382)
Issuance of common stock under employee stock plans, net of related tax benefits0.5 — 59 — — — 59 
March 31, 2024232.5 $2 $8,883 $33,088 $(1,365)$102 $40,710 
December 31, 2022
238.0 $2 $9,084 $29,647 $(2,490)$87 $36,330 
Net income
— — — 1,989 — 15 2,004 
Other comprehensive income — — — — 440 2 442 
Repurchase and retirement of common stock, including excise tax
(1.3)— (51)(575)— — (626)
Dividends and dividend equivalents— — — (354)— — (354)
Issuance of common stock under employee stock plans, net of related tax benefits
0.4 — 6 — — — 6 
Convertible debenture repurchases, conversions and tax adjustments
— — (342)— — — (342)
March 31, 2023237.1 $2 $8,697 $30,707 $(2,050)$104 $37,460 

See accompanying notes.

-6-

Elevance Health, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
March 31, 2024
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
 
1.     Organization
References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving over 46 million medical members through our affiliated health plans as of March 31, 2024. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also to unaffiliated health plans, including pharmacy services, dental, vision and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum HealthCare, Simply Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health, Carelon Behavioral Health and CareMore.
We have organized our brand portfolio into the following core go-to-market brands:
•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;
•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and
•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation. For additional discussion regarding our segments, including the changes made, see Note 15 “Segment Information” included in this Quarterly Report on Form 10-Q.

-7-

2.     Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”), unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three months ended March 31, 2024 and 2023 have been recorded. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2024, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2023 included in our 2023 Annual Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $499 and $294 at March 31, 2024 and December 31, 2023, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
-8-

For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.
Mortgage loans on real estate are classified as held for investment and are reported at their amortized cost basis net of allowance under the caption “Other invested assets” in our consolidated balance sheets. Amortized cost is the amount at which the loan is originated, adjusted for accrued interest, amortization of premium, discount and net deferred fees or costs, collection of cash and write-offs.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $212 at each of March 31, 2024 and December 31, 2023.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $89 and $87 at March 31, 2024 and December 31, 2023, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables
-9-

are reported net of an allowance for doubtful accounts of $956 and $941 at March 31, 2024 and December 31, 2023, respectively.
Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at March 31, 2024 or December 31, 2023. For the three months ended March 31, 2024 and 2023, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 changed the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year to our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. The adoption did not have an overall material impact on our financial statements.
Recent Accounting Guidance Not Yet Adopted: In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Income Taxes (Topic 740) ("ASU 2023-09"). The amendments in ASU 2023-09 are intended to improve income tax disclosures, primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for our fiscal year beginning after December 15, 2024. The amendments are to be applied on a prospective basis, although retrospective adoption is permitted. We do not believe the adoption of ASU 2023-09 will have a material impact on our consolidated financial statements or disclosures.
In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our fiscal year beginning after December 15, 2023, and interim periods within our fiscal year beginning after December 15, 2024. The amendments are to be applied retrospectively to all prior periods presented in the financial statements, and upon transition, the significant segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. We are currently evaluating the effects the adoption of ASU 2023-07 will have on our consolidated financial statements and related disclosures.
In August 2023, the FASB issued Accounting Standards Update No. 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement (“ASU 2023-05”). ASU 2023-05 clarifies existing guidance to reduce diversity in practice and requires a joint venture to recognize and initially measure its assets and liabilities using a new basis of accounting, at fair value, upon formation. These amendments are effective prospectively for all joint venture formations with a formation date on or after January 1, 2025. We do not believe the adoption of ASU 2023-05 will have a material impact on our consolidated financial statements and disclosures.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2023 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations, cash flows or disclosures.
-10-

3.    Business Acquisitions and Divestitures
Completed Acquisitions
On March 11, 2024, we completed our acquisition of Paragon Healthcare, Inc. (“Paragon”). Paragon, which operates as part of CarelonRx, provides infusion services and injectable therapies through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of March 31, 2024, the purchase price was allocated to the tangible and intangible net assets acquired based on management's initial estimates of their fair values, of which $553 has been allocated to finite-lived intangible assets and $635 to goodwill. The majority of the goodwill is not deductible for income tax purposes. As of March 31, 2024, the initial accounting for the acquisition has not been finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of March 31, 2024, the purchase price was allocated to the tangible and intangible net assets acquired based on management’s estimates of their fair values, of which $820 has been allocated to finite-lived intangible assets and $893 to goodwill. Measurement period adjustments during the three months ended March 31, 2024 were $(5). The majority of goodwill is not deductible for income tax purposes. As of March 31, 2024, the initial accounting for the acquisition was finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
Divestiture
On April 1, 2024, we completed the sale of our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard entered into a product distribution partnership. The related net assets held for sale and results of operations for the life and disability businesses to be divested as of and for the three months ending March 31, 2024 were not material.
Pending Acquisitions
On December 31, 2023, we entered into an agreement to acquire Centers Plan for Healthy Living LLC and Centers for Specialty Care Group IPA, LLC (“Centers”). Centers is a managed long-term care plan that serves New York state Medicaid and dually-eligible Medicaid/Medicare members, enabling adults with long-term care needs and disabilities to live safely and independently in their own home. This acquisition aligns with our strategic plan to grow the Health Benefits segment and leverage industry-leading expertise while serving Medicaid and dually eligible populations. The acquisition is expected to close in the third quarter of 2024 and is subject to standard closing conditions and customary approvals.
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition is subject to closing conditions and approvals.

-11-

4.    Business Optimization Initiatives
During the third quarter of 2023, based on a strategic review of our operations, assets and investments, management implemented the “2023-2024 Business Efficiency Program” to enhance operating efficiency, refine the focus of our investments and optimize our physical footprint. The 2023-2024 Business Efficiency Program includes the write-off of certain information technology assets and contract exit costs, a reduction in staff including the relocation of certain job functions, and the impairment of assets associated with the closure or partial closure of data centers and offices. The 2023-2024 Business Efficiency Program is expected to be substantially complete by the end of the third quarter of 2024. Cash outlays associated with this program, which primarily relate to the personnel-related costs, are expected to be paid through 2024.
The ending balances related to the total liabilities for employee termination costs under the 2023-2024 Business Efficiency Program at March 31, 2024 and December 31, 2023 were $150 and $191, respectively, and were recorded in the Corporate & Other reportable segment. During the quarter ended March 31, 2024 there were no charges or releases related to employee termination costs under the 2023-2024 Business Efficiency Program, and payments were $41.
5.     Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.
-12-

A summary of current and long-term fixed maturity securities, available-for-sale, at March 31, 2024 and December 31, 2023 is as follows:
Cost or
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Allowance
For Credit
Losses		Estimated
Fair Value
 
March 31, 2024
Fixed maturity securities:
United States Government securities$1,858 $6 $(73)$— $1,791 
Government sponsored securities127 — (4)— 123 
Foreign government securities73 — (1)— 72 
States, municipalities and political subdivisions, tax-exempt3,722 55 (150)— 3,627 
Corporate securities16,099 256 (575)(2)15,778 
Residential mortgage-backed securities4,204 27 (302)— 3,929 
Commercial mortgage-backed securities1,971 12 (89)(2)1,892 
Other asset-backed securities3,275 28 (105)— 3,198 
Total fixed maturity securities$31,329 $384 $(1,299)$(4)$30,410 
December 31, 2023
Fixed maturity securities:
United States Government securities$1,873 $25 $(54)$— $1,844 
Government sponsored securities112 1 (3)— 110 
Foreign government securities5 1 (2)— 4 
States, municipalities and political subdivisions, tax-exempt3,985 69 (152)— 3,902 
Corporate securities14,838 322 (580)(2)14,578 
Residential mortgage-backed securities4,071 40 (279)— 3,832 
Commercial mortgage-backed securities2,174 13 (138)(2)2,047 
Other asset-backed securities4,278 25 (130)— 4,173 
Total fixed maturity securities$31,336 $496 $(1,338)$(4)$30,490 
Other asset-backed securities primarily consists of collateralized loan obligations and other debt securities.
-13-

For fixed maturity securities in an unrealized loss position at March 31, 2024 and December 31, 2023, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss		Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss
March 31, 2024
Fixed maturity securities:
United States Government securities46 $1,188 $(29)48$306 $(44)
Government sponsored securities4 40 — 3951 (4)
Foreign government securities
5 10 — 24 (1)
States, municipalities and political subdivisions, tax-exempt231 449 (4)1,0011,656 (146)
Corporate securities906 2,324 (31)2,4225,775 (544)
Residential mortgage-backed securities239 1,026 (14)1,6311,958 (288)
Commercial mortgage-backed securities84 364 (6)4151,059 (83)
Other asset-backed securities126 454 (16)4141,288 (89)
Total fixed maturity securities1,641 $5,855 $(100)5,972$12,097 $(1,199)
December 31, 2023
Fixed maturity securities:
United States Government securities35 $552 $(9)44 $370 $(45)
Government sponsored securities— — — 4052 (3)
Foreign government securities
— — — 24 (2)
States, municipalities and political subdivisions, tax-exempt203354 (2)1,0341,811 (150)
Corporate securities389608 (15)2,6246,871 (565)
Residential mortgage-backed securities
183438 (5)1,6202,075 (274)
Commercial mortgage-backed securities
112353 (6)5341,317 (132)
Other asset-backed securities110394 (18)7612,342 (112)
Total fixed maturity securities1,032 $2,699 $(55)6,659$14,842 $(1,283)
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of March 31, 2024, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions.
Allowances for credit losses have been recorded in the amount of $4 at both March 31, 2024 and December 31, 2023, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest.


-14-

The amortized cost and fair value of fixed maturity securities at March 31, 2024, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost		Estimated
Fair Value
Due in one year or less$369 $365 
Due after one year through five years6,038 5,900 
Due after five years through ten years11,099 10,864 
Due after ten years7,648 7,460 
Mortgage-backed securities6,175 5,821 
Total fixed maturity securities$31,329 $30,410 
During the three months ended March 31, 2024 and 2023, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $5,401 and $5,410, respectively.
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at March 31, 2024 and December 31, 2023 is as follows:
 March 31, 2024December 31, 2023
Equity securities:
Exchange traded funds$382 $106 
Common equity securities52 45 
Private equity securities77 78 
Total$511 $229 
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments is reported on a one or three month lag due to the timing of when we receive financial information from the companies.
On April 12, 2024, we entered into an agreement to partner with Clayton, Dubilier & Rice (“CD&R”) to accelerate innovation in care delivery across multiple regions in the United States by bringing together through a new company, (“NewCo”), certain care delivery and enablement assets of Carelon Management Services Inc., a Carelon Health business (“CMSI Assets”), and two CD&R portfolio businesses, apree health and Millennium Physician Group. Our investment in NewCo will be through a combination of cash, an existing equity investment in apree health, and the contribution of CMSI Assets. We will account for our initial minority ownership interest in NewCo as an equity method investment. Further, in connection with our equity investment, each party will have certain rights and obligations, including certain put, call, and purchase price true-up options, for which the estimated value will be determinable at the time of the incremental investments. The contribution of CMSI Assets and businesses to be contributed by CD&R to NewCo are subject to standard closing conditions and customary approvals.
-15-

Investment (Losses) and Gains
Net investment (losses) and gains for the three months ended March 31, 2024 and 2023 are as follows:
Three Months Ended 
 March 31
20242023
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales$22 $10 
Gross realized losses from sales(159)(115)
Impairment losses recognized in income
(2)(7)
Net realized losses from sales of fixed maturity securities(139)(112)
Equity securities:
Unrealized gains (losses) recognized on equity securities still held at the end of the period
2 (1)
Net realized losses recognized on equity securities sold during the period
— (1)
Net gains (losses) on equity securities2 (2)
Other investments:
Gross gains16 27 
Gross losses(20)(1)
Impairment losses recognized in income(25)(3)
Net (losses) gains on other investments
(29)23 
Net losses on investments$(166)$(91)
Accrued Investment Income
At March 31, 2024 and December 31, 2023, accrued investment income totaled $294 and $301, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,592 and $2,380 at March 31, 2024 and December 31, 2023, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of March 31, 2024 and December 31, 2023. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
At March 31, 2024 and December 31, 2023, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,351 and $2,255, respectively, of United States Government securities for $241 and $99, respectively, and of residential mortgage-backed securities for $0 and $26, respectively.
6.    Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.
-16-

We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $209 and $211 at March 31, 2024 and December 31, 2023, respectively.
During the three months ended March 31, 2024, we recognized gains of $11 and losses of $6, respectively, on non-hedging derivatives. During the three months ended March 31, 2023, we recognized gains of $12 and losses of $34 on non-hedging derivatives, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 7, “Fair Value,” included in this Quarterly Report on Form 10-Q.
7.    Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. These assets and liabilities are classified into one of three levels of hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 7 “Fair Value,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K.
A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at March 31, 2024 and December 31, 2023 is as follows:
-17-

Level ILevel IILevel IIITotal
March 31, 2024
Assets:
Cash equivalents$1,155$—$—$1,155
Fixed maturity securities, available-for-sale:
United States Government securities—1,791—1,791
Government sponsored securities—123—123
Foreign government securities—72—72
States, municipalities and political subdivisions, tax-exempt—3,627—3,627
Corporate securities—15,7265215,778
Residential mortgage-backed securities—3,914153,929
Commercial mortgage-backed securities—1,881111,892
Other asset-backed securities—2,4787203,198
Total fixed maturity securities, available-for-sale—29,61279830,410
Equity securities:
Exchange traded funds382——382
Common equity securities1537—52
Private equity securities——7777
Total equity securities3973777511
Other invested assets - common equity securities102——102
Securities lending collateral—2,594—2,594
Derivatives - other assets—2—2
Total assets$1,654$32,245$875$34,774
Percentage of total assets at fair value
5%93%2%100%
Liabilities:
Derivatives - other liabilities$—$(61)$—$(61)
Total liabilities$—$(61)$—$(61)
December 31, 2023
Assets:
Cash equivalents$2,210$—$—$2,210
Fixed maturity securities, available-for-sale:
United States Government securities—1,844—1,844
Government sponsored securities—110—110
Foreign government securities—4—4
States, municipalities and political subdivisions, tax-exempt—3,902—3,902
Corporate securities—14,5324614,578
Residential mortgage-backed securities—3,83023,832
Commercial mortgage-backed securities—2,047—2,047
Other asset-backed securities—3,6345394,173
Total fixed maturity securities, available-for-sale—29,90358730,490
Equity securities:
Exchange traded funds106——106
Common equity securities1233—45
Private equity securities——7878
Total equity securities1183378229
Other invested assets - common equity securities111——111
Securities lending collateral—2,382—2,382
Derivatives - other assets—10—10
Total assets$2,439$32,328$665$35,432
Percentage of total assets at fair value
7%91%2%100%
Liabilities:
Derivatives - other liabilities$—$(40)$—$(40)
Total liabilities$—$(40)$—$(40)
-18-

There were no individually material transfers into or out of Level III during the three months ended March 31, 2024 or 2023. There were no adjustments to quoted market prices obtained from the pricing services during the three months ended March 31, 2024 or 2023.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition of Paragon in the first quarter of 2024 and the acquisition of BioPlus in the first quarter of 2023. The net assets acquired in our acquisitions of Paragon and BioPlus and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of tangible assets acquired and liabilities assumed were recorded at their carrying values as of the acquisition date, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Paragon and BioPlus were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Also in 2023, we entered into a shareholder’s agreement which included certain put and call options on our minority interest ownership of Liberty Dental. The resulting net put option liability was recorded at its fair value measured at the date of acquisition using Level III inputs with an election not to mark the derivative to market. Other than the assets acquired and liabilities assumed in our acquisitions of Paragon and BioPlus and the net put option on Liberty Dental, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three months ended March 31, 2024 or 2023.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
See Note 7 “Fair Value,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K for details on the methods and assumptions used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets.
-19-

A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at March 31, 2024 and December 31, 2023 is as follows:
 Carrying
Value		Estimated Fair Value
 Level ILevel IILevel IIITotal
March 31, 2024
Assets:
Other invested assets$6,611 $— $— $6,580 $6,580 
Liabilities:
Debt:
Short-term borrowings225 — 225 — 225 
Commercial paper
1,350 — 1,350 — 1,350 
Notes24,876 — 23,046 — 23,046 
December 31, 2023
Assets:
Other invested assets$5,996 $— $— $5,972 $5,972 
Liabilities:
Debt:
Short-term borrowings225 — 225 — 225 
Notes24,895 — 23,569 — 23,569 
8.     Income Taxes
During the three months ended March 31, 2024 and 2023, we recognized income tax expense of $690 and $615, respectively, which represent an effective income tax rate of 23.5% for both periods.
Income taxes payable totaled $38 at March 31, 2024 and income taxes receivable totaled $543 at December 31, 2023. We recognize the income tax payable as a liability under the caption “Other current liabilities” and the income tax receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.
-20-

9. Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the three months ended March 31, 2024 and 2023 is as follows:
20242023
Gross medical claims payable, beginning of period$15,865 $15,348 
Ceded medical claims payable, beginning of period(7)(6)
Net medical claims payable, beginning of period15,858 15,342 
Net incurred medical claims:
Current period30,708 30,751 
Prior periods redundancies(1,205)(1,068)
Total net incurred medical claims29,503 29,683 
Net payments attributable to:
Current period medical claims19,580 19,948 
Prior periods medical claims9,606 9,593 
Total net payments29,186 29,541 
Net medical claims payable, end of period16,175 15,484 
Ceded medical claims payable, end of period8 7 
Gross medical claims payable, end of period$16,183 $15,491 
At March 31, 2024, the total of net incurred but not reported liabilities plus expected development on reported claims was $724, $4,323 and $11,128 for the claim years 2022 and prior, 2023 and 2024, respectively.
The favorable development recognized in the three months ended March 31, 2024 resulted from faster than expected development of completion factors from the latter part of 2023 as well as trend factors in late 2023 developing more favorably than originally expected. The favorable development recognized in the three months ended March 31, 2023 resulted primarily from trend factors in late 2022 developing more favorably than expected and favorable development in the completion factors resulting from the latter part of 2022 developing faster than expected.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:
20242023
Total net incurred medical claims$29,503 $29,683 
Quality improvement and other claims expense1,043 1,103 
Benefit expense$30,546 $30,786 
The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of March 31, 2024 is as follows:
Total
Net medical claims payable, end of period$16,175 
Ceded medical claims payable, end of period8 
Insurance lines other than short duration276 
Gross medical claims payable, end of period$16,459 
-21-

10.     Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At March 31, 2024 and December 31, 2023, we had $24,851 and $24,870, respectively, outstanding under these notes.
We have an unsecured surplus note with an outstanding principal balance of $25 at both March 31, 2024 and December 31, 2023.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of March 31, 2024, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.4%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of March 31, 2024, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at any time during the three months ended March 31, 2024 or the year ended December 31, 2023.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. At March 31, 2024 and December 31, 2023, we had $1,350 and $0, respectively, outstanding under this program. Beginning June 30, 2023, we have reclassified our commercial paper balances from long-term debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $225 of outstanding short-term borrowings from the FHLBs at each of March 31, 2024 and December 31, 2023.
All debt is a direct obligation of Elevance Health, Inc., except for the surplus note and the FHLBs borrowings.
11.     Commitments and Contingencies
Litigation and Regulatory Proceedings
We are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or probable or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible or probable loss or range of losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings.
With respect to the cases described below, we contest liability and/or the amount of damages in each matter, and we believe we have meritorious defenses. We do not believe the outcome of any known pending or threatened legal actions or proceedings will, in the aggregate, have a material impact on our financial position. However, unanticipated outcomes do
-22-

sometimes occur, which could result in liabilities in excess of our accruals and could have a material adverse effect on our consolidated financial position or results of operations.
In addition to the lawsuits described below, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings (“government actions”). These government actions include routine and special inquiries by and disclosures to state insurance departments, state attorneys general, U.S. Regulatory Agencies, the U.S. Attorney General and subcommittees of the U.S. Congress. Such government actions could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these government actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.
In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.
In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the opt-out deadline.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In compliance with the Subscriber Settlement Agreement, we paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by us of $596, which was accrued in 2020.
-23-

Four notices of appeal of the Final Approval Order were heard by a panel of the United States Court of Appeals for the Eleventh Circuit in September 2023 (the “Eleventh Circuit”), and the Eleventh Circuit affirmed the Court’s Final Approval Order approving the Subscriber Settlement Agreement in October 2023. Petitions for rehearing were filed by certain appellants in November 2023 and December 2023 and were denied in January 2024. As a result, the Eleventh Circuit issued a mandate terminating the jurisdiction of the Eleventh Circuit in February 2024. In March 2024, Home Depot, one of the appellants, filed a petition for certiorari to the United States Supreme Court. On the respondents' request, the United States Supreme Court granted an extension to respond until May 2024. In the event that all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, determining that Ohio v. American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the provider groups’ boycott claims are subject to the rule of reason. In December 2023, the Court denied defendants’ motion for summary judgment on providers’ damage claims as time-barred and speculative and provider plaintiffs’ motion for partial summary judgment on the defendants’ single entity defense due to the existence of genuine issues of material fact. In January 2024, the Court issued orders (i) denying defendants’ motion for summary judgment on (a) all claims by certain hospital providers and (b) any claims based on the Blue system's rules other than exclusive serviced areas or BlueCard and (ii) denying provider plaintiffs’ motion for partial summary judgment on defendants’ common law trademark claims. Provider plaintiffs’ motion for class certification, filed in October 2020, remains pending. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.) (“Alaska Air”); JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.) (“Jet Blue”); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.) (dismissed without prejudice in June 2023); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.); Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.) (“VHS”). In February 2023, the Court denied the defendants’ motion to dismiss based on a statute of limitations defense in Alaska Air and Jet Blue. In September 2023, the California court presiding over the VHS case, upheld its prior order granting in part defendants’ motion to strike based on the statute of limitations. We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.
Express Scripts, Inc. PBM Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit sought to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms (the “Pricing Claim”); (ii) was required to provide competitive benchmark pricing to us through the term of the ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.
-24-

Express Scripts disputed our contractual claims and it sought declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claimed that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q were (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which the District Court denied in March 2023. In November 2023, the District Court issued a final judgment ending the lawsuit in the District Court after the parties settled and stipulated to dismiss the only remaining claim that had not been disposed of by the court order or stipulation. In December 2023, we filed a notice of appeal with the United States Court of Appeal for the Second Circuit (the “Second Circuit”), regarding the Pricing Claim. In February 2024, the Second Circuit ordered the parties to participate in mediation. The mediation occurred in March 2024 and was unsuccessful. The ultimate outcome of this appeal cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, we filed an answer. In March 2023, discovery commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert discovery to be completed by February 2025. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. Our remaining commitment under this agreement at March 31, 2024 is approximately $432. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.
-25-

We formed CarelonRx, to market and offer pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own, starting in the second quarter of 2019. The comprehensive pharmacy services portfolio includes all core pharmacy services, such as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database and member services. CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C. (“CVS”), which is a subsidiary of CVS Health Corporation, pursuant to an agreement, that is set to terminate on December 31, 2025. Beginning in the first quarter of 2024, CarelonRx is assuming responsibility for pharmacy mail order front-end intake and member services from CVS.
12.     Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of our cash dividend activity for the three months ended March 31, 2024 and 2023 is as follows: 
Declaration DateRecord DatePayment Date
Cash
Dividend
per Share
Total
Three Months Ended March 31, 2024
January 23, 2024March 8, 2024March 22, 2024$1.63$379 
Three Months Ended March 31, 2023
January 24, 2023March 10, 2023March 24, 2023$1.48$351 
On April 16, 2024, our Audit Committee declared a second quarter 2024 dividend to shareholders of $1.63 per share, payable on June 25, 2024 to shareholders of record at the close of business on June 10, 2024.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.
A summary of common stock repurchases for the three months ended March 31, 2024 and 2023 is as follows:
Three Months Ended March 31
 20242023
Shares repurchased1.1 1.3 
Average price per share$492.76 $476.66 
Aggregate cost$566 $622 
Authorization remaining at the end of the period$3,633 $6,254 
For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt,” included in this Quarterly Report on Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K.
-26-

Stock Incentive Plans
A summary of stock option activity for the three months ended March 31, 2024 is as follows:
Number of
Shares		Weighted-
Average
Option Price
per Share		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at January 1, 20243.0 $327.14 
Granted0.5 499.11 
Exercised(0.3)288.95 
Forfeited or expired— 431.01 
Outstanding at March 31, 20243.2 356.58 6.44$521 
Exercisable at March 31, 20242.2 297.24 5.23$482 
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the three months ended March 31, 2024 is as follows:
Restricted
Stock Shares
and Units		Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 20241.1 $423.94 
Granted0.6 499.00 
Vested(0.6)352.33 
Forfeited— 456.61 
Nonvested at March 31, 20241.1 475.31 
During the three months ended March 31, 2024, we granted approximately 0.3 restricted stock units that are contingent upon us achieving earnings targets over the three-year period from 2024 to 2026. These grants have been included in the activity shown above but will be subject to adjustment at the end of 2026 based on results in the three-year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K.
The following weighted-average assumptions were used to estimate the fair values of options granted during the three months ended March 31, 2024 and 2023:
Three Months Ended March 31
20242023
Risk-free interest rate4.28 %3.95 %
Volatility factor28.00 %29.00 %
Quarterly dividend yield0.327 %0.316 %
Weighted-average expected life (years)4.404.40
-27-

The following weighted-average fair values per option or share were determined for the three months ended March 31, 2024 and 2023: 
Three Months Ended March 31
20242023
Options granted during the period$134.53 $127.14 
Restricted stock awards granted during the period499.00 469.31 
-28-

13.     Accumulated Other Comprehensive (Loss) Income
A reconciliation of the components of accumulated other comprehensive (loss) income at March 31, 2024 and 2023 is as follows:
Three Months Ended 
 March 31
20242023
Net unrealized investment (losses) gains:
Beginning of period balance$(632)$(1,755)
Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $50 and $(85), respectively
(162)337 
Amounts reclassified from accumulated other comprehensive loss, net of tax benefit of $(33) and $(29), respectively
106 90 
Other comprehensive (loss) income
(56)427 
Other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0, respectively
— (2)
End of period balance(688)(1,330)
Non-credit components of impairments on investments:
Beginning of period balance(3)(3)
Other comprehensive loss, net of tax benefit of $0 and $1, respectively
— (2)
End of period balance(3)(5)
Net cash flow hedges:
Beginning of period balance(211)(229)
Other comprehensive income, net of tax (expense) benefit of $(1) and $8, respectively
2 11 
End of period balance(209)(218)
Pension and other postretirement benefits:
Beginning of period balance(459)(499)
Other comprehensive income, net of tax expense of $(1) and $(1), respectively
4 2 
End of period balance(455)(497)
Future policy benefits:
Beginning of period balance10 13 
Other comprehensive (loss) income, net of tax expense of $0 and $0, respectively
(2)2 
End of period balance8 15 
Foreign currency translation adjustments:
Beginning of period balance(18)(17)
Other comprehensive income, net of tax expense of $0 and $0, respectively
— 2 
End of period balance(18)(15)
Total:
Total beginning of period accumulated other comprehensive loss(1,313)(2,490)
Total other comprehensive (loss) income, net of tax benefit (expense) of $15, and $(106), respectively
(52)442 
Total other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0 respectively
— (2)
Total end of period accumulated other comprehensive loss$(1,365)$(2,050)
-29-

14.     Shareholders' Earnings per Share
The denominator for basic and diluted shareholders' earnings per share for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023
Denominator for basic shareholders' earnings per share – weighted-average shares
232.7 237.5 
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures
1.5 2.2 
Denominator for diluted shareholders' earnings per share
234.2 239.7 
During the three months ended March 31, 2024 and 2023, weighted-average shares related to certain stock options of 0.6 and 0.4 respectively, were excluded from the denominator for diluted shareholders' earnings per share because the stock options were anti-dilutive.
During the three months ended March 31, 2024, we issued approximately 0.6 restricted stock units under our stock incentive plans, 0.3 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2024 through 2026. During the three months ended March 31, 2023, we issued approximately 0.6 restricted stock units under our stock incentive plans, 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2023 through 2025. The contingent restricted stock units have been excluded from the denominators for diluted shareholders' earnings per share and will be included only if and when the contingency is met.
15.     Segment Information
We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. During the fourth quarter of 2023, we moved our Carelon Global Solutions international businesses from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation.
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEHB program members. Our Health Benefits segment also includes our National Government Services business. The Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental, vision and supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy services business. CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy services portfolio, which includes all core pharmacy services, such as home delivery and specialty
pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug
database and member services.
Our Carelon Services segment integrates physical, behavioral, social and pharmacy services to deliver whole health affordably through creating value by offering market-competitive services, powered by analytics. Carelon Services offers a broad array of healthcare related services and capabilities to internal and external customers including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services and subrogation services, as well as health and wellness programs. At the end of 2023, Carelon Services integrated Carelon Global Solutions into the Carelon family of offerings. The companies under Carelon Global Solutions have been providing services related to data management, information technology and business operations since 2019 and were previously included within our Corporate & Other segment.
Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an operating segment, as well as corporate expenses not allocated to our other reportable segments.
-30-

We define operating revenues to include premium income, product revenue and service fees. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating expense.
Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, in addition to certain administrative and other services provided by our international businesses, which are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.
Financial data by reportable segment for the three months ended March 31, 2024 and 2023 is as follows:
Carelon
Health
Benefits		CarelonRxCarelon
Services		TotalCorporate
& Other		EliminationsTotal
Three Months Ended March 31, 2024
Premiums$35,382 $— $408 $408 $— $(94)$35,696 
Product revenue— 4,499 — 4,499 — — 4,499 
Service fees1,876 1 197 198 4 — 2,078 
Operating revenue - unaffiliated37,258 4,500 605 5,105 4 (94)42,273 
Operating revenue - affiliated— 3,567 3,404 6,971 123 (7,094)— 
Operating revenue - total$37,258 $8,067 $4,009 $12,076 $127 $(7,188)$42,273 
Operating gain (loss)$2,287 $523 $290 $813 $(84)$— $3,016 
Three Months Ended March 31, 2023
Premiums$35,534 $— $410 $410 $— $(76)$35,868 
Product revenue— 4,022 — 4,022 — — 4,022 
Service fees1,746 — 208 208 54 — 2,008 
Operating revenue - unaffiliated37,280 4,022 618 4,640 54 (76)41,898 
Operating revenue - affiliated— 4,002 2,842 6,844 37 (6,881)— 
Operating revenue - total$37,280 $8,024 $3,460 $11,484 $91 $(6,957)$41,898 
Operating gain (loss)
$2,149 $512 $229 $741 $(59)$— $2,831 
For segment reporting, we present all capitated risk arrangements on a gross basis; therefore, eliminations also include adjustments for unaffiliated capitated risk arrangements that are recognized on a net basis under GAAP, as well as affiliated eliminations.
-31-

A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023
Reportable segments’ operating revenue$42,273 $41,898 
Net investment income465 387 
Net losses on financial instruments(161)(113)
Total revenues$42,577 $42,172 
A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023
Income before income tax expense$2,939 $2,619 
Net investment income(465)(387)
Net losses on financial instruments161 113 
Interest expense265 251 
Amortization of other intangible assets116 235 
Reportable segments’ operating gain$3,016 $2,831 
-32-


ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the accompanying consolidated financial statements and notes, as well as our consolidated financial statements and notes as of and for the year ended December 31, 2023 and the MD&A included in our 2023 Annual Report on Form 10-K. References to the terms “we,” “our,” “us,” or “Elevance Health” used throughout this MD&A refer to Elevance Health, Inc., an Indiana corporation, and, unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.
Results of operations, cost of care trends, investment yields and other measures for the three months ended March 31, 2024 are not necessarily indicative of the results and trends that may be expected for the full year ending December 31, 2024, or any other period.
Overview
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving over 46 million medical members through our affiliated health plans as of March 31, 2024. We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans, and serve members as the Blue Cross or Blue Cross and Blue Shield licensee in 14 states. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health, Carelon Behavioral Health and CareMore.
We have organized our brand portfolio into the following core go-to-market brands:
•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;
•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and
•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation.For additional information, see Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our 2023 Annual Report on Form 10-K.
Business Trends
We made the decision to expand our participation in the Individual state- or federally-facilitated marketplaces (the “Public Exchange”) for 2024. For 2024, we are offering Individual Public Exchange products in 141 of the 143 rating regions in which we operate, in comparison to 138 of 143 rating regions in 2023. As described in “Regulatory Trends and
-33-

Uncertainties” below, we expect growth in our Public Exchange membership as Medicaid members who are no longer eligible for Medicaid coverage continue to exit the Medicaid program and seek coverage elsewhere. Changes to our business environment are likely to continue as elected officials at the national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to taxes and fees. In addition, growth in our government-sponsored business exposes us to increased regulatory oversight.
CarelonRx markets and offers pharmacy services to our affiliated health plan customers throughout the country, as well as to customers outside of the health plans we own. Our comprehensive pharmacy services portfolio includes all core pharmacy services, such as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database and member services. CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C. (“CVS”), which is a subsidiary of CVS Health Corporation, pursuant to a five year agreement that is set to terminate on December 31, 2025. CarelonRx also operates a specialty pharmacy. Beginning in the first quarter of 2024, CarelonRx is assuming responsibility for pharmacy mail order front-end intake and member services from CVS.
Pricing Trends: We strive to price our health benefit products consistent with anticipated underlying medical cost trends. We frequently make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken by existing competitors and new market entrants. Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments. Product pricing remains competitive.
If the approvals of any annual premium rate changes by contracted government agencies are delayed, we are required to defer the recognition of any premium rate increases to the period in which the premium rates become final. The impact of this deferral can be significant in the period in which the increased premium rates are first recognized depending on the magnitude of the premium rate increase, the number of members to which it applies and the length of the delay between the effective date of the rate increase and the final contract date. Premium rate decreases are recognized in the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period in which the contract amendment affecting the rate is finalized.
Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of these services. We work to mitigate these trends through various medical management programs such as care and condition management, program integrity and specialty pharmacy management and utilization management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics of our members, epidemics, pandemics, advances in medical technology, new high-cost prescription drugs, provider contracting inflation, labor costs and healthcare provider or member fraud.
For additional discussion regarding business trends, see Part I, Item 1, “Business” included in our 2023 Annual Report on Form 10-K.
Regulatory Trends and Uncertainties
Under the Consolidated Appropriations Act of 2023, Congress decoupled Medicaid eligibility redeterminations from the Public Health Emergency initially declared in January 2020 relating to COVID-19. As a result, states were permitted to begin removing ineligible beneficiaries from their Medicaid programs starting April 1, 2023, and the majority of our Medicaid markets began doing so as of June 30, 2023. This process is anticipated to take up to 14 months to complete, although most states are expected to complete the redetermination process by June 30, 2024. As redeterminations have resumed, we have experienced a decline in our Medicaid membership. Over time, we expect growth in our commercial plans, including through the Public Exchanges, as members who are no longer eligible for Medicaid coverage in our 14 commercial states seek coverage elsewhere.
-34-

The Inflation Reduction Act of 2022, which was signed into law in August 2022, contains a variety of provisions that impact our business including an extension of the American Rescue Plan Act of 2021’s enhanced Premium Tax Credits (“PTC”) through 2025; imposing a new corporate alternative minimum tax; providing a one percent excise tax on repurchases of stock; allowing the Centers for Medicare and Medicaid Services (“CMS”) to negotiate prices on a limited set of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost sharing in Medicare Parts B and D; redesigning of the Medicare Part D benefit; adding a requirement that drug manufacturers pay rebates if prices increase beyond inflation; and delaying the implementation of the Trump Administration Medicare drug rebate rule until 2032. The extension of the enhanced PTC has allowed for growth in Individual Public Exchange enrollment as Medicaid eligibility redeterminations have resumed, supporting continuity of coverage for more people.
The Consolidated Appropriations Act of 2021 (the “2021 Appropriations Act”) has impacted and in the future may have a material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation, mental health parity reporting, and reporting on pharmacy benefits and drug costs. The requirements of the 2021 Appropriations Act applicable to us had varying effective dates, some of which were effective in December 2021 and during 2022, and others that were extended into 2023 and 2024 since the enactment of the 2021 Appropriations Act.
The health plan price transparency regulations issued by the U.S. Departments of Health and Human Services, Labor and Treasury required us in 2022 to begin disclosing detailed pricing information regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers and historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we were required to make available to members personalized out-of-pocket cost information and the underlying negotiated rates for 500 covered healthcare items and services, including prescription drugs. Effective January 1, 2024, this requirement has expanded to include all items and services.
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”), continues to impact our business and results of operations, including pricing, minimum medical loss ratios and the geographies in which our products are available. We also expect further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving methodology for ratings and quality bonus payments. CMS also frequently proposes changes to its program that audits data submitted under the risk adjustment programs in ways that could increase financial recoveries from plans.
For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, “Business – Regulation,” Part I, Item 1A, “Risk Factors” and the “Regulatory Trends and Uncertainties” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2023 Annual Report on Form 10-K.
Other Significant Items
Business and Operational Matters
During the third quarter of 2023, based on a strategic review of our operations, assets and investments, management implemented the “2023-2024 Business Efficiency Program” to refine the focus of our investments and optimize our physical footprint. The 2023-2024 Business Efficiency Program includes the write-off of certain information technology assets and contract exit costs, a reduction in staff including the relocation of certain job functions, and the impairment of assets associated with the closure or partial closure of data centers and offices. The 2023-2024 Business Efficiency Program is expected to be substantially complete by the end of the third quarter of 2024. For additional information, see Note 4, “Business Optimization Initiatives” of the Notes to Consolidated Financial Statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q.
-35-

Pursuant to CMS’ Medicare Advantage Star ratings system, CMS annually awards between 1.0 and 5.0 Stars to Medicare Advantage plans based on performance in several categories. Plans must have a Star rating of 4.0 or higher to qualify for bonus payments. In March 2024, CMS informed us that it had updated our 2024 Star ratings from their October 2023 announcement. As a result, we now estimate approximately 49% of our Medicare Advantage members to be enrolled in plans rated at least 4.0-Star for 2024 Star ratings (payment year 2025), based on our January 2024 enrollment, compared to 64% of our Medicare Advantage members being in plans rated at least 4.0-Star for 2023 Star ratings (payment year 2024), based on September 2022 enrollment. This change in 2024 Star ratings from 2023 Star ratings is expected to reduce our 2025 operating revenue by approximately $310 million, and we expect to partially mitigate this financial impact through various strategies such as operating expense efficiencies, capital deployment alternatives and network enhancements.
Acquisitions and Divestitures
Completed Acquisitions
On March 11, 2024, we completed our acquisition of Paragon Healthcare, Inc. (“Paragon”). Paragon, which operates as part of CarelonRx, provides infusion services and injectable therapies through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve.
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve.
Divestiture
On April 1, 2024, we completed the sale of our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard entered into a product distribution partnership.
Pending Acquisitions
On December 31, 2023, we entered into an agreement to acquire Centers Plan for Healthy Living LLC and Centers for Specialty Care Group IPA, LLC (“Centers”). Centers is a managed long-term care plan that serves New York state Medicaid and dually-eligible Medicaid/Medicare members, enabling adults with long-term care needs and disabilities to live safely and independently in their own home. This acquisition aligns with our strategic plan to grow the Health Benefits segment and leverage industry-leading expertise while serving Medicaid and dually eligible populations. The acquisition is expected to close in the third quarter of 2024 and is subject to standard closing conditions and customary approvals.
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition is subject to closing conditions and approvals.
Pending Equity Investment
On April 12, 2024, we entered into an agreement to partner with Clayton, Dubilier & Rice (“CD&R”) to accelerate innovation in care delivery across multiple regions in the United States by bringing together through a new company, (“ NewCo”), certain care delivery and enablement assets of Carelon Management Services Inc., a Carelon Health business (“CMSI Assets”), and two CD&R portfolio businesses, apree health and Millennium Physician Group. Our investment in NewCo will be through a combination of cash, an existing equity investment in apree health, and the contribution of CMSI
-36-

Assets. We will account for our initial minority ownership interest in NewCo as an equity method investment. Further, in connection with our equity investment, each party will have certain rights and obligations, including certain put, call, and purchase price true-up options, for which the estimated value will be determinable at the time of the incremental investments. The contribution of CMSI Assets and businesses to be contributed by CD&R to NewCo are subject to standard closing conditions and customary approvals.
For additional information, see Note 3, “Business Acquisitions and Divestitures,” and Note 5, “Investments” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Litigation Matters
In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the “Court”) captioned In re Blue Cross Blue Shield Antitrust Litigation (“BCBSA Litigation”), the BCBSA and Blue Cross and/or Blue Shield licensees, including us (the “Blue plans”) previously approved a settlement agreement and release with the plaintiffs representing a putative nationwide class of health plan subscribers (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. Generally, the lawsuits in the BCBSA Litigation challenge elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. The Subscriber Settlement Agreement applies only to the subscriber class. The defendants continue to contest the consolidated cases brought by the provider plaintiffs.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). In compliance with the Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the Company of $596, which amount was accrued in 2020. The Final Approval Order was appealed to the United States Court of Appeals for the Eleventh Circuit (the “Eleventh Circuit”), which affirmed the Final Approval Order in October 2023. Petitions for rehearing were denied in January 2024, and the Eleventh Circuit issued a mandate terminating its jurisdiction in February 2024. In March 2024, Home Depot, one of the appellants, filed a petition for certiorari to the United States Supreme Court. On the respondents request, the United States Supreme Court granted an extension until May 2024. In the event all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement. For additional information regarding the BCBSA Litigation, see Note 14, “Commitments and Contingencies – Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust Litigation,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of our 2023 Annual Report on Form 10-K.
Selected Operating Performance
For the twelve months ended March 31, 2024, total medical membership declined by 3.9%. This was primarily driven by Medicaid membership attrition and lapses exceeding sales in our Employer Group risk-based and Medicare businesses. These decreases were partially offset by increases in our Employer Group fee-based, Individual, BlueCard and Federal Employees Health Benefits (“FEHB”) businesses, resulting from sales exceeding lapses.
Operating revenue for the three months ended March 31, 2024 was $42,273, an increase of $375, or 0.9%, from the three months ended March 31, 2023. This increase was primarily a result of premium rate increases in all lines of business to more accurately reflect medical cost trends. Increased product revenue from our CarelonRx business, including a full quarter of revenue from BioPlus in 2024, also contributed to the overall increase. These increases were partially offset by overall declines in premiums driven by Medicaid membership attrition.
Net income for the three months ended March 31, 2024 was $2,249, an increase of $245, or 12.2%, from the three months ended March 31, 2023. This increase was primarily due to improved operating gain performance in our Health Benefits, Carelon Services and CarelonRx businesses, lower amortization of other intangible assets and increased net investment income. These increases were partially offset by increased net losses on financial instruments, increased income tax expense due to higher income before taxes and an increased operating loss in our Corporate and Other segment.
Our fully-diluted shareholders’ earnings per share (“EPS”) was $9.59 for the three months ended March 31, 2024, which represented a 15.5% increase from EPS of $8.30 for the three months ended March 31, 2023. This increase in EPS for the
-37-

three months ending March 31, 2024 resulted primarily from increased shareholders' net income, as well as fewer diluted shares outstanding.
Operating cash flow for the three months ended March 31, 2024 and 2023 was $1,978 and $6,469, respectively. The decrease in net cash provided by operating activities was primarily due to the timing of CMS payments received in the prior year quarter, with the April 2023 premium payments being received in the first quarter of 2023.
Membership and Other Metrics
The following table presents our medical membership by customer type as of March 31, 2024 and 2023. Also included below are other membership by product and other metrics. The membership data and other metrics presented are unaudited and in certain instances include estimates of the number of members represented by each contract at the end of the period. The CarelonRx Quarterly Adjusted Scripts metric represents adjusted script volume based on the number of days a prescription covers. On an adjusted basis, one 90-day script counts the same as three 30-day scripts. The Carelon Services Consumers Served metric represents the number of consumers receiving one or more healthcare-related services from Carelon Services who are members of our affiliated health plans as well as those who are members of non-affiliated health plans. For a more detailed description of our medical membership, see the “Membership” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2023 Annual Report on Form 10-K.
  
March 31  
20242023Change% Change
Medical Membership (in thousands)
Individual1,246 942 30432.3 %
Employer Group Risk-Based3,648 3,798 (150)(3.9)%
Commercial Risk-Based4,894 4,740 1543.2 %
BlueCard®
6,825 6,607 2183.3 %
Employer Group Fee-Based20,622 20,278 3441.7 %
Commercial Fee-Based27,447 26,885 5622.1 %
Medicare Advantage2,017 2,053 (36)(1.8)%
Medicare Supplement896 925 (29)(3.1)%
Total Medicare2,913 2,978 (65)(2.2)%
Medicaid9,327 11,889 (2,562)(21.5)%
Federal Employees Health Benefits (“FEHB”)1,658 1,632 26 1.6 %
Total Medical Membership46,239 48,124 (1,885)(3.9)%
Other Membership (in thousands)
Life and Disability Members4,469 4,771 (302)(6.3)%
Dental Members6,970 6,743 227 3.4 %
Dental Administration Members1,841 1,697 144 8.5 %
Vision Members10,251 9,904 347 3.5 %
Medicare Part D Standalone Members262 264 (2)(0.8)%
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts77.0 75.7 1.3 1.7 %
Carelon Services Consumers Served102.9 104.0 (1.1)(1.1)%
Medical Membership
The decrease in medical membership was primarily driven by Medicaid membership attrition, including eligibility redeterminations and certain market exits, and lapses exceeding sales in our Employer Group risk-based and Medicare
-38-

businesses. These decreases were partially offset by increases in our Employer Group fee-based, Individual, BlueCard and FEHB businesses, resulting from sales exceeding lapses.
Other Membership
Our other membership has the potential to be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to our health business. Life and disability membership decreased primarily due to lapses associated with our Employer Group risk-based business. Dental membership increased primarily due to favorable sales in our Individual, Employer Group fee-based and FEHB businesses, partially offset by lapses in our Employer Group risk-based business. Dental administration membership increased primarily due to favorable in-group change with other BCBSA plans associated with the FEHB program. Vision membership increased due to sales exceeding lapses in our Employer Group fee-based and Individual businesses and increased sales associated with our Medicare Advantage plans.
Consolidated Results of Operations
Our consolidated summarized results of operations and other financial information for the three months ended March 31, 2024 and 2023 are as follows: 
Three Months Ended 
 March 31
Change
2024 vs. 2023
20242023$%
Total operating revenue$42,273$41,898$375 0.9 %
Net investment income46538778 20.2 %
Net losses on financial instruments(161)(113)(48)42.5 %
Total revenues42,57742,172405 1.0 %
Benefit expense30,54630,786(240)(0.8)%
Cost of products sold3,8253,481344 9.9 %
Operating expense
4,8864,80086 1.8 %
Other expense1 
381486(105)(21.6)%
Total expenses39,63839,55385 0.2 %
Income before income tax expense2,9392,619320 12.2 %
Income tax expense69061575 12.2 %
Net income$2,249$2,004$245 12.2 %
Net income attributable to noncontrolling interests
(3)(15)12 NM
Shareholders’ net income$2,246$1,989$257 12.9 %
Average diluted shares outstanding234.2239.7(5.5)(2.3)%
Diluted shareholders’ earnings per share
$9.59$8.30$1.29 15.5 %
Effective tax rate23.5 %23.5 %
0 bp3
Benefit expense ratio2
85.6 %85.8 %
(20) bp3
Operating expense ratio4
11.6 %11.5 %
10 bp3
Income before income tax expense as a percentage of total revenues6.9 %6.2 %
70 bp3
Shareholders’ net income as a percentage of total revenues5.3 %4.8 %
50 bp3
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM    Not meaningful.
1    Includes interest expense and amortization of other intangible assets.
2    Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the three months ended March 31, 2024 and 2023 were $35,696 and $35,868, respectively.
3    bp = basis point; one hundred basis points = 1%.
4    Operating expense ratio represents operating expense as a percentage of total operating revenue.
-39-

Three Months Ended March 31, 2024 Compared to the Three Months Ended March 31, 2023
Total operating revenue increased primarily as a result of premium rate increases in all lines of business to reflect medical cost trends. Increased product revenue from our CarelonRx business also contributed to the overall increase. These increases were partially offset by overall declines in premiums driven by Medicaid membership attrition.
Net investment income increased primarily due to higher income from fixed maturity securities.
Net losses on financial instruments increased primarily due to increased losses on equity securities and fixed maturity securities.
Benefit expense decreased primarily due to Medicaid membership attrition, partially offset by increases due to medical cost trends in our other Health Benefits businesses.
Our benefit expense ratio decreased primarily driven by premium rate increases in our Health Benefits segment to reflect medical cost trends.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated customers. Cost of products sold increased as the corresponding pharmacy product revenues increased.
Operating expense increased primarily due to increased spend to support growth and integration costs related to recent acquisitions.
Our operating expense ratio increased slightly primarily due to the increase in operating expenses, partially offset by the favorable impact of operating revenue growth.
Other expense declined primarily due to decreased amortization of other intangible assets. In the first quarter of 2023, we had increased amortization of other intangible assets as the amortization period of certain intangible assets was shortened to align with the dates our new branding took place.
Our shareholders’ net income as a percentage of total revenues increased in 2024 as compared to 2023 as a result of all factors discussed above.
Reportable Segments Results of Operations
Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted accounting principles (“GAAP”). We also calculate operating gain and operating margin to further aid investors in understanding and analyzing our core operating results and comparing them among periods. We define operating revenue as premium income, product revenue and service fees. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net losses on financial instruments, interest expense, amortization of other intangible assets or income taxes, as these items are managed in our corporate shared service environment and are not the responsibility of operating segment management. Operating margin is calculated as operating gain divided by operating revenue. We use these measures as a basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This information is not intended to be considered in isolation or as a substitute for income before income tax expense, shareholders’ net income or EPS prepared in accordance with GAAP, and may not be comparable to similarly titled measures reported by other companies. For a reconciliation of reportable segments’ operating revenue to the amounts of total revenue included in the consolidated statements of income and a reconciliation of income before income tax expense to reportable segments’ operating gain, see Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to
-40-

conform to the current presentation.For additional information, see Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
The following table presents a summary of the reportable segment financial information for the three months ended March 31, 2024 and 2023:
 Three Months Ended 
 March 31
Change
 
20242023$%
Operating Revenue
Health Benefits$37,258$37,280$(22)(0.1)%
CarelonRx
8,0678,02443 0.5 %
Carelon Services
4,0093,460549 15.9 %
Corporate & Other1279136 39.6 %
Eliminations (7,188)(6,957)(231)3.3 %
Total operating revenue$42,273$41,898$375 0.9 %
Operating Gain (Loss)
Health Benefits$2,287$2,149$138 6.4 %
CarelonRx52351211 2.1 %
Carelon Services29022961 26.6 %
Corporate & Other(84)(59)(25)42.4 %
Total operating gain$3,016 $2,831 $185 6.5 %
Operating Margin
Health Benefits6.1 %5.8 %30 bp
CarelonRx6.5 %6.4 %10 bp
Carelon Services7.2 %6.6 %60 bp
Total operating margin
7.1 %6.8 %30 bp
bp = basis point; one hundred basis points = 1%.
Three Months Ended March 31, 2024 Compared to the Three Months Ended March 31, 2023
Health Benefits
Operating revenue decreased slightly, primarily as a result of lower premiums driven by Medicaid membership attrition, including eligibility redeterminations and certain market exits, mostly offset by premium rate increases in all lines of business to reflect medical cost trend.
Operating gain increased primarily as a result of premium yields, including due to disciplined commercial underwriting, partially offset by the impact of Medicaid membership attrition.
CarelonRx
Operating revenue increased primarily due to a full three months of revenue from BioPlus in 2024 and higher prescription volume associated with growth in external pharmacy members, partially offset by the impact of the Medicaid membership attrition.
The increase in operating gain was primarily driven by growth of product revenue, partially offset by expenses associated with the launch of additional services by CarelonRx.
-41-

Carelon Services
Operating revenue increased primarily due to the continued expansion of our medical management, behavioral health and post-acute care services.
The increase in operating gain was primarily driven by improved performance in our behavioral health and medical management businesses, partially offset by the impact of the Medicaid membership attrition.
Corporate & Other
Operating revenue increased primarily due to higher affiliated revenues.
Operating loss increased primarily due to an increase in unallocated corporate expenses.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, goodwill and other intangible assets and investments. Our accounting policies related to these items are discussed in our 2023 Annual Report on Form 10-K in Note 2, “Basis of Presentation and Significant Accounting Policies,” to our audited consolidated financial statements as of and for the year ended December 31, 2023, as well as in the “Critical Accounting Policies and Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” As of March 31, 2024, our critical accounting policies and estimates have not changed from those described in our 2023 Annual Report on Form 10-K.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. Our accounting policies related to medical claims payable are discussed in the references cited above. As of March 31, 2024, our critical accounting policies and estimates related to medical claims payable have not changed from those described in our 2023 Annual Report on Form 10-K. For a reconciliation of the beginning and ending balance for medical claims payable for the three months ended March 31, 2024 and 2023, see Note 9, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the three months ended March 31, 2024 and 2023, which are the trend and completion factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations.
Favorable Developments by 
Changes in Key Assumptions
Three Months Ended 
 March 31
20242023
Assumed trend factors$571 $772 
Assumed completion factors634 296 
Total$1,205 $1,068 
-42-

The favorable development recognized in the three months ended March 31, 2024 resulted from favorable development in the completion factors resulting from the latter part of 2023 developing faster than expected as well as trend factors in late 2023 developing more favorably than originally expected. The favorable development recognized in the three months ended March 31, 2023 resulted primarily from trend factors in late 2022 developing more favorably than expected. Favorable development in the completion factors resulting from the latter part of 2022 developing faster than expected also contributed to the favorable development for the three months ended March 31, 2023.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 63.8% and 64.9% for the three months ended March 31, 2024 and 2023, respectively. This ratio serves as an indicator of claims processing speed whereby speed for claims payments was slightly lower during the three months ended March 31, 2024 as compared to the three months ended March 31, 2023.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims payable less prior year redundancies in the current period in order to demonstrate the development of prior year reserves. For the three months ended March 31, 2024, this metric was 8.2%, driven by both favorable completion factor development from 2023 and favorable trend factor development at the end of 2023. For the three months ended March 31, 2023, this metric was 7.5%, largely driven by favorable trend factor development at the end of 2022 as well as favorable completion factor development from 2022.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred medical claims and the consistency in our methodology. For the three months ended March 31, 2024, this metric was 1.0%, which was calculated using the redundancy of $1,205. For the three months ended March 31, 2023, the comparable metric was 0.9%, which was calculated using the redundancy of $1,068. We believe these metrics demonstrate an appropriate and consistent level of reserve conservatism.
New Accounting Pronouncements
For information regarding new accounting pronouncements that were issued or became effective during the three months ended March 31, 2024 that had, or are expected to have, a material impact on our financial position, results of operations or financial statement disclosures, see the “Recently Adopted Accounting Guidance” and “Recent Accounting Guidance Not Yet Adopted” sections of Note 2, “Basis of Presentation and Significant Accounting Policies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Liquidity and Capital Resources
Sources and Uses of Capital
Our cash receipts result primarily from premiums, product revenue, service fees, investment income, proceeds from the sale or maturity of our investment securities, proceeds from borrowings and proceeds from the issuance of common stock under our employee stock plans. Cash disbursements result mainly from claims payments, operating expenses, taxes, purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.
For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included in the “Liquidity and Capital Resources” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2023 Annual Report on Form 10-K.
For additional information regarding our sources and uses of capital during the three months ended March 31, 2024, see Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock – Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-43-

Liquidity
A summary of our major sources and uses of cash and cash equivalents for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023Change
Sources of Cash:
Net cash provided by operating activities$1,978 $6,469 $(4,491)
Issuances of short- and long-term debt, net of repayments1,350 991 359 
Proceeds from issuance of common stock under employee stock plans97 43 54 
Total sources of cash3,425 7,503 (4,078)
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and redemptions(670)(1,421)751 
Purchases of subsidiaries, net of cash acquired(1,120)(1,638)518 
Repurchase and retirement of common stock(566)(622)56 
Purchases of property and equipment(279)(301)22 
Cash dividends(379)(351)(28)
Changes in bank overdrafts(586)(291)(295)
Other uses of cash, net(125)(125)— 
Total uses of cash(3,725)(4,749)1,024 
Effect of foreign exchange rates on cash and cash equivalents— 1 (1)
Net (decrease) increase in cash and cash equivalents
$(300)$2,755 $(3,055)
The decrease in net cash provided by operating activities was primarily due to the timing of CMS payments received in the prior year quarter, with the April 2023 premium payments being received in the first quarter of 2023.
Other significant changes in sources or uses of cash year-over-year included reduced purchases of investments, net of proceeds from sales, maturities, calls and redemptions, lower amounts for purchases of subsidiaries, net of cash acquired, and an increase in the issuance of short- and long term debt, net of repayments. These were partially offset by a decline in bank overdrafts outstanding.
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity securities of $37,147 at March 31, 2024. Since December 31, 2023, total cash, cash equivalents and investments in fixed maturity and equity securities decreased by $98, primarily due to the purchase of subsidiaries, bank overdrafts outstanding, the repurchase and retirement of common stock, cash dividends, and the purchase of property and equipment, partially offset by net cash provided by operating activities and the issuance of short- and long-term debt, net of repayments.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our subsidiaries.
At March 31, 2024, we held $988 of cash, cash equivalents and investments at the parent company, which are available for general corporate use, including investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and debt and interest payments.
-44-

Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more information on our debt, including redemptions and issuances, see Note 10, “Debt,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our consolidated balance sheets included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total equity. Total debt is the sum of short-term borrowings, current portion of long-term debt and long-term debt, less current portion. We believe our debt-to-capital ratio assists investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated debt-to-capital ratio was 39.4% and 38.9% as of March 31, 2024 and December 31, 2023, respectively.
Our senior debt is rated “A” by S&P Global Ratings, “BBB+” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor Service, Inc. and “bbb+” by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Capital Resources
We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our subsidiaries, the financing of possible acquisitions or business expansions.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. We had no amounts outstanding under the 5-Year Facility as of March 31, 2024 or December 31, 2023. As of March 31, 2024, we were in compliance with all of the debt covenants under the 5-Year Facility.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. Should commercial paper issuance become unavailable, we have the ability to use a combination of cash on hand and/or our 5-Year Facility to redeem any outstanding commercial paper upon maturity. At March 31, 2024 and December 31, 2023, we had $1,350 and $0, respectively, outstanding under our commercial paper program. Beginning June 30, 2023, we have reclassified our commercial paper balances, if any, from long-term debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $225 of outstanding short-term borrowings from the FHLBs at each of March 31, 2024 and December 31, 2023.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
-45-

For additional information regarding our sources and uses of capital at March 31, 2024, see Note 5, “Investments,” Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock – Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries’ states of domicile have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and health maintenance organizations largely based on the National Association of Insurance Commissioners (“NAIC”) Risk-Based Capital (RBC) for Health Organizations Model Act (the “RBC Model Act”). These RBC requirements are intended to measure capital adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual insurance company’s business. In general, under the RBC Model Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of December 31, 2023, which was the most recent date for which reporting was required, were in excess of all applicable mandatory RBC requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our California subsidiaries. For additional information, see Note 22, “Statutory Information,” in our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K.
Future Sources and Uses of Liquidity
We believe that cash on hand, future operating cash receipts, investments and funds available under our commercial paper program, our 5-Year Facility and borrowings available from the FHLBs will be adequate to fund our expected cash disbursements over the next twelve months.
There have been no material changes to our long-term liquidity requirements as disclosed in Part II, Item 7 of our 2023 Annual Report on Form 10-K. For additional updates regarding our estimated long-term liquidity requirements, see Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and the “Other Contingencies” and “Contractual Obligations and Commitments” sections of Note 11 “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. We believe that funds from future operating cash flows, cash and investments and funds available under our 5-Year Facility and/or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.
-46-

FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; information technology disruptions; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.
-47-

ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” included in our 2023 Annual Report on Form 10-K. There have been no material changes to any of these risks since December 31, 2023.

ITEM 4.    CONTROLS AND PROCEDURES
We carried out an evaluation as of March 31, 2024, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Exchange Act. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
There have been no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS
For information regarding legal proceedings at March 31, 2024, see the “Litigation and Regulatory Proceedings,” and “Other Contingencies” sections of Note 11, “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which information is incorporated herein by reference.

ITEM 1A.    RISK FACTORS
There have been no material changes to the risk factors disclosed in our 2023 Annual Report on Form 10-K.
-48-

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated:
Period
Total Number
of Shares
Purchased1 
Average
Price Paid
per Share
Total Number
of Shares
Purchased
as Part
of Publicly
Announced
Programs2
Approximate
Dollar Value
of Shares
that May Yet
Be Purchased
Under the
Programs
(in millions, except share and per share data)    
January 1, 2024 to January 31, 2024480,285 $475.26 479,559 $3,971 
February 1, 2024 to February 29, 2024311,446 502.61 310,932 3,815 
March 1, 2024 to March 31, 2024558,218 504.76 359,094 3,633 
1,349,949 1,149,585 
1    Total number of shares purchased includes 200,364 shares delivered to or withheld by us in connection with employee payroll tax withholding upon the exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated changes in equity are shown net of these shares purchased.
2    Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board of Directors evaluates periodically. During the three months ended March 31, 2024, we repurchased 1,149,585 shares at a total cost of $566 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. The most recent authorized increase to the program was $5,000 on January 24, 2023 by our Audit Committee, pursuant to authorization granted by the Board of Directors. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time.

ITEM 3.    DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4.    MINE SAFETY DISCLOSURES
None.
ITEM 5.    OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the three months ended March 31, 2024, none of our directors or officers (as defined in Rule-1(f) of the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408 of Regulation S-K.
-49-

ITEM 6.    EXHIBITS
Exhibit
Number
 Exhibit
3.1 
3.2 
4.7 Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.
10.2 (p)*
(q)*
(r)
*
10.3 
10.4 
*
10.9 (d)*
31.1 
31.2 
32.1 
32.2 
101.INS
XBRL Instance Document - the instant document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH
Inline XBRL Taxonomy Extension Schema Document.
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
*Indicates management contracts or compensatory plans or arrangements.

-50-

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ELEVANCE HEALTH, INC.
Registrant
April 18, 2024By: 
/S/  MARK B. KAYE
 
Mark B. Kaye
Executive Vice President and Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
April 18, 2024By: 
/S/  RONALD W. PENCZEK
 Ronald W. Penczek
Chief Accounting Officer and Controller
(Principal Accounting Officer)
-51-
 EX-10.2P 2 exhibit102poptionagreement.htm EX-10.2 (P) Document
EXHIBIT 10.2(p)

Schedule A
Notice of Option Grant
Participant:        [●]
Company:        Elevance Health, Inc.
Notice:    You have been granted the following nonqualified stock option to purchase shares of common stock of the Company in accordance with the terms of the Plan and the attached Nonqualified Stock Option Award Agreement.
Plan:    2017 Elevance Health Incentive Compensation Plan
Grant:    
Grant Date: [●]
Grant Number: [●]
Option Price per Share: [●]
Number of Shares under
Option: [●]
        
                                                            
Exercisability:    Subject to the terms of the Plan and this Agreement, your Option will become exercisable on and after the dates indicated below as to the number of Shares set forth below opposite each such date, plus any Shares as to which your Option could have been exercised previously but was not so exercised.


SharesDate
 [●] [●]
 [●] [●]
 [●] [●]


    In the event that a Change of Control (as defined in the Plan) occurs before your Termination (as defined in the Plan), your Option will remain subject to the terms of this Agreement, unless the successor company does not assume your Option. If a successor company does not assume your Option, then your Option shall become fully exercisable immediately prior to the Change of Control.
Expiration Date:    Your Option will expire ten years from the Grant Date, subject to earlier termination as set forth in the Plan and this Agreement.
Acceptance:    In order to accept your Options, you must electronically accept this Agreement through the Company’s broker at any time within ninety (90) days after the Grant Date. To effect your acceptance, please follow the instructions included with your grant materials. Acceptance of the Agreement includes acceptance of the terms and conditions of the Plan. If you do not timely and electronically accept this Agreement, this Agreement will be null and void at the end of the 90th day after the Grant Date and you will have no right or claim to the Options described above.




Nonqualified Stock Option Award Agreement
This Nonqualified Stock Option Award Agreement (this “Agreement”) dated as of the Grant Date (the “Grant Date”) set forth in the Notice of Option Grant attached as Schedule A hereto (the “Grant Notice”) is made between Elevance Health, Inc. (the “Company”) and the Participant set forth in the Grant Notice. The Grant Notice is included in and made part of this Agreement. The Company and Participant expressly agree and acknowledge that Participant’s entry into this Agreement is not a condition of Participant’s employment with the Company, and that Participant is not required to enter into this Agreement or accept any Stock Option Award as a condition of Participant’s employment with the Company or a Subsidiary or Affiliate. Capitalized terms not defined herein or in the Grant Notice are defined in the Plan.
1.Grant of the Option. Subject to the provisions of this Agreement and the provisions of the Plan, the Company hereby grants to Participant, pursuant to the Plan, the right and option (the “Option”) to purchase all or any part of the number of shares of common stock of the Company (“Shares”) as set forth in the Grant Notice at an Option Price (“Option Price”) per share and on the other terms as set forth in the Grant Notice. This Option is intended to be a nonqualified stock option for federal income tax purposes.
2.Method of Exercise of the Option.
(a)Participant may exercise the Option, to the extent then exercisable, by delivering a notice to the Company’s captive broker in a form specified or accepted by the captive broker, specifying the number of Shares with respect to which the Option is being exercised.
(b)At the time Participant exercises the Option, Participant shall pay the Option Price of the Shares as to which the Option is being exercised and applicable taxes (i) in United States dollars by personal check, bank draft or money order; (ii) subject to such terms, conditions and limitations as the Compensation and Talent Committee of the Board of Directors of the Company (“Committee”) may prescribe, by tendering (either by actual delivery or attestation) unencumbered Shares previously acquired by Participant having an aggregate Fair Market Value at the time of exercise equal to the total Option Price of the Shares for which the Option is so exercised; (iii) subject to such terms, conditions and limitations as the Committee may prescribe, a cashless (broker-assisted) exercise that complies with all applicable laws; or (iv) by a combination of the consideration provided for in the foregoing clauses (i), (ii) and (iii).
3.Termination. The Option shall terminate upon Participant’s Termination for any reason and no Shares may thereafter be purchased under the Option except as provided below. Notwithstanding anything contained in this Agreement, (i) a Participant who is in a position of Vice President or above must give at least 30 days advance written notice of his Termination due to resignation (including Retirement) in order for the Participant to exercise the Option for any period that may apply below and (ii) in no event shall the Option be exercisable after the Expiration Date. If less than 30 days advance written notice is given, the Option shall be immediately canceled, including the portion of the Option that is otherwise exercisable.1
(a)Retirement. If Participant’s Termination is due to Retirement (for purposes of this Agreement, defined as Participant’s Termination after attaining age fifty-five (55) with at least ten (10) completed years of service or after attaining age sixty-five (65)), the Option shall continue to become exercisable according to the schedule set forth in the Grant Notice; provided that the Option shall terminate on the five-year anniversary of the date of Participant’s Retirement but not later than the Expiration Date set forth in the Grant Notice; provided, further, that if Participant’s Termination is due to Retirement during the calendar year of the Grant Date, the Option shall be immediately terminated on a pro-rata basis, measured by the number of completed full months in that calendar year during which Participant was employed by the Company or an Affiliate (e.g., if Participant’s Retirement occurs in September, 33.3% (or 4/12) of the Option shall be immediately terminated), and the non-terminated portion of the Option shall continue to become exercisable according to the schedule set forth in the Grant Notice.1
1 This retirement provision is deleted in non-annual retention grants.
2

2024 Stock Option


(b)Death and Disability. If Participant’s Termination is due to Participant’s death or Disability (for purposes of this Agreement, as defined in the applicable Elevance Health Long-Term Disability Plan), the Option shall immediately become fully exercisable and shall terminate on the five-year anniversary of the date of such Termination but not later than the Expiration Date set forth in the Grant Notice.
(c)Termination without Cause or for Good Reason. Unless Sections 3(a) or 3(e) are applicable, if Participant’s Termination is by the Company or an Affiliate without Cause (for purposes of this Agreement, defined as a violation of “conduct” as such term is defined in the Elevance Health HR Corrective Action Policy and if Participant participates in the Elevance Health Executive Agreement Plan (the "Agreement Plan"), the Key Associate Agreement or the Key Sales Associate Agreement also as defined in that plan or agreement) or voluntarily by Participant, the following shall apply:
(i)Unless clause (ii) applies, the Option, to the extent fully exercisable as of the date of such Termination, shall thereafter be exercisable only for a period of ninety (90) days from the date of such Termination, but not later than the Expiration Date set forth in the Grant Notice.
(ii)If Participant is receiving severance (or similar post-termination compensation in connection with a termination) under any severance plan of, or agreement with, the Company or an Affiliate , and any portion of the Option remains unexercisable as of Participant’s Termination, the Option shall continue to become exercisable through the earlier of (A) the last day of the period for which Participant is receiving such severance/compensation or (B) the last day of the schedule set forth in the Grant Notice. The Option shall be exercisable for a period of ninety (90) days from the date the severance period ends, but not later than the Expiration Date set forth in the Grant Notice.

(d)Cause. If Participant’s Termination is for Cause, even if on the date of such Termination Participant has met the definition of Retirement or Disability, then the portion of the Option that has not been exercised shall immediately terminate.
(e)Termination after Change of Control. Notwithstanding any other provision of this Agreement, including Section 3(c), if after a Change of Control Participant’s Termination is (i) by the Company or an Affiliate without Cause or (ii) if Participant participates in the Executive Agreement Plan, by Participant for Good Reason (as defined in the Executive Agreement Plan), the Option shall immediately become fully exercisable and shall terminate on the five-year anniversary of the date of such Termination but not later than the Expiration Date set forth in the Grant Notice.
4.Transferability of the Option. The Option shall not be transferable or assignable by Participant except as provided in this Section 4 and the Option shall be exercisable, during Participant’s lifetime, only by him/her or, during periods of legal disability, by his/her guardian or other legal representative. No Option shall be subject to execution, attachment, or similar process. Participant shall have the right to appoint any individual or legal entity in writing, in accordance with procedures established by the Company’s broker, to receive any Option (to the extent not previously terminated or forfeited) under this Agreement upon Participant’s death, to the extent permitted by law. The effectiveness of any such designation, and any revocation or replacement thereof, shall be determined in accordance with procedures established by the Company’s broker. If Participant dies without such designation, the Option will become part of Participant’s estate.
5.Taxes and Withholdings. At the time of receipt of Shares upon the exercise of all or any part of the Option, Participant shall pay to the Company in cash (or make other arrangements, in accordance with Article XVIII of the Plan, for the satisfaction of) any taxes of any kind required by law to be withheld with respect to such Shares; provided, however, that pursuant to any procedures, and subject to any limitations as the Committee may prescribe and subject to applicable law, Participant may elect to satisfy, in whole or in part, such withholding obligations by (a) withholding Shares otherwise deliverable to Participant pursuant to the Option (provided, however, that the amount of any Shares so withheld shall not exceed the amount necessary to satisfy required Federal, state, local and non-United States withholding obligations using the minimum statutory withholding rates for Federal, state, local and/or non-U.S. tax purposes, including payroll taxes, that are applicable to supplemental
3

2024 Stock Option


taxable income) and/or (b) tendering to the Company Shares owned by Participant (or Participant and Participant’s spouse jointly) based, in each case, on the Fair Market Value of the Shares on the payment date as determined by the Committee. Any such election made by Participant must be irrevocable, made in writing, signed by Participant, and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate. Please refer to the Plan’s prospectus for tax considerations by jurisdiction.
6.No Rights as a Shareholder. Neither Participant nor any other person shall become the beneficial owner of the Shares subject to the Option, nor have any rights to dividends or other rights as a shareholder with respect to any such Shares, until Participant has actually received such Shares following the exercise of the Option in accordance with the terms of the Plan and this Agreement.
7.Restrictive Covenants. For purposes of Sections 7, 8, and 9 of this Agreement, Company shall mean Elevance Health, Inc. and its Subsidiaries and Affiliates. Participant acknowledges that Participant has the right to consult with counsel at Participant’s sole expense. As a condition to receipt of the Stock Option Grant made under this Agreement, which Participant and the Company agree is fair and reasonable consideration, Participant agrees as follows, subject to any applicable provisions of Appendix A:
(a)    Confidentiality.
(i)    Participant recognizes that the Company derives substantial economic value from information created and used in its business which is not generally known by the public, including, but not limited to, plans, designs, concepts, computer programs, formulae, and equations; product fulfillment and supplier information; customer and supplier lists, and confidential business practices of the Company, Affiliates, and any of its customers, vendors, business partners or suppliers; profit margins and the prices and discounts the Company obtains or has obtained or at which it sells or has sold or plans to sell its products or services (except for public pricing lists); manufacturing, assembling, labor and sales plans and costs; business and marketing plans, ideas, or strategies; confidential financial performance and projections; employee compensation; employee staffing and recruiting plans and employee personal information; and other confidential concepts and ideas related to the Company’s business (collectively, “Confidential Information”). Participant expressly acknowledges and agrees that by virtue of his/her employment with the Company, Participant will have access to and will use in the course of Participant’s duties certain Confidential Information and that Confidential Information constitutes trade secrets and confidential and proprietary business information of the Company, all of which is the exclusive property of the Company. For purposes of this Agreement, Confidential Information includes, but is not limited to, information that constitutes a trade secret under applicable state or federal law. Confidential Information does not include information that Participant establishes by clear and convincing evidence is or may become known to Participant or to the public from sources outside the Company and through means other than a breach of this Agreement.
(ii)    Participant agrees that Participant will not for himself or herself or for any other person or entity, directly or indirectly, without the prior written consent of the Company, while employed by the Company and thereafter: (A) use Confidential Information for the benefit of any person or entity other than the Company or its affiliates; (B) remove, copy, duplicate or otherwise reproduce any document or tangible item embodying or pertaining to any of the Confidential Information, except as required to perform Participant’s duties for the Company or its affiliates; or (C) while employed and thereafter, publish, release, disclose or deliver or otherwise make available to any third party any Confidential Information by any communication, including oral, documentary, electronic or magnetic information transmittal device or media. Upon Termination, Participant shall return all Confidential Information and all other property of the Company. This obligation of non-disclosure and non-use of information shall continue to exist for so long as such information remains Confidential Information.

(b)    Non-Competition. During any period in which Participant is employed by the Company, and during a period of time after Participant’s Termination (the “Restriction Period”) which, unless otherwise limited by applicable state law, is (i) twenty-four (24) months for Executive Vice Presidents and the President & Chief Executive Officer, and (ii) the greater of the period of severance or twelve (12) months for all other Participants, Participant will not, without prior written consent of the Company, directly or through the direction or control of others, obtain a Competitive Position or perform a Restricted Activity in the Restricted Territory for a Competitor, as those terms are defined herein.
4

2024 Stock Option


(i)Competitive Position means any employment or performance of services with a Competitor (A) the same as or similar to the services that Participant performed for the Company in the last twenty-four (24) months of Participant’s employment with Company (the “Look Back Period”), or (B) in the performance of which Participant will likely use any Confidential Information of the Company.
(ii)Restricted Territory means any geographic area in which the Company does business and which Participant provided services in, had responsibility for, had a material presence or influence in, or had access to Confidential Information about, such business, within the Look Back Period.
(iii)Restricted Activity means any activity for which Participant had responsibility for the Company or about which Participant had Confidential Information within the Look Back Period.
(iv)Competitor means any entity or individual (other than the Company) engaged in any one or more of the following: management of network-based managed care plans and programs; administration of managed care services; provision of health insurance, long-term care insurance, dental, life, or disability insurance; administration of flexible spending accounts, COBRA continuation coverage, coordination of benefits, or subrogation services; or the provision, delivery, or administration of health benefit plans or health care services such as pharmacy benefits management (including Specialty pharmacy), value-based care delivery, behavioral health, palliative care, care for chronic and complex conditions, digital healthcare platforms, medical benefits management solutions, or health care research (including health economics and outcomes); or any other aspects of the business or products or services offered by the Company, as to which Participant had responsibilities or received Confidential Information about, during the Look Back Period.
(v)The restrictions contained in this subsection (b) shall not apply to attorneys who accept a Competitive Position that consists of practicing law.
(vi)If Participant receives an offer of a Competitive Position with a Competitor, as those terms are defined above, Participant shall notify the Company’s Chief Human Resources Officer, via the contact information provided in the Summary, within five business days of receiving the offer and such notification shall include a detailed description of the job responsibilities and the identity of the Competitor. The description must be specific enough for the Company to determine whether Participant’s new opportunity constitutes a violation of the Agreement.
(c)    Non-Solicitation of Customers. During any period in which Participant is employed by the Company, and during the Restriction Period after Participant’s Termination, Participant will not, either individually or as an employee, partner, consultant, independent contractor, owner, agent, or in any other capacity, directly or through the direction or control of others, for a Competitor of the Company as defined in subsection (b) above:
(i)    Solicit business from any client, account, or medical care provider of the Company that Participant had contact with, participated in contact with, had or shared responsibility for, or had access to Confidential Information about, during the Look Back Period; or
(ii)    Solicit business from any client, account, or medical care provider that the Company pursued, and Participant had contact with, responsibility for, or knowledge of Confidential Information about, by reason of Participant’s employment with the Company, during the Look Back Period.
For purposes of this paragraph (c), an individual policyholder in a plan maintained by the Company or by a client or account of the Company under which individual policies are issued, or a certificate holder in such plan under which group policies are issued, shall not be considered a client or account subject to this restriction solely by reason of being such a policyholder or certificate holder.
(d)    Non-Solicitation of Employees. During any period in which Participant is employed by the Company, and during the Restriction Period after Participant’s Termination, Participant will not, either individually or as an employee, partner, independent contractor, owner, agent, or in any other capacity,
5

2024 Stock Option


directly or indirectly, solicit, hire, attempt to solicit or hire, or participate in any attempt to solicit or hire, for any non-Company entity:
(i)    Any officer or employee of the Company whom the Participant knows to have access to or possession of Confidential Information that would give an unfair advantage to a Competitor;
(ii)    Any officer or employee of the Company who, on or at any time during the six (6) months immediately preceding the date of such solicitation or hire, held the position of Director or above with the Company;
(iii)    Any officer or employee of the Company to whom Participant reported, or who reported to Participant, on or at any time during the six (6) months immediately preceding the dates of such solicitation or hire; or
(iv)    Any person who is or was an officer or employee of the Company during the six (6) months immediately preceding the date of such solicitation or hire, or whom the Participant was involved in recruiting while the Participant was employed by the Company.
(e)    Non-Disparagement. Subject to the limitations in Section 7(f) below, Participant agrees that he/she will not, nor will he/she cause or assist any other person to, make any statement to a third party or take any action which is intended to or would reasonably have the effect of disparaging or harming the Company or the business reputation of the Company’s directors, employees, officers, or managers, or make any verbal or written statement to any media outlet regarding the Company.
(f)    Agreement Limitations. Nothing in this Agreement prohibits Participant from (i) disclosing Workplace Conduct or the existence of a settlement involving Workplace Conduct that concerns conduct that Participant reasonably believes under state, federal, or common law to be illegal harassment, illegal retaliation, a wage & hour violation, or sexual assault, or that is recognized as against a clear mandate of public policy; (ii) disclosing Workplace Conduct that Participant has reason to believe is otherwise unlawful; or (iii) reporting possible violations of law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of any federal, state, or local law or regulation. “Workplace Conduct” means conduct occurring in the workplace, at work-related events coordinated by or through the Company, or between Employees, or between the Company and any Employee, off the workplace premises. Participant does not need the prior authorization of the Company to make any such reports or disclosures and Participant is not required to notify the Company that Participant has made such reports or disclosures. Disclosures protected by this Section may include a disclosure of trade secret information provided that it must comply with the restrictions in the Defend Trade Secrets Act of 2016 (DTSA). The DTSA provides that no individual will be held criminally or civilly liable under Federal or State trade secret law for the disclosure of a trade secret that: (i) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and made solely for the purpose of reporting or investigating a suspected violation of law; or, (ii) is made in a complaint or other document if such filing is under seal so that it is not made public. Also, an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order. If Participant is covered by Section 7 of the National Labor Relations Act (NLRA) because Participant is not in a supervisor or management role, nothing in this Agreement shall prohibit Participant from using information Participant acquires regarding the wages, benefits, or other terms and conditions of employment at the Company for any purpose protected under the NLRA.
(g) Assignment of Intellectual Property. Participant agrees that he or she is expected to use his or her inventive and creative capacities for the benefit of the Company and to contribute, where possible, to the Company’s intellectual property in the ordinary course of employment.

6

2024 Stock Option


(i) “Inventions” mean any inventions, discoveries, improvements, designs, processes, machines, products, innovations, business methods or systems, know how, ideas or concepts, and related technologies or methodologies, whether or not shown or described in writing or reduced to practice and whether patentable or not. “Works” mean original works of authorship, including, but not limited to: literary works (including all written material), mask works, computer programs, formulas, tests, notes, data compilations, databases, artistic and graphic works (including designs, graphs, drawings, blueprints, and other works), recordings, models, photographs, slides, motion pictures, and audio visual works; whether copyrightable or not, and regardless of the form or manner in which documented or recorded. “Trademarks” mean any trademarks, service marks, trade dress or names, symbols, special wording, or devices used to identify a business or its business activities whether subject to trademark protection or not. The foregoing terms are collectively referred to herein as “Intellectual Property.”
(ii) Participant assigns to the Company or its nominee Participant’s entire right, title and interest in and to all Inventions that are made, conceived, or reduced to practice by Participant, alone or jointly with others, during Participant’s employment with the Company (whether during working hours or not) that: (A) relate to the Company’s business or the Company’s actual or anticipated research or development; (B) involve the use or assistance of any tools, time, material, personnel, information, or facility of the Company; or (C) result from or relate to any work, services, or duties undertaken by Participant for the Company.

(iii) Participant recognizes that all Works and Trademarks conceived, created, or reduced to practice by Participant, alone or jointly with others, during Participant’s employment shall to the fullest extent permissible by law be considered the Company’s sole and exclusive property and “works made for hire” as defined in the U.S. Copyright Laws for purposes of United States law and the law of any other country adhering to the “works made for hire” or similar notion or doctrine, and will be considered the Company’s property from the moment of creation or conception forward for all purposes without the need for any further action or agreement by Participant or the Company. If any such Works, Trademarks, or portions thereof shall not be legally qualified as a works made for hire in the United States or elsewhere or shall subsequently be held to not be a work made for hire or not the exclusive property of the Company, Participant hereby assigns to the Company all of Participant’s rights, title, and interest, past, present, and future, to such Works or Trademarks. Participant will not engage in any unauthorized publication or use of such Company Works or Trademarks, nor will Participant use same to compete with or otherwise cause damage to the business interests of the Company.

(iv) It is the purpose and intent of this Section 7(g) to convey to the Company all of the rights (inclusive of moral rights) and interests of every kind, that Participant may hold in Inventions, Works, Trademarks, and other intellectual property that are covered by clauses (g)(i) through (g)(iii) above (“Company Intellectual Property”), past, present, and future; and Participant waives any right that Participant may have to assert moral rights or other claims contrary to the foregoing understanding. It is understood that this means that in addition to the original work product (be it invention, plan, idea, know how, concept, development, discovery, process, method, or any other legally recognized item that can be legally owned), the Company exclusively owns all rights in any and all derivative works, copies, improvements, patents, registrations, claims, or other embodiments of ownership or control arising or resulting from an item of assigned Company Intellectual Property everywhere such may arise throughout the world. The decision whether or not to commercialize or market any Company Intellectual Property is within the Company's sole discretion and for the Company’s sole benefit and no royalty will be due to Participant as a result of the Company's efforts to commercialize or market any such invention. In the event that there is any Invention, Work, Trademark, or other form of intellectual property that is incorporated into any product or service of the Company that Participant retains any ownership of or rights in despite the assignments created by this Agreement, then Participant hereby grants to the Company and its assigns a nonexclusive, perpetual, irrevocable, fully paid-up, royalty-free, worldwide license to the use and control of any such item that is so incorporated and any derivatives thereof, including all rights to make, use, sell, reproduce, display, modify, or distribute the item and its derivatives. All assignments of rights provided for in this Agreement are understood to be fully completed and immediately effective and enforceable assignments by Participant of all intellectual property rights in Company Intellectual Property. When requested to do so by the Company, either during or subsequent to employment with the Company, Participant will (A) execute all documents requested by the Company to affirm or effect the vesting in the Company of the entire right, title and interest in and to the Company Intellectual Property at issue, and all patent, trademark, and/or copyright applications filed or issuing on such property; (B) execute all documents requested by the Company for filing and obtaining of patents, trademarks and/or copyrights; and (C) provide assistance that the Company reasonably requires to protect its right, title and interest in
7

2024 Stock Option


the Company Intellectual Property, including, but not limited to, providing declarations and testifying in administrative and legal proceedings with regard to Company Intellectual Property.

(v) Power of Attorney: Participant hereby irrevocably appoints the Company as his or her agent and attorney in fact to execute any documents and take any action necessary for applications, registrations, or similar measures needed to secure the issuance of letters patent, copyright or trademark registration, or other legal establishment of the Company’s ownership and control rights in Company Intellectual Property in the event that Participant’s signature or other action is necessary and cannot be secured due to Participant’s physical or mental incapacity or for any other reason.

(vi) Participant will make and maintain, and not destroy, notes and other records related to the conception, creation, discovery, and other development of Company Intellectual Property. These records shall be considered the exclusive property of the Company and are covered by clauses (g)(i) through (g)(v) above. During employment and for a period of one (1) year thereafter, Participant will promptly disclose to the Company (without revealing the trade secrets of any third party) any Intellectual Property that Participant creates, conceives, or contributes to, alone or with others, that involve, result from, relate to, or may reasonably be anticipated to have some relationship to the line of business the Company is engaged in or its actual or anticipated research or development activity.

(vii) Participant will not claim rights in, or control over, any Invention, Work, or Trademark as something excluded from Section 7(g) because it was conceived or created prior to being employed by the Company (a “Prior Work”) unless such item is identified in reasonable detail in a separate writing, signed by Participant and sent to stock.admin@elevancehealth.com on or before the date Participant accepts this Agreement. Participant will not incorporate any such Prior Work into any work or product of the Company without prior written authorization from the Company to do so; and, if such incorporation does occur, Participant grants the Company and its assigns a nonexclusive, perpetual, irrevocable, fully paid-up, royalty-free, worldwide license to the use and control of any such item that is so incorporated and any derivatives thereof, including all rights to make, use, sell, reproduce, display, modify, or distribute the item and its derivatives.

(viii) The assignment provisions in this Section 7(g) are limited to only those inventions that lawfully can be assigned by an employee to an employer. Some examples of state laws limiting the scope of assignable inventions are Delaware Code Title 19 Section 805; Kansas Statutes Section 44-130; Minnesota Statutes 13A Section 181.78; North Carolina General Statutes Article 10A, Chapter 66, Commerce and Business, Section 66-57.1; Utah Code Sections 34-39-l through 34-39-3, "Employment Inventions Act"; and Washington Rev. Code, Title 49 RCW: Labor Regulations, Chapter 49.44.140. NOTICE: By accepting this Agreement, Participant acknowledges that to the extent one of the foregoing laws applies, Participant’s assignment pursuant to this Section 7(g) will not apply to an invention for which no equipment, supplies, facility, or trade secret information of the Company was used and which was developed entirely on Participant’s own time, unless: (A) the invention relates directly to the business of the Company or to the Company's actual or anticipated research or development; or (B) the invention results from any work performed by Participant for the Company. Similarly, to the extent California Labor Code Section 2870 or Illinois 765ILCS1060/1-3 "Participants Patent Act" controls, then the notice in the preceding sentence applies, absent the word “directly” in clause (A).

8.    Return of Consideration.
(a)If at any time Participant breaches any provision of this Agreement, then:
(i)All unexercised stock options under any Designated Plan (defined below) whether or not otherwise vested shall cease to be exercisable and shall immediately terminate;

(ii)Participant shall forfeit any outstanding restricted stock, restricted stock unit, or other outstanding equity award made under any Designated Plan and not otherwise vested on the date of breach; and

(iii)Participant shall pay to the Company (A) for each share of common stock of the Company (“Common Share”) acquired on exercise of an option under a Designated Plan within the 24
8

2024 Stock Option


months prior to such breach, the excess of the fair market value of a Common Share on the date of exercise over the exercise price, and (B) for each share of restricted stock, restricted stock unit and/or performance stock unit that became vested under any Designated Plan within the 24 months prior to such breach, the fair market value (on the date of vesting) of a Common Share.

Any amount to be repaid pursuant to this Section 8 shall be held by Participant in constructive trust for the benefit of the Company and shall, upon written notice from the Company, within 10 days of such notice, be paid by Participant to the Company. Any amount described in clauses (i) and (ii) that Participant forfeits as a result of a breach of the provisions of Section 7 shall not reduce any money damages that would be payable to the Company as compensation for such breach and shall not reduce or alter the Company’s ability to recover payment of severance based on Participant’s breach of a restrictive covenant in any severance plan or arrangement between the Company and Participant.
(b)The amount to be repaid pursuant to this Section shall be determined on a gross basis, without reduction for any taxes incurred or withheld, as of the date of the realization event, and without regard to any subsequent change in the fair market value of a Common Share. The Company shall have the right to offset such amount against any amounts otherwise owed to Participant by the Company (whether as wages, vacation pay, or pursuant to any benefit plan or other compensatory arrangement other than any amount pursuant to any nonqualified deferred compensation plan under Section 409A of the Code).
(c)    For purposes of this Section 8, a “Designated Plan” is each stock option, restricted stock, or other equity compensation or long-term incentive compensation plan under which Participant has received equity awards from the Company.
(d)    The return of consideration under this Section 8 is meant to reimburse the Company for some of the harm caused by Participant’s wrongful conduct; however, it is not a full measure of the damage caused by Participant’s conduct and does not preclude the Company from seeking the recovery of any and all damages caused by Participant and injunctive relief.
9.    Equitable Relief, Remedies, Reformation, Assignment, Jury Trial Waiver, and Miscellaneous
(a)Participant acknowledges that each provision of Sections 7 and 8 of this Agreement is reasonable and necessary to preserve the legitimate business interests of the Company, its present and potential business activities and the economic benefits derived therefrom; that they will not prevent him or her from earning a livelihood in Participant’s chosen business and are not an undue restraint on the trade of Participant, or any of the public interests which may be involved.
(b)Participant agrees that beyond the amounts otherwise to be provided under Section 8 this Agreement, the Company will be damaged by a violation of the terms of this Agreement and the amount of such damage may be difficult to measure. Participant agrees that if Participant commits or threatens to commit a breach of any of the covenants and agreements contained in Section 7 then, to the extent permitted by applicable law, the Company shall have the right to seek and obtain all appropriate injunctive and other equitable remedies, without posting bond therefor, except as required by law, in addition to any other rights and remedies that may be available at law or under this Agreement, it being acknowledged and agreed that any such breach would cause irreparable injury to the Company and that money damages would not provide an adequate remedy. Tolling: Further, if Participant violates Section 7 hereof Participant agrees that the period of violation shall be added to the period in which Participant’s activities are restricted.
(c)The parties agree that the covenants contained herein are severable. If an arbitrator or court shall hold that the duration, scope, area, or activity restrictions stated herein are unreasonable under circumstances then existing, or under applicable state law, the arbitrator or court shall reform or modify the restrictions or enforce the restrictions to such lesser extent as is allowed by law.
9

2024 Stock Option


(d)EACH PARTY, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AS TO ANY ISSUE RELATING HERETO IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT.
(e)In the event of a breach of this Agreement, the prevailing party shall be entitled to the recovery of its reasonable attorneys’ fees and expenses (including not only costs of court, but also expert fees, travel expenses, and other expenses incurred), and any other legal or equitable relief allowed by law.
(f)Nothing in this Agreement limits or reduces any common law or statutory duty Participant owes to the Company, nor does this Agreement limit or eliminate any remedies available to the Company for a violation of such duties. This Agreement will survive the expiration or termination of Participant’s employment with the Company and/or any assignee pursuant to Section 9(g) and shall, likewise, continue to apply and be valid notwithstanding any change in Participant’s duties, responsibilities, position, or title. Nothing in this Agreement creates a contract for term employment or limits either party’s right to end the employment relationship between them.
(g)This Agreement, including the restrictions on Participant’s activities set forth herein, also applies to any parent, subsidiary, affiliate, successor and assign of the Company to which Participant provides services or about which Participant receives Confidential Information. The Company shall have the right to assign this Agreement at its sole election without the need for further notice to or consent by Participant.
(h)This instrument and the Plan contain the entire agreement between the Parties with respect to the subject matter hereof (the grant contemplated by this Agreement). All representations, promises, and prior or contemporaneous understandings regarding this grant are merged into, and expressed in this instrument. If Participant is subject to a prior agreement (including any prior equity award agreement) with the Company containing confidentiality, non-solicitation, noncompetition and/or invention assignment provisions, then by accepting this agreement, Participant acknowledges and agrees that the confidentiality, non-solicitation, noncompetition, and/or invention assignment provisions of this Agreement (including but not limited to those set forth in Sections 7, 8, and 9 and Appendix A) shall supersede those in any such prior agreements and shall apply thereunder as if fully set forth therein. The preceding sentence shall not apply to supersede or otherwise invalidate any legally enforceable restrictive covenant of a longer duration than set forth herein, if such covenant was entered into in connection with the sale of a business. This Agreement shall not be amended, modified, or supplemented without the written agreement of the Parties at the time of such amendment, modification, or supplement and must be signed by an officer of the Company (unless such amendment, modification, or supplementation is by order of a court or arbitrator). The headings herein are for convenience only and shall not affect the terms of the Agreement.

10.    Survival of Provisions. The obligations contained in this Agreement shall survive the Termination of Participant’s employment with the Company and shall be fully enforceable thereafter.
11.    Cooperation. Upon the receipt of reasonable notice from the Company (including from outside counsel to the Company), Participant agrees that while employed by the Company and for two years (or, if longer, for so long as any claim referred to in this Section remains pending) after Participant’s Termination, Participant will respond and provide information with regard to matters in which Participant has knowledge as a result of Participant’s employment with the Company, and will provide reasonable assistance to the Company, its Affiliates and their respective representatives in defense of any claims that may be made against the Company or any Affiliate, and will assist the Company and any Affiliate in the prosecution of any claims that may be made by the Company or any Affiliate, to the extent that such claims may relate to the period of Participant’s employment with the Company (or any predecessor); provided, that with respect to periods after Participant’s Termination, the Company shall reimburse Participant for any out-of-pocket expenses incurred in providing such assistance and if Participant is required to provide more than ten (10) hours of assistance per week after his/her Termination then the Company shall pay Participant a reasonable amount of money for his/her services at a rate agreed to between the Company and Participant; and provided further that after Participant’s Termination such assistance shall not unreasonably interfere with Participant’s business or personal obligations. Participant agrees to promptly inform the Company if Participant becomes aware of any lawsuits involving such claims that may be filed or threatened against the Company or any Affiliate. Participant also agrees to promptly inform the Company (to the extent Participant is
10

2024 Stock Option


legally permitted to do so) if Participant is asked to assist in any investigation of the Company or any Affiliate (or their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company or any Affiliate with respect to such investigation and shall not do so unless legally required. Provided, however, that Participant is not required to inform the Company of any investigation by a governmental agency or entity resulting from the reporting of possible violations of federal securities law or regulation to any governmental agency or entity, and Participant may participate in such investigation, without informing the Company.
12.    No Right to Continued Employment. Neither the Options nor any terms contained in this Agreement shall confer upon Participant any express or implied right to be retained in the employment or service of the Company or any Affiliate for any period, nor restrict in any way the right of the Company, which right is hereby expressly reserved, to terminate Participant’s employment or service at any time for any reason, subject to applicable law. Participant acknowledges and agrees that any right to exercise the Option lapse is earned only by continuing as an Employee of the Company or an Affiliate or satisfaction of any other applicable terms and conditions contained in the Plan and this Agreement, and not through the act of being hired, being granted the Option, or acquiring Shares hereunder.
13.    The Plan. This Agreement is subject to all the terms, provisions, and conditions of the Plan, which are incorporated herein by reference, and to such regulations as may from time to time be adopted by the Committee. Unless defined herein, capitalized terms are as defined in the Plan. In the event of any conflict between the provisions of the Plan and this Agreement, the provisions of the Plan shall control, and this Agreement shall be deemed to be modified accordingly. The Plan and the prospectus describing the Plan can be found on the Company’s HR intranet. A paper copy of the Plan and the prospectus shall be provided to Participant upon Participant’s written request to the Company at Elevance Health, Inc., 220 Virginia Avenue, Indianapolis, Indiana 46204, Attention: Corporate Secretary, Shareholder Services Department.
14.    Compliance with Laws and Regulations.
(a)The Option and the obligation of the Company to sell and deliver Shares hereunder shall be subject in all respects to (i) all applicable Federal and state laws, rules, and regulations and (ii) any registration, qualification, approvals, or other requirements imposed by any government or regulatory agency or body which the Committee shall, in its discretion, determine to be necessary or applicable. Moreover, the Option may not be exercised if its exercise, or the receipt of Shares pursuant thereto, would be contrary to applicable law. If at any time the Company determines, in its discretion, that the listing, registration or qualification of Shares upon any national securities exchange or under any state or Federal law, or the consent or approval of any governmental regulatory body, is necessary or desirable, the Company shall not be required to deliver any certificates for Shares to Participant or any other person pursuant to this Agreement unless and until such listing, registration, qualification, consent or approval has been effected or obtained, or otherwise provided for, free of any conditions not acceptable to the Company.
(b)The Shares received upon the exercise of the Option shall have been registered under the Securities Act of 1933 (“Securities Act”). If Participant is an “affiliate” of the Company, as that term is defined in Rule 144 under the Securities Act (“Rule 144”), Participant may not sell the Shares received except in compliance with Rule 144. Certificates representing Shares issued to an “affiliate” of the Company may bear a legend setting forth such restrictions on the disposition or transfer of the Shares as the Company deems appropriate to comply with Federal and state securities laws.
(c)If at the time of exercise of all or part of the Option, the Shares are not registered under the Securities Act, and/or there is no current prospectus in effect under the Securities Act with respect to the Shares, Participant shall execute, prior to the delivery of any Shares to Participant by the Company pursuant to this Agreement, an agreement (in such form as the Company may specify) in which Participant represents and warrants that Participant is purchasing or acquiring the shares acquired under this Agreement for Participant's own account, for investment only and not with a view to the resale or distribution thereof, and represents and agrees that any subsequent offer for sale or distribution of any kind of such Shares shall be made only pursuant to either (i) a registration statement on an appropriate form under the Securities Act, which registration statement has become effective and is current with regard to the Shares being offered or sold, or (ii) a specific exemption from the
11

2024 Stock Option


registration requirements of the Securities Act, but in claiming such exemption Participant shall, prior to any offer for sale of such Shares, obtain a prior favorable written opinion, in form and substance satisfactory to the Company, from counsel for or approved by the Company, as to the applicability of such exemption thereto.
15.    Notices. All notices by Participant or Participant’s assignees shall be addressed to Elevance Health, Inc., 220 Virginia Avenue, Indianapolis, Indiana 46204, Attention: Stock Administration, or such other address as the Company may from time to time specify. All notices to Participant shall be addressed to Participant at Participant’s address in the Company's records.
16.    Other Plans. Participant acknowledges that any income derived from the exercise of the Option shall not affect Participant’s participation in, or benefits under, any other benefit plan or other contract or arrangement maintained by the Company or any Affiliate.
17.    Recoupment Policy for Incentive Compensation. The Company's Recoupment Policy for Incentive Compensation, as may be amended from time to time, shall apply to the Option, any Shares acquired upon exercise of the Option and any profits realized from the sale of such Shares to the extent that Participant is covered by such policy. If Participant is covered by such policy, the policy may apply to recoup the Option, any Shares acquired upon exercise of the Option or profits realized from the sale of Shares previously covered by the Option either before, on or after the date on which Participant becomes subject to such policy.
ELEVANCE HEALTH, INC.
By:      _____________________________
Printed: Ramiro G. Peru
Its:     Chair, Compensation and Talent Committee of the Board of Directors


12

2024 Stock Option


APPENDIX A

Alabama:
If Alabama law is deemed to apply, then the following applies to Participant: (a) Section 7(d) is rewritten as follows: “While employed and for a period of twelve (12) months from Termination, Participant will not participate in soliciting any Covered Employee of the Company who is in a Sensitive Position to leave the employment of the Company on behalf of (or for the benefit of) a Competitor nor will Participant knowingly assist a Competitor in efforts to hire a Covered Employee away from the Company.  As used in this Section 7(d), a “Covered Employee” is an Employee with whom Participant worked, as to whom Participant had supervisory responsibilities, or regarding which Participant received Confidential Information during the Look Back Period. An Employee in a “Sensitive Position” refers to an Employee who is uniquely essential to the management, organization, or service of the business;” and (b) Section 7(c) is limited to prohibiting the solicitation of persons or entities who have a current business relationship with the Company.

Arizona:
If Arizona law is deemed to apply, then the following applies to Participant: (a) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret; and (b) the restrictions in Section 7(c) shall be limited to the Restricted Territory.

Arkansas, Connecticut, Montana, and South Carolina:
If Arkansas, Connecticut, Montana, or South Carolina law is deemed to apply, then the following applies to Participant: Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.

California:
If California law is deemed to apply, then the following applies to Participant: (a) the noncompetition restriction in Section 7(b) shall not apply; (b) the Employee non-solicitation restrictions in Section 7(d) shall not apply; and (c) Section 7(c) shall be limited to situations where Participant is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law). The preceding sentence supersedes any contradictory provision in any prior agreements between Participant and the Company regarding noncompetition or non-solicitation.

Colorado:
If Colorado law is deemed to apply, then the following applies to Participant:

(a) Section 7(b) shall apply only if Participant earns Annualized Cash Compensation equivalent to or greater than the Threshold Amount for Highly Compensated Workers and to the extent that the conduct in violation of Section 7(b) is aided by Participant’s use or disclosure of the Company’s trade secrets.
(b) Section 7(c) shall apply only if Participant earns Annualized Cash Compensation equivalent to or greater than sixty percent (60%) of the Threshold Amount for Highly Compensated Workers and to the extent that the conduct in violation of Section 7(c) is aided by Participant’s use or disclosure of the Company’s trade secrets.
(c) Section 7(d) shall not apply.
(d) “Annualized Cash Compensation” means: (1) the amount of gross salary or wage amount, the fee amount, or other compensation amount for the full year, if the worker was employed or engaged for a full year; or (2) the compensation that the worker would have earned, based on the worker’s gross salary or wage amount, fee, or other compensation if the worker was not employed or engaged for a full year. In determining whether a worker’s cash compensation exceeds the threshold amount, where the worker has been employed for less than a calendar year, the
13

2024 Stock Option


worker’s cash compensation exceeds the threshold amount if the worker would reasonably expect to earn more than the threshold amount during a calendar year of employment.
(e) “Threshold Amount for Highly Compensated Workers” means the greater of the threshold amount for highly compensated workers as determined by the Division of Labor Standards and Statistics in the Department of Labor and Employment, as of August 10, 2022 or the date Participant accepts this Agreement.
(f) Nothing contained in this Agreement shall be construed to prohibit Participant from disclosing information that: (1) arises from Participant’s general training, knowledge, skill, or experience, whether gained on the job or otherwise; (2) is readily ascertainable to the public; or (3) a worker otherwise has a right to disclose as legally protected conduct.
(g) Participant acknowledges that Participant received notice of this Agreement (including, but not limited to, the provisions of Section 7: (1) before Participant accepted the Company’s offer of employment (if Participant is a new hire); or (2) at least fourteen (14) days before the earlier of (I) Participant’s acceptance of this Agreement, or (II) the effective date of any additional compensation or change in the terms or conditions of employment that provides consideration for the covenants in Section 7.
Georgia:
If Participant resides in Georgia and is subject to Georgia law, then Section 7(d) shall be limited to targeting for solicitation or hire Employees who are located within the Restricted Territory.

Illinois:
If Participant resides in Illinois and is subject to Illinois law, then:
(a) The provisions of Section 7(c) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $45,000 per year in 2022-2026, $47,500 per year in 2027-2031, $50,000 per year in 2032-2036, and $52,500 beginning on January 1, 2037;
(b) The provisions of Section 7(d) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $45,000 per year in 2022-2026, $47,500 per year in 2027-2031, $50,000 per year in 2032-2036, and $52,500 beginning on January 1, 2037;
(c) The provisions of Section 7(b) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $75,000 per year in 2022-2026, $80,000 per year in 2027-2031, $85,000 per year in 2032-2036, and $90,000 beginning on January 1, 2037;
d) The provisions of Section 7(b) shall not apply if Participant is covered by a collective bargaining agreement under the Illinois Public Relations Act;

(e) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret;
(f) Participant acknowledges that Participant has been advised to consult with an attorney about this Agreement and has been given an opportunity to do so; and
(g) If Participant is a new hire, Participant acknowledges that Participant has been provided a copy of this Agreement at least 14 calendar days before the commencement of employment. If Participant is an existing Employee, Participant acknowledges that Participant has been given at least 14 calendar days to review this Agreement.
Indiana:
If Participant resides in Indiana and is subject to Indiana law, then the restrictions on Participant under Section 7(d) shall apply only with respect to soliciting, hiring, attempting to solicit or hire, or participating in any attempt to solicit or hire individuals who themselves had access to Confidential Information in the prior six months.
Louisiana:
If Louisiana law is deemed to apply, then the following applies to Participant: (a) the “Restricted Territory” defined in Section 7 of the Agreement is understood to cover the following parishes in Louisiana and all counties outside
14

2024 Stock Option


Louisiana where Participant had responsibilities for the Company: Acadia, Allen, Ascension, Assumption, Avoyelles, Beauregard, Bienville, Bossier, Caddo, Calcasieu, Caldwell, Cameron, Catahoula, Claiborne, Concordia, DeSoto, East Baton Rouge, East Carroll, East Feliciana, Evangeline, Franklin, Grant, Iberia, Iberville, Jackson, Jefferson, Jefferson Davis, LaSalle, Lafayette, Lafourche, Lincoln, Livingston, Madison, Morehouse, Natchitoches, Orleans, Ouachita, Plaquemines, Pointe Coupee, Rapides, Red River, Richland, Sabine, St. Bernard, St. Charles, St. Helena, St. James, St. John The Baptist, St. Landry, St. Martin, St. Mary, St. Tammany, Tangipahoa, Tensas, Terrebonne, Union, Vermilion, Vernon, Washington, Webster, West Baton Rouge, West Carroll, West Feliciana, Winn; and (b) the restrictions in Section 7(c) (as well as Section 7(b)) shall be limited to the foregoing parishes and counties.
Maine:
If Maine law is deemed to apply, then the following applies to Participant: (a) Participant acknowledges that if Participant is a new hire Participant received a copy of this Agreement prior to receiving a formal offer of employment from the Company and was given at least three business days to consider the Agreement before signing; (b) Section 7(b) will not take effect until one year of employment or a period of six months from the date the agreement is signed, whichever is later; and (c) Section 7(b) shall not apply if Participant earns at or below 400% of the federal poverty level.
Maryland:
If Maryland law is deemed to apply, then the following applies to Participant: Section 7(b) shall not apply if Participant earns equal to or less than $15/hour or $31,200 annually.
Massachusetts:
If Participant resides or works in Massachusetts for at least the thirty days preceding Participant’s Termination, then the Company will notify Participant within ten (10) business days of Participant’s Termination whether the Company decides to waive Section 7(b) or make these provisions enforceable by paying Participant garden leave as provided by the Massachusetts Noncompetition Agreement Act, G.L. c. 149, S. 24L. In addition, if Massachusetts law is deemed to apply, then the following applies to Participant:

(a) Section 7(b) will not apply if Participant’s employment is terminated without “cause” or if Participant is terminated as part of a reduction in force. Participant further understands that for the limited purpose of the application of the non-competition clause in Section 7(b) of the Agreement, “cause” to terminate Participant’s employment exists if Participant has (i) committed, admitted committing, or plead guilty to a felony or crime involving moral turpitude, fraud, theft, misappropriation, or dishonesty, (ii) violated a material term of this Agreement or Company policy, (iii) engaged in insubordination, or failed or refused to perform assigned duties of Participant’s position despite reasonable opportunity to perform, (iv) failed to exercise reasonable care and diligence in the exercise of Participant’s duties for the Company, or (iv) engaged in conduct or omissions that Participant knew, or should have known (with the exercise of reasonable care), would cause, or be likely to cause, harm to the Company or its reputation in the business community;

(b) Participant acknowledges that Participant has been advised to consult with an attorney about this Agreement and has been given an opportunity to do so;

(c) the Restricted Period applicable to Section 7(b) shall be limited to a period of one year following Participant’s Termination (as well as while Participant is employed by the Company); however, if Participant breaches Section 7(b) of this Agreement, and also breaches Participant’s fiduciary duty to the Company and/or has unlawfully taken, physically or electronically, any Company records, then such Restricted Period shall be extended to a period of two (2) years from Termination;

(d) Participant acknowledges that (i) if Participant is being initially hired by the Company, that Participant received a copy of this Agreement prior to receiving a formal offer of employment from the Company or at least ten (10) business days before commencement of Participant’s employment by the Company, whichever came first; or (ii) if Participant was already employed by the Company at the time of signing this Agreement, that Participant was provided a copy hereof at least ten (10) business days before the effective date of this Agreement;

15

2024 Stock Option


(e) the tolling language Section 10(b) shall only apply to any breach of Section 7(c) and (d) (i.e., the tolling language shall not apply to Section 7(b)); and

(f) Section 7(b) shall not apply to Participant following Termination if Participant is: classified as non-exempt under the FLSA; 18 years or younger; or an undergraduate or graduate student in an internship or other short-term employment relationship while enrolled in college or graduate school.
Minnesota:
If Minnesota law is deemed to apply, then the restrictions in Section 7(b) shall be limited to situations in which Participant is aided in his or her conduct by the use or disclosure of Confidential Information.

Nebraska:
If Nebraska law is deemed to apply, then the following applies to Participant: (a) Section 7(c) is limited to the solicitation of persons or entities with which Participant did business and had personal business-related contact during the Look Back Period; and (b) Section 7(b) is limited to restricting Participant from working for a Company client or account with whom the Participant did business and had personal business-related contact during the Look Back Period.

Nevada:
If Nevada law is deemed to apply, then the following applies to Participant: (a) Section 7 does not preclude Participant from providing services to any former client or customer of the Company if: (1) Participant did not solicit the former customer or client; (2) the customer or client voluntarily chose to leave and seek services from Participant; and (3) Participant is otherwise complying with the limitations in this Agreement as to time and scope of activity to be restrained; and (b) Section 7(b) does not apply if Participant is paid solely an hourly wage, exclusive of tips or gratuities.
New Hampshire:
If New Hampshire law is deemed to apply, then the following applies to Participant: (a) Section 7(b) does not apply if Participant earns an hourly rate less than or equal to 200 percent of the federal minimum wage; and (b) Participant acknowledges that Participant was given a copy of this Agreement prior to a change in job classification or the offer of employment.
New York:
If New York law is deemed to apply, then the following applies to Participant: Section 7(c) shall be modified to exclude those clients or customers who became a client or customer of the Company as a result of Participant’s independent contact and business development efforts with the customer or client prior to and independent from his/her employment with the Company.
North Carolina:
If North Carolina law is deemed to apply, then the following applies to Participant: (a) the Look Back Period shall be calculated looking back twenty-four (24) months from the date of enforcement and not from the date Participant’s employment ends; and (b) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.
North Dakota:
If North Dakota law is deemed to apply, then the following applies to Participant: (a) the noncompetition restriction in Section 7(b) shall not apply; and (b) Section 7(c) shall be limited to situations where Participant is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law).
Oklahoma:
If Oklahoma law is deemed to apply, then the following applies to Participant: (i) Section 7(c) is limited to preclude only the direct solicitation of established customers of the Company for the purpose of doing any business that would compete with the Company’s business; and (ii) the noncompetition restrictions in Section 7(b) shall not apply.

16

2024 Stock Option


Oregon:
If Oregon law is deemed to apply, then the following applies to Participant: the restrictions in Section 7(b) shall apply only if: (a) Participant is engaged in administrative, executive or professional work and performs predominantly intellectual, managerial, or creative tasks, exercises discretion and independent judgment and earns a salary or is otherwise exempt from Oregon's minimum wage and overtime laws; (b) the Company has a "protectable interest" (meaning, access to trade secrets or competitively sensitive confidential business or professional information); and (c) the total amount of Participant's annual gross salary and commission, calculated on an annual basis, at the time of Participant's Termination, exceeds $100,533 adjusted annually for inflation pursuant to the Consumer Price Index for All Urban Consumers, West Region (All Items), as published by the Bureau of Labor Statistics of the United States Department of Labor immediately preceding the calendar year of Participant’s Termination. However, if Participant does not meet requirements of either (a) or (c) (or both), the Company may, on a case-by-case basis, decide to make Section 7(b) enforceable as to Participant (as allowed by Oregon law), by agreeing in writing to pay Participant, during the period of time Participant is restrained from competing, the greater of: (i) compensation equal to at least 50 percent of Participant’s annual gross base salary and commissions at the time of Termination; or (ii) fifty percent of $100,533 adjusted annually for inflation pursuant to the Consumer Price Index for All Urban Consumers, West Region (All Items), as published by the Bureau of Labor Statistics of the United States Department of Labor immediately preceding the calendar year of Participant’s Termination. If Participant is an existing Employee, Participant acknowledges that this Agreement was entered into upon a subsequent bona fide advancement of Participant by the Company; namely the Company is conferring upon Participant equity awards that, if accepted by Participant, will supplement Participant’s compensation.

Puerto Rico:
If Puerto Rico law is deemed to apply, then the following applies to Participant: (a) the Restricted Period and the Look Back Period in Section 7 shall be, in each case, only a period of twelve (12) months; (b) the Restricted Territory shall be limited to the territory of Puerto Rico; (c) the customer restriction in Section 7(c) shall be limited to clients, accounts, and medical care providers that were personally serviced by Participant during the Look Back Period and had an active business relationship with the Company within the last thirty (30) days prior to Participant’s Termination; and (d) the tolling provision in Section 10(b) shall not apply.

Rhode Island:
If Rhode Island law is deemed to apply, then Section 7(b) shall not apply to Participant following Termination if Participant is: classified as non-exempt under the FLSA; an undergraduate or graduate student in an internship or short-term employment relationship; 18 years of age or younger; or a low wage Participant (defined as earning less than 250% of the federal poverty level).

Utah:
If Utah law is deemed to apply, then the following applies to Participant: (a) the Restricted Period applicable to Section 7(b) shall be limited to a period of one year following Termination (as well as while Participant is employed by the Company).

Virginia:
If Virginia law is deemed to apply, then the following applies to Participant: (a) Section 7(b)-(d) shall not apply if Participant is a “low wage Participant.” A “low wage Participant” refers to a Participant whose average weekly earnings (calculated by dividing Participant's earnings during the period of 52 weeks immediately preceding Termination by 52, or if Participant worked fewer than 52 weeks, by the number of weeks that Participant was actually paid during the 52-week period) are less than the average weekly wage of the Commonwealth of Virginia as determined pursuant to subsection B of Virginia Code § 65.2-500. "Low-wage Participant" includes interns, students, apprentices, or trainees employed, with or without pay, at a trade or occupation in order to gain work or educational experience. "Low-wage Participant" also includes an individual who has independently contracted with another person to perform services independent of an employment relationship and who is compensated for such services by such person at an hourly rate that is less than the median hourly wage for the Commonwealth of Virginia for all occupations as reported, for the preceding year, by the Bureau of Labor Statistics of the U.S. Department of Labor. However, "low-wage Participant" does not include any Participant whose earnings are derived, in whole or in predominant part, from sales commissions, incentives, or bonuses paid to Participant by the Company; (b) Section
17

2024 Stock Option


7 does not preclude Participant from providing services to any client or customer of the Company if Participant did not initiate contact with or solicit the former customer or client; and (c) Participant’s nondisclosure obligation in Section 7(a) shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.

Washington (state):
If Participant resides in Washington at the time this Agreement is entered, Participant acknowledges that Participant was given at least ten (10) business days to consider this Agreement before accepting it.
In addition, if Washington law controls, then for so long as Washington law controls, the Agreement will be modified and applied as follows:
(a) Section 7(b) shall apply following Termination only if Participant’s annualized earnings from the Company exceed $100,000.00 per year (adjusted annually in accordance with Section 5 of Washington HP 1450), and Section 7(b) shall apply during employment only if Participant earns at least twice the Washington minimum hourly wage (subject to the common law duty of loyalty and the Company’s Code of Conduct);
(b) for purposes of the application of the non-competition provision in Section 7(b), Participant understands that the non-competition provision will not be enforced against Participant if Participant is terminated from employment without “cause” or if Participant is laid off, unless the Company pays Participant during the Restricted Period an amount equal to Participant’s base salary at Termination less any compensation earned by Participant during the Restricted Period. Participant further understands that for the limited purpose of the application of the non-competition clause in Section 7(b) of the Agreement, “cause” to terminate Participant’s employment exists if Participant has (i) committed, admitted committing, or plead guilty to a felony or crime involving moral turpitude, fraud, theft, misappropriation, or dishonesty, (ii) violated a material term of this Agreement or Company policy, (iii) engaged in insubordination, or failed or refused to perform assigned duties of my position despite reasonable opportunity to perform, (iv) failed to exercise reasonable care and diligence in the exercise of Participant’s duties for the Company, or (iv) engaged in conduct or omissions that Participant knew, or should have known (with the exercise of reasonable care), would cause, or be likely to cause, harm to the Company or its reputation in the business community; and
(c) Participant further acknowledges that if Participant is a new Employee, Participant has had advance notice of the terms of this Agreement prior to accepting the Company’s offer of employment.
Washington, D.C.
Participant acknowledges that Participant was given a copy of Washington, D.C., Council Bill 24-256 (“Bill 24-256”) prior to or contemporaneously with accepting this Agreement.
If Participant is a “Covered Employee” as defined by Bill 24-256 and Participant is not a “Highly Compensated Employee,” as defined by Bill 24-256, the following applies to Participant: (1) Section 7(b) shall not apply; (2) “Confidential Information” shall, in all instances, be limited to information owned or possessed by the Company which is not available to the general public and which the Company has taken reasonable steps to ensure is protected from improper disclosure; (3) Participant is precluded, during Participant’s employment with the Company, from accepting money or a thing of value for performing work for a person other than the Company, where doing so can reasonably be concluded to result in (a) Participant’s disclosure or use of Confidential Information or “Proprietary employer information,” as defined by Bill 24-256; (b) a conflict with the Company’s established rules regarding conflicts of interest, or (c) impairment of the Company’s ability to comply with federal law, the law of the District of Columbia, or a contract or grant agreement.
If Participant is a “Covered Participant” as defined by Bill 24-256 and Participant is a “Highly Compensated Participant,” as defined by Bill 24-256, the following applies to Participant: (1) Participant acknowledges that
18

2024 Stock Option


Participant was given a copy of this Agreement at least 14 days before Participant commenced employment with the Company (if Participant is a new hire) or Participant was given a copy of this Agreement at least 14 days before Participant was required to accept this Agreement (if Participant is an existing Employee); (2) “Confidential Information” shall, in all instances, be limited to information owned or possessed by the Company which is not available to the general public and which the Company has taken reasonable steps to ensure is protected from improper disclosure; (3) the Restricted Period for purposes of the non-competition provision in Section 7(b) shall be limited to a period of twelve (12) months following Termination (and while Participant is employed by the Company); and (4) Participant is notified that The District of Columbia Ban on Non-Compete Agreements Amendment Act of 2020 limits the use of non-compete agreements. It allows employers to request non-compete agreements from “highly compensated employees” under certain conditions. The Company has determined that you are a highly compensated employee. For more information about the Ban on Non-Compete Agreements Amendment Act of 2020, contact the District of Columbia Department of Employment Services (DOES).

Wisconsin:
If Wisconsin law is deemed to apply, then the following applies to Participant: (a) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret; (b) the tolling provision in Section 10(b) shall not apply; and (c) Section 7(d) is rewritten as follows: “While employed and for a period of twelve (12) months following Termination, Participant will not participate in soliciting any “Covered Employee” of the Company that is in a “Sensitive Position” to leave the employment of the Company on behalf of (or for the benefit of) a Competitor; nor will Participant knowingly assist a Competitor in efforts to hire a Covered Employee away from the Company.  As used in this Section 7(d), a “Covered Employee” is an Employee with whom Participant worked, as to whom Participant had supervisory responsibilities, or regarding whom Participant received Confidential Information during the Look Back Period. A Participant in a “Sensitive Position” refers to an Employee who is in a management, supervisory, sales, research and development, or similar role where the Employee is provided Confidential Information or is involved in business dealings with the Company’s clients.”

19

2024 Stock Option

 EX-10.2Q 3 exhibit102qrsuagreement.htm EX-10.2 (Q) Document
EXHIBIT 10.2(q)

Schedule A
Notice of Restricted Stock Unit Grant

Participant:[●]
Company:Elevance Health, Inc.
Notice:You have been granted the following award of restricted stock units of common stock of the Company in accordance with the terms of the Plan and the attached Restricted Stock Unit Award Agreement.
Plan:2017 Elevance Health Incentive Compensation Plan
Grant:
Grant Date: [●]
Grant Number: [●]
Number of Restricted Stock Units: [●]
Period of Restriction:The Period of Restriction applicable to the number of your Restricted Stock Units listed in the “Shares” column below, and any related Dividend Equivalents, shall commence on the Grant Date and shall lapse on the date listed in the “Lapse Date” column below.
SharesLapse Date
[●][●]
[●][●]
[●][●]
In the event that a Change of Control (as defined in the Plan) occurs before your Termination (as defined in the Plan), your Restricted Stock Unit Grant will remain subject to the terms of this Agreement, unless the successor company does not assume the Restricted Stock Unit Grant. If the successor company does not assume the Restricted Stock Unit Grant, then the Period of Restriction shall immediately lapse upon a Change of Control and the Shares covered by the award shall be delivered as soon as practicable following the Change of Control, provided that in the event that the Restricted Stock Unit Grant is deferred compensation within the meaning of Code Section 409A, such Shares shall only be delivered upon the Change of Control if such Change of Control is a “change in control event” within the meaning of Code Section 409A and the delivery is made in accordance with Treasury Regulation 1-409A-3(j)(ix).
Acceptance:
In order to accept your Restricted Stock Units, you must electronically accept this Agreement through the Company’s broker at any time within ninety (90) days after the Grant Date. To effect your acceptance, please follow the instructions included with your grant materials. Acceptance of the Agreement includes acceptance of the terms and conditions of the Plan. If you do not timely and electronically accept this Agreement, this Agreement will be null and void at the end of the 90th day after the Grant Date and you will have no right or claim to the Restricted Stock Units described above.

1
2024 LTIP Restricted Stock Unit


Restricted Stock Unit Award Agreement
This Restricted Stock Unit Award Agreement (this “Agreement”) dated as of the Grant Date (the “Grant Date”) set forth in the Notice of Restricted Stock Unit Grant attached as Schedule A hereto (the “Grant Notice”) is made between Elevance Health, Inc. (the “Company”) and the Participant set forth in the Grant Notice. The Grant Notice is included in and made part of this Agreement. The Company and Participant expressly agree and acknowledge that Participant’s entry into this Agreement is not a condition of Participant’s employment with the Company, and that Participant is not required to enter into this Agreement or accept Restricted Stock Units as a condition of Participant’s employment with the Company or a Subsidiary or Affiliate. Capitalized terms not defined herein or in the Grant Notice are defined in the Plan.
1.Period of Restriction. The Period of Restriction with respect to the Restricted Stock Units shall be as set forth in the Grant Notice (the “Period of Restriction”). Participant acknowledges that prior to the expiration of the applicable portion of the Period of Restriction, the Restricted Stock Units may not be sold, transferred, pledged, assigned, encumbered, alienated, hypothecated, or otherwise disposed of (whether voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy)). Upon the expiration of the applicable portion of the Period of Restriction described in the attached Grant Notice, the restrictions set forth in this Agreement with respect to the Restricted Stock Units theretofore subject to such expired Period of Restriction shall lapse and the Shares covered by the related portion of the award shall be delivered as soon as practicable thereafter, except as may be provided in other sections of this Agreement.
2.Ownership. Upon expiration of the applicable portion of the Period of Restriction described in the attached Grant Notice, the Company shall transfer the Shares covered by the related portion of the award to Participant’s account with the Company’s captive broker.
3.Termination.
(a)Retirement. If Participant’s Termination is due to Retirement (for purposes of this Agreement, defined as Participant’s Termination after attaining age fifty-five (55) with at least ten (10) completed years of service or after attaining age sixty-five (65)), the restrictions upon the Restricted Stock Units shall continue to lapse throughout the Period of Restriction and the Shares covered by the related portion of the Restricted Stock Units shall continue to be delivered upon the applicable Lapse Date; provided, however, that if Participant’s Termination due to Retirement is during the calendar year of the Grant Date, the Restricted Stock Units shall be forfeited on a pro-rata basis, measured by the number of completed full months in that calendar year during which Participant was employed by the Company or an Affiliate (e.g., if Participant’s Retirement occurs in September, 33.3% (or 4/12) of the Restricted Stock Units will be forfeited), and the Period of Restriction on the non-forfeited portion of the Restricted Stock Units shall continue to lapse throughout the Period of Restriction described in the attached Grant Notice and the Shares covered by the related portion of the Restricted Stock Units shall continue to be delivered upon the applicable Lapse Date.1
(b)Death and Disability. If Participant’s Termination is due to death or Disability (for purposes of this Agreement, as defined in the applicable Elevance Health Long-Term Disability Plan), then the Period of Restriction shall immediately lapse, causing any restrictions which would otherwise remain on the Restricted Stock Units to immediately lapse, and the Shares covered by the Restricted Stock Units shall be delivered as soon as practicable thereafter.
(c)Without Cause or for Good Reason. Unless 3(a) is applicable, if Participant’s Termination is by the Company or an Affiliate without Cause (for purposes of this Agreement, defined as a violation of “conduct” as such term is defined in the Elevance Health HR Corrective Action Policy and if Participant participates in the Elevance Health Executive Agreement Plan (the "Agreement Plan"), the Key Associate Agreement or the Key Sales Associate Agreement also as defined in that plan or agreement) and Participant is
1 This retirement provision is deleted in non-annual retention grants.
2
2024 LTIP Restricted Stock Unit


receiving severance (or similar post-termination compensation in connection with a termination) under any severance plan of, or agreement with, the Company or an Affiliate and any portion of the Period of Restriction has not lapsed as of Participant’s Termination, the Period of Restriction shall continue to lapse through the earlier of (A) the last day of the period for which Participant is receiving such severance/compensation or (B) the last Lapse Date in the schedule set forth in the Grant Notice. The foregoing shall also apply to a Participant who participates in the Agreement Plan and receives severance under the Agreement Plan for a termination by Participant for Good Reason (as defined in the Agreement Plan).

(d)Other Terminations. If Participant’s Termination is (i) by the Company or an Affiliate for Cause even if on the date of such Termination Participant has met the definition of Retirement or Disability or (ii) by Participant for any reason other than death, Disability, Retirement, or Good Reason as described in Section 3(c), then all Restricted Stock Units for which the Period of Restriction had not lapsed prior to the date of such Termination shall be immediately forfeited.
(e) Termination after Change of Control. Notwithstanding any other provision of this Agreement, including Section 3(c), if after a Change of Control Participant’s Termination is (i) by the Company or an Affiliate without Cause (for purposes of this Agreement, defined as a violation of “conduct” as such term is defined in the Elevance Health HR Corrective Action Policy and if Participant participates in the Agreement Plan, the Key Associate Agreement or the Key Sales Associate Agreement also as defined in that plan or agreement) or (ii) if Participant participates in the Agreement Plan, by Participant for Good Reason (as defined in the Agreement Plan), then the Period of Restriction on all Restricted Stock Units shall immediately lapse, causing any restrictions which would otherwise remain on the Restricted Stock Units to immediately lapse and the Shares covered by the Restricted Stock Units shall be delivered as soon as practicable thereafter. Notwithstanding any provision of this Agreement to the contrary, in the event that the restrictions on any Restricted Stock Units lapse under any provision of this Section 3 by reason of any Termination and such Termination occurs within the two year period following a Change of Control that is a “change in control event” within the meaning of Code Section 409A, the Shares subject to Participant’s Restricted Stock Units shall be delivered to Participant upon such Termination.
4.Transferability of the Restricted Stock Units. Participant shall have the right to appoint any individual or legal entity in writing, in accordance with procedures established by the Company’s broker, to receive any Restricted Stock Units (to the extent not previously terminated or forfeited) under this Agreement upon Participant’s death, to the extent permitted by law. The effectiveness of any such designation, and any revocation or replacement thereof, shall be determined in accordance with procedures established by the Company’s broker. If Participant dies without such designation, the Restricted Stock Units will become part of Participant’s estate.
5.Dividend Equivalents. In the event the Company declares a dividend on Shares (as defined in the Plan), for each unvested Restricted Stock Unit on the dividend payment date, Participant shall be credited with a Dividend Equivalent, payable in cash, with a value equal to the value of the declared dividend. The Dividend Equivalents shall be subject to the same restrictions as the unvested Restricted Stock Units to which they relate. No interest or other earnings shall be credited on the Dividend Equivalents. Subject to continued employment with the Company and Affiliates in accordance with Section 3, the restrictions with respect to the Dividend Equivalents shall lapse at the same time and in the same proportion as the restrictions on the initial award of Restricted Stock Units. No additional Dividend Equivalents shall be accrued for Participant’s benefit with respect to record dates occurring prior to the Grant Date, or with respect to record dates occurring on or after the date, if any, on which Participant has forfeited the Restricted Stock Units, or any Restricted Stock Units have been settled. If Participant is a “specified employee” within the meaning of Code Section 409A, payment of any Dividend Equivalents subject to Code Section 409A and payable upon a termination of employment shall be subject to a six-month delay. The Dividend Equivalents shall be subject to all such other provisions set forth herein and may be used to satisfy any or all obligations for the payment of any tax attributable to the Dividend Equivalents and/or Restricted Stock Units.
6.Taxes and Withholdings. Upon the expiration of the applicable portion of the Period of Restriction (and delivery of the underlying Shares), or as of which the value of any Restricted Stock Units first becomes includible in Participant’s gross income for income tax purposes, Participant shall satisfy all obligations for
3
2024 LTIP Restricted Stock Unit


the payment of any tax attributable to the Restricted Stock Units. Participant shall notify the Company if Participant wishes to pay the Company in cash, check or with shares of Elevance Health common stock already owned for the satisfaction of any taxes of any kind required by law to be withheld with respect to such Restricted Stock Units. Any such election made by Participant must be irrevocable, made in writing, signed by Participant, and shall be subject to any restrictions or limitations that the Compensation and Talent Committee of the Board of Directors of the Company (“Committee”), in its sole discretion, deems appropriate. If Participant does not notify the Company in writing at least 14 days prior to the Lapse Date of the applicable portion of the Period of Restriction, the Committee is authorized to take any such other action as may be necessary or appropriate, as determined by the Committee, to satisfy all obligations for the payment of such taxes. Such other actions may include withholding the required amounts from other compensation payable to Participant, a sell-to-cover transaction or such other method determined by the Committee, in its discretion. Please refer to the Plan’s prospectus for tax considerations by jurisdiction.
7.Restrictive Covenants. For purposes of Sections 7, 8, and 9 of this Agreement, Company shall mean Elevance Health, Inc. and its Subsidiaries and Affiliates. Participant acknowledges that Participant has the right to consult with counsel at Participant’s sole expense. As a condition to receipt of the Restricted Stock Unit Grant made under this Agreement, which Participant and the Company agree is fair and reasonable consideration, Participant agrees as follows, subject to any applicable provisions of Appendix A:
(a)Confidentiality.
(i)Participant recognizes that the Company derives substantial economic value from information created and used in its business which is not generally known by the public, including, but not limited to, plans, designs, concepts, computer programs, formulae, and equations; product fulfillment and supplier information; customer and supplier lists, and confidential business practices of the Company and any of its customers, vendors, business partners or suppliers; profit margins and the prices and discounts the Company obtains or has obtained or at which it sells or has sold or plans to sell its products or services (except for public pricing lists); manufacturing, assembling, labor and sales plans and costs; business and marketing plans, ideas, or strategies; confidential financial performance and projections; employee compensation; employee staffing and recruiting plans and employee personal information; and other confidential concepts and ideas related to the Company’s business (collectively, “Confidential Information”). Participant expressly acknowledges and agrees that by virtue of his/her employment with the Company, Participant will have access to and will use in the course of Participant’s duties certain Confidential Information and that Confidential Information constitutes trade secrets and confidential and proprietary business information of the Company, all of which is the exclusive property of the Company. For purposes of this Agreement, Confidential Information includes, but is not limited to, information that constitutes a trade secret under applicable state or federal law. Confidential Information does not include information that Participant establishes by clear and convincing evidence is or may become known to Participant or to the public from sources outside the Company and through means other than a breach of this Agreement.
(ii)Participant agrees that Participant will not for himself or herself or for any other person or entity, directly or indirectly, without the prior written consent of the Company, while employed by the Company and thereafter: (A) use Confidential Information for the benefit of any person or entity other than the Company or its affiliates; (B) remove, copy, duplicate or otherwise reproduce any document or tangible item embodying or pertaining to any of the Confidential Information, except as required to perform Participant’s duties for the Company or its affiliates; or (C) while employed and thereafter, publish, release, disclose or deliver or otherwise make available to any third party any Confidential Information by any communication, including oral, documentary, electronic or magnetic information transmittal device or media. Upon Termination, Participant shall return all Confidential Information and all other property of the Company. This obligation of non-disclosure and non-use of information shall continue to exist for so long as such information remains Confidential Information.
(b)Non-Competition. During any period in which Participant is employed by the Company, and during a period of time after Participant’s Termination (the “Restriction Period”) which, unless otherwise limited by applicable state law, is (i) twenty-four (24) months for Executive Vice Presidents and the President & Chief Executive Officer, and (ii) the greater of the period of severance or twelve (12) months for all
4
2024 LTIP Restricted Stock Unit


other Participants, Participant will not, without prior written consent of the Company, directly or through the direction or control of others, obtain a Competitive Position or perform a Restricted Activity in the Restricted Territory for a Competitor, as those terms are defined herein.
(i)Competitive Position means any employment or performance of services with a Competitor (A) the same as or similar to the services that Participant performed for the Company in the last twenty-four (24) months of Participant’s employment with Company (the “Look Back Period”), or (B) in the performance of which Participant will likely use any Confidential Information of the Company.
(ii)Restricted Territory means any geographic area in which the Company does business and which Participant provided services in, had responsibility for, had a material presence or influence in, or had access to Confidential Information about, such business, within the Look Back Period.
(iii)Restricted Activity means any activity for which Participant had responsibility for the Company or about which Participant had Confidential Information within the Look Back Period.
(iv)Competitor means any entity or individual (other than the Company) engaged in any one or more of the following: management of network-based managed care plans and programs; administration of managed care services; provision of health insurance, long-term care insurance, dental, life, or disability insurance; administration of flexible spending accounts, COBRA continuation coverage, coordination of benefits, or subrogation services; or the provision, delivery, or administration of health benefit plans or health care services such as pharmacy benefits management (including Specialty pharmacy), value-based care delivery, behavioral health, palliative care, care for chronic and complex conditions, digital healthcare platforms, medical benefits management solutions, or health care research (including health economics and outcomes); or any other aspects of the business or products or services offered by the Company, as to which Participant had responsibilities or received Confidential Information about, during the Look Back Period.
(v)The restrictions contained in this subsection (b) shall not apply to attorneys who accept a Competitive Position that consists of practicing law.
(vi)If Participant receives an offer of a Competitive Position with a Competitor, as those terms are defined above, Participant shall notify the Company’s Chief Human Resources Officer, via the contact information provided in the award brochure, within five business days of receiving the offer and such notification shall include a detailed description of the job responsibilities and the identity of the Competitor. The description must be specific enough for the Company to determine whether Participant’s new opportunity constitutes a violation of the Agreement.
(c)    Non-Solicitation of Customers. During any period in which Participant is employed by the Company, and during the Restriction Period after Participant’s Termination, Participant will not, either individually or as an employee, partner, consultant, independent contractor, owner, agent, or in any other capacity, directly or through the direction or control of others, for a Competitor of the Company as defined in subsection (b) above:
(i)    Solicit business from any client, account, or medical care provider of the Company that Participant had contact with, participated in contact with, had or shared responsibility for, or had access to Confidential Information about, during the Look Back Period; or
(ii)    solicit business from any client, account, or medical care provider that the Company pursued, and Participant had contact with, responsibility for, or knowledge of Confidential Information about, by reason of Participant’s employment with the Company, during the Look Back Period.
For purposes of this paragraph (c), an individual policyholder in a plan maintained by the Company or by a client or account of the Company under which individual policies are issued, or a certificate holder in such plan under which group policies are issued, shall not be considered a client or account subject to this restriction solely by reason of being such a policyholder or certificate holder.
5
2024 LTIP Restricted Stock Unit


(d)    Non-Solicitation of Employees. During any period in which Participant is employed by the Company, and during the Restriction Period after Participant’s Termination, Participant will not, either individually or as an employee, partner, independent contractor, owner, agent, or in any other capacity, directly or indirectly, solicit, hire, attempt to solicit or hire, or participate in any attempt to solicit or hire, for any non-Company entity:
(i)Any officer or employee of the Company whom Participant knows to have access to or possession of Confidential Information that would give an unfair advantage to a Competitor;
(ii)Any officer or employee of the Company who, on or at any time during the six (6) months immediately preceding the date of such solicitation or hire, held the position of Director or above with the Company;
(iii)Any officer or employee of the Company to whom Participant reported, or who reported to Participant, on or at any time during the six (6) months immediately preceding the dates of such solicitation or hire; or
(iv)Any person who is or was an officer or employee of the Company during the six (6) months immediately preceding the date of such solicitation or hire, or whom the Participant was involved in recruiting while the Participant was employed by the Company.
(e)    Non-Disparagement. Subject to the limitations in Section 7(f) below, Participant agrees that he/she will not, nor will he/she cause or assist any other person to, make any statement to a third party or take any action which is intended to or would reasonably have the effect of disparaging or harming the Company or the business reputation of the Company’s directors, employees, officers, or managers, or make any verbal or written statement to any media outlet regarding the Company.
(f)    Agreement Limitations. Nothing in this Agreement prohibits Participant from (i) disclosing Workplace Conduct or the existence of a settlement involving Workplace Conduct that concerns conduct that Participant reasonably believes under state, federal, or common law to be illegal harassment, illegal retaliation, a wage & hour violation, or sexual assault, or that is recognized as against a clear mandate of public policy; (ii) disclosing Workplace Conduct that Participant has reason to believe is otherwise unlawful; or (iii) reporting possible violations of law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of any federal, state, or local law or regulation. “Workplace Conduct” means conduct occurring in the workplace, at work-related events coordinated by or through the Company, or between Employees, or between the Company and any Employee, off the workplace premises. Participant does not need the prior authorization of the Company to make any such reports or disclosures and Participant is not required to notify the Company that Participant has made such reports or disclosures. Disclosures protected by this Section may include a disclosure of trade secret information provided that it must comply with the restrictions in the Defend Trade Secrets Act of 2016 (DTSA). The DTSA provides that no individual will be held criminally or civilly liable under Federal or State trade secret law for the disclosure of a trade secret that: (i) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and made solely for the purpose of reporting or investigating a suspected violation of law; or, (ii) is made in a complaint or other document if such filing is under seal so that it is not made public. Also, an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order. If Participant is covered by Section 7 of the National Labor Relations Act (NLRA) because Participant is not in a supervisor or management role, nothing in this Agreement shall prohibit Participant from using information Participant acquires regarding the wages, benefits, or other terms and conditions of employment at the Company for any purpose protected under the NLRA.

6
2024 LTIP Restricted Stock Unit


(g)    Assignment of Intellectual Property. Participant agrees that he or she is expected to use his or her inventive and creative capacities for the benefit of the Company and to contribute, where possible, to the Company’s intellectual property in the ordinary course of employment.
(i)    “Inventions” mean any inventions, discoveries, improvements, designs, processes, machines, products, innovations, business methods or systems, know how, ideas or concepts, and related technologies or methodologies, whether or not shown or described in writing or reduced to practice and whether patentable or not. “Works” mean original works of authorship, including, but not limited to: literary works (including all written material), mask works, computer programs, formulas, tests, notes, data compilations, databases, artistic and graphic works (including designs, graphs, drawings, blueprints, and other works), recordings, models, photographs, slides, motion pictures, and audio visual works; whether copyrightable or not, and regardless of the form or manner in which documented or recorded. “Trademarks” mean any trademarks, service marks, trade dress or names, symbols, special wording, or devices used to identify a business or its business activities whether subject to trademark protection or not. The foregoing terms are collectively referred to herein as “Intellectual Property.”
(ii)    Participant assigns to the Company or its nominee Participant’s entire right, title and interest in and to all Inventions that are made, conceived, or reduced to practice by Participant, alone or jointly with others, during Participant’s employment with the Company (whether during working hours or not) that: (A) relate to the Company’s business or the Company’s actual or anticipated research or development; (B) involve the use or assistance of any tools, time, material, personnel, information, or facility of the Company; or (C) result from or relate to any work, services, or duties undertaken by Participant for the Company.
(iii)    Participant recognizes that all Works and Trademarks conceived, created, or reduced to practice by Participant, alone or jointly with others, during Participant’s employment shall to the fullest extent permissible by law be considered the Company’s sole and exclusive property and “works made for hire” as defined in the U.S. Copyright Laws for purposes of United States law and the law of any other country adhering to the “works made for hire” or similar notion or doctrine, and will be considered the Company’s property from the moment of creation or conception forward for all purposes without the need for any further action or agreement by Participant or the Company. If any such Works, Trademarks, or portions thereof shall not be legally qualified as a works made for hire in the United States or elsewhere or shall subsequently be held to not be a work made for hire or not the exclusive property of the Company, Participant hereby assigns to the Company all of Participant’s rights, title, and interest, past, present, and future, to such Works or Trademarks. Participant will not engage in any unauthorized publication or use of such Company Works or Trademarks, nor will Participant use same to compete with or otherwise cause damage to the business interests of the Company.
(iv)    It is the purpose and intent of this Section 7(g) to convey to the Company all of the rights (inclusive of moral rights) and interests of every kind, that Participant may hold in Inventions, Works, Trademarks, and other intellectual property that are covered by clauses (g)(i) through (g)(iii) above (“Company Intellectual Property”), past, present, and future; and Participant waives any right that Participant may have to assert moral rights or other claims contrary to the foregoing understanding. It is understood that this means that in addition to the original work product (be it invention, plan, idea, know how, concept, development, discovery, process, method, or any other legally recognized item that can be legally owned), the Company exclusively owns all rights in any and all derivative works, copies, improvements, patents, registrations, claims, or other embodiments of ownership or control arising or resulting from an item of assigned Company Intellectual Property everywhere such may arise throughout the world. The decision whether or not to commercialize or market any Company Intellectual Property is within the Company's sole discretion and for the Company’s sole benefit and no royalty will be due to Participant as a result of the Company's efforts to commercialize or market any such invention. In the event that there is any Invention, Work, Trademark, or other form of intellectual property that is incorporated into any product or service of the Company that Participant retains any ownership of or rights in despite the assignments created by this Agreement, then Participant hereby grants to the Company and its assigns a nonexclusive, perpetual, irrevocable, fully paid-up, royalty-free, worldwide license to the use and control of any
7
2024 LTIP Restricted Stock Unit


such item that is so incorporated and any derivatives thereof, including all rights to make, use, sell, reproduce, display, modify, or distribute the item and its derivatives. All assignments of rights provided for in this Agreement are understood to be fully completed and immediately effective and enforceable assignments by Participant of all intellectual property rights in Company Intellectual Property. When requested to do so by the Company, either during or subsequent to employment with the Company, Participant will (A) execute all documents requested by the Company to affirm or effect the vesting in the Company of the entire right, title and interest in and to the Company Intellectual Property at issue, and all patent, trademark, and/or copyright applications filed or issuing on such property; (B) execute all documents requested by the Company for filing and obtaining of patents, trademarks and/or copyrights; and (C) provide assistance that the Company reasonably requires to protect its right, title and interest in the Company Intellectual Property, including, but not limited to, providing declarations and testifying in administrative and legal proceedings with regard to Company Intellectual Property.
(v)    Power of Attorney: Participant hereby irrevocably appoints the Company as his or her agent and attorney in fact to execute any documents and take any action necessary for applications, registrations, or similar measures needed to secure the issuance of letters patent, copyright or trademark registration, or other legal establishment of the Company’s ownership and control rights in Company Intellectual Property in the event that Participant’s signature or other action is necessary and cannot be secured due to Participant’s physical or mental incapacity or for any other reason.
(vi)    Participant will make and maintain, and not destroy, notes and other records related to the conception, creation, discovery, and other development of Company Intellectual Property. These records shall be considered the exclusive property of the Company and are covered by clauses (g)(i) through (g)(v) above. During employment and for a period of one (1) year thereafter, Participant will promptly disclose to the Company (without revealing the trade secrets of any third party) any Intellectual Property that Participant creates, conceives, or contributes to, alone or with others, that involve, result from, relate to, or may reasonably be anticipated to have some relationship to the line of business the Company is engaged in or its actual or anticipated research or development activity.
(vii)    Participant will not claim rights in, or control over, any Invention, Work, or Trademark as something excluded from Section 7(g) because it was conceived or created prior to being employed by the Company (a “Prior Work”) unless such item is identified in reasonable detail in a separate writing, signed by Participant and sent to stock.admin@elevancehealth.com on or before the date Participant accepts this Agreement. Participant will not incorporate any such Prior Work into any work or product of the Company without prior written authorization from the Company to do so; and, if such incorporation does occur, Participant grants the Company and its assigns a nonexclusive, perpetual, irrevocable, fully paid-up, royalty-free, worldwide license to the use and control of any such item that is so incorporated and any derivatives thereof, including all rights to make, use, sell, reproduce, display, modify, or distribute the item and its derivatives.
(viii)    The assignment provisions in this Section 7(g) are limited to only those inventions that lawfully can be assigned by an employee to an employer. Some examples of state laws limiting the scope of assignable inventions are Delaware Code Title 19 Section 805; Kansas Statutes Section 44-130; Minnesota Statutes 13A Section 181.78; North Carolina General Statutes Article 10A, Chapter 66, Commerce and Business, Section 66-57.1; Utah Code Sections 34-39-l through 34-39-3, "Employment Inventions Act"; and Washington Rev. Code, Title 49 RCW: Labor Regulations, Chapter 49.44.140. NOTICE: By accepting this Agreement, Participant acknowledges that to the extent one of the foregoing laws applies, Participant’s assignment pursuant to this Section 7(g) will not apply to an invention for which no equipment, supplies, facility, or trade secret information of the Company was used and which was developed entirely on Participant’s own time, unless: (A) the invention relates directly to the business of the Company or to the Company's actual or anticipated research or development; or (B) the invention results from any work performed by Participant for the Company. Similarly, to the extent California Labor Code Section 2870 or Illinois 765ILCS1060/1-3 "Participants Patent Act" controls, then the notice in the preceding sentence applies, absent the word “directly” in clause (A).
8
2024 LTIP Restricted Stock Unit



8.    Return of Consideration.

(a)If at any time Participant breaches any provision of this Agreement, then:
(i)All unexercised stock options under any Designated Plan (defined below) whether or not otherwise vested shall cease to be exercisable and shall immediately terminate;
(ii)Participant shall forfeit any outstanding restricted stock, restricted stock unit, or other outstanding equity award made under any Designated Plan and not otherwise vested on the date of breach; and
(iii)Participant shall pay to the Company (A) for each share of common stock of the Company (“Common Share”) acquired on exercise of an option under a Designated Plan within the 24 months prior to such breach, the excess of the fair market value of a Common Share on the date of exercise over the exercise price, and (B) for each share of restricted stock, restricted stock unit and/or performance stock unit that became vested under any Designated Plan within the 24 months prior to such breach, the fair market value (on the date of vesting) of a Common Share.
Any amount to be repaid pursuant to this Section 8 shall be held by Participant in constructive trust for the benefit of the Company and shall, upon written notice from the Company, within 10 days of such notice, be paid by Participant to the Company. Any amount described in clauses (i) and (ii) that Participant forfeits as a result of a breach of the provisions of Section 7 shall not reduce any money damages that would be payable to the Company as compensation for such breach and shall not reduce or alter the Company’s ability to recover payment of severance based on Participant’s breach of a restrictive covenant in any severance plan or arrangement between the Company and Participant.
(b)The amount to be repaid pursuant to this Section shall be determined on a gross basis, without reduction for any taxes incurred or withheld, as of the date of the realization event, and without regard to any subsequent change in the fair market value of a Common Share. The Company shall have the right to offset such amount against any amounts otherwise owed to Participant by the Company (whether as wages, vacation pay, or pursuant to any benefit plan or other compensatory arrangement other than any amount pursuant to any nonqualified deferred compensation plan under Section 409A of the Code).
(c)For purposes of this Section 8, a “Designated Plan” is each stock option, restricted stock, or other equity compensation or long-term incentive compensation plan under which Participant has received equity awards from the Company.
(d)The return of consideration under this Section 8 is meant to reimburse the Company for some of the harm caused by Participant’s wrongful conduct; however, it is not a full measure of the damage caused by Participant’s conduct and does not preclude the Company from seeking the recovery of any and all damages caused by Participant and injunctive relief.
9.    Equitable Relief, Remedies, Reformation, Assignment, Jury Trial Waiver, and Miscellaneous
(a)Participant acknowledges that each provision of Sections 7 and 8 of this Agreement is reasonable and necessary to preserve the legitimate business interests of the Company, its present and potential business activities, and the economic benefits derived therefrom; that they will not prevent him or her from earning a livelihood in Participant’s chosen business and are not an undue restraint on the trade of Participant, or any of the public interests which may be involved.
(b)Participant agrees that beyond the amounts otherwise to be provided under Section 8 this Agreement, the Company will be damaged by a violation of the terms of this Agreement and the
9
2024 LTIP Restricted Stock Unit


amount of such damage may be difficult to measure. Participant agrees that if Participant commits or threatens to commit a breach of any of the covenants and agreements contained in Section 7 then, to the extent permitted by applicable law, the Company shall have the right to seek and obtain all appropriate injunctive and other equitable remedies, without posting bond therefor, except as required by law, in addition to any other rights and remedies that may be available at law or under this Agreement, it being acknowledged and agreed that any such breach would cause irreparable injury to the Company and that money damages would not provide an adequate remedy. Tolling: Further, if Participant violates Section 7 hereof Participant agrees that the period of violation shall be added to the period in which Participant’s activities are restricted.
(c)The parties agree that the covenants contained herein are severable. If an arbitrator or court shall hold that the duration, scope, area, or activity restrictions stated herein are unreasonable under circumstances then existing, or under applicable state law, the arbitrator or court shall reform or modify the restrictions or enforce the restrictions to such lesser extent as is allowed by law.
(d)EACH PARTY, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AS TO ANY ISSUE RELATING HERETO IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT.
(e)In the event of a breach of this Agreement, the prevailing party shall be entitled to the recovery of its reasonable attorneys’ fees and expenses (including not only costs of court, but also expert fees, travel expenses, and other expenses incurred), and any other legal or equitable relief allowed by law.
(f)Nothing in this Agreement limits or reduces any common law or statutory duty Participant owes to the Company, nor does this Agreement limit or eliminate any remedies available to the Company for a violation of such duties. This Agreement will survive the expiration or termination of Participant’s employment with the Company and/or any assignee pursuant to Section 9(g) and shall, likewise, continue to apply and be valid notwithstanding any change in Participant’s duties, responsibilities, position, or title. Nothing in this Agreement creates a contract for term employment or limits either party’s right to end the employment relationship between them.
(g)This Agreement, including the restrictions on Participant’s activities set forth herein, also applies to any parent, subsidiary, affiliate, successor and assign of the Company to which Participant provides services or about which Participant receives Confidential Information. The Company shall have the right to assign this Agreement at its sole election without the need for further notice to or consent by Participant.
(h)This instrument and the Plan contain the entire agreement between the Parties with respect to the subject matter hereof (the grant contemplated by this Agreement). All representations, promises, and prior or contemporaneous understandings regarding this grant are merged into, and expressed in this instrument. If Participant is subject to a prior agreement (including any prior equity award agreement) with the Company containing confidentiality, non-solicitation, noncompetition and/or invention assignment provisions, then by accepting this Agreement, Participant acknowledges and agrees that the confidentiality, non-solicitation, noncompetition, and/or invention assignment provisions of this Agreement (including but not limited to those set forth in Sections 7, 8, and 9 and Appendix A) shall supersede those in any such prior agreements and shall apply thereunder as if fully set forth therein. The preceding sentence shall not apply to supersede or otherwise invalidate any legally enforceable restrictive covenant of a longer duration than set forth herein, if such covenant was entered into in connection with the sale of a business. This Agreement shall not be amended, modified, or supplemented without the written agreement of the Parties at the time of such amendment, modification, or supplement and must be signed by an officer of the Company (unless such amendment, modification, or supplementation is by order of a court or arbitrator). The headings herein are for convenience only and shall not affect the terms of the Agreement.

10.    Survival of Provisions. The obligations contained in this Agreement shall survive Participant’s Termination according to their terms and shall be fully enforceable thereafter.

10
2024 LTIP Restricted Stock Unit


11.    Cooperation. Upon the receipt of reasonable notice from the Company (including from outside counsel to the Company), Participant agrees that while employed by the Company and for two years (or, if longer, for so long as any claim referred to in this Section remains pending) after Participant’s Termination, Participant will respond and provide information with regard to matters in which Participant has knowledge as a result of Participant’s employment with the Company, and will provide reasonable assistance to the Company, its Affiliates and their respective representatives in defense of any claims that may be made against the Company or any Affiliate, and will assist the Company and any Affiliate in the prosecution of any claims that may be made by the Company or any Affiliate, to the extent that such claims may relate to the period of Participant’s employment with the Company (or any predecessor); provided, that with respect to periods after Participant’s Termination, the Company shall reimburse Participant for any out-of-pocket expenses incurred in providing such assistance and if Participant is required to provide more than ten (10) hours of assistance per week after his/her Termination then the Company shall pay Participant a reasonable amount of money for his/her services at a rate agreed to between the Company and Participant; and provided further that after Participant’s Termination such assistance shall not unreasonably interfere with Participant’s business or personal obligations. Participant agrees to promptly inform the Company if Participant becomes aware of any lawsuits involving such claims that may be filed or threatened against the Company or any Affiliate. Participant also agrees to promptly inform the Company (to the extent Participant is legally permitted to do so) if Participant is asked to assist in any investigation of the Company or any Affiliate (or their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company or any Affiliate with respect to such investigation and shall not do so unless legally required. Provided, however, that Participant is not required to inform the Company of any investigation by a governmental agency or entity resulting from the reporting of possible violations of federal securities law or regulation to any governmental agency or entity, and Participant may participate in such investigation, without informing the Company.

12.    No Rights as a Shareholder. Participant shall have no rights of a shareholder (including, without limitation, dividend and voting rights) with respect to the Restricted Stock Units, for record dates occurring on or after the Grant Date and prior to the date any such Restricted Stock Units vest in accordance with this Agreement.
13.    No Right to Continued Employment. Neither the Restricted Stock Units nor any terms contained in this Agreement shall confer upon Participant any express or implied right to be retained in the employment or service of the Company or any Affiliate for any period, nor restrict in any way the right of the Company, which right is hereby expressly reserved, to terminate Participant’s employment or service at any time for any reason, subject to applicable law. Participant acknowledges and agrees that any right to have restrictions on the Restricted Stock Units lapse is earned only by continuing as an Employee of the Company or an Affiliate or satisfaction of any other applicable terms and conditions contained in the Plan and this Agreement, and not through the act of being hired, being granted the Restricted Stock Units, or acquiring Shares hereunder.
14.    The Plan. This Agreement is subject to all the terms, provisions, and conditions of the Plan, which are incorporated herein by reference, and to such regulations as may from time to time be adopted by the Committee. Unless defined herein, capitalized terms are as defined in the Plan. In the event of any conflict between the provisions of the Plan and this Agreement, the provisions of the Plan shall control, and this Agreement shall be deemed to be modified accordingly. The Plan and the prospectus describing the Plan can be found on the Company’s HR intranet. A paper copy of the Plan and the prospectus shall be provided to Participant upon Participant’s written request to the Company at Elevance Health, Inc., 220 Virginia Avenue, Indianapolis, Indiana 46204, Attention: Corporate Secretary, Shareholder Services Department.
15.    Compliance with Laws and Regulations.
(a)The Restricted Stock Units and the obligation of the Company to deliver Shares hereunder shall be subject in all respects to (i) all applicable Federal and state laws, rules, and regulations and (ii) any registration, qualification, approvals, or other requirements imposed by any government or regulatory agency or body which the Committee shall, in its discretion, determine to be necessary or applicable. Moreover, the Company shall not deliver any certificates for Shares to Participant or any other person pursuant to this Agreement if doing so would be contrary to applicable law. If at any time the Company determines, in its discretion, that the listing, registration or qualification of Shares upon any national securities exchange or under any state or Federal law, or the
11
2024 LTIP Restricted Stock Unit


consent or approval of any governmental regulatory body, is necessary or desirable, the Company shall not be required to deliver any certificates for Shares to Participant or any other person pursuant to this Agreement unless and until such listing, registration, qualification, consent or approval has been effected or obtained, or otherwise provided for, free of any conditions not acceptable to the Company.


(b)The Shares received upon the expiration of the applicable portion of the Period of Restriction shall have been registered under the Securities Act of 1933 (“Securities Act”). If Participant is an “affiliate” of the Company, as that term is defined in Rule 144 under the Securities Act (“Rule 144”), Participant may not sell the Shares received except in compliance with Rule 144. Certificates representing Shares issued to an “affiliate” of the Company may bear a legend setting forth such restrictions on the disposition or transfer of the Shares as the Company deems appropriate to comply with Federal and state securities laws.
(c)If, at any time, the Shares are not registered under the Securities Act, and/or there is no current prospectus in effect under the Securities Act with respect to the Shares, Participant shall execute, prior to the delivery of any Shares to Participant by the Company pursuant to this Agreement, an agreement (in such form as the Company may specify) in which Participant represents and warrants that Participant is purchasing or acquiring the shares acquired under this Agreement for Participant’s own account, for investment only and not with a view to the resale or distribution thereof, and represents and agrees that any subsequent offer for sale or distribution of any kind of such Shares shall be made only pursuant to either (i) a registration statement on an appropriate form under the Securities Act, which registration statement has become effective and is current with regard to the Shares being offered or sold, or (ii) a specific exemption from the registration requirements of the Securities Act, but in claiming such exemption Participant shall, prior to any offer for sale of such Shares, obtain a prior favorable written opinion, in form and substance satisfactory to the Company, from counsel for or approved by the Company, as to the applicability of such exemption thereto.
16.    Code Section 409A Compliance. Except with respect to Participants who are Retirement eligible or become Retirement eligible before the calendar year containing the second Lapse Date as shown on the Grant Notice, it is intended that this Agreement meet the short-term deferral exception from Code Section 409A. This Agreement and the Plan shall be administered in a manner consistent with this intent and any provision that would cause the Agreement or Plan to fail to satisfy this exception shall have no force and effect. Notwithstanding anything contained herein to the contrary, Shares in respect of any Restricted Stock Units that (a) constitute “nonqualified deferred compensation” as defined under Code Section 409A and (b) vest as a consequence of Participant’s Termination shall not be delivered until the date that Participant incurs a “separation from service” within the meaning of Code Section 409A (or, if Participant is a “specified employee” within the meaning of Code Section 409A and the regulations promulgated thereunder, the date that is six months following the date of such “separation from service” (or death, if earlier)). In addition, each amount to be paid or benefit to be provided to Participant pursuant to this Agreement that constitutes deferred compensation subject to Code Section 409A, shall be construed as a separate identified payment for purposes of Code Section 409A.
17.    Notices. All notices by Participant or Participant’s assignees shall be addressed to Elevance Health, Inc., 220 Virginia Avenue, Indianapolis, Indiana 46204, Attention: Stock Administration, or such other address as the Company may from time to time specify. All notices to Participant shall be addressed to Participant at Participant’s address in the Company’s records.
18.    Other Plans. Participant acknowledges that any income derived from the Restricted Stock Units shall not affect Participant’s participation in, or benefits under, any other benefit plan or other contract or arrangement maintained by the Company or any Affiliate.
19.    Recoupment Policy for Incentive Compensation. The Company's Recoupment Policy for Incentive Compensation, as may be amended from time to time, shall apply to the Restricted Stock Units, any Shares delivered hereunder, and any profits realized on the sale of such Shares to the extent that Participant is covered by such policy. If Participant is covered by such policy, the policy may apply to recoup Restricted Stock
12
2024 LTIP Restricted Stock Unit


Units awarded, any Shares delivered hereunder or profits realized on the sale of such Shares either before, on or after the date on which Participant becomes subject to such policy.
    
ELEVANCE HEALTH, INC.
    
By:        
            ______________________________
        Printed:    Ramiro G. Peru
        Its:    Chair, Compensation and Talent Committee
                            of the Board of Directors


    

13
2024 LTIP Restricted Stock Unit


APPENDIX A
Alabama:
If Alabama law is deemed to apply, then the following applies to Participant: (a) Section 7(d) is rewritten as follows: “While employed and for a period of twelve (12) months from Termination, Participant will not participate in soliciting any Covered Employee of the Company who is in a Sensitive Position to leave the employment of the Company on behalf of (or for the benefit of) a Competitor nor will Participant knowingly assist a Competitor in efforts to hire a Covered Employee away from the Company.  As used in this Section 7(d), a “Covered Employee” is an Employee with whom Participant worked, as to whom Participant had supervisory responsibilities, or regarding which Participant received Confidential Information during the Look Back Period. An Employee in a “Sensitive Position” refers to an Employee who is uniquely essential to the management, organization, or service of the business;” and (b) Section 7(c) is limited to prohibiting the solicitation of persons or entities who have a current business relationship with the Company.
Arizona:
If Arizona law is deemed to apply, then the following applies to Participant: (a) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret; and (b) the restrictions in Section 7(c) shall be limited to the Restricted Territory.
Arkansas, Connecticut, Montana, and South Carolina:
If Arkansas, Connecticut, Montana, or South Carolina law is deemed to apply, then the following applies to Participant: Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.
California:
If California law is deemed to apply, then the following applies to Participant: (a) the noncompetition restriction in Section 7(b) shall not apply; (b) the Employee non-solicitation restrictions in Section 7(d) shall not apply; and (c) Section 7(c) shall be limited to situations where Participant is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law). The preceding sentence supersedes any contradictory provision in any prior agreements between Participant and the Company regarding noncompetition or non-solicitation.

Colorado:
If Colorado law is deemed to apply, then the following applies to Participant:
(a) Section 7(b) shall apply only if Participant earns Annualized Cash Compensation equivalent to or greater than the Threshold Amount for Highly Compensated Workers and to the extent that the conduct in violation of Section 7(b) is aided by Participant’s use or disclosure of the Company’s trade secrets.
(b) Section 7(c) shall apply only if Participant earns Annualized Cash Compensation equivalent to or greater than sixty percent (60%) of the Threshold Amount for Highly Compensated Workers and to the extent that the conduct in violation of Section 7(c) is aided by Participant’s use or disclosure of the Company’s trade secrets.
(c) Section 7(d) shall not apply.




14
2024 LTIP Restricted Stock Unit


(d) “Annualized Cash Compensation” means: (1) the amount of gross salary or wage amount, the fee amount, or other compensation amount for the full year, if the worker was employed or engaged for a full year; or (2) the compensation that the worker would have earned, based on the worker’s gross salary or wage amount, fee, or other compensation if the worker was not employed or engaged for a full year. In determining whether a worker’s cash compensation exceeds the threshold amount, where the worker has been employed for less than a calendar year, the worker’s cash compensation exceeds the threshold amount if the worker would reasonably expect to earn more than the threshold amount during a calendar year of employment.

(e) “Threshold Amount for Highly Compensated Workers” means the greater of the threshold amount for highly compensated workers as determined by the Division of Labor Standards and Statistics in the Department of Labor and Employment, as of August 10, 2022, or the date Participant accepts this Agreement.
(f) Nothing contained in this Agreement shall be construed to prohibit Participant from disclosing information that: (1) arises from Participant’s general training, knowledge, skill, or experience, whether gained on the job or otherwise; (2) is readily ascertainable to the public; or (3) a worker otherwise has a right to disclose as legally protected conduct.
(g) Participant acknowledges that Participant received notice of this Agreement (including, but not limited to, the provisions of Section 7: (1) before Participant accepted the Company’s offer of employment (if Participant is a new hire); or (2) at least fourteen (14) days before the earlier of (I) Participant’s acceptance of this Agreement, or (II) the effective date of any additional compensation or change in the terms or conditions of employment that provides consideration for the covenants in Section 7.
Georgia:
If Participant resides in Georgia and is subject to Georgia law, then Section 7(d) shall be limited to targeting for solicitation or hire Employees who are located within the Restricted Territory.

Illinois:
If Participant resides in Illinois and is subject to Illinois law, then:
(a) The provisions of Section 7(c) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $45,000 per year in 2022-2026, $47,500 per year in 2027-2031, $50,000 per year in 2032-2036, and $52,500 beginning on January 1, 2037;
(b) The provisions of Section 7(d) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $45,000 per year in 2022-2026, $47,500 per year in 2027-2031, $50,000 per year in 2032-2036, and $52,500 beginning on January 1, 2037;
(c) The provisions of Section 7(b) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $75,000 per year in 2022-2026, $80,000 per year in 2027-2031, $85,000 per year in 2032-2036, and $90,000 beginning on January 1, 2037;
(d) The provisions of Section 7(b) shall not apply if Participant is covered by a collective bargaining agreement under the Illinois Public Relations Act;
(e) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret;
(f) Participant acknowledges that Participant has been advised to consult with an attorney about this Agreement and has been given an opportunity to do so; and
(g) If Participant is a new hire, Participant acknowledges that Participant has been provided a copy of this Agreement at least 14 calendar days before the commencement of employment. If Participant is an existing Employee, Participant acknowledges that Participant has been given at least 14 calendar days to review this Agreement.
15
2024 LTIP Restricted Stock Unit


Indiana:
If Participant resides in Indiana and is subject to Indiana law, then the restrictions on Participant under Section 7(d) shall apply only with respect to soliciting, hiring, attempting to solicit or hire, or participating in any attempt to solicit or hire individuals who themselves had access to Confidential Information in the prior six months.

Louisiana:
If Louisiana law is deemed to apply, then the following applies to Participant: (a) the “Restricted Territory” defined in Section 7 of the Agreement is understood to cover the following parishes in Louisiana and all counties outside Louisiana where Participant had responsibilities for the Company: Acadia, Allen, Ascension, Assumption, Avoyelles, Beauregard, Bienville, Bossier, Caddo, Calcasieu, Caldwell, Cameron, Catahoula, Claiborne, Concordia, DeSoto, East Baton Rouge, East Carroll, East Feliciana, Evangeline, Franklin, Grant, Iberia, Iberville, Jackson, Jefferson, Jefferson Davis, LaSalle, Lafayette, Lafourche, Lincoln, Livingston, Madison, Morehouse, Natchitoches, Orleans, Ouachita, Plaquemines, Pointe Coupee, Rapides, Red River, Richland, Sabine, St. Bernard, St. Charles, St. Helena, St. James, St. John The Baptist, St. Landry, St. Martin, St. Mary, St. Tammany, Tangipahoa, Tensas, Terrebonne, Union, Vermilion, Vernon, Washington, Webster, West Baton Rouge, West Carroll, West Feliciana, Winn; and (b) the restrictions in Section 7(c) (as well as Section 7(b)) shall be limited to the foregoing parishes and counties.
Maine:
If Maine law is deemed to apply, then the following applies to Participant: (a) Participant acknowledges that if Participant is a new hire Participant received a copy of this Agreement prior to receiving a formal offer of employment from the Company and was given at least three business days to consider the Agreement before signing; (b) Section 7(b) will not take effect until one year of employment or a period of six months from the date the agreement is signed, whichever is later; and (c) Section 7(b) shall not apply if Participant earns at or below 400% of the federal poverty level.
Maryland:
If Maryland law is deemed to apply, then the following applies to Participant: Section 7(b) shall not apply if Participant earns equal to or less than $15/hour or $31,200 annually.
Massachusetts:
If Participant resides or works in Massachusetts for at least the thirty days preceding Participant’s Termination, then the Company will notify Participant within ten (10) business days of Participant’s Termination whether the Company decides to waive Section 7(b) or make these provisions enforceable by paying Participant garden leave as provided by the Massachusetts Noncompetition Agreement Act, G.L. c. 149, S. 24L. In addition, if Massachusetts law is deemed to apply, then the following applies to Participant:
(a) Section 7(b) will not apply if Participant’s employment is terminated without “cause” or if Participant is terminated as part of a reduction in force. Participant further understands that for the limited purpose of the application of the non-competition clause in Section 7(b) of the Agreement, “cause” to terminate Participant’s employment exists if Participant has (i) committed, admitted committing, or plead guilty to a felony or crime involving moral turpitude, fraud, theft, misappropriation, or dishonesty, (ii) violated a material term of this Agreement or Company policy, (iii) engaged in insubordination, or failed or refused to perform assigned duties of Participant’s position despite reasonable opportunity to perform, (iv) failed to exercise reasonable care and diligence in the exercise of Participant’s duties for the Company, or (iv) engaged in conduct or omissions that Participant knew, or should have known (with the exercise of reasonable care), would cause, or be likely to cause, harm to the Company or its reputation in the business community;
(b) Participant acknowledges that Participant has been advised to consult with an attorney about this Agreement and has been given an opportunity to do so;
(c) the Restricted Period applicable to Section 7(b) shall be limited to a period of one year following Participant’s Termination (as well as while Participant is employed by the Company); however, if Participant breaches Section 7(b) of this Agreement, and also breaches Participant’s fiduciary duty to the Company and/or has unlawfully taken,
16
2024 LTIP Restricted Stock Unit


physically or electronically, any Company records, then the Restricted Period shall be extended to a period of two (2) years from Termination;
(d) Participant acknowledges that (i) if Participant is being initially hired by the Company, that Participant received a copy of this Agreement prior to receiving a formal offer of employment from the Company or at least ten (10) business days before commencement of Participant’s employment by the Company, whichever came first; or (ii) if Participant was already employed by the Company at the time of signing this Agreement, that Participant was provided a copy hereof at least ten (10) business days before the effective date of this Agreement;
(e) the tolling language Section 10(b) shall only apply to any breach of Section 7(c) and (d) (i.e., the tolling language shall not apply to Section 7(b)); and
(f) Section 7(b) shall not apply to Participant following Termination if Participant is: classified as non-exempt under the FLSA; 18 years or younger; or an undergraduate or graduate student in an internship or other short-term employment relationship while enrolled in college or graduate school.
Minnesota:
If Minnesota law is deemed to apply, then the restrictions in Section 7(b) shall be limited to situations in which Participant is aided in his or her conduct by the use or disclosure of Confidential Information.

Nebraska:
If Nebraska law is deemed to apply, then the following applies to Participant: (a) Section 7(c) is limited to the solicitation of persons or entities with which Participant did business and had personal business-related contact during the Look Back Period; and (b) Section 7(b) is limited to restricting Participant from working for a Company client or account with whom the Participant did business and had personal business-related contact during the Look Back Period.

Nevada:
If Nevada law is deemed to apply, then the following applies to Participant: (a) Section 7 does not preclude Participant from providing services to any former client or customer of the Company if: (1) Participant did not solicit the former customer or client; (2) the customer or client voluntarily chose to leave and seek services from Participant; and (3) Participant is otherwise complying with the limitations in this Agreement as to time and scope of activity to be restrained; and (b) Section 7(b) does not apply if Participant is paid solely an hourly wage, exclusive of tips or gratuities.
New Hampshire:
If New Hampshire law is deemed to apply, then the following applies to Participant: (a) Section 7(b) does not apply if Participant earns an hourly rate less than or equal to 200 percent of the federal minimum wage; and (b) Participant acknowledges that Participant was given a copy of this Agreement prior to a change in job classification or the offer of employment.
New York:
If New York law is deemed to apply, then the following applies to Participant: Section 7(c) shall be modified to exclude those clients or customers who became a client or customer of the Company as a result of Participant’s independent contact and business development efforts with the customer or client prior to and independent from his/her employment with the Company.
North Carolina:
If North Carolina law is deemed to apply, then the following applies to Participant: (a) the Look Back Period shall be calculated looking back twenty-four (24) months from the date of enforcement and not from the date Participant’s employment ends; and (b) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.
17
2024 LTIP Restricted Stock Unit


North Dakota:
If North Dakota law is deemed to apply, then the following applies to Participant: (a) the noncompetition restriction in Section 7(b) shall not apply; and (b) Section 7(c) shall be limited to situations where Participant is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law).
Oklahoma:
If Oklahoma law is deemed to apply, then the following applies to Participant: (i) Section 7(c) is limited to preclude only the direct solicitation of established customers of the Company for the purpose of doing any business that would compete with the Company’s business; and (ii) the noncompetition restrictions in Section 7(b) shall not apply.
Oregon:
If Oregon law is deemed to apply, then the following applies to Participant: the restrictions in Section 7(b) shall apply only if: (a) Participant is engaged in administrative, executive or professional work and performs predominantly intellectual, managerial, or creative tasks, exercises discretion and independent judgment and earns a salary or is otherwise exempt from Oregon's minimum wage and overtime laws; (b) the Company has a "protectable interest" (meaning, access to trade secrets or competitively sensitive confidential business or professional information); and (c) the total amount of Participant's annual gross salary and commission, calculated on an annual basis, at the time of Participant's Termination, exceeds $100,533 adjusted annually for inflation pursuant to the Consumer Price Index for All Urban Consumers, West Region (All Items), as published by the Bureau of Labor Statistics of the United States Department of Labor immediately preceding the calendar year of Participant’s Termination. However, if Participant does not meet requirements of either (a) or (c) (or both), the Company may, on a case-by-case basis, decide to make Section 7(b) enforceable as to Participant (as allowed by Oregon law), by agreeing in writing to pay Participant, during the period of time Participant is restrained from competing, the greater of: (i) compensation equal to at least 50 percent of Participant’s annual gross base salary and commissions at the time of Termination; or (ii) fifty percent of $100,533 adjusted annually for inflation pursuant to the Consumer Price Index for All Urban Consumers, West Region (All Items), as published by the Bureau of Labor Statistics of the United States Department of Labor immediately preceding the calendar year of Participant’s Termination. If Participant is an existing Employee, Participant acknowledges that this Agreement was entered into upon a subsequent bona fide advancement of Participant by the Company; namely the Company is conferring upon Participant equity awards that, if accepted by Participant, will supplement Participant’s compensation.
Puerto Rico:
If Puerto Rico law is deemed to apply, then the following applies to Participant: (a) the Restricted Period and the Look Back Period in Section 7 shall be, in each case, only a period of twelve (12) months; (b) the Restricted Territory shall be limited to the territory of Puerto Rico; (c) the customer restriction in Section 7(c) shall be limited to clients, accounts, and medical care providers that were personally serviced by Participant during the Look Back Period and had an active business relationship with the Company within the last thirty (30) days prior to Participant’s Termination; and (d) the tolling provision in Section 10(b) shall not apply.
Rhode Island:
If Rhode Island law is deemed to apply, then Section 7(b) shall not apply to Participant following Termination if Participant is: classified as non-exempt under the FLSA; an undergraduate or graduate student in an internship or short-term employment relationship; 18 years of age or younger; or a low wage Participant (defined as earning less than 250% of the federal poverty level).
Utah:
If Utah law is deemed to apply, then the following applies to Participant: (a) the Restricted Period applicable to Section 7(b) shall be limited to a period of one year following Termination (as well as while Participant is employed by the Company).



18
2024 LTIP Restricted Stock Unit


Virginia:
If Virginia law is deemed to apply, then the following applies to Participant: (a) Section 7(b)-(d) shall not apply if Participant is a “low wage Participant.” A “low wage Participant” refers to a Participant whose average weekly earnings (calculated by dividing Participant's earnings during the period of 52 weeks immediately preceding Termination by 52, or if Participant worked fewer than 52 weeks, by the number of weeks that Participant was actually paid during the 52-week period) are less than the average weekly wage of the Commonwealth of Virginia as determined pursuant to subsection B of Virginia Code § 65.2-500. "Low-wage Participant" includes interns, students, apprentices, or trainees employed, with or without pay, at a trade or occupation in order to gain work or educational experience. "Low-wage Participant" also includes an individual who has independently contracted with another person to perform services independent of an employment relationship and who is compensated for such services by such person at an hourly rate that is less than the median hourly wage for the Commonwealth of Virginia for all occupations as reported, for the preceding year, by the Bureau of Labor Statistics of the U.S. Department of Labor. However, "low-wage Participant" does not include any Participant whose earnings are derived, in whole or in predominant part, from sales commissions, incentives, or bonuses paid to Participant by the Company; (b) Section 7 does not preclude Participant from providing services to any client or customer of the Company if Participant did not initiate contact with or solicit the former customer or client; and (c) Participant’s nondisclosure obligation in Section 7(a) shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.
Washington (state):
If Participant resides in Washington at the time this Agreement is entered, Participant acknowledges that Participant was given at least ten (10) business days to consider this Agreement before accepting it.
In addition, if Washington law controls, then for so long as Washington law controls, the Agreement will be modified and applied as follows:
(a) Section 7(b) shall apply following Termination only if Participant’s annualized earnings from the Company exceed $100,000.00 per year (adjusted annually in accordance with Section 5 of Washington HP 1450), and Section 7(b) shall apply during employment only if Participant earns at least twice the Washington minimum hourly wage (subject to the common law duty of loyalty and the Company’s Code of Conduct);
(b) for purposes of the application of the non-competition provision in Section 7(b), Participant understands that the non-competition provision will not be enforced against Participant if Participant is terminated from employment without “cause” or if Participant is laid off, unless the Company pays Participant during the Restricted Period an amount equal to Participant’s base salary at Termination less any compensation earned by Participant during the Restricted Period. Participant further understands that for the limited purpose of the application of the non-competition clause in Section 7(b) of the Agreement, “cause” to terminate Participant’s employment exists if Participant has (i) committed, admitted committing, or plead guilty to a felony or crime involving moral turpitude, fraud, theft, misappropriation, or dishonesty, (ii) violated a material term of this Agreement or Company policy, (iii) engaged in insubordination, or failed or refused to perform assigned duties of my position despite reasonable opportunity to perform, (iv) failed to exercise reasonable care and diligence in the exercise of Participant’s duties for the Company, or (iv) engaged in conduct or omissions that Participant knew, or should have known (with the exercise of reasonable care), would cause, or be likely to cause, harm to the Company or its reputation in the business community; and
(c) Participant further acknowledges that if Participant is a new Employee, Participant has had advance notice of the terms of this Agreement prior to accepting the Company’s offer of employment.






19
2024 LTIP Restricted Stock Unit


Washington, D.C.:
Participant acknowledges that Participant was given a copy of Washington, D.C., Council Bill 24-256 (“Bill 24-256”) prior to or contemporaneously with accepting this Agreement.
If Participant is a “Covered Employee” as defined by Bill 24-256 and Participant is not a “Highly Compensated Employee,” as defined by Bill 24-256, the following applies to Participant: (1) Section 7(b) shall not apply; (2) “Confidential Information” shall, in all instances, be limited to information owned or possessed by the Company which is not available to the general public and which the Company has taken reasonable steps to ensure is protected from improper disclosure; (3) Participant is precluded, during Participant’s employment with the Company, from accepting money or a thing of value for performing work for a person other than the Company, where doing so can reasonably be concluded to result in (a) Participant’s disclosure or use of Confidential Information or “Proprietary employer information,” as defined by Bill 24-256; (b) a conflict with the Company’s established rules regarding conflicts of interest, or (c) impairment of the Company’s ability to comply with federal law, the law of the District of Columbia, or a contract or grant agreement.
If Participant is a “Covered Participant” as defined by Bill 24-256 and Participant is a “Highly Compensated Participant,” as defined by Bill 24-256, the following applies to Participant: (1) Participant acknowledges that Participant was given a copy of this Agreement at least 14 days before Participant commenced employment with the Company (if Participant is a new hire) or Participant was given a copy of this Agreement at least 14 days before Participant was required to accept this Agreement (if Participant is an existing Employee); (2) “Confidential Information” shall, in all instances, be limited to information owned or possessed by the Company which is not available to the general public and which the Company has taken reasonable steps to ensure is protected from improper disclosure; (3) the Restricted Period for purposes of the non-competition provision in Section 7(b) shall be limited to a period of twelve (12) months following Termination (and while Participant is employed by the Company); and (4) Participant is notified that The District of Columbia Ban on Non-Compete Agreements Amendment Act of 2020 limits the use of non-compete agreements. It allows employers to request non-compete agreements from “highly compensated employees” under certain conditions. The Company has determined that you are a highly compensated employee. For more information about the Ban on Non-Compete Agreements Amendment Act of 2020, contact the District of Columbia Department of Employment Services (DOES).
Wisconsin:
If Wisconsin law is deemed to apply, then the following applies to Participant: (a) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret; (b) the tolling provision in Section 10(b) shall not apply; and (c) Section 7(d) is rewritten as follows: “While employed and for a period of twelve (12) months following Termination, Participant will not participate in soliciting any “Covered Employee” of the Company that is in a “Sensitive Position” to leave the employment of the Company on behalf of (or for the benefit of) a Competitor; nor will Participant knowingly assist a Competitor in efforts to hire a Covered Employee away from the Company.  As used in this Section 7(d), a “Covered Employee” is an Employee with whom Participant worked, as to whom Participant had supervisory responsibilities, or regarding whom Participant received Confidential Information during the Look Back Period. A Participant in a “Sensitive Position” refers to an Employee who is in a management, supervisory, sales, research and development, or similar role where the Employee is provided Confidential Information or is involved in business dealings with the Company’s clients.”
20
2024 LTIP Restricted Stock Unit
 EX-10.2R 4 exhibit102rpsuagreement.htm EX-10.2 (R) Document
EXHIBIT 10.2(r)
Schedule A
Notice of Performance Stock Unit Grant
Participant:[●]
Company:Elevance Health, Inc.
Notice:You have been granted the following award of performance stock units of common stock of the Company in accordance with the terms of the Plan and the attached Performance Stock Unit Agreement.
Plan:2017 Elevance Health Incentive Compensation Plan
Grant:
Grant Date: [●]
Grant Number: [●]
Number of Performance Stock Units: [●]
Performance Period:The Performance Period is the three calendar year period that begins on the January 1 of the calendar year that includes the Grant Date. Subject to achievement of the performance measures described in the Long Term Stock Incentive Plan Brochure (“Summary”), the number of your Performance Stock Units listed in the “Shares” column, and any related Dividend Equivalents, shall vest on the later of the date listed in the “Vesting Date” column or the date the Compensation and Talent Committee of the Board of Directors of Elevance Health, Inc. certifies the performance results. Unless otherwise provided in the Agreement, you must be employed on the Vesting Date to receive any Performance Stock Units payable under the Agreement. Achievement of the performance measures may increase or decrease the total number of Performance Stock Units covered by the Grant and any related Dividend Equivalents that vest on the Vesting Date.
SharesVesting Date
[●][●]
Achievement of the performance measures must be approved by the Compensation and Talent Committee of the Board of Directors of Elevance Health, Inc. The performance measures as described in the Summary, including any modifications to such performance measures, are incorporated into, and made part of the Agreement.
In the event that a Change of Control (as defined in the Plan) occurs before your Termination (as defined in the Plan), your Performance Stock Unit Grant will remain subject to the terms of this Agreement, unless the successor company does not assume the Performance Stock Unit Grant. If the successor company does not assume the Performance Stock Unit Grant, then the Performance Stock Units shall immediately vest upon a Change of Control and the Shares covered by the award shall be delivered as soon as practicable following the Change of Control, provided that in the event that the Performance Stock Units are deferred compensation within the meaning of Code Section 409A, such Stock Units shall only be delivered upon the Change of Control if such Change of Control is a “change in control event” within the meaning of Code Section 409A and the delivery is made in accordance with Treasury Regulation 1-409A-3(j)(ix).
Acceptance:In order to accept your Performance Stock Units, you must electronically accept this Agreement through the Company’s broker at any time within ninety (90) days after the Grant Date. To effect your acceptance, please follow the instructions included with your grant materials. Acceptance of the Agreement includes acceptance of the terms and conditions of the Plan. If you do not timely and electronically accept this Agreement, this Agreement will be null and void at the end of the 90th day after the Grant Date and you will have no right or claim to the Performance Stock Units described above.
Performance Share Award Agreement



Performance Stock Unit Award Agreement
This Performance Stock Unit Award Agreement (this “Agreement”) dated as of the Grant Date (the “Grant Date”) set forth in the Notice of Performance Stock Unit Grant attached as Schedule A hereto (the “Grant Notice”) is made between Elevance Health, Inc. (the “Company”) and the Participant set forth in the Grant Notice. The Grant Notice is included in and made part of this Agreement. The Company and Participant expressly agree and acknowledge that Participant’s entry into this Agreement is not a condition of Participant’s employment with the Company, and that Participant is not required to enter into this Agreement or accept Restricted Stock Units as a condition of Participant’s employment with the Company or a Subsidiary or Affiliate. Capitalized terms not defined herein or in the Grant Notice or the Summary are defined in the Plan.
1.Performance Period. The Performance Period with respect to the Performance Stock Units shall be as set forth in the Grant Notice (the “Performance Period”). Participant acknowledges that the Performance Stock Units may not be sold, transferred, pledged, assigned, encumbered, alienated, hypothecated, or otherwise disposed of (whether voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy)). Upon the completion of the Performance Period and subject to the performance measures described in the Summary, the restrictions set forth in this Agreement with respect to the Performance Stock Units theretofore subject to such completed Performance Period shall lapse and the Shares covered by the related portion of the award shall be delivered as soon as practicable thereafter, except as may be provided in other sections of this Agreement.
2.Ownership. Upon expiration of the applicable portion of the Performance Period and subject to the performance measure described in the Summary, the Company shall transfer the Shares covered by the related portion of the award to Participant’s account with the Company’s captive broker.
3.Termination.
(a)Retirement. If Participant’s Termination is due to Retirement (for purposes of this Agreement, defined as Participant’s Termination after attaining age fifty-five (55) with at least ten (10) completed years of service) or after attaining age sixty-five (65), Participant shall become vested in a prorata number of Performance Stock Units based on actual achievement of the performance measures set forth in the Summary. For purposes of the preceding, the prorata number of the Performance Stock Units shall be equal to (i) the number of Performance Stock Units set forth in the Grant Notice, adjusted for actual achievement of performance measures, plus any Dividend Equivalents multiplied by (ii) a fraction, the numerator of which shall be the number of full calendar months Participant is employed with the Company during the Measurement Period and the denominator of which shall be 36 calendar months. For purposes of the Agreement, the Measurement Period is (A) the same as the Performance Period for a Participant employed on the first day of the Performance Period, and (B) the 36 month period beginning on the Grant Date for all other Participants. The shares covered by the related portion of the award shall be delivered upon the applicable Vesting Date. 1
(b)Death and Disability. If Participant’s Termination is due to death or Disability (for purposes of this Agreement, as defined in the applicable Elevance Health Long-Term Disability Plan), then the Performance Period shall immediately lapse, causing any restrictions which would otherwise remain on the Performance Stock Units to immediately lapse, and the Shares covered by the award shall be delivered as soon as practicable thereafter.
(c)Without Cause or for Good Reason. If Participant’s Termination is by the Company or an Affiliate without Cause (for purposes of this Agreement, defined as a violation of “conduct” as such term is defined in the Elevance Health HR Corrective Action Policy and if Participant participates in the Elevance Health Executive Agreement Plan (the "Agreement Plan"), the Key Associate Agreement, or the Key Sales Associate Agreement also as defined in that plan or agreement), Participant shall become vested in a prorata number of Performance Stock Units based on actual achievement of the performance measures set forth in the Summary. For purposes of the preceding, the prorata number of the Performance Stock Units shall be equal to (i) the number of
1 This retirement provision is deleted in non-annual retention grants.
2
2024 Performance Stock Unit



Performance Stock Units set forth in the Grant Notice, adjusted for actual achievement of performance measures, plus any Dividend Equivalents multiplied by (ii) a fraction, the numerator of which shall be the number of full calendar months elapsed from the first day of the Measurement Period through Participant’s date of Termination and the denominator of which shall be 36 calendar months. The shares covered by the related portion of the award shall be delivered upon the applicable Vesting Date. The foregoing shall also apply to a Participant who participates in the Agreement Plan and receives severance under the Agreement Plan for a termination by Participant for Good Reason (as defined in the Agreement Plan).
(d)Other Terminations. If Participant’s Termination is (i) by the Company or an Affiliate for Cause even if on the date of such Termination Participant has met the definition of Retirement or Disability or (ii) by Participant for any reason other than death, Disability, Retirement, Good Reason or without Cause, then all Performance Stock Units for which the Performance Period had not lapsed prior to the date of such Termination shall be immediately forfeited.
(e)Termination after Change of Control. Notwithstanding any other provision of the Agreement, including Section 3(c), if after a Change of Control Participant’s Termination is (i) by the Company or an Affiliate without Cause or (ii), if Participant participates in the Agreement Plan, by Participant for Good Reason (as defined in the Agreement Plan), then there shall be paid out in cash to Participant within 30 days following Termination the value of the Performance Stock Units to which Participant would have been entitled if performance achieved 100% of the target performance measures as described in the Summary. Notwithstanding any provision of this Agreement to the contrary, in the event that Participant becomes entitled to vest in Performance Stock Units under any provision of this Section 3 by reason of any Termination and such Termination occurs within the two-year period following a Change of Control that is a “change in control event” within the meaning of Code Section 409A, Participant’s Performance Stock Units shall be paid to Participant upon such Termination.
4.Transferability of the Performance Stock Units. Participant shall have the right to appoint any individual or legal entity in writing, in accordance with procedures established by the Company’s broker, to receive any Performance Stock Units (to the extent not previously terminated or forfeited) under this Agreement upon Participant’s death, to the extent permitted by law. The effectiveness of any such designation, and any revocation or replacement thereof, shall be determined in accordance with procedures established by the Company’s broker. If Participant dies without such designation, the Performance Stock Units will become part of Participant’s estate.
5.Dividend Equivalents. In the event the Company declares a dividend on Shares (as defined in the Plan), for each unvested Performance Stock Unit on the dividend payment date, Participant shall be credited with a Dividend Equivalent, payable in cash, with a value equal to the value of the declared dividend. The Dividend Equivalents shall be subject to the same restrictions as the unvested Performance Stock Units to which they relate. No interest or other earnings shall be credited on the Dividend Equivalents, provided that additional Dividend Equivalents may be awarded or forfeited in the same proportion as the number of Performance Stock Units determined to be awarded or forfeited based on the achievement of the performance measures. Subject to continued employment with the Company and Affiliates in accordance with Section 3 and, as applicable, achievement of performance measures, the restrictions with respect to the Dividend Equivalents shall lapse at the same time and in the same proportion as restrictions on the initial award of Performance Stock Units. No additional Dividend Equivalents shall be accrued for Participant’s benefit with respect to record dates occurring prior to the Grant Date, or with respect to record dates occurring on or after the date, if any, on which Participant has forfeited the Performance Stock Units or any Performance Stock Units have been settled. If Participant is a “specified employee” within the meaning of Code Section 409A, payment of any Dividend Equivalents subject to Code Section 409A and payable upon a termination of employment shall be subject to a six-month delay. The Dividend Equivalents shall be subject to all such other provisions set forth herein and may be used to satisfy any or all obligations for the payment of any tax attributable to the Dividend Equivalents and/or Performance Stock Units.
3
2024 Performance Stock Unit



6.Taxes and Withholdings. Upon the expiration of the applicable portion of the Performance Period (and delivery of the underlying Shares), or as of which the value of any Performance Stock Units first becomes includible in Participant’s gross income for income tax purposes, Participant shall satisfy all obligations for the payment of any tax attributable to the Performance Stock Units. Participant shall notify the Company if Participant wishes to pay the Company in cash, check or with shares of Elevance Health common stock already owned for the satisfaction of any taxes of any kind required by law to be withheld with respect to such Performance Stock Units. Any such election made by Participant must be irrevocable, made in writing, signed by Participant, and shall be subject to any restrictions or limitations that the Compensation and Talent Committee of the Board of Directors of the Company (“Committee”), in its sole discretion deems appropriate. If Participant does not notify the Company in writing at least 14 days prior to the end of the Performance Period, the Committee is authorized to take any such other action as may be necessary or appropriate, as determined by the Committee, to satisfy all obligations for the payment of such taxes. Such other actions may include withholding the required amounts from other compensation payable to Participant, a sell-to-cover transaction or such other method determined by the Committee, in its discretion. Please refer to the Plan’s prospectus for tax considerations by jurisdiction.
7.Restrictive Covenants. For purposes of Sections 7, 8, and 9 of this Agreement, Company shall mean Elevance Health, Inc. and its subsidiaries and Affiliates. Participant acknowledges that Participant has the right to consult with counsel at Participant’s sole expense. As a condition to receipt of the Performance Stock Unit Grant made under this Agreement, which Participant and the Company agree is fair and reasonable consideration, Participant agrees as follows, subject to any applicable provisions of Appendix A:
(a)Confidentiality.
(i)    Participant recognizes that the Company derives substantial economic value from information created and used in its business which is not generally known by the public, including, but not limited to, plans, designs, concepts, computer programs, formulae, and equations; product fulfillment and supplier information; customer and supplier lists, and confidential business practices of the Company, Affiliates, and any of its customers, vendors, business partners or suppliers; profit margins and the prices and discounts the Company obtains or has obtained or at which it sells or has sold or plans to sell its products or services (except for public pricing lists); manufacturing, assembling, labor and sales plans and costs; business and marketing plans, ideas, or strategies; confidential financial performance and projections; employee compensation; employee staffing and recruiting plans and employee personal information; and other confidential concepts and ideas related to the Company’s business (collectively, “Confidential Information”). Participant expressly acknowledges and agrees that by virtue of his/her employment with the Company, Participant will have access to and will use in the course of Participant’s duties certain Confidential Information and that Confidential Information constitutes trade secrets and confidential and proprietary business information of the Company, all of which is the exclusive property of the Company. For purposes of this Agreement, Confidential Information includes, but is not limited to, information that constitutes a trade secret under applicable state or federal law. Confidential Information does not include information that Participant establishes by clear and convincing evidence is or may become known to Participant or to the public from sources outside the Company and through means other than a breach of this Agreement.
(ii)    Participant agrees that Participant will not for himself or herself or for any other person or entity, directly or indirectly, without the prior written consent of the Company, while employed by the Company and thereafter: (A) use Confidential Information for the benefit of any person or entity other than the Company or its affiliates; (B) remove, copy, duplicate or otherwise reproduce any document or tangible item embodying or pertaining to any of the Confidential Information, except as required to perform Participant’s duties for the Company or its affiliates; or (C) while employed and thereafter, publish, release, disclose or deliver or otherwise make available to any third party any Confidential Information by any communication, including oral, documentary, electronic or magnetic information transmittal device or media. Upon Termination, Participant shall return all Confidential Information and all other property of the Company. This obligation of non-disclosure and non-use of information shall continue to exist for so long as such information remains Confidential Information.
4
2024 Performance Stock Unit



(b)Non-Competition. During any period in which Participant is employed by the Company, and during a period of time after Participant’s Termination (the “Restriction Period”) which, unless otherwise limited by applicable state law, is (i) twenty-four (24) months for Executive Vice Presidents and the President & Chief Executive Officer, and (ii) the greater of the period of severance or twelve (12) months for all other Participants, Participant will not, without prior written consent of the Company, directly or through the direction or control of others, obtain a Competitive Position or perform a Restricted Activity in the Restricted Territory for a Competitor, as those terms are defined herein.
(i)Competitive Position means any employment or performance of services with a Competitor (A) the same as or similar to the services that Participant performed for the Company in the last twenty-four (24) months of Participant’s employment with Company (the “Look Back Period”), or (B) in the performance of which Participant will likely use any Confidential Information of the Company.
(ii)Restricted Territory means any geographic area in which the Company does business and which Participant provided services in, had responsibility for, had a material presence or influence in, or had access to Confidential Information about, such business, within the Look Back Period.
(iii)Restricted Activity means any activity for which Participant had responsibility for the Company or about which Participant had Confidential Information within the Look Back Period.
(iv)Competitor means any entity or individual (other than the Company) engaged in any one or more of the following: management of network-based managed care plans and programs; administration of managed care services; provision of health insurance, long-term care insurance, dental, life, or disability insurance; administration of flexible spending accounts, COBRA continuation coverage, coordination of benefits, or subrogation services; or the provision, delivery, or administration of health benefit plans or health care services such as pharmacy benefits management (including Specialty pharmacy), value-based care delivery, behavioral health, palliative care, care for chronic and complex conditions, digital healthcare platforms, medical benefits management solutions, or health care research (including health economics and outcomes); or any other aspects of the business or products or services offered by the Company, as to which Participant had responsibilities or received Confidential Information about, during the Look Back Period.
(v)The restrictions contained in this subsection (b) shall not apply to attorneys who accept a Competitive Position that consists of practicing law.
(vi)If Participant receives an offer of a Competitive Position with a Competitor, as those terms are defined above, Participant shall notify the Company’s Chief Human Resources Officer, via the contact information provided in the Summary, within five business days of receiving the offer and such notification shall include a detailed description of the job responsibilities and the identity of the Competitor. The description must be specific enough for the Company to determine whether Participant’s new opportunity constitutes a violation of the Agreement.
(c)    Non-Solicitation of Customers. During any period in which Participant is employed by the Company, and during the Restriction Period after Participant’s Termination, Participant will not, either individually or as an employee, partner, consultant, independent contractor, owner, agent, or in any other capacity, directly or through the direction or control of others, for a Competitor of the Company as defined in subsection (b) above:
(i)    Solicit business from any client, account, or medical care provider of the Company that Participant had contact with, participated in contact with, had or shared responsibility for, or had access to Confidential Information about, during the Look Back Period; or
(ii)    Solicit business from any client, account, or medical care provider that the Company pursued, and Participant had contact with, responsibility for, or knowledge of Confidential Information about, by reason of Participant’s employment with the Company, during the Look Back Period.
For purposes of this paragraph (c), an individual policyholder in a plan maintained by the Company or by a client or account of the Company under which individual policies are issued, or a certificate holder in such plan under which group policies are issued, shall not be considered a client or account subject to this restriction solely by reason of being such a policyholder or certificate holder.
5
2024 Performance Stock Unit



(d)    Non-Solicitation of Employees. During any period in which Participant is employed by the Company, and during the Restriction Period after Participant’s Termination, Participant will not, either individually or as an employee, partner, independent contractor, owner, agent, or in any other capacity, directly or indirectly, solicit, hire, attempt to solicit or hire, or participate in any attempt to solicit or hire, for any non-Company entity:
(i)    Any officer or employee of the Company whom the Participant knows to have access to or possession of Confidential Information that would give an unfair advantage to a Competitor;
(ii)    Any officer or employee of the Company who, on or at any time during the six (6) months immediately preceding the date of such solicitation or hire, held the position of Director or above with the Company;
(iii)    Any officer or employee of the Company to whom Participant reported, or who reported to Participant, on or at any time during the six (6) months immediately preceding the dates of such solicitation or hire; or
(iv)    Any person who is or was an officer or employee of the Company during the six (6) months immediately preceding the date of such solicitation or hire, or whom the Participant was involved in recruiting while Participant was employed by the Company.
(e)    Non-Disparagement. Subject to the limitations in Section 7(f) below, Participant agrees that he/she will not, nor will he/she cause or assist any other person to, make any statement to a third party or take any action which is intended to or would reasonably have the effect of disparaging or harming the Company or the business reputation of the Company’s directors, employees, officers, or managers, or make any verbal or written statement to any media outlet regarding the Company.
(f)    Agreement Limitations. Nothing in this Agreement prohibits Participant from (i) disclosing Workplace Conduct or the existence of a settlement involving Workplace Conduct that concerns conduct that Participant reasonably believes under state, federal, or common law to be illegal harassment, illegal retaliation, a wage & hour violation, or sexual assault, or that is recognized as against a clear mandate of public policy; (ii) disclosing Workplace Conduct that Participant has reason to believe is otherwise unlawful; or (iii) reporting possible violations of law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of any federal, state, or local law or regulation. “Workplace Conduct” means conduct occurring in the workplace, at work-related events coordinated by or through the Company, or between Employees, or between the Company and any Employee, off the workplace premises. Participant does not need the prior authorization of the Company to make any such reports or disclosures and Participant is not required to notify the Company that Participant has made such reports or disclosures. Disclosures protected by this Section may include a disclosure of trade secret information provided that it must comply with the restrictions in the Defend Trade Secrets Act of 2016 (DTSA). The DTSA provides that no individual will be held criminally or civilly liable under Federal or State trade secret law for the disclosure of a trade secret that: (i) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and made solely for the purpose of reporting or investigating a suspected violation of law; or, (ii) is made in a complaint or other document if such filing is under seal so that it is not made public. Also, an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order. If Participant is covered by Section 7 of the National Labor Relations Act (NLRA) because Participant is not in a supervisor or management role, nothing in this Agreement shall prohibit Participant from using information Participant acquires regarding the wages, benefits, or other terms and conditions of employment at the Company for any purpose protected under the NLRA.
6
2024 Performance Stock Unit



(g) Assignment of Intellectual Property. Participant agrees that he or she is expected to use his or her inventive and creative capacities for the benefit of the Company and to contribute, where possible, to the Company’s intellectual property in the ordinary course of employment.

(i) “Inventions” mean any inventions, discoveries, improvements, designs, processes, machines, products, innovations, business methods or systems, know how, ideas or concepts, and related technologies or methodologies, whether or not shown or described in writing or reduced to practice and whether patentable or not. “Works” mean original works of authorship, including, but not limited to: literary works (including all written material), mask works, computer programs, formulas, tests, notes, data compilations, databases, artistic and graphic works (including designs, graphs, drawings, blueprints, and other works), recordings, models, photographs, slides, motion pictures, and audio visual works; whether copyrightable or not, and regardless of the form or manner in which documented or recorded. “Trademarks” mean any trademarks, service marks, trade dress or names, symbols, special wording, or devices used to identify a business or its business activities whether subject to trademark protection or not. The foregoing terms are collectively referred to herein as “Intellectual Property.”

(ii) Participant assigns to the Company or its nominee Participant’s entire right, title and interest in and to all Inventions that are made, conceived, or reduced to practice by Participant, alone or jointly with others, during Participant’s employment with the Company (whether during working hours or not) that: (A) relate to the Company’s business or the Company’s actual or anticipated research or development; (B) involve the use or assistance of any tools, time, material, personnel, information, or facility of the Company; or (C) result from or relate to any work, services, or duties undertaken by Participant for the Company.
(iii) Participant recognizes that all Works and Trademarks conceived, created, or reduced to practice by Participant, alone or jointly with others, during Participant’s employment shall to the fullest extent permissible by law be considered the Company’s sole and exclusive property and “works made for hire” as defined in the U.S. Copyright Laws for purposes of United States law and the law of any other country adhering to the “works made for hire” or similar notion or doctrine, and will be considered the Company’s property from the moment of creation or conception forward for all purposes without the need for any further action or agreement by Participant or the Company. If any such Works, Trademarks, or portions thereof shall not be legally qualified as a works made for hire in the United States or elsewhere or shall subsequently be held to not be a work made for hire or not the exclusive property of the Company, Participant hereby assigns to the Company all of Participant’s rights, title, and interest, past, present, and future, to such Works or Trademarks. Participant will not engage in any unauthorized publication or use of such Company Works or Trademarks, nor will Participant use same to compete with or otherwise cause damage to the business interests of the Company.

7
2024 Performance Stock Unit



(iv) It is the purpose and intent of this Section 7(g) to convey to the Company all of the rights (inclusive of moral rights) and interests of every kind, that Participant may hold in Inventions, Works, Trademarks, and other intellectual property that are covered by clauses (g)(i) through (g)(iii) above (“Company Intellectual Property”), past, present, and future; and Participant waives any right that Participant may have to assert moral rights or other claims contrary to the foregoing understanding. It is understood that this means that in addition to the original work product (be it invention, plan, idea, know how, concept, development, discovery, process, method, or any other legally recognized item that can be legally owned), the Company exclusively owns all rights in any and all derivative works, copies, improvements, patents, registrations, claims, or other embodiments of ownership or control arising or resulting from an item of assigned Company Intellectual Property everywhere such may arise throughout the world. The decision whether or not to commercialize or market any Company Intellectual Property is within the Company's sole discretion and for the Company’s sole benefit and no royalty will be due to Participant as a result of the Company's efforts to commercialize or market any such invention. In the event that there is any Invention, Work, Trademark, or other form of intellectual property that is incorporated into any product or service of the Company that Participant retains any ownership of or rights in despite the assignments created by this Agreement, then Participant hereby grants to the Company and its assigns a nonexclusive, perpetual, irrevocable, fully paid-up, royalty-free, worldwide license to the use and control of any such item that is so incorporated and any derivatives thereof, including all rights to make, use, sell, reproduce, display, modify, or distribute the item and its derivatives. All assignments of rights provided for in this Agreement are understood to be fully completed and immediately effective and enforceable assignments by Participant of all intellectual property rights in Company Intellectual Property. When requested to do so by the Company, either during or subsequent to employment with the Company, Participant will (A) execute all documents requested by the Company to affirm or effect the vesting in the Company of the entire right, title and interest in and to the Company Intellectual Property at issue, and all patent, trademark, and/or copyright applications filed or issuing on such property; (B) execute all documents requested by the Company for filing and obtaining of patents, trademarks and/or copyrights; and (C) provide assistance that the Company reasonably requires to protect its right, title and interest in the Company Intellectual Property, including, but not limited to, providing declarations and testifying in administrative and legal proceedings with regard to Company Intellectual Property.

(v) Power of Attorney: Participant hereby irrevocably appoints the Company as his or her agent and attorney in fact to execute any documents and take any action necessary for applications, registrations, or similar measures needed to secure the issuance of letters patent, copyright or trademark registration, or other legal establishment of the Company’s ownership and control rights in Company Intellectual Property in the event that Participant’s signature or other action is necessary and cannot be secured due to Participant’s physical or mental incapacity or for any other reason.

(vi) Participant will make and maintain, and not destroy, notes and other records related to the conception, creation, discovery, and other development of Company Intellectual Property. These records shall be considered the exclusive property of the Company and are covered by clauses (g)(i) through (g)(v) above. During employment and for a period of one (1) year thereafter, Participant will promptly disclose to the Company (without revealing the trade secrets of any third party) any Intellectual Property that Participant creates, conceives, or contributes to, alone or with others, that involve, result from, relate to, or may reasonably be anticipated to have some relationship to the line of business the Company is engaged in or its actual or anticipated research or development activity.

(vii) Participant will not claim rights in, or control over, any Invention, Work, or Trademark as something excluded from Section 7(g) because it was conceived or created prior to being employed by the Company (a “Prior Work”) unless such item is identified in reasonable detail in a separate writing, signed by Participant and sent to stock.admin@elevancehealth.com on or before the date Participant accepts this Agreement. Participant will not incorporate any such Prior Work into any work or product of the Company without prior written authorization from the Company to do so; and, if such incorporation does occur, Participant grants the Company and its assigns a nonexclusive, perpetual, irrevocable, fully paid-up, royalty-free, worldwide license to the use and control of any such item that is so incorporated and any derivatives thereof, including all rights to make, use, sell, reproduce, display, modify, or distribute the item and its derivatives.

8
2024 Performance Stock Unit



(viii) The assignment provisions in this Section 7(g) are limited to only those inventions that lawfully can be assigned by an employee to an employer. Some examples of state laws limiting the scope of assignable inventions are Delaware Code Title 19 Section 805; Kansas Statutes Section 44-130; Minnesota Statutes 13A Section 181.78; North Carolina General Statutes Article 10A, Chapter 66, Commerce and Business, Section 66-57.1; Utah Code Sections 34-39-l through 34-39-3, "Employment Inventions Act"; and Washington Rev. Code, Title 49 RCW: Labor Regulations, Chapter 49.44.140. NOTICE: By accepting this Agreement, Participant acknowledges that to the extent one of the foregoing laws applies, Participant’s assignment pursuant to this Section 7(g) will not apply to an invention for which no equipment, supplies, facility, or trade secret information of the Company was used and which was developed entirely on Participant’s own time, unless: (A) the invention relates directly to the business of the Company or to the Company's actual or anticipated research or development; or (B) the invention results from any work performed by Participant for the Company. Similarly, to the extent California Labor Code Section 2870 or Illinois 765ILCS1060/1-3 "Participants Patent Act" controls, then the notice in the preceding sentence applies, absent the word “directly” in clause (A).

8.Return of Consideration.
(a)If at any time Participant breaches any provision of this Agreement, then:
(i)All unexercised stock options under any Designated Plan (defined below) whether or not otherwise vested shall cease to be exercisable and shall immediately terminate;
(ii)Participant shall forfeit any outstanding restricted stock, restricted stock unit, or other outstanding equity award made under any Designated Plan and not otherwise vested on the date of breach; and
(iii)Participant shall pay to the Company (A) for each share of common stock of the Company (“Common Share”) acquired on exercise of an option under a Designated Plan within the 24 months prior to such breach, the excess of the fair market value of a Common Share on the date of exercise over the exercise price, and (B) for each share of restricted stock, restricted stock unit and/or performance stock unit that became vested under any Designated Plan within the 24 months prior to such breach, the fair market value (on the date of vesting) of a Common Share.
Any amount to be repaid pursuant to this Section 8 shall be held by Participant in constructive trust for the benefit of the Company and shall, upon written notice from the Company, within 10 days of such notice, be paid by Participant to the Company. Any amount described in clauses (i) and (ii) that Participant forfeits as a result of a breach of the provisions of Section 7 shall not reduce any money damages that would be payable to the Company as compensation for such breach and shall not reduce or alter the Company’s ability to recover payment of severance based on Participant’s breach of a restrictive covenant in any severance plan or arrangement between the Company and Participant.
(b)The amount to be repaid pursuant to this Section shall be determined on a gross basis, without reduction for any taxes incurred or withheld, as of the date of the realization event, and without regard to any subsequent change in the fair market value of a Common Share. The Company shall have the right to offset such amount against any amounts otherwise owed to Participant by the Company (whether as wages, vacation pay, or pursuant to any benefit plan or other compensatory arrangement other than any amount pursuant to any nonqualified deferred compensation plan under Section 409A of the Code).
(c)    For purposes of this Section 8, a “Designated Plan” is each stock option, restricted stock, or other equity compensation or long-term incentive compensation plan under which Participant has received equity awards from the Company.
(d)    The return of consideration under this Section 8 is meant to reimburse the Company for some of the harm caused by Participant’s wrongful conduct; however, it is not a full measure of the damage caused by Participant’s conduct and does not preclude the Company from seeking the recovery of any and all damages caused by Participant and injunctive relief.
9
2024 Performance Stock Unit



9.Equitable Relief, Remedies, Reformation, Assignment, Jury Trial Waiver, and Miscellaneous
(a)Participant acknowledges that each provision of Sections 7 and 8 of this Agreement is reasonable and necessary to preserve the legitimate business interests of the Company, its present and potential business activities and the economic benefits derived therefrom; that they will not prevent him or her from earning a livelihood in Participant’s chosen business and are not an undue restraint on the trade of Participant, or any of the public interests which may be involved.
(b)Participant agrees that beyond the amounts otherwise to be provided under Section 8 this Agreement, the Company will be damaged by a violation of the terms of this Agreement and the amount of such damage may be difficult to measure. Participant agrees that if Participant commits or threatens to commit a breach of any of the covenants and agreements contained in Section 7 then, to the extent permitted by applicable law, the Company shall have the right to seek and obtain all appropriate injunctive and other equitable remedies, without posting bond therefor, except as required by law, in addition to any other rights and remedies that may be available at law or under this Agreement, it being acknowledged and agreed that any such breach would cause irreparable injury to the Company and that money damages would not provide an adequate remedy. Tolling: Further, if Participant violates Section 7 hereof Participant agrees that the period of violation shall be added to the period in which Participant’s activities are restricted.
(c)The parties agree that the covenants contained herein are severable. If an arbitrator or court shall hold that the duration, scope, area, or activity restrictions stated herein are unreasonable under circumstances then existing, or under applicable state law, the arbitrator or court shall reform or modify the restrictions or enforce the restrictions to such lesser extent as is allowed by law.
(d)EACH PARTY, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AS TO ANY ISSUE RELATING HERETO IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT.
(e)In the event of a breach of this Agreement, the prevailing party shall be entitled to the recovery of its reasonable attorneys’ fees and expenses (including not only costs of court, but also expert fees, travel expenses, and other expenses incurred), and any other legal or equitable relief allowed by law.
(f)Nothing in this Agreement limits or reduces any common law or statutory duty Participant owes to the Company, nor does this Agreement limit or eliminate any remedies available to the Company for a violation of such duties. This Agreement will survive the expiration or termination of Participant’s employment with the Company and/or any assignee pursuant to Section 9(g) and shall, likewise, continue to apply and be valid notwithstanding any change in Participant’s duties, responsibilities, position, or title. Nothing in this Agreement creates a contract for term employment or limits either party’s right to end the employment relationship between them.
(g)This Agreement, including the restrictions on Participant’s activities set forth herein, also applies to any parent, subsidiary, affiliate, successor and assign of the Company to which Participant provides services or about which Participant receives Confidential Information. The Company shall have the right to assign this Agreement at its sole election without the need for further notice to or consent by Participant.
(h)This instrument and the Plan contain the entire agreement between the Parties with respect to the subject matter hereof (the grant contemplated by this Agreement). All representations, promises, and prior or contemporaneous understandings regarding this grant are merged into, and expressed in this instrument. If Participant is subject to a prior agreement (including any prior equity award agreement) with the Company containing confidentiality, non-solicitation, noncompetition and/or invention assignment provisions, then by accepting this Agreement, Participant acknowledges and agrees that the confidentiality, non-solicitation,
10
2024 Performance Stock Unit



noncompetition, and/or invention assignment provisions of this Agreement (including but not limited to those set forth in Sections 7, 8, and 9 and Appendix A) shall supersede those in any such prior agreements and shall apply thereunder as if fully set forth therein. The preceding sentence shall not apply to supersede or otherwise invalidate any legally enforceable restrictive covenant of a longer duration than set forth herein, if such covenant was entered into in connection with the sale of a business. This Agreement shall not be amended, modified, or supplemented without the written agreement of the Parties at the time of such amendment, modification, or supplement and must be signed by an officer of the Company (unless such amendment, modification, or supplementation is by order of a court or arbitrator). The headings herein are for convenience only and shall not affect the terms of the Agreement.

10.Survival of Provisions. The obligations contained in this Agreement shall survive the Termination of Participant’s employment with the Company according to their terms and shall be fully enforceable thereafter.
11.Cooperation. Upon the receipt of reasonable notice from the Company (including from outside counsel to the Company), Participant agrees that while employed by the Company and for two years (or, if longer, for so long as any claim referred to in this Section remains pending) after Participant’s Termination, Participant will respond and provide information with regard to matters in which Participant has knowledge as a result of Participant’s employment with the Company, and will provide reasonable assistance to the Company, its Affiliates and their respective representatives in defense of any claims that may be made against the Company or any Affiliate, and will assist the Company and its Affiliates in the prosecution of any claims that may be made by the Company or any Affiliate, to the extent that such claims may relate to the period of Participant’s employment with the Company (or any predecessor); provided, that with respect to periods after Participant’s Termination, the Company shall reimburse Participant for any out-of-pocket expenses incurred in providing such assistance and if Participant is required to provide more than ten (10) hours of assistance per week after Participant’s Termination then the Company shall pay Participant a reasonable amount of money for his/her services at a rate agreed to between the Company and Participant; and provided further that after Participant’s Termination such assistance shall not unreasonably interfere with Participant’s business or personal obligations. Participant agrees to promptly inform the Company if Participant becomes aware of any lawsuits involving such claims that may be filed or threatened against the Company or any Affiliate. Participant also agrees to promptly inform the Company (to the extent Participant is legally permitted to do so) if Participant is asked to assist in any investigation of the Company or any Affiliate (or their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company or any Affiliate with respect to such investigation and shall not do so unless legally required. Provided, however, that Participant is not required to inform the Company of any investigation by a governmental agency or entity resulting from the reporting of possible violations of federal securities law or regulation to any governmental agency or entity, and Participant may participate in such investigation, without informing the Company.
12.No Rights as a Shareholder. Participant shall have no rights of a shareholder (including, without limitation, dividend and voting rights) with respect to the Performance Stock Units, for record dates occurring on or after the Grant Date and prior to the date any such Performance Stock Units vest in accordance with this Agreement.
13.No Right to Continued Employment. Neither the Performance Stock Units nor any terms contained in this Agreement shall confer upon Participant any express or implied right to be retained in the employment or service of the Company or any Affiliate for any period, nor restrict in any way the right of the Company, which right is hereby expressly reserved, to terminate Participant’s employment or service at any time for any reason, subject to applicable law. Participant acknowledges and agrees that any right to have restrictions on the Performance Stock Units lapse is earned only by continuing as an Employee of the Company or an Affiliate or satisfaction of any other applicable terms and conditions contained in the Plan and this Agreement, and not through the act of being hired, being granted the Performance Stock Units, or acquiring Shares hereunder.
14.The Plan. This Agreement is subject to all the terms, provisions, and conditions of the Plan, which are incorporated herein by reference, and to such regulations as may from time to time be adopted by the Committee. Unless defined herein, capitalized terms are as defined in the Plan. In the event of any conflict between the provisions of the Plan and this Agreement, the provisions of the Plan shall control, and this Agreement shall be deemed to be modified accordingly. The Plan and the prospectus describing the Plan can be found on the Company’s HR intranet. A paper copy of the Plan and the prospectus shall be provided to Participant upon
11
2024 Performance Stock Unit



Participant’s written request to the Company at Elevance Health, Inc., 220 Virginia Avenue, Indianapolis, Indiana 46204, Attention: Corporate Secretary, Shareholder Services Department.
15.Compliance with Laws and Regulations.
(a)The Performance Stock Units and the obligation of the Company to deliver Shares hereunder shall be subject in all respects to (i) all applicable Federal and state laws, rules, and regulations and (ii) any registration, qualification, approvals, or other requirements imposed by any government or regulatory agency or body which the Committee shall, in its discretion, determine to be necessary or applicable. Moreover, the Company shall not deliver any certificates for Shares to Participant or any other person pursuant to this Agreement if doing so would be contrary to applicable law. If at any time the Company determines, in its discretion, that the listing, registration or qualification of Shares upon any national securities exchange or under any state or Federal law, or the consent or approval of any governmental regulatory body, is necessary or desirable, the Company shall not be required to deliver any certificates for Shares to Participant or any other person pursuant to this Agreement unless and until such listing, registration, qualification, consent or approval has been effected or obtained, or otherwise provided for, free of any conditions not acceptable to the Company.
(b)The Shares received upon the expiration of the applicable portion of the Performance Period shall have been registered under the Securities Act of 1933 (“Securities Act”). If Participant is an “affiliate” of the Company, as that term is defined in Rule 144 under the Securities Act (“Rule 144”), Participant may not sell the Shares received except in compliance with Rule 144. Certificates representing Shares issued to an “affiliate” of the Company may bear a legend setting forth such restrictions on the disposition or transfer of the Shares as the Company deems appropriate to comply with Federal and state securities laws.
(c)If, at any time, the Shares are not registered under the Securities Act, and/or there is no current prospectus in effect under the Securities Act with respect to the Shares, Participant shall execute, prior to the delivery of any Shares to Participant by the Company pursuant to this Agreement, an agreement (in such form as the Company may specify) in which Participant represents and warrants that Participant is purchasing or acquiring the shares acquired under this Agreement for Participant’s own account, for investment only and not with a view to the resale or distribution thereof, and represents and agrees that any subsequent offer for sale or distribution of any kind of such Shares shall be made only pursuant to either (i) a registration statement on an appropriate form under the Securities Act, which registration statement has become effective and is current with regard to the Shares being offered or sold, or (ii) a specific exemption from the registration requirements of the Securities Act, but in claiming such exemption Participant shall, prior to any offer for sale of such Shares, obtain a prior favorable written opinion, in form and substance satisfactory to the Company, from counsel for or approved by the Company, as to the applicability of such exemption thereto.
16.Code Section 409A Compliance. Except with respect to Participants who are Retirement eligible or become Retirement eligible before the calendar year containing the Vesting Date as shown on the Grant Notice, it is intended that this Agreement meet the short-term deferral exception from Code Section 409A. This Agreement and the Plan shall be administered in a manner consistent with this intent and any provision that would cause the Agreement or Plan to fail to satisfy this exception shall have no force and effect. Notwithstanding anything contained herein to the contrary, Shares in respect of any Performance Stock Units that (a) constitute “nonqualified deferred compensation” as defined in Code Section 409A and (b) vest as a consequence of Participant’s Termination shall not be delivered until the date that Participant incurs a “separation from service” within the meaning of Code Section 409A (or, if Participant is a “specified employee” within the meaning of Code Section 409A and the regulations promulgated thereunder, the date that is six months following the date of such “separation from service” (or death, if earlier). In addition, each amount to be paid or benefit to be provided to Participant pursuant to this Agreement that constitutes deferred compensation subject to Code Section 409A, shall be construed as a separate identified payment for purposes of Code Section 409A.
17.Notices. All notices by Participant or Participant’s assignees shall be addressed to Elevance Health, Inc., 220 Virginia Avenue, Indianapolis, Indiana 46204, Attention: Stock Administration, or such other address as the Company may from time to time specify. All notices to Participant shall be addressed to Participant at Participant’s address in the Company’s records.
12
2024 Performance Stock Unit



18.Other Plans. Participant acknowledges that any income derived from the Performance Stock Units shall not affect Participant’s participation in, or benefits under, any other benefit plan or other contract or arrangement maintained by the Company or any Affiliate.
19.Recoupment Policy for Incentive Compensation. The Company's Recoupment Policy for Incentive Compensation, as may be amended from time to time, shall apply to the Performance Stock Units, any Shares delivered hereunder, and any profits realized on the sale of such Shares to the extent that Participant is covered by such policy. If Participant is covered by such policy, the policy may apply to recoup Performance Stock Units awarded, any Shares delivered hereunder or profits realized on the sale of such Shares either before, on or after the date on which Participant becomes subject to such policy.

    ELEVANCE HEALTH, INC.
    By:        
            ______________________________
        Printed:    Ramiro G. Peru
        Its:    Chair, Compensation and Talent Committee
            of the Board of Directors

13
2024 Performance Stock Unit



APPENDIX A

Alabama:
If Alabama law is deemed to apply, then the following applies to Participant: (a) Section 7(d) is rewritten as follows: “While employed and for a period of twelve (12) months from Termination, Participant will not participate in soliciting any Covered Employee of the Company who is in a Sensitive Position to leave the employment of the Company on behalf of (or for the benefit of) a Competitor nor will Participant knowingly assist a Competitor in efforts to hire a Covered Employee away from the Company.  As used in this Section 7(d), a “Covered Employee” is an Employee with whom Participant worked, as to whom Participant had supervisory responsibilities, or regarding which Participant received Confidential Information during the Look Back Period. An Employee in a “Sensitive Position” refers to an Employee who is uniquely essential to the management, organization, or service of the business;” and (b) Section 7(c) is limited to prohibiting the solicitation of persons or entities who have a current business relationship with the Company.
Arizona:
If Arizona law is deemed to apply, then the following applies to Participant: (a) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret; and (b) the restrictions in Section 7(c) shall be limited to the Restricted Territory.
Arkansas, Connecticut, Montana, and South Carolina:
If Arkansas, Connecticut, Montana, or South Carolina law is deemed to apply, then the following applies to Participant: Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.
California:
If California law is deemed to apply, then the following applies to Participant: (a) the noncompetition restriction in Section 7(b) shall not apply; (b) the Employee non-solicitation restrictions in Section 7(d) shall not apply; and (c) Section 7(c) shall be limited to situations where Participant is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law). The preceding sentence supersedes any contradictory provision in any prior agreements between Participant and the Company regarding noncompetition or non-solicitation.

Colorado:
If Colorado law is deemed to apply, then the following applies to Participant:
(a) Section 7(b) shall apply only if Participant earns Annualized Cash Compensation equivalent to or greater than the Threshold Amount for Highly Compensated Workers and to the extent that the conduct in violation of Section 7(b) is aided by Participant’s use or disclosure of the Company’s trade secrets.
(b) Section 7(c) shall apply only if Participant earns Annualized Cash Compensation equivalent to or greater than sixty percent (60%) of the Threshold Amount for Highly Compensated Workers and to the extent that the conduct in violation of Section 7(c) is aided by Participant’s use or disclosure of the Company’s trade secrets.
(c) Section 7(d) shall not apply.
(d) “Annualized Cash Compensation” means: (1) the amount of gross salary or wage amount, the fee amount, or other compensation amount for the full year, if the worker was employed or engaged for a full year; or (2) the compensation that the worker would have earned, based on the worker’s gross salary or wage amount, fee, or other compensation if the worker was not employed or engaged for a full year. In determining whether a worker’s cash compensation exceeds the threshold amount, where the worker has been employed for less than a calendar year, the worker’s cash compensation exceeds the threshold amount if the worker would reasonably expect to earn more than the threshold amount during a calendar year of employment.
14
2024 Performance Stock Unit





(e) “Threshold Amount for Highly Compensated Workers” means the greater of the threshold amount for highly compensated workers as determined by the Division of Labor Standards and Statistics in the Department of Labor and Employment, as of August 10, 2022 or the date Participant accepts this Agreement.
(f) Nothing contained in this Agreement shall be construed to prohibit Participant from disclosing information that: (1) arises from Participant’s general training, knowledge, skill, or experience, whether gained on the job or otherwise; (2) is readily ascertainable to the public; or (3) a worker otherwise has a right to disclose as legally protected conduct.
(g) Participant acknowledges that Participant received notice of this Agreement (including, but not limited to, the provisions of Section 7: (1) before Participant accepted the Company’s offer of employment (if Participant is a new hire); or (2) at least fourteen (14) days before the earlier of (I) Participant’s acceptance of this Agreement, or (II) the effective date of any additional compensation or change in the terms or conditions of employment that provides consideration for the covenants in Section 7.
Georgia:
If Participant resides in Georgia and is subject to Georgia law, then Section 7(d) shall be limited to targeting for solicitation or hire Employees who are located within the Restricted Territory.

Illinois:
If Participant resides in Illinois and is subject to Illinois law, then:
(a) The provisions of Section 7(c) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $45,000 per year in 2022-2026, $47,500 per year in 2027-2031, $50,000 per year in 2032-2036, and $52,500 beginning on January 1, 2037;
(b) The provisions of Section 7(d) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $45,000 per year in 2022-2026, $47,500 per year in 2027-2031, $50,000 per year in 2032-2036, and $52,500 beginning on January 1, 2037;
(c) The provisions of Section 7(b) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $75,000 per year in 2022-2026, $80,000 per year in 2027-2031, $85,000 per year in 2032-2036, and $90,000 beginning on January 1, 2037;
(d) The provisions of Section 7(b) shall not apply if Participant is covered by a collective bargaining agreement under the Illinois Public Relations Act;
(e) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret;
(f) Participant acknowledges that Participant has been advised to consult with an attorney about this Agreement and has been given an opportunity to do so; and
(g) If Participant is a new hire, Participant acknowledges that Participant has been provided a copy of this Agreement at least 14 calendar days before the commencement of employment. If Participant is an existing Employee, Participant acknowledges that Participant has been given at least 14 calendar days to review this Agreement.
Indiana:
If Participant resides in Indiana and is subject to Indiana law, then the restrictions on Participant under Section 7(d) shall apply only with respect to soliciting, hiring, attempting to solicit or hire, or participating in any attempt to solicit or hire individuals who themselves had access to Confidential Information in the prior six months.
15
2024 Performance Stock Unit



Louisiana:
If Louisiana law is deemed to apply, then the following applies to Participant: (a) the “Restricted Territory” defined in Section 7 of the Agreement is understood to cover the following parishes in Louisiana and all counties outside Louisiana where Participant had responsibilities for the Company: Acadia, Allen, Ascension, Assumption, Avoyelles, Beauregard, Bienville, Bossier, Caddo, Calcasieu, Caldwell, Cameron, Catahoula, Claiborne, Concordia, DeSoto, East Baton Rouge, East Carroll, East Feliciana, Evangeline, Franklin, Grant, Iberia, Iberville, Jackson, Jefferson, Jefferson Davis, LaSalle, Lafayette, Lafourche, Lincoln, Livingston, Madison, Morehouse, Natchitoches, Orleans, Ouachita, Plaquemines, Pointe Coupee, Rapides, Red River, Richland, Sabine, St. Bernard, St. Charles, St. Helena, St. James, St. John The Baptist, St. Landry, St. Martin, St. Mary, St. Tammany, Tangipahoa, Tensas, Terrebonne, Union, Vermilion, Vernon, Washington, Webster, West Baton Rouge, West Carroll, West Feliciana, Winn; and (b) the restrictions in Section 7(c) (as well as Section 7(b)) shall be limited to the foregoing parishes and counties.
Maine:
If Maine law is deemed to apply, then the following applies to Participant: (a) Participant acknowledges that if Participant is a new hire Participant received a copy of this Agreement prior to receiving a formal offer of employment from the Company and was given at least three business days to consider the Agreement before signing; (b) Section 7(b) will not take effect until one year of employment or a period of six months from the date the agreement is signed, whichever is later; and (c) Section 7(b) shall not apply if Participant earns at or below 400% of the federal poverty level.
Maryland:
If Maryland law is deemed to apply, then the following applies to Participant: Section 7(b) shall not apply if Participant earns equal to or less than $15/hour or $31,200 annually.
Massachusetts:
If Participant resides or works in Massachusetts for at least the thirty days preceding Participant’s Termination, then the Company will notify Participant within ten (10) business days of Participant’s Termination whether the Company decides to waive Section 7(b) or make these provisions enforceable by paying Participant garden leave as provided by the Massachusetts Noncompetition Agreement Act, G.L. c. 149, S. 24L. In addition, if Massachusetts law is deemed to apply, then the following applies to Participant:
(a) Section 7(b) will not apply if Participant’s employment is terminated without “cause” or if Participant is terminated as part of a reduction in force. Participant further understands that for the limited purpose of the application of the non-competition clause in Section 7(b) of the Agreement, “cause” to terminate Participant’s employment exists if Participant has (i) committed, admitted committing, or plead guilty to a felony or crime involving moral turpitude, fraud, theft, misappropriation, or dishonesty, (ii) violated a material term of this Agreement or Company policy, (iii) engaged in insubordination, or failed or refused to perform assigned duties of Participant’s position despite reasonable opportunity to perform, (iv) failed to exercise reasonable care and diligence in the exercise of Participant’s duties for the Company, or (iv) engaged in conduct or omissions that Participant knew, or should have known (with the exercise of reasonable care), would cause, or be likely to cause, harm to the Company or its reputation in the business community;
(b) Participant acknowledges that Participant has been advised to consult with an attorney about this Agreement and has been given an opportunity to do so;
(c) the Restricted Period applicable to Section 7(b) shall be limited to a period of one year following Participant’s Termination (as well as while Participant is employed by the Company); however, if Participant breaches Section 7(b) of this Agreement, and also breaches Participant’s fiduciary duty to the Company and/or has unlawfully taken, physically or electronically, any Company records, then such Restricted Period shall be extended to a period of two (2) years from Termination;
16
2024 Performance Stock Unit



(d) Participant acknowledges that (i) if Participant is being initially hired by the Company, that Participant received a copy of this Agreement prior to receiving a formal offer of employment from the Company or at least ten (10) business days before commencement of Participant’s employment by the Company, whichever came first; or (ii) if Participant was already employed by the Company at the time of signing this Agreement, that Participant was provided a copy hereof at least ten (10) business days before the effective date of this Agreement;
(e) the tolling language Section 10(b) shall only apply to any breach of Section 7(c) and (d) (i.e., the tolling language shall not apply to Section 7(b)); and
(f) Section 7(b) shall not apply to Participant following Termination if Participant is: classified as non-exempt under the FLSA; 18 years or younger; or an undergraduate or graduate student in an internship or other short-term employment relationship while enrolled in college or graduate school.
Minnesota:
If Minnesota law is deemed to apply, then the restrictions in Section 7(b) shall be limited to situations in which Participant is aided in his or her conduct by the use or disclosure of Confidential Information.

Nebraska:
If Nebraska law is deemed to apply, then the following applies to Participant: (a) Section 7(c) is limited to the solicitation of persons or entities with which Participant did business and had personal business-related contact during the Look Back Period; and (b) Section 7(b) is limited to restricting Participant from working for a Company client or account with whom the Participant did business and had personal business-related contact during the Look Back Period.

Nevada:
If Nevada law is deemed to apply, then the following applies to Participant: (a) Section 7 does not preclude Participant from providing services to any former client or customer of the Company if: (1) Participant did not solicit the former customer or client; (2) the customer or client voluntarily chose to leave and seek services from Participant; and (3) Participant is otherwise complying with the limitations in this Agreement as to time and scope of activity to be restrained; and (b) Section 7(b) does not apply if Participant is paid solely an hourly wage, exclusive of tips or gratuities.
New Hampshire:
If New Hampshire law is deemed to apply, then the following applies to Participant: (a) Section 7(b) does not apply if Participant earns an hourly rate less than or equal to 200 percent of the federal minimum wage; and (b) Participant acknowledges that Participant was given a copy of this Agreement prior to a change in job classification or the offer of employment.
New York:
If New York law is deemed to apply, then the following applies to Participant: Section 7(c) shall be modified to exclude those clients or customers who became a client or customer of the Company as a result of Participant’s independent contact and business development efforts with the customer or client prior to and independent from his/her employment with the Company.
North Carolina:
If North Carolina law is deemed to apply, then the following applies to Participant: (a) the Look Back Period shall be calculated looking back twenty-four (24) months from the date of enforcement and not from the date Participant’s employment ends; and (b) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.
17
2024 Performance Stock Unit



North Dakota:
If North Dakota law is deemed to apply, then the following applies to Participant: (a) the noncompetition restriction in Section 7(b) shall not apply; and (b) Section 7(c) shall be limited to situations where Participant is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law).
Oklahoma:
If Oklahoma law is deemed to apply, then the following applies to Participant: (i) Section 7(c) is limited to preclude only the direct solicitation of established customers of the Company for the purpose of doing any business that would compete with the Company’s business; and (ii) the noncompetition restrictions in Section 7(b) shall not apply.
Oregon:
If Oregon law is deemed to apply, then the following applies to Participant: the restrictions in Section 7(b) shall apply only if: (a) Participant is engaged in administrative, executive or professional work and performs predominantly intellectual, managerial, or creative tasks, exercises discretion and independent judgment and earns a salary or is otherwise exempt from Oregon's minimum wage and overtime laws; (b) the Company has a "protectable interest" (meaning, access to trade secrets or competitively sensitive confidential business or professional information); and (c) the total amount of Participant's annual gross salary and commission, calculated on an annual basis, at the time of Participant's Termination, exceeds $100,533 adjusted annually for inflation pursuant to the Consumer Price Index for All Urban Consumers, West Region (All Items), as published by the Bureau of Labor Statistics of the United States Department of Labor immediately preceding the calendar year of Participant’s Termination. However, if Participant does not meet requirements of either (a) or (c) (or both), the Company may, on a case-by-case basis, decide to make Section 7(b) enforceable as to Participant (as allowed by Oregon law), by agreeing in writing to pay Participant, during the period of time Participant is restrained from competing, the greater of: (i) compensation equal to at least 50 percent of Participant’s annual gross base salary and commissions at the time of Termination; or (ii) fifty percent of $100,533 adjusted annually for inflation pursuant to the Consumer Price Index for All Urban Consumers, West Region (All Items), as published by the Bureau of Labor Statistics of the United States Department of Labor immediately preceding the calendar year of Participant’s Termination. In addition, if Participant is a new hire, Participant acknowledges that Participant was notified in a written offer of employment received at least two weeks before the commencement of employment that a noncompetition agreement was a condition of employment. If Participant is an existing Employee, Participant acknowledges that this Agreement was entered into upon a subsequent bona fide advancement of Participant by the Company; namely the Company is conferring upon Participant equity awards that, if accepted by Participant, will supplement Participant’s compensation.
Puerto Rico:
If Puerto Rico law is deemed to apply, then the following applies to Participant: (a) the Restricted Period and the Look Back Period in Section 7 shall be, in each case, only a period of twelve (12) months; (b) the Restricted Territory shall be limited to the territory of Puerto Rico; (c) the customer restriction in Section 7(c) shall be limited to clients, accounts, and medical care providers that were personally serviced by Participant during the Look Back Period and had an active business relationship with the Company within the last thirty (30) days prior to Participant’s Termination; and (d) the tolling provision in Section 10(b) shall not apply.
Rhode Island:
If Rhode Island law is deemed to apply, then Section 7(b) shall not apply to Participant following Termination if Participant is: classified as non-exempt under the FLSA; an undergraduate or graduate student in an internship or short-term employment relationship; 18 years of age or younger; or a low wage Participant (defined as earning less than 250% of the federal poverty level).
Utah:
If Utah law is deemed to apply, then the following applies to Participant: (a) the Restricted Period applicable to Section 7(b) shall be limited to a period of one year following Termination (as well as while Participant is employed by the Company).
18
2024 Performance Stock Unit



Virginia:
If Virginia law is deemed to apply, then the following applies to Participant: (a) Section 7(b)-(d) shall not apply if Participant is a “low wage Participant.” A “low wage Participant” refers to a Participant whose average weekly earnings (calculated by dividing Participant's earnings during the period of 52 weeks immediately preceding Termination by 52, or if Participant worked fewer than 52 weeks, by the number of weeks that Participant was actually paid during the 52-week period) are less than the average weekly wage of the Commonwealth of Virginia as determined pursuant to subsection B of Virginia Code § 65.2-500. "Low-wage Participant" includes interns, students, apprentices, or trainees employed, with or without pay, at a trade or occupation in order to gain work or educational experience. "Low-wage Participant" also includes an individual who has independently contracted with another person to perform services independent of an employment relationship and who is compensated for such services by such person at an hourly rate that is less than the median hourly wage for the Commonwealth of Virginia for all occupations as reported, for the preceding year, by the Bureau of Labor Statistics of the U.S. Department of Labor. However, "low-wage Participant" does not include any Participant whose earnings are derived, in whole or in predominant part, from sales commissions, incentives, or bonuses paid to Participant by the Company; (b) Section 7 does not preclude Participant from providing services to any client or customer of the Company if Participant did not initiate contact with or solicit the former customer or client; and (c) Participant’s nondisclosure obligation in Section 7(a) shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.
Washington (state):
If Participant resides in Washington at the time this Agreement is entered, Participant acknowledges that Participant was given at least ten (10) business days to consider this Agreement before accepting it.
In addition, if Washington law controls, then for so long as Washington law controls, the Agreement will be modified and applied as follows:
(a) Section 7(b) shall apply following Termination only if Participant’s annualized earnings from the Company exceed $100,000.00 per year (adjusted annually in accordance with Section 5 of Washington HP 1450), and Section 7(b) shall apply during employment only if Participant earns at least twice the Washington minimum hourly wage (subject to the common law duty of loyalty and the Company’s Code of Conduct);
(b) for purposes of the application of the non-competition provision in Section 7(b), Participant understands that the non-competition provision will not be enforced against Participant if Participant is terminated from employment without “cause” or if Participant is laid off, unless the Company pays Participant during the Restricted Period an amount equal to Participant’s base salary at Termination less any compensation earned by Participant during the Restricted Period. Participant further understands that for the limited purpose of the application of the non-competition clause in Section 7(b) of the Agreement, “cause” to terminate Participant’s employment exists if Participant has (i) committed, admitted committing, or plead guilty to a felony or crime involving moral turpitude, fraud, theft, misappropriation, or dishonesty, (ii) violated a material term of this Agreement or Company policy, (iii) engaged in insubordination, or failed or refused to perform assigned duties of my position despite reasonable opportunity to perform, (iv) failed to exercise reasonable care and diligence in the exercise of Participant’s duties for the Company, or (iv) engaged in conduct or omissions that Participant knew, or should have known (with the exercise of reasonable care), would cause, or be likely to cause, harm to the Company or its reputation in the business community; and
(c) Participant further acknowledges that if Participant is a new Employee, Participant has had advance notice of the terms of this Agreement prior to accepting the Company’s offer of employment.
Washington, D.C.
Participant acknowledges that Participant was given a copy of Washington, D.C., Council Bill 24-256 (“Bill 24-256”) prior to or contemporaneously with accepting this Agreement.
19
2024 Performance Stock Unit



If Participant is a “Covered Employee” as defined by Bill 24-256 and Participant is not a “Highly Compensated Employee,” as defined by Bill 24-256, the following applies to Participant: (1) Section 7(b) shall not apply; (2) “Confidential Information” shall, in all instances, be limited to information owned or possessed by the Company which is not available to the general public and which the Company has taken reasonable steps to ensure is protected from improper disclosure; (3) Participant is precluded, during Participant’s employment with the Company, from accepting money or a thing of value for performing work for a person other than the Company, where doing so can reasonably be concluded to result in (a) Participant’s disclosure or use of Confidential Information or “Proprietary employer information,” as defined by Bill 24-256; (b) a conflict with the Company’s established rules regarding conflicts of interest, or (c) impairment of the Company’s ability to comply with federal law, the law of the District of Columbia, or a contract or grant agreement.
If Participant is a “Covered Participant” as defined by Bill 24-256 and Participant is a “Highly Compensated Participant,” as defined by Bill 24-256, the following applies to Participant: (1) Participant acknowledges that Participant was given a copy of this Agreement at least 14 days before Participant commenced employment with the Company (if Participant is a new hire) or Participant was given a copy of this Agreement at least 14 days before Participant was required to accept this Agreement (if Participant is an existing Employee); (2) “Confidential Information” shall, in all instances, be limited to information owned or possessed by the Company which is not available to the general public and which the Company has taken reasonable steps to ensure is protected from improper disclosure; (3) the Restricted Period for purposes of the non-competition provision in Section 7(b) shall be limited to a period of twelve (12) months following Termination (and while Participant is employed by the Company); and (4) Participant is notified that The District of Columbia Ban on Non-Compete Agreements Amendment Act of 2020 limits the use of non-compete agreements. It allows employers to request non-compete agreements from “highly compensated employees” under certain conditions. The Company has determined that you are a highly compensated employee. For more information about the Ban on Non-Compete Agreements Amendment Act of 2020, contact the District of Columbia Department of Employment Services (DOES).
Wisconsin:
If Wisconsin law is deemed to apply, then the following applies to Participant: (a) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret; (b) the tolling provision in Section 10(b) shall not apply; and (c) Section 7(d) is rewritten as follows: “While employed and for a period of twelve (12) months following Termination, Participant will not participate in soliciting any “Covered Employee” of the Company that is in a “Sensitive Position” to leave the employment of the Company on behalf of (or for the benefit of) a Competitor; nor will Participant knowingly assist a Competitor in efforts to hire a Covered Employee away from the Company.  As used in this Section 7(d), a “Covered Employee” is an Employee with whom Participant worked, as to whom Participant had supervisory responsibilities, or regarding whom Participant received Confidential Information during the Look Back Period. A Participant in a “Sensitive Position” refers to an Employee who is in a management, supervisory, sales, research and development, or similar role where the Employee is provided Confidential Information or is involved in business dealings with the Company’s clients.”
20
2024 Performance Stock Unit
 EX-10.4 5 exhibit104executiveagreeme.htm EX-10.4 Document


EXHIBIT 10.4







Elevance Health
EXECUTIVE AGREEMENT PLAN
(Amended and Restated as of March 1, 2024)

















































TABLE OF CONTENTS


ARTICLE 1 PURPOSE AND INTENT    1
1.1    Purpose and Intent    1
ARTICLE 2 ELIGIBILITY AND PARTICIPATION    1
2.1    Participation    1
2.2    Termination of Participation    1
ARTICLE 3 SEVERANCE BENEFITS    2
3.1    Eligible Separation from Service    2
3.2    Severance Pay    2
3.3    Other Benefits During Severance Period    4
3.4    Payment    6
3.5    Waiver and Release    6
3.6    Restrictive Covenants and Intellectual Property    7
3.7    Return of Consideration    7
3.8    Equitable Relief and Other Remedies    8
3.9    Survival of Provisions    9
3.10    Cooperation    9
ARTICLE 4 ADDITIONAL CHANGE IN CONTROL BENEFITS    9
4.1    Equity Vesting Upon Change in Control    9
4.2    Guaranteed Annual Bonus for Year of Change in Control    10
4.3    Equity Vesting Upon Termination Without Cause or for Good Reason (With Change in Control)    10
4.4    Pro-Rata Bonus Payment Upon Termination Without Cause or for Good Reason (With Change in Control)    11
4.5    Amount Based on Qualified and Supplemental 401(k) Match    12
4.6    Certain Taxes    12
ARTICLE 5 CLAIMS    12
5.1    Good Reason Determinations    12
5.2    Claims Procedure    13
5.3    Claim Review Procedure    13
ARTICLE 6 ADMINISTRATION    13
6.1    Committee    13
6.2    Committee Membership    14
6.3    Duties    14
6.4    Binding Authority    15
6.5    Indemnification    15
6.6    Information    15
ARTICLE 7 GENERAL PROVISIONS    15
7.1    No Property Interest    15
7.2    Other Rights    15
i

7.3    Amendment or Termination    16
7.4    Successors    16
7.5    Severability    16
7.6    No Employment Rights    16
7.7    Transferability of Rights    16
7.8    Beneficiary    17
7.9    Company Action    17
7.10    Entire Document    17
7.11    Plan Year    17
7.12    Governing Law    17
ARTICLE 8 DEFINITIONS    18
8.1    Definitions    18
EXHIBIT A – EMPLOYMENT AGREEMENT
EXHIBIT B – WAIVER AND RELEASE
EXHIBIT C – RESTRICTIVE COVENANTS AND INTELLECTUAL PROPERTY
























ii

Elevance Health
Executive Agreement Plan
(Amended and Restated as of March 1, 2024)

ARTICLE 1
PURPOSE AND INTENT

1.1 Purpose and Intent. Elevance Health, Inc., an Indiana corporation with its principal
place of business in Indianapolis, Indiana (“Elevance Health”), maintains the Elevance Health Executive Agreement Plan (the “Plan”), most recently amended and restated effective June 28, 2022. The Plan is hereby amended and restated effective March 1, 2024. Words and phrases used with initial capitals in the Plan and not otherwise defined when first used are defined in Article 8.

The Plan is intended to provide certain key executive employees of Elevance Health and its subsidiaries and affiliates (collectively, the “Company”) compensation if they are involuntarily terminated with an Eligible Separation of Service, as that term is defined below, so as to attract and retain such employees and motivate them to enhance the value of the Company. The Plan is intended to be an unfunded welfare plan subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) or, to the extent it is determined to be a pension plan subject to ERISA, an unfunded pension plan maintained primarily for the purpose of providing deferred compensation to a select group of management or highly compensated employees. Participation in the Plan does not affect the at-will nature of the Participant’s employment with the Company.

ARTICLE 2
ELIGIBILITY AND PARTICIPATION

2.1    Participation. An Executive (as defined in Article 8) shall become a Participant
(“Participant”) upon mutual execution by the Executive and the Company of an agreement, substantially in the form attached as Exhibit A (“Employment Agreement”) within the time period stated below. Each such executed Employment Agreement shall form part of this Plan and is incorporated into this Plan by this reference. As soon as practicable after the date an individual becomes an Executive, the Committee or its delegate shall deliver a copy of the Plan to the Executive, advise the Executive of his or her eligibility, and offer him or her for a period of forty- five (45) days the opportunity to enter into an Employment Agreement. If an Executive does not enter into an Employment Agreement within such forty-five (45) day period, the Executive shall have no further opportunity to become a Participant in the Plan unless either the Chief Executive Officer or the Chief Human Resources Officer of the Company or his or her delegate, in his or her sole discretion, in writing, affords the Executive a new or extended opportunity to become a Participant in the Plan.

2.2    Termination of Participation. A Participant’s participation in the Plan shall automatically terminate, without notice to or consent of the Participant, upon the earliest to occur of the following events:



1

(a)    termination of the Participant’s employment with the Company for any reason that is not an Eligible Separation from Service as defined below;

(b)    the one-year anniversary of a written notice (pursuant to the terms of the Employment Agreement) of the termination of the Participant’s Employment Agreement.

ARTICLE 3
SEVERANCE BENEFITS

3.1    Eligible Separation from Service. Each Participant shall be entitled to Severance
Pay and other benefits under the Plan in the amount set forth in Sections 3.2 and 3.3 (and, if applicable, Sections 4.3, 4.4, and 4.5) (collectively, “Severance Benefits”) only if the Participant incurs an Eligible Separation from Service while a Participant. Entitlement to Severance Benefits is subject to the terms and conditions of this Plan, including the Participant’s compliance with Section 3.6 hereof and the Participant’s execution and delivery of a valid and unrevoked Waiver and Release Agreement as required by Section 3.5. For this purpose, an “Eligible Separation from Service” is:

(a)    a Separation from Service by reason of a termination of the Participant’s employment by the Company for any reason other than death, disability, Cause, or Transfer of Business; or

(b)    a Separation from Service by reason of a termination of the Participant’s employment by the Participant for Good Reason.

Severance Benefits shall be payable with respect to a Separation from Service only if the separation meets the above definition of Eligible Separation from Service. For avoidance of doubt, none of the following shall be an Eligible Separation from Service: (i) termination of the Participant’s employment upon death or disability, (ii) termination of the Participant’s employment by the Company for Cause or upon Transfer of Business, or (iii) any voluntary resignation that does not constitute a termination of the Participant’s employment for Good Reason.

3.2    Severance Pay.

(a)    The aggregate amount of severance pay (“Severance Pay”) to which a Participant who incurs an Eligible Separation from Service is entitled under the Plan shall be the product of the amount described in clause (i), multiplied by the applicable percentage described in clause (ii), with such product then reduced by the amount, if any, described in clause (iii), each as set forth below and taking into account clause (iv) below. Severance Pay shall be payable, as described in Section 3.4, over the applicable period (“Severance Period”) described in clause (iv) and specified in the table that follows. For the avoidance of doubt, Severance Pay is calculated and expressed in the aggregate and not as an annual amount.

(i)    If a Vice President, Senior Vice President, Executive Vice President, or Chief Executive Officer, the amount described in this clause is the sum of the Participant’s
2

Annual Base Salary and Annual Target Bonus; if an Other Key Executive, the amount described in this clause is only the Participant’s Annual Base Salary;

(ii)    The applicable percentage set forth in the table below, as determined under clause (iv) below, for the Participant’s employment classification at the time of the Eligible Separation from Service (but disregarding any adverse change in employment classification during an Imminent Change in Control Period or within thirty-six (36) months after a Change in Control).

(iii)    The amount described in this clause is the sum of: (A) any severance or similar amounts payable to the Participant pursuant to any national, state, or local law, regulation, or other governmental provision within or outside the United States, including but not limited to payments under the Federal Worker Adjustment and Retraining Notification Act (WARN); and (B) any termination, severance, or similar amounts payable to the Participant under any other termination or severance plan, policy, or program of the Company (including, for the avoidance of doubt, any individual agreement covering the Participant or corporate transaction agreement to which the Company is a party that provides for payment of such amounts to the Participant).

(iv)    In the event a Participant’s Eligible Separation from Service occurs outside an Imminent Change in Control Period and outside the thirty-six (36) month period following a Change in Control, the applicable percentage is the percentage set forth in column (A) below and the applicable Severance Period is the period set forth in column (B) below. In the event the Participant’s Eligible Separation from Service occurs either (I) within an Imminent Change in Control Period and the contemplated Change in Control occurs within one year of the Participant’s Eligible Separation from Service, or (II) within the thirty-six (36) month period following a Change in Control, then the applicable percentage is the percentage set forth in column (C) below and the applicable Severance Period is the period set forth in column (D) below.

(A)
(B)
(C)
(D)
Position
Percentage (absent Change in Control)
Severance Period (absent Change in Control)
Percentage (Change in Control)
Severance Period (Change in Control)
Other Key Executive
100%
One year
100%
One year
Senior Vice President or Vice President
100%
One year
100%
One year
Executive Vice President 1 or Chief Executive Officer
200%
Two years
300%
Three years
Executive Vice President2
200%
Two years
200%
Two years

1Applies to an Executive who became a Participant before May 15, 2018, is classified as an Executive Vice President as of May 15, 2018, and remains an Executive Vice President until the time of an Eligible Separation from Service as provided in (ii) of Section 3.2(a).


3

2Applies to an Executive classified as an Executive Vice President at the time of an Eligible Separation from Service as provided in (ii) of Section 3.2(a) and who either (a) first became a Participant on or after May 15, 2018, or (b) is a Participant as of May 14, 2018, in another employment classification and his or her employment classification changes to Executive Vice President on or after May 15, 2018.

(b)    Example of Severance Pay calculation under Section 3.2(a): For an Executive Vice President who incurs an Eligible Separation from Service outside of a Change in Control period, Severance Pay is calculated as (Annual Base Salary + Annual Target Bonus) x 200% and, because the applicable Severance Period is two years, the result is divided by 24 months to determine the amount payable each month (or divided by 48 to determine a semi-monthly amount).

(c)    There shall be no duplication of severance benefits in any manner. For example, no Participant shall be entitled to Severance Pay hereunder for more than one position with the Company.

(d)    A Participant receiving Severance Pay shall not be obligated to secure new employment, but each Participant shall report promptly to the Company any actual employment obtained during the Severance Period. Severance Pay under the Plan shall not be subject to mitigation except: (i) as described in the reduction and nonduplication provisions of Sections 3.2(a)(iii) and 3.2(b); and (ii) under Section 3.3 with respect to eligibility for health benefits and life insurance coverage. Severance Pay shall be subject to Section 3.7 (“Return of Consideration”).

(e)    Severance Periods shall be measured from the date of the Eligible Separation from Service.

3.3    Other Benefits During Severance Period.

(a)    Severance Benefits for a Participant entitled to Severance Pay pursuant to Section 3.2 shall include the following additional benefits during the applicable Severance Period:

(i)    continued participation for him or her (and for his or her eligible dependents) in the Company’s health benefit plan on the same basis (other than payment of contributions) applicable to active employees from time to time; provided that the Participant and his or her eligible dependents assume the cost, on an after-tax basis, for such continued coverage, and further provided that this coverage shall terminate prior to the end of the Severance Period when the Participant (or his or her eligible dependents, as applicable) becomes entitled to health benefit plan coverage (whether or not comparable to plans of the Company) from any successor employer; and

(ii)    on or about January 31 of the year following the year in which the Separation from Service occurs and continuing on or about each January 31 until the year following the year in which the Participant’s health benefit plan coverage ceases pursuant to Section 3.3(a)(i), the Company will make a payment to the Participant equal to the amount the Participant paid during the immediately preceding calendar year for health benefit plan continuation coverage described in Section 3.3(a)(i) that exceeds the amount that the Participant would have paid if the Participant paid for such continued health benefit plan coverage on the same basis as applicable to active employees, provided that each such
4

cash payment by the Company pursuant to this Section 3.3(a)(ii) shall be considered a separate payment and not one of a series of payments for purposes of Section 409A; and

(iii)    continued participation for him or her in the Company’s life insurance benefit plan on the same basis (including payment of contributions) as active employees from time to time (and subject to any applicable conversion rights); provided that this coverage shall terminate prior to the end of the Severance Period when the Participant (or his or her eligible dependents, as applicable) becomes entitled to life insurance benefit plan coverage (whether or not comparable to coverage of the Company) from any successor employer; and

(iv)    if the cash credits portion of the Directed Executive Compensation program is available to active employees at the Participant’s Executive level and the Executive was a Participant prior to June 1, 2018, the continuation of Directed Executive Compensation monthly cash payments, provided that each such cash payment by the Company pursuant to this Section 3.3(a)(iv) shall be considered a separate payment and not one of a series of payments for purposes of Section 409A; and

(v)    if the core credits portion of the Directed Executive Compensation program is available to active employees at the Participant’s Executive level and the Executive was a Participant prior to June 1, 2018, the Company shall reimburse the Participant’s expenses for eligible expenses during the Severance Period. Such reimbursement shall be made no later than the last day of the calendar year following the calendar year in which the Participant incurs the eligible expense. In no event will the amount of expenses so reimbursed by the Company in one year affect the amount of expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year. Each reimbursement of the Participant’s expenses pursuant to this Section 3.3(a)(v) shall be considered a separate payment and not one of a series of payments for purposes of Section 409A.

Neither Executive nor his or her dependents shall be eligible for continued participation in any disability income plan or travel accident insurance plan, or for active participation in any tax- qualified or nonqualified retirement plan of the Company during the Severance Period. Nothing herein shall be deemed to restrict the right of the Company to amend or terminate any plan in a manner generally applicable to active employees.

(b)    The period of continuation coverage to which the Participant is entitled (at the Participant’s sole expense and subject to timely election by the Participant and/or any eligible dependents) under Section 601 et seq. of ERISA (the “COBRA Continuation Period”) shall begin when coverage described in Section 3.3(a)(i) ends.

(c)    Eligible Participants shall be entitled to reasonable outplacement counseling with an outplacement firm of the Company’s selection in a form and manner determined by the Company, provided, however, that a Participant must conclude such services by December 31st of the second taxable year following the Participant’s Separation from Service or such earlier date established by the Company. The Company shall reimburse the Participant for such expenses or
5

pay the outplacement firm as the case may be, no later than December 31st of the third taxable year following the Participant’s Separation from Service.

3.4    Payment. Severance Pay (including payments pursuant to Section 4.5, if applicable) and payments provided under Section 3.3(a)(ii), if any, shall commence to be paid as soon as practicable after the 45th day after the Eligible Separation from Service and shall be paid in substantially equal monthly payments (or more frequent periodic installments corresponding to the Company’s normal payroll practices for Executive employees) over the Severance Period. Each such payment shall be considered a separate payment and not part of a series of installments for purposes of the short-term deferral rules under Treasury Regulation Section 1.409A-1(b)(4)(i), and the exemption for involuntary terminations under separation pay plans under Treasury Regulation Section 1.409A-1(b)(9)(iii). As a result, the following payments are exempt from the requirements of Section 409A of the Code:

(a)    Payments that are made on or before the 15th day of the third month of the calendar year following the year of the Eligible Separation from Service, and

(b)    Any additional payments that are made on or before the last day of the second calendar year following the year of the Executive’s Eligible Separation from Service and that do not exceed the lesser of two times:

(i)    The Executive’s annualized compensation based upon the annual rate of pay for services provided to the Company for the Executive’s taxable year that precedes the taxable year in which the Eligible Separation from Service occurs (adjusted for any increase during that year that was expected to continue indefinitely if the Executive had not incurred a Separation from Service); or

(ii)    the limit under Section 401(a)(17) of the Code then in effect.

Notwithstanding the foregoing, in the event Severance Pay is paid to an Executive who is a Key Employee during the taxable year in which the Separation from Service occurs, to the extent the payments to be made during the first six month period following the Executive’s Eligible Separation from Service exceed the amounts exempt from Section 409A of the Code under Sections 3.4(a) and 3.4(b) above, the excess amount shall be withheld and will be instead paid on the first day of the seventh month following the Executive’s Eligible Separation from Service. Any withheld amount shall include interest thereon, from the date that they would have been paid absent such delay through the date of payment, at 120% of the applicable six-month short-term federal rate, determined under Section 1274(d) of the Code (the “AFR”).

3.5    Waiver and Release. In order to receive benefits under the Plan, a Participant must execute and deliver to the Company a valid Waiver and Release Agreement within thirty (30) days of his or her date of Separation from Service, in a form tendered by the Company, which shall be substantially in the form of the Waiver and Release Agreement attached hereto as Exhibit B, with any changes thereto approved by the Company’s counsel prior to execution. No benefits shall be paid under the Plan until the Participant has executed and returned his or her Waiver and Release Agreement and the period within which a Participant may revoke his or her Waiver and Release Agreement has expired without revocation. A Participant may revoke his or her signed Waiver
6

and Release Agreement within seven (7) days (or such other period provided by law) after signing the Waiver and Release Agreement. Any such revocation must be made in writing and must be received by the Company within such seven (7) day (or such other) period. A Participant who does not submit a signed Waiver and Release Agreement to the Company within thirty (30) days of his or her Separation from Service shall not be eligible to receive any Severance Benefits under the Plan. A Participant who timely revokes his or her Waiver and Release Agreement shall not be eligible to receive any Severance Benefits under the Plan.

3.6    Restrictive Covenants and Intellectual Property. Without limiting his or her other duties and obligations hereunder, each Participant agrees, as a condition of participation in this Plan, to comply with the following:

(a)    Before Acceptance of an Equity Award. If the Participant has not yet accepted an Equity Award (as defined in Article 8) when the Participant signs an Employment Agreement to become a Participant in this Plan, the Participant agrees to comply with the restrictive covenants and intellectual property obligations set forth in Exhibit C of this Plan, to the extent applicable to the Participant under the terms of Exhibit C.

(b)    Upon and After Acceptance of an Equity Award. The Participant agrees that, upon accepting an Equity Award (whether before or after signing an Employment Agreement to become a Participant in this Plan), the Participant becomes bound by restrictive covenant(s) and intellectual property obligations as applicable to the Participant under the terms of the Equity Award agreement. The Participant further agrees that such covenant(s) and obligations are deemed to be incorporated herein by reference immediately upon Participant’s acceptance of each Equity Award throughout the Participant’s participation in this Plan and shall thereupon supersede the restrictive covenants and intellectual property obligations set forth in Exhibit C or any previously granted Equity Award. The Participant expressly acknowledges and agrees that compliance with the restrictive covenants and intellectual property obligations in his or her most recently accepted Equity Award containing such provisions becomes, upon acceptance of the Equity Award, a condition of entitlement to Severance Benefits under this Plan, without regard to the Plan amendment and notice provisions in Section 7.3 of this Plan.

A Participant’s compliance with or violation of this Section 3.6 shall be determined by the Company (and not by the Committee or any other party acting as a fiduciary of this Plan).

3.7    Return of Consideration.

(a)    If at any time a Participant breaches any provision of Section 3.6 or Section 3.10, the Company shall cease to provide any further Severance Pay or other benefits under the Plan and the Participant shall repay to the Company all Severance Pay and other benefits previously received under the Plan. Any amount subject to potential repayment pursuant to this Section 3.7 shall be held by the Participant in constructive trust for the benefit of the Company and shall, upon written notice from the Company, within 10 days of such notice, be paid by the Participant to the Company. The return of consideration under this Section 3.7 is meant to reimburse the Company for some of the harm caused by Participant’s wrongful conduct; however, it is not a full measure of the damage caused by Participant’s conduct and does not preclude the Company from seeking
7

the recovery of any and all damages caused by Participant or from seeking injunctive relief, including relief provided under any other plan or agreement (including, but not limited to, Equity Award agreements).

(b)    The amount to be repaid pursuant to this Section 3.7 shall be determined on a gross basis, without reduction for any taxes incurred. The Company shall have the right to offset such amount against any amounts otherwise owed to the Participant by the Company (whether as wages, vacation pay, or pursuant to any benefit plan or other compensatory arrangement other than any amount pursuant to any nonqualified deferred compensation plan under Section 409A of the Code).

3.8    Equitable Relief and Other Remedies. As a condition of participation in this Plan:

(a)    The Participant acknowledges that each provision of Section 3.6 and 3.7 of the Plan
(i) is reasonable and necessary to preserve the legitimate business interests of the Company, its present and potential business activities, and the economic benefits derived therefrom; (ii) will not prevent him or her from earning a livelihood in the Participant’s chosen business; and (iii) is not an undue restraint on the trade of the Participant or any of the public interests that may be involved.

(b)    The Participant agrees that, in the event of the Participant’s breach of Section 3.6 or 3.10, the Company will be damaged beyond the amounts otherwise to be provided under this Plan and the Employment Agreement, and the amount of such damage may be difficult to measure. The Participant agrees that if the Participant commits or threatens to commit a breach of any of the covenants and agreements applicable to Participant under Sections 3.6 or 3.10, then, to the extent permitted by applicable law, the Company shall have the right to seek and obtain all appropriate injunctive and other equitable remedies, without posting bond therefor, except as required by law, in addition to any other rights and remedies that may be available at law or under this Plan, it being acknowledged and agreed that any such breach would cause irreparable injury to the Company and that money damages alone would not provide an adequate remedy.

(c)    The parties agree that any covenants contained or incorporated herein are severable. The parties further agree that the Company’s rights under Section 3.7 should be enforced to the fullest extent permitted by law irrespective of whether the Company seeks equitable relief in addition to relief provided therein or if a court or arbitrator deems equitable relief to be inappropriate.

(d)    EACH PARTY, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AS TO ANY ISSUE RELATING HERETO IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS PLAN (INCLUDING THE EMPLOYMENT AGREEMENT AND INCLUDING ANY COVENANTS CONTAINED OR INCORPORATED HEREIN).

(e)    In the event of a breach of Participant’s obligations under Section 3.6 or 3.10, the prevailing party shall be entitled to the recovery of its reasonable attorneys’ fees and expenses (including not only costs of court, but also expert fees, travel expenses, and other expenses incurred), and any other legal or equitable relief allowed by law.

8

3.9    Survival of Provisions. The obligations contained in Sections 3.6, 3.7, 3.8 and Section 3.10 shall survive the cessation of the Participant’s employment with the Company, regardless of the Participant’s entitlement to Severance Pay and other benefits hereunder or under the Employment Agreement and shall be fully enforceable thereafter.

3.10    Cooperation. Upon the receipt of reasonable notice from the Company (including from outside counsel to the Company), the Participant agrees that while employed by the Company and for two years (or, if longer, for so long as any claim referred to in this Section remains pending) after the termination of Participant’s employment for any reason, the Participant will respond and provide information with regard to matters in which the Participant has knowledge as a result of the Participant’s employment with the Company, and will provide reasonable assistance to the Company, its affiliates and their respective representatives in defense of any claims that may be made against the Company or its affiliates, and will assist the Company and its affiliates in the prosecution of any claims that may be made by the Company or its affiliates, to the extent that such claims may relate to the period of the Participant’s employment with the Company (or any predecessor); provided, that with respect to periods after the termination of the Participant’s employment, the Company shall reimburse the Participant for any out-of-pocket expenses incurred in providing such assistance and if the Participant is required to provide more than ten (10) hours of assistance per week after his termination of employment then the Company shall pay the Participant a reasonable amount of money for his services at a rate agreed to between the Company and the Participant; and provided further that after the Participant’s termination of employment with the Company such assistance shall not unreasonably interfere with the Participant’s business or personal obligations. The Participant agrees to promptly inform the Company if the Participant becomes aware of any lawsuits involving such claims that may be filed or threatened against the Company or its affiliates. The Participant also agrees to promptly inform the Company (to the extent the Participant is legally permitted to do so) if the Participant is asked to assist in any investigation of the Company or its affiliates (or their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company or its affiliates with respect to such investigation and shall not do so unless legally required. Provided, however, the Participant is not required to inform the Company of any investigation by a governmental agency or entity resulting from the reporting of possible violations of federal securities law or regulation to any governmental agency or entity, and the Participant may participate in such investigation, without informing the Company.

ARTICLE 4

ADDITIONAL CHANGE IN CONTROL BENEFITS

4.1    Equity Vesting Upon Change in Control.

(a)    If the conditions of Section 4.1(b) are satisfied, then as of the date of the Change in Control, all Options and SARs of a Participant shall become fully and immediately exercisable, all Restricted Stock shall become fully vested and nonforfeitable and forthwith delivered to a Participant if not previously delivered, and there shall be paid out in cash to the Participant within 30 days following the effective date of the Change in Control the value of the Performance Shares
9

to which the Participant would have been entitled if performance achieved 100% of the target performance goals established for such Performance Shares.

(b)    Both of the following conditions must be satisfied in order for Section 4.1(a) to apply:
(i)    A Change in Control must occur, and

(ii)    on or prior to such Change in Control either Elevance Health has not confirmed the continuation of the following awards without economic change, or the successor to Elevance Health in such Change in Control has not, on or prior to such Change in Control, assumed and continued the following awards without economic change:

(A)    any and all outstanding options (“Options”) to purchase Common Stock (or stock that has been converted into Common Stock),

(B)    any and all stock appreciation rights (“SARs”) based on appreciation in the value of Common Stock,

(C)    any and all restricted Common Stock (or deferred rights thereto, including restricted stock units), regardless of whether such restrictions are scheduled to lapse based on service or performance or both (“Restricted Stock”), and

(D)    any outstanding awards providing for the payment of a variable number of shares of Common Stock dependent on the achievement of performance goals, or of an amount based on the fair market value of such shares or the appreciation thereof (“Performance Shares”),

in each case, awarded to a Participant under any Plan, contract or arrangement for Options, SARs, Restricted Stock, or Performance Shares.

4.2    Guaranteed Annual Bonus for Year of Change in Control. This Section 4.2 does not apply to Participants who are classified as Other Key Executives. If a Change in Control occurs, each Participant’s annual bonus for the fiscal year in which the Change in Control occurs shall be in an amount (“Guaranteed Amount”) equal to the greater of (a) the Participant’s Target Bonus for such fiscal year, or (b) the bonus that is determined in the ordinary course under each annual bonus or short-term incentive plan (as determined by the Committee in its sole discretion) (a “Bonus Plan”) covering the Participant for the fiscal year in which the Change in Control occurs. The Guaranteed Amount shall be paid in a lump sum at the normal time for the payment of a bonus under the applicable Bonus Plan.

4.3    Equity Vesting Upon Termination Without Cause or for Good Reason (With Change in Control). This Section 4.3 does not apply to Participants who are classified as Other Key Executives.

10

(a)    If the conditions of Section 4.3(b) are satisfied, then as of the date of the Participant’s Eligible Separation from Service (i) all Pre-Change (as defined below) Options and Pre-Change SARs of such Participant shall become fully and immediately exercisable, (ii) all Pre- Change Restricted Stock shall become fully vested and nonforfeitable and forthwith delivered to the Participant if not previously delivered, and (iii) there shall be paid out in cash to the Participant within 45 days following the Separation from Service the value of the Pre-Change Performance Shares to which the Participant would have been entitled if performance achieved 100% of the target performance goals established for such Performance Shares.

(b)    Both of the following conditions must be satisfied in order for Section 4.3(a) to
apply:

(i)    the Participant must have had a Separation from Service within the thirty- six (36) month period following a Change in Control by reason of (A) a termination of the Participant’s employment by the Company other than for Cause, death, or disability, or (B) a termination of the Participant’s employment by the Participant for Good Reason; and

(ii)    the Participant must have executed and delivered a valid Waiver and Release Agreement as required by Section 3.5, and the period for revoking such Waiver and Release Agreement must have elapsed.

(c)    For purposes of this Section 4.3 a “Pre-Change” Option, SAR, Restricted Stock, or
Performance Share means (i) an award of an Option, SAR, Restricted Stock or Performance Share which was outstanding on both the date of the Change in Control and the date of the Eligible Separation from Service, and (ii) an award of an Option, SAR, Restricted Stock or Performance Share assumed and continued by a successor to Elevance Health in such Change in Control without economic change.

4.4    Pro-Rata Bonus Payment Upon Termination Without Cause or for Good Reason (With Change in Control). This Section 4.4 does not apply to Participants who are classified as Other Key Executives.

(a)    If the conditions of Section 4.4(b) are satisfied, then for the fiscal year in which the Participant’s Eligible Separation from Service occurs, the Participant shall be entitled to a pro-rata bonus (the “Pro-Rata Bonus”) equal to the product of the applicable amount described in (i), multiplied by the fraction determined in (ii):

(i)    the applicable amount is the Guaranteed Amount described in Section 4.2 for the fiscal year in which the Eligible Separation from Service occurs, and

(ii)    a fraction, the numerator of which is the number of days in such fiscal year before the date of the Eligible Separation from Service, and the denominator of which is the total number of days in such fiscal year.

The Pro-Rata Bonus shall be paid in a lump sum at the normal time for payment of a bonus under the applicable Bonus Plan.


11

(b)    Both of the following conditions must be satisfied in order for Section 4.4(a) to apply:
(i)    the Participant must have had an Eligible Separation from Service within the thirty-six (36) month period following a Change in Control by reason of (A) a termination of the Participant’s employment by the Company other than for Cause, death, or disability, or (B) a termination of the Participant’s employment by the Participant for Good Reason; and

(ii)    the Participant must have executed and delivered a valid Waiver and Release Agreement as required by Section 3.5, and the period for revoking such Waiver and Release Agreement must have elapsed.

4.5    Amount Based on Qualified and Supplemental 401(k) Match. This Section 4.5
does not apply to Participants who are classified as Other Key Executives. If the conditions of Section 4.4(b) are satisfied, Severance Pay pursuant to Section 3.2 shall be increased by an amount equal to the value of employer matching contributions to the Participant’s qualified and supplemental 401(k) accounts, as if Severance Pay had been considered eligible earnings in those programs. This amount is equal to the product of:

(a)    Severance Pay, multiplied by

(b)    the maximum matching contribution percentage applicable to the Participant under the Company’s 401(k) plan.

4.6    Certain Taxes. If it is determined that any benefit received or deemed received by the Participant from the Company pursuant to this Plan or otherwise (collectively, “Payments”) is or will become subject to any excise tax under Section 4999 of the Code or any similar tax payable under any United States federal, state, local or other law, but not including any tax payable under Section 409A of the Code (such excise tax and all such similar taxes collectively, “Excise Taxes”), then the Participant shall receive in respect of such Payments whichever of (a) or (b) below would result in the Participant retaining, after application of all applicable income taxes, Excise Taxes, and other taxes (“All Applicable Taxes”), the greater after-tax amount (the “After-Tax Benefit”); where:

(a)    is the Payments; and

(b)    is a reduced amount of Payments sufficient to avoid the imposition of Excise Taxes.

ARTICLE 5

CLAIMS

5.1    Good Reason Determinations. Any Participant who believes he or she has a right
to resign for Good Reason may apply to the Committee for written confirmation that an event constituting Good Reason has occurred with respect to such Participant. The Committee shall confirm or deny in writing that Good Reason exists within 21 days following receipt of any such

12

application. Any confirmation of Good Reason by the Committee shall be binding on the Company. For purposes of this Section 5.1, reference to the Committee includes the Committee’s delegate.

5.2    Claims Procedure. If any Participant has (a) a claim for benefits under the Plan (including the Employment Agreement), (b) a claim for clarification of his or her rights under the Plan (including the Employment Agreement), to the extent not provided for in Section 5.1, or (c) a claim for breach by the Company of its obligations under Plan (including the Employment Agreement), then the Participant (or his or her designee) (a “Claimant”) may file with the Committee a written claim setting forth the amount and nature of the claim, supporting facts, and the Claimant’s address. A claim shall be filed within six (6) months of (i) the date on which the claim first arises or (ii) if later, the earliest date on which the Participant knows or should know of the facts giving rise to a claim. The Committee shall notify the Claimant of its decision in writing (including via email) within 60 days after its receipt of a claim, unless otherwise agreed by the Claimant. In special circumstances the Committee may extend for a further 60 days the deadline for its decision, provided the Committee notifies the Claimant of the need for the extension within 60 days after its receipt of a claim. If a claim is denied, the written notice of denial shall set forth the reasons for such denial, refer to pertinent provisions of the Plan or Employment Agreement on which the denial is based, describe any additional material or information necessary for the Claimant to realize the claim, and explain the claim review procedure under the Plan.

5.3    Claim Review Procedure. A Claimant whose claim has been denied (or such Claimant’s duly authorized representative) may file, within 60 days after notice of such denial is received by the Claimant, a written request for review of such claim by the Committee. If a request is so filed, the Committee shall review the claim and notify the Claimant in writing of its decision within 45 days after receipt of such request, unless otherwise agreed by the Claimant. In special circumstances, the Committee may extend for up to 45 additional days the deadline for its decision, provided the Committee notifies the Claimant of the need for the extension within 45 days after its receipt of the request for review. The notice of the final decision of the Committee shall include the reasons for its decision and specific references to the provisions of the Plan or Employment Agreement on which the decision is based. The decision of the Committee shall be final and binding on all parties.

ARTICLE 6

ADMINISTRATION

6.1    Committee. The Chief Human Resources Officer of Elevance Health (“CHRO”)
shall appoint not less than three (3) members of a committee, to serve at the pleasure of the CHRO to administer this Plan. Members of the Committee may but need not be employees of the Company and may but need not be Participants in the Plan. A member of the Committee who is a Participant shall not vote or act upon any matter which relates solely to such member as a Participant, and a member of the Committee shall not vote or act upon any matter that relates solely to a Participant who is the direct manager or a direct report of the Committee member. All decisions of the Committee shall be by a vote or written evidence of intention of the majority of its members and all decisions of the Committee shall be final and binding.
13

6.2    Committee Membership. Any member of the Committee may resign at any time by giving thirty days’ advance written notice to the CHRO and to the remaining members (if any) of the Committee. A member of the Committee who at the time of his or her appointment to the Committee was an employee or director of the Company, and who for any reason becomes neither an employee nor director of the Company, shall cease to be a member of the Committee effective on the date he or she is neither an employee nor a director of the Company unless the CHRO affirmatively continues his or her appointment as a member of the Committee. If there is any vacancy in the membership of the Committee, the remaining members shall constitute the full Committee. The CHRO may fill any vacancy in the membership of the Committee, or enlarge the Committee, by giving written notice of appointment to the person so appointed and to the other members (if any) of the Committee, effective as stated in such written notice. However, the CHRO shall not be required to fill any vacancy in the membership of the Committee if there remain at least three members of the Committee. Any notice required by this Section may be waived by the person entitled thereto.

6.3    Duties. The Committee shall have the power and duty in its sole and absolute discretion to do all things necessary or convenient to effect the intent and purposes of the Plan, whether or not such powers and duties are specifically set forth herein, and, by way of amplification and not limitation of the foregoing, the Committee shall have the power in its sole and absolute discretion to:

(a)    provide rules for the management, operation, and administration of the Plan, and, from time to time, amend or supplement such rules;

(b)    construe the Plan in its sole and absolute discretion to the fullest extent permitted by law, which construction shall be final and binding;

(c)    correct any defect, supply any omission, or reconcile any inconsistency in the Plan in such manner and to such extent as it shall deem appropriate in its sole discretion to carry the same into effect;

(d)    make determinations relevant to a Participant’s eligibility for benefits under the Plan, including but not limited to determinations as to Eligible Separation from Service, Cause (except as otherwise provided in Section 8.1.3), Good Reason, and Transfer of Business;

(e)    enforce the Plan in accordance with its terms and the Committee’s construction of the Plan as provided in subsection (b) above;

(f)    delegate any of its powers to any individual(s) it authorizes in writing; and

(g)    do all other acts and things necessary or proper in its judgment to carry out the purposes of the Plan in accordance with its terms and intent.

Notwithstanding the foregoing, the Committee shall not have the authority to resolve a matter that relates solely to the rights or benefits of one or more executive officers (and not to all participants generally), which authority shall be reserved exclusively to the Compensation and Talent Committee of the Board of Directors.

14

6.4    Binding Authority. The decisions of the Committee or its duly authorized delegate within the powers conferred by the Plan shall be final and conclusive for all purposes of the Plan and shall not be subject to any appeal or review other than pursuant to Sections 5.2 and 5.3.

6.5    Indemnification. The Company shall indemnify and hold harmless each member of the Committee, any delegate of the Committee in the performance of functions delegated by the Committee, and each other officer or employee of the Company acting on behalf of the Committee or the Company with respect to this Plan, against any and all expenses and liabilities arising out of his or her own membership on the Committee, service as Plan Administrator, or other actions respecting this Plan on behalf of the Company, except for expenses and liabilities arising out of such person’s gross negligence or willful misconduct. A person indemnified under this Section who seeks indemnification hereunder (“Indemnitee”) shall tender to the Company a request that the Company defend any claim with respect to which the Indemnitee seeks indemnification under this Section and shall fully cooperate with the Company in the defense of such claim. If the Company shall fail to timely assume the defense of such claim, then the Indemnitee may control the defense of such claim. However, no settlement of any claim otherwise indemnified under this Section shall be subject to indemnity hereunder unless the Company consents in writing to such settlement.

6.6    Information. The Company and each Participant shall furnish to the Committee in writing all information the Committee may deem appropriate for the exercise of its powers and duties in the administration of the Plan. Such information may include, but shall not be limited to, the names of all Participants, their earnings and their dates of birth, employment, retirement, or death. Such information shall be conclusive for all purposes of the Plan, and the Committee shall be entitled to rely thereon without any investigation thereof.

ARTICLE 7

GENERAL PROVISIONS

7.1    No Property Interest. The Plan is unfunded. Severance Pay shall be paid
exclusively from the general assets of the Company and any liability of the Company to any person with respect to benefits payable under the Plan shall give rise solely to a claim as an unsecured creditor against the general assets of the Company. Any Participant who may have or claim any interest in or right to any compensation, payment or benefit payable hereunder, shall rely solely upon the unsecured promise of the Company for the payment thereof, and nothing herein contained shall be construed to give to or vest in the Participant or any other person now or at any time in the future, any right, title, interest or claim in or to any specific asset, fund, reserve, account, insurance or annuity policy or contract, or other property of any kind whatsoever owned by the Company, or in which the Company may have any right, title or interest now or at any time in the future.

7.2    Other Rights. Except as specifically provided herein, the Plan shall not affect or impair the rights or obligations of the Company or a Participant under any other written plan, contract, arrangement, or pension, profit sharing or other compensation plan. Participation in the Plan is voluntary, and no Executive shall be required to enter into an Employment Agreement.
15

7.3    Amendment or Termination. The Plan, including but not limited to any provision of the Plan incorporated by reference into an Employment Agreement, may be amended, modified, suspended, or terminated unilaterally by Elevance Health at any time; provided, however, that no such amendment, modification, suspension, or termination shall adversely affect the rights to which a Participant would be entitled under his or her Employment Agreement if the Participant incurred a Separation from Service immediately prior to the amendment or termination unless: (a) the affected Participant approves such amendment in writing, (b) the amendment is effective no earlier than one (1) year after the Participant has received written notice of the amendment, or (c) the amendment is required (as determined by the Committee) by law (including any provision of the Code) whether such requirement impacts the Company or any Participant. The proviso in the first sentence shall not apply to provisions incorporated by reference pursuant to Section 3.6. An amendment of the Plan (including any Employment Agreement) that (i) does not adversely affect the rights to which a Participant would be entitled under the Plan or Employment Agreement, or (ii) is required by law (as described above), may be approved by the CHRO. No amendment or termination of the Plan shall accelerate (or defer) the time of any payment under the Plan that is “deferred compensation” subject to Section 409A of the Code if such acceleration (or deferral) would subject such deferred compensation to additional tax or penalties under Section 409A.

7.4    Successors. All obligations of Elevance Health under the Plan shall be binding on any successor to Elevance Health, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of Elevance Health, and any such successor shall be required to perform the obligations of Elevance Health under the Plan in the same manner and to the same extent that Elevance Health would be required to perform such obligations if no such succession had taken place.

7.5    Severability. If any term or condition of the Plan shall be invalid or unenforceable to any extent or in any application, then the remainder of the Plan, with the exception of such invalid or unenforceable provision, shall not be affected thereby and shall continue in effect and application to its fullest extent. If, however, the Committee determines in its sole discretion that any term or condition of the Plan (including any Employment Agreement) which is invalid or unenforceable is material to the interests of the Company, the Committee may declare the Plan (including any Employment Agreement) null and void in its entirety or may declare any affected Employment Agreement null and void in its entirety.

7.6    No Employment Rights. Neither the establishment of the Plan, any provisions of the Plan, nor any action of the Committee shall be held or construed to confer upon any employee the right to a continuation of employment by the Company. Subject to any benefits that may be due under the terms of the Plan (including the Employment Agreement), the Company reserves the right to dismiss any employee, or otherwise deal with any employee to the same extent as though the Plan had not been adopted.

7.7    Transferability of Rights. The Company shall have the right to transfer all of its rights and obligations under the Plan (including an Employment Agreement) with respect to one or more Participants to any purchaser of all or any part of the Company’s business in a Transfer of Business or otherwise without the consent of any Participant. No Participant or spouse of a
16

Participant shall have any right to commute, encumber, transfer, or otherwise dispose of or alienate any present or future right or expectancy which the Participant or such spouse may have at any time to receive payments of benefits hereunder, which benefits, and the right thereto, are expressly declared to be non-assignable and nontransferable, except to the extent required by law. Any attempt to transfer or assign a benefit, or any rights granted hereunder, by a Participant or the spouse of a Participant shall, in the sole discretion of the Committee (after consideration of such facts as it deems pertinent), be grounds for terminating any rights of the Participant or his or her spouse to any portion of the Plan benefits not previously paid.

7.8    Beneficiary. Any payment due under this Plan after the death of the Participant shall be paid to the Participant’s beneficiary under the Company’s group term life insurance benefit. If and to the extent Section 409A permits acceleration of payments of deferred compensation upon death, the Committee in its sole discretion may accelerate and pay in a lump sum, discounted at a rate approved by the payee, any Severance Pay payable after the death of a Participant.

7.9    Company Action. Any action required or permitted of Elevance Health (or the Company) under this Plan shall be duly and properly taken if taken by the Compensation and Talent Committee of the Board of Directors, or by any officer of Elevance Health to which the Compensation Committee has delegated (generally or specifically) and not withdrawn the right or power to take such action.

7.10    Entire Document. The Plan (including applicable Employment Agreements), as amended and restated herein and including all exhibits hereto and documents incorporated by reference herein, supersedes all prior versions of the Plan, any contradictory provisions of an employment agreement entered into between the Company and any Participant pursuant to a prior version of the Plan, and any and all prior practices, understandings, agreements, descriptions, and non-written arrangements respecting severance, except for written employment or severance contracts signed by the Company with individuals other than Participants. Notwithstanding the foregoing and for the avoidance of doubt, this Plan makes reference to certain compensation elements that may be subject to the Elevance Health, Inc. Incentive Compensation Recoupment Policy, as amended from time to time (the “Policy”); nothing in this Plan is intended to affect, or shall be construed as affecting, the Policy’s application to any Participant.

7.11    Plan Year. The fiscal records of the Plan shall be kept on the basis of a plan year, which is the calendar year.

7.12    Governing Law. This is an employee benefit plan subject to ERISA and shall be governed by and construed in accordance with ERISA and, to the extent applicable and not preempted by ERISA, the law of the State of Indiana applicable to contracts made and to be performed entirely within that State, without regard to its conflict of law principles.

17

ARTICLE 8

DEFINITIONS

8.1    Definitions.    The following words and phrases as used herein shall have the following meanings, unless a different meaning is required by the context:

8.1.1    “Annual Base Salary” means the highest annualized rate of regular salary in effect for the Participant (a) during the one-year period before Separation from Service or, if higher, (b) during the period commencing one year prior to a Change in Control and ending upon Separation from Service.

8.1.2    “Board of Directors” means the Board of Directors of Elevance Health.

8.1.3    “Cause”, unless otherwise defined for purposes of termination of employment in a written employment agreement between the Company and the Participant, shall mean any act or failure to act on the part of the Participant which constitutes:

(i)    fraud, embezzlement, theft, or dishonesty against the Company;

(ii)    material violation of law in connection with or in the course of the Participant’s duties or employment with the Company;

(iii)    commission of any felony

(iv)    violation of Section 3.6 of the Plan, as determined by the Company (and not by the Committee or any other party acting as an ERISA fiduciary);

(v)    any other material breach of the Employment Agreement;

(vi)    material breach of any written employment policy of the Company;

(vii)    conduct which tends to bring the Company into substantial public disgrace or disrepute; or

(viii)    a material violation of the Company’s Standards of Ethical Business Conduct;

provided, however, that with respect to a termination of employment during an Imminent Change in Control Period or within the thirty-six (36) month period after a Change in Control, clauses (f) and (h) shall apply only if such material breach or violation is grounds for immediate termination under the terms of such written employment policy or standards, and clauses (d), (e), and (g) shall apply only if such violation, breach, or conduct is willful.

8.1.4    “Change in Control” means the first to occur of the following events with respect to Elevance Health:

18

(a)    any person (as such term is used in Rule 13d-5 of the Securities and Exchange Commission (“SEC”) under the Securities Exchange Act of 1934 (the “Exchange Act”) or group (as such term is defined in Section 13(d) of the Exchange Act), other than a subsidiary of Elevance Health or any employee benefit plan (or any related trust) of the Company, becomes the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of 20% or more of the common stock of Elevance Health (“Common Stock”) or of other voting securities representing 20% or more of the combined voting power of all voting securities of Elevance Health; provided, however, that (i) no Change in Control shall be deemed to have occurred solely by reason of any such acquisition by a corporation with respect to which, after such acquisition, more than 80% of both the common stock of such corporation and the combined voting power of the voting securities of such corporation are then beneficially owned, directly or indirectly, by the persons who were the Beneficial Owners of the Common Stock and other voting securities of Elevance Health immediately before such acquisition, in substantially the same proportion as their ownership of the Common Stock and other voting securities of Elevance Health immediately before such acquisition; (ii) if any person or group owns 20% or more but less than 30% of the combined voting power of the Common Stock and other voting securities of Elevance Health and such person or group has a “No Change in Control Agreement” (as defined below) with the Company, no Change in Control shall be deemed to have occurred solely by reason of such ownership for so long as the No Change in Control Agreement remains in effect and such person or group is not in violation of the No Change in Control Agreement; and (iii) once a Change in Control occurs under this subsection (a), the occurrence of the next Change in Control (if any) under this subsection (a) shall be determined by reference to a person or group other than the person or group whose acquisition of Beneficial Ownership created such prior Change in Control unless the original person or group has in the meantime ceased to own 20% or more of the Common Stock of Elevance Health or other voting securities representing 20% or more of the combined voting power of all voting securities of Elevance Health; or

(b)    within any period of thirty-six (36) or fewer consecutive months individuals who, as of the first day of such period were members of the Board of Directors of Elevance Health (the “Incumbent Directors”) cease for any reason to constitute at least 75% of the members of the Board; provided, however, that (i) any individual who becomes a Member of the Board of Directors after the first day of such period whose nomination for election to the Board was approved by a vote or written consent of at least 75% of the Members of the Board of Directors who are then Incumbent Directors shall be considered an Incumbent Director, but excluding, for this purpose, any such individual whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of the directors of the Company (as such terms are used in Rule 14a-11 of the SEC under the Exchange Act) or an Imminent Change in Control or other transaction described in subsection (a) above or (c) below; and (ii) once a Change in Control occurs under this subsection (b), the occurrence of the next Change in Control (if any) under this subsection (b)    shall be determined by reference to a period of thirty-six- (36) or fewer consecutive months beginning not earlier than the date immediately after the date of such prior Change in Control; or

19

(c)    closing of a transaction that is any of the following:

(i)    merger, reorganization or consolidation of Elevance Health (“Merger”), after which (A) the individuals and entities who were the respective beneficial owners of the Common Stock and other voting securities of Elevance Health immediately before such Merger do not beneficially own, directly or indirectly, more than 60% of, respectively, the Common Stock or the combined voting power of the common stock and voting securities of the corporation resulting from such Merger, in substantially the same proportion as their ownership of the Common Stock and other voting securities of Elevance Health immediately before such Merger;

(ii)    a Merger after which individuals who were members of the Board of Directors of Elevance Health immediately before the Merger do not comprise a majority of the members of the board of directors of the corporation resulting from such Merger;

(iii)    a sale or other disposition by Elevance Health of all or substantially all of the assets owned by it (a “Sale”) after which the individuals and entities who were the respective beneficial owners of the Common Stock and other voting securities of Elevance Health immediately before such Sale do not beneficially own, directly or indirectly, more than 60% of, respectively, the Common Stock or the combined voting power of the common stock and voting securities of the transferee in such Sale in substantially the same proportion as their ownership of the Common Stock and other voting securities of Elevance Health immediately before such Sale; or

(iv)    a Sale after which individuals who were members of the Board of Directors of Elevance Health immediately before the Sale do not comprise a majority of the members of the board of directors of the transferee corporation.

8.1.5    “Code” means the Internal Revenue Code of 1986, as amended from time to time.
8.1.6    “Committee” means a committee appointed by the Chief Human Resources Officer of Elevance Health to administer this Plan.

8.1.7    “Common Stock” has the meaning set forth in Section 8.1.4.

8.1.8    “Eligible Separation from Service” has the meaning set forth in Section 3.1.

8.1.9    "Equity Award” means an award granted under the 2017 Elevance Health Incentive Compensation Plan (as amended and restated from time to time) or any predecessor or successor plan thereto.

8.1.10    “Executive” means any person employed in the United States by Elevance Health or a Subsidiary in a position of Vice President, Senior Vice President, Executive Vice

20

President, or Chief Executive Officer (“CEO”); provided, however, that any person who becomes so employed by virtue of an acquisition, merger, or similar transaction shall not be an Executive for purposes of this Plan unless and until designated as such by the Chief Human Resources Officer of Elevance Health. In addition, the Chief Executive Officer of Elevance Health, in her or his sole discretion, may expressly designate, in writing, any person employed by Elevance Health or a Subsidiary (a) outside the United States in an aforenamed position, or (b) in a position below that of Vice President (the latter category to be referred to as an “Other Key Executive”), as an Executive eligible to participate in the Plan.

8.1.11    “Good Reason” for a termination of employment shall mean, for Participants who are classified as the Company’s CEO, Executive Vice President, Senior Vice President, or Vice President:

(a)    The occurrence of an event described in clause (c)(ii) or (c)(v) below within the thirty-six (36) month period after a Change in Control; or

(b)    The occurrence of an event described in clause (c)(i), (c)(iii), or (c)(iv) below at any time (i.e., regardless of a Change in Control).

(c)    Events:

(i)    A material reduction during any twenty-four (24) consecutive month period in the Participant’s Annual Salary, or in the Participant’s annual total cash compensation (including Annual Salary and Target Bonus), but excluding in either case any reduction both (A) applicable to management employees generally, and
(B) and not implemented during an Imminent Change in Control Period or within the thirty-six (36) month period after a Change in Control;

(ii)    A material adverse change, without the Participant’s prior consent, in the Participant’s position, duties, or responsibilities as an Executive of the Company and provided, however, that this clause shall not apply in connection with a Transfer of Business if the position offered to the Participant by the transferee is substantially comparable in position, duties, and responsibilities with the position, duties, and responsibilities of the Participant prior to such Transfer of Business;

(iii)    The Company’s material breach of this Plan or the Employment Agreement;

(iv)    A change, without the Participant’s prior consent, in the Participant’s principal work location to a location more than 50 miles from the Participant’s prior work location and more than 50 miles from the Participant’s principal residence as of the date of such change in work location;

(v)    The failure of any successor to the Company by merger, consolidation, or acquisition of all or substantially all of the business of the Company or by Transfer of Business to assume the Company’s obligations under this Plan (including any Employment Agreements).
21

Notwithstanding the foregoing provisions of this definition, Good Reason shall not exist if the Participant has in his or her sole discretion agreed in writing that such event shall not be Good Reason. In addition, a Separation from Service shall not be considered to be for Good Reason unless: (A) within sixty (60) days of the occurrence of the event(s) claimed to be Good Reason the Participant notifies the Committee in writing of the reasons he or she believes that Good Reason exists; (B) the Company has failed to correct a circumstance that would otherwise be Good Reason within thirty (30) days of receipt of such notice; and (C) the Participant terminates his or her employment within sixty (60) days of such thirty (30) day period (or, if earlier, within 60 days of the date the Committee confirms to the Participant pursuant to Section 5.1 that Good Reason exists).

8.1.12    “Imminent Change in Control Period” means the period:

(a)    beginning on the date of (i) the public announcement (whether by advertisement, press release, press interview, public statement, SEC filing or otherwise) of a proposal or offer which, if consummated, would be a Change in Control, (ii) the making to a director or executive officer of the Company of a written proposal which, if consummated, would be a Change in Control, or (iii) approval by the Board of Directors or the stockholders of Elevance Health of a transaction that, upon closing, would be a Change in Control; and

(b)    ending upon the first to occur of (i) a public announcement that the prospective Change in Control contemplated by the event(s) described in paragraph (a) has been terminated or abandoned, (ii) the occurrence of the contemplated Change in Control, or (iii) the first annual anniversary of the beginning of the Imminent Change in Control Period.

8.1.13    “Key Employee” means for the period January 1 through December 31, each individual identified by the Company as of the immediately preceding September 30 as a “key employee,” as defined under Code Section 416(i), disregarding Code Section 416(i)(5).

8.1.14    “No Change in Control Agreement” means a legal, binding and enforceable agreement executed by and in effect between a person or all members of a group and Elevance Health that provides that: (a) such person or group shall be bound by the agreement for the time period of not less than five (5) years from its date of execution; (b) such person or group shall not acquire beneficial ownership or voting control equal to a percentage of the Common Stock or the voting power of other voting securities of Elevance Health that exceeds a percentage specified in the agreement which percentage shall in all events be less than 30%; (c) such person or group may not designate for election as directors a number of directors in excess of 25% of the number of directors on the Board; and (d) such person or group shall vote the Common Stock and other voting securities of Elevance Health in all matters in the manner directed by the majority of the Incumbent Directors. If any agreement described in the preceding sentence is violated by such person or group or is amended in a fashion such that it no longer satisfies the requirements of the preceding sentence, such agreement shall, as of the date of such violation or amendment, be treated for purposes hereof as no longer constituting a No Change in Control Agreement.
22

8.1.15    “Participant” means any Executive who is eligible to participate in the Plan, has become a Participant in accordance with Section 2.1, and has not had such participation terminated pursuant to Section 2.2.

8.1.16    "Pre-Change” (with respect to Options, SARs, Restricted Stock, and Performance Shares) shall have the meaning set forth in Section 4.3(c).

8.1.17    “Separation from Service” means a termination of the Participant’s employment with the Company which constitutes a “separation from service” within the meaning of Section 409A(a)(2)(A)(i) of the Code. Notwithstanding the preceding sentence, a Separation from Service shall not include:

(i)    The disposition by the Company of the subsidiary or affiliate that employs the Participant if such employing subsidiary or affiliate adopts this Plan and continues (by assignment or otherwise) to be the employer of the Participant under the Employment Agreement; or

(ii)    A termination of employment in a Transfer of Business in connection with which the Participant receives a bona fide offer of employment from the transferee (or an affiliate of the transferee), whether or not accepted, for which purpose a bona fide offer of employment is an offer of employment effective on the closing of the Transfer of Business on terms that does not have an effect described in clauses (c)(i), (c)(ii), (c)(iv) or (c)(v) of this Plan’s definition of Good Reason.

A Participant shall cooperate with the transferee in a Transfer of Business by completing such employment applications and providing such other information as the transferee may need in order to make a bona fide offer of employment. A Participant who fails to provide such cooperation shall be deemed to have received and rejected a bona fide offer of employment.

8.1.18    “Subsidiary” means a business entity that is at least eighty percent (80%) owned, directly or indirectly, by Elevance Health, Inc.

8.1.19    “Target Bonus” means the Target Bonus Percentage times the Annual
Salary.

8.1.20    “Target Bonus Percentage” means the sum of the highest annualized target
bonus percentage(s) (as a percentage of salary) in effect for the Participant:

(a)    during the one-year period before Separation from Service; or

(b)    if higher, during the period commencing one year prior to a Change in Control and ending upon Separation of Service,

under each regular annual bonus or a short-term incentive plan including but not limited to Elevance Health’s Annual Incentive Plan or successor plans and any sales incentive plans (as determined by the Committee in its sole discretion) covering the Participant.


23

8.1.21    "Transfer of Business" means a transfer of the Participant's position to another entity, as part of either:

(a)    A transfer to such entity as a going concern of all or part of the business function of the Company in which the Participant was employed; or

(b)    An outsourcing to another entity of a business function of the Company in which the Participant was employed.


IN WITNESS WHEREOF, this amended and restated Plan is executed as of the date set forth below by the authorized delegate of the Company.



ELEVANCE HEALTH, INC.


________________________________________
Michael J. Berry
Vice President, Total Rewards

Date: __________________________________


24

EXHIBIT A
EMPLOYMENT AGREEMENT

EMPLOYMENT AGREEMENT (the “Agreement”) dated as of ______________ (the “Agreement Date”), between Elevance Health Inc., an Indiana corporation (“Elevance Health”) with its headquarters and principal place of business in Indianapolis, Indiana (Elevance Health, together with its subsidiaries and affiliates are collectively referred to herein as the “Company”),
and _______________________ (the “Executive”).

W I T N E S S E T H

WHEREAS, the Company desires to retain the services of Executive and to provide
Executive an opportunity to receive severance to which Executive is not otherwise entitled in return for the diligent and loyal performance of Executive’s duties and Executive’s agreement to reasonable and limited restrictions on Executive’s post-employment conduct to protect the Company’s investments in its intellectual property, employee workforce, customer relationships, and goodwill;

WHEREAS, the Company has established the Elevance Health Executive Agreement Plan (“Plan”) to provide certain benefits for participants who enter into an employment agreement in the form of this Agreement;

WHEREAS, Executive is not required to execute this Agreement as a condition of continued employment and remains an employee at will regardless of whether Executive signs the Agreement; rather, Executive is entering into this Agreement to enjoy the substantial additional payments and benefits available under the Plan; and

NOW THEREFORE, in consideration of the foregoing, of the mutual promises contained herein and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows. Capitalized terms not otherwise defined herein shall have the meanings assigned to them in the Plan.

1.    POSITION/DUTIES.

(a)    Executive shall serve in the position communicated to Executive in writing by or on behalf of the Company’s senior leadership, provided the Company may from time to time assign Executive such other positions, duties, authorities, and/or responsibilities as are commensurate with Executive’s skills and talents.

(b)    Executive shall comply with Company policies and procedures, and shall devote all of Executive’s business time, energy, skill, best efforts, and undivided business loyalty to the performance of Executive’s duties with the Company. Executive further agrees that while employed by the Company, Executive shall not perform any services for remuneration for or on behalf of any other entity without the advance written consent of the Company.

2.    EMPLOYMENT PERIOD. Executive’s employment under this Agreement shall commence on the Agreement Date listed above and shall terminate in accordance with the
25

termination provisions of Section 6 of this Agreement. Either party may notify the other in writing of the termination of this Agreement without terminating Executive’s employment with the Company; in such event, Executive (a) shall remain an employee at will of the Company, and (b) shall, until the earlier of the Executive’s termination of employment or the one-year anniversary of such notice, remain covered by this Agreement and a Participant in the Plan.

3.    BASE SALARY. The Company agrees to pay Executive at the annual base salary rate communicated to Executive in writing by or on behalf of the Company’s senior leadership, payable in accordance with the regular payroll practices of the Company. Executive’s base salary shall be subject to annual review by the Company.

4.    BONUS. Executive shall be eligible to receive consideration for an annual bonus upon such terms as adopted from time to time by the Company. The target bonus for which Executive is eligible for the year in which this Agreement is executed, in accordance with the terms of the applicable bonus plan/policy, has been communicated to Executive in writing by or on behalf of the Company’s senior leadership.

5.    BENEFITS. Executive, his or her spouse or domestic partner, and eligible dependents shall be entitled to participate in any employee benefit plan that the Company has adopted or may adopt, maintain, or contribute to for the benefit of its executives at a level commensurate with Executive’s position, subject to satisfying the applicable eligibility and contribution requirements therefor. Notwithstanding the foregoing, the Company may modify or terminate any employee benefit plan at any time in accordance with its terms.

6.    TERMINATION. Executive’s employment and the Employment Period shall terminate on the first of the following to occur:

(a)    DISABILITY. Subject to applicable law, upon 10 days’ prior written notice by the Company to Executive of termination due to Disability. “Disability” shall have the meaning defined in the Company’s Long Term Disability Plan.

(b)    DEATH. Automatically on the date of death of Executive.

(c)    CAUSE. The Company may terminate Executive’s employment hereunder for Cause immediately upon written notice by the Company to Executive of a termination for Cause. “Cause” shall have the meaning defined for that term in the Plan.

(d)    WITHOUT CAUSE. Upon written notice by the Company to Executive of an involuntary termination without Cause, other than for death or Disability.

(e)    BY EXECUTIVE. Upon at least thirty (30) days’ advance written notice by the Executive to the Company with or without Good Reason as defined in the Plan. If the Executive fails to provide this advance notice, the Executive will immediately forfeit any vested but unexercised Options granted on or after July 1, 2018.

26

7.    CONSEQUENCES OF TERMINATION. Executive’s entitlement to payments and benefits upon a termination of employment that constitutes an Eligible Separation from Service shall be as set forth in the Plan.

8.    RELEASE. Any and all amounts payable and benefits or additional rights provided pursuant to this Agreement beyond Accrued Benefits shall be payable only if Executive delivers to the Company and does not revoke a general release of all claims in a form tendered by the Company which shall be substantially similar to the form attached as Exhibit B to the Plan or such other form acceptable to the Company within the applicable time period set forth in the Plan.

9.    RESTRICTIVE COVENANTS AND INTELLECTUAL PROPERTY. Executive acknowledges that he or she has been given an opportunity to review the Plan including, as applicable, Restrictive Covenants and Intellectual Property as set forth in Appendix C of the Plan, and agrees to comply with the covenants and obligations applicable to Executive under Sections 3.6 and 3.10 of the Plan, and acknowledges that such covenants and obligations, and the remedies for violation thereof, as set forth in the Plan, are reasonable and necessary to preserve the legitimate business interests of the Company, its present and potential business activities, and the economic benefits derived therefrom; will not prevent Executive from earning a livelihood in Executive’s chosen business; and are not an undue restraint on the trade of Executive, or any of the public interest that may be involved. Executive’s obligations contained in this Section 9 and in Section 10 below shall survive the cessation of the Employment Period and Executive’s employment with the Company and shall be fully enforceable thereafter.

10.    COOPERATION. While employed by the Company and for two years (or, if longer, for so long as any claim referred to in Section 3.10 of the Plan remains pending) after the termination of Executive’s employment for any reason, Executive will provide cooperation and assistance to the Company as provided in Section 3.10 of the Plan.

11.    NOTIFICATION OF EXISTENCE OF AGREEMENT. Executive agrees that in the event that Executive is offered employment with another employer (including service as a partner of any partnership or service as an independent contractor) at any time during the existence of this Agreement, or such other period in which post termination obligations of this Agreement apply, Executive shall immediately advise said other employer (or partnership) of the existence of Executive’s obligations under this Agreement and the Plan and shall immediately provide said employer (or partnership or service recipient) with a copy of the Plan and the covenants incorporated by reference into Section 3.6 of the Plan.

12.    NOTIFICATION OF SUBSEQUENT EMPLOYMENT. Executive shall report promptly to the Company any employment with another employer (including service as a partner of any partnership or service as an independent contractor or establishment of any business as a sole proprietor) obtained during the period in which Executive’s post-termination obligations set forth in Section 9 of this Agreement and Section 3.6 of the Plan apply.

13.    NOTICE. For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (i) on the date of delivery if delivered by hand, (ii) on the date of transmission, if

27

delivered by confirmed e-mail, (iii) on the first business day following the date of deposit if delivered by guaranteed overnight delivery service, or (iv) on the fourth business day following the date delivered or mailed by United States registered or certified mail, return receipt requested, postage prepaid, addressed as follows:

If to Executive:
At the address (or to the facsimile number) shown on the records of the Company

If to the Company:
Chief Human Resources Officer Elevance Health, Inc.
220 Virginia Avenue
Indianapolis, IN 46204

or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt.

14.    SECTION HEADINGS; INCONSISTENCY. The section headings used in this Agreement are included solely for convenience and shall not affect, or be used in connection with, the interpretation of this Agreement. In the event of any inconsistency between the terms of this Agreement and any form, award, plan or policy of the Company, the terms of this Agreement shall control.

15.    SUCCESSORS AND ASSIGNS - BINDING EFFECT. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns, as the case may be. The Company may assign this Agreement to any affiliate of the Company and to any successor or assign of all or a substantial portion of the Company’s business. Executive may not assign or transfer any of his or her rights or obligations under this Agreement.

16.    SEVERABILITY. The provisions of this Agreement shall be deemed severable, and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.

17.    DISPUTE RESOLUTION. The dispute resolution provisions set forth in the Plan (including but not limited to the ERISA claims procedures the jury trial waiver set forth therein) shall apply to and govern any dispute arising out of or relating to this Agreement.

18.    GOVERNING LAW. This Agreement forms part of an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 (“ERISA”) and shall be governed by and construed in accordance with ERISA and, to the extent applicable and not preempted by ERISA, the law of the State of Indiana applicable to contracts made and to be performed entirely within that State, without regard to its conflicts of law principles.

19.    MISCELLANEOUS. No provision of this Agreement may be waived, modified, or discharged unless such waiver, modification or discharge is agreed to in writing and signed by
28

Executive and such officer or director as may be designated by the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. This Agreement and the Plan and together with all exhibits thereto, and documents incorporated therein by reference, sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement.

20.    OTHER EMPLOYMENT ARRANGEMENTS. Except as provided in Section 2.1(a)(i) of the Plan, any severance or change in control plan or agreement (other than the Plan) or other similar agreements or arrangements between Executive and the Company shall, effective as of the Agreement Date, be superseded by this Agreement and the Plan and shall therefore terminate and be null and void and of no force or effect. For the avoidance of doubt, the preceding sentence shall not apply to outstanding Equity Awards held by the Participant on the Agreement Date.


IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

ELEVANCE HEALTH, INC.

By:_________________________________

Chief Human Resources Officer

Date:

__________________________________


EXECUTIVE

____________________________________

Print Name

Date:
____________________________________



29

EXHIBIT B
WAIVER AND RELEASE

This is a Waiver and Release (“Release”) between ______________ (“Executive”) and Elevance Health, Inc. (the “Company”). The Company and the Executive agree that they have entered into this Release voluntarily, and that it is intended to be a legally binding commitment between them.

1.    In consideration for the promises made herein by the Executive, the Company agrees as follows:

(a)    Severance Pay. The Company will pay to the Executive the Severance Pay and other benefits as defined in, and pursuant to the terms and conditions of, the Elevance Health Executive Agreement Plan (the “Plan”). The Company will also pay Executive accrued but unused vacation pay for his or her accrued but unused vacation days.

(b)    Unemployment Compensation. The Company will not contest the decision of the appropriate regulatory commission regarding unemployment compensation that may be due to the Executive.

2.    In consideration for and contingent upon the Executive’s right to receive the severance pay and other benefits described in the Plan and the Employment Agreement and this Release, Executive hereby agrees as follows:

(a)    General Waiver and Release. Except as provided in Paragraph 2.(k) below, Executive and any person acting through or under the Executive hereby release, waive and forever discharge the Company, its past subsidiaries and its past and present affiliates, and their respective successors and assigns, and their respective present or past officers, trustees, directors, shareholders, executives and agents of each of them, from any and all claims, demands, actions, liabilities and other claims for relief and remuneration whatsoever (including without limitation attorneys’ fees and expenses), whether known or unknown, absolute, contingent or otherwise (each, a “Claim”), arising or which could have arisen up to and including the date of his execution of this Release, arising out of or relating to Executive’s employment or cessation and termination of employment, or any other written or oral agreement, any change in Executive’s employment status, any benefits or compensation, any tortious injury, breach of contract, wrongful discharge (including any Claim for constructive discharge), infliction of emotional distress, slander, libel or defamation of character, and any Claims arising under Title VII of the Civil Rights Act of 1964 (as amended by the Civil Rights Act of 1991), the Americans With Disabilities Act, the Rehabilitation Act of 1973, the Equal Pay Act, the Older Workers Benefits Protection Act, the Age Discrimination in Employment Act, the Employee Retirement Income Security Act of 1974, or any other federal, state or local statute, law, ordinance, regulation, rule or executive order, any tort or contract claims, and any of the claims, matters and issues which could have been asserted by Executive against the Company or its subsidiaries and affiliates in any legal, administrative or other proceeding. Executive agrees that if any action is brought in his or her name before any court or administrative body, Executive will not accept any payment of monies in connection therewith.
30

(b)    Waiver Under Section 1542 of the California Civil Code. Executive, for Executive’s predecessors, successors and assigns, hereby waives all rights which Executive may have under Section 1542 of the Civil Code of the State of California, which reads as follows:

“A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.”

I have read this code section, and I am now aware of it. I freely, knowingly, and expressly waive and relinquish any rights or benefits I may have because of this statute and/or other state or federal statutes or common law principles which are similar, or which have a similar purpose, and acknowledge that I am releasing claims I know about as well as claims I may not know about. This waiver is not a mere recital but is a knowing waiver of the rights and benefits otherwise available under said Section 1542.

(c)    For Montana Associates Only. I expressly waive all rights under Montana Code Annotated Section 28-1-1602 which provides: “A general release does not extend to claims that the creditor does not know or suspect to exist in the creditor’s favor at the time of executing the release, which, if known by the creditor, must have materially affected the creditor’s settlement with the debtor.” I understand that I am referred to in this statute as the “creditor” and the Company or other Releasees are referred to as the “debtor.”

(d)    For North Dakota Associates Only. I expressly waive all rights that I may have under any state or local statute, executive order, regulation, common law and/or public policy relating to unknown claims, including but not limited to North Dakota Century Code Section 9-13-02.

(e)    For South Dakota Associates Only. I expressly waive all rights that I may have under any state or local statute, executive order, regulation, common law and/or public policy relating to unknown claims, including but not limited to South Dakota Codified Laws Section 20-7-11.

(f)    Executive acknowledges that he or she has received all leaves (paid or unpaid) to which Executive is entitled. By making this Agreement, Executive acknowledges that the Company does not admit that it has done anything wrong, and the Company specifically states that it has not violated or abridged any federal, state, or local law or ordinance, or any right or obligation that it may owe or may have owed Executive. Company policy encourages reporting within the Company possible violations of any law by or on behalf of the Company, and no one has interfered with Executive’s opportunity to report such violations.

(g)    Executive has returned all Company property, information and/or documents in Executive’s possession or control to the Company. Executive further agrees that he or she has not retained and will not retain any copies, duplicates, reproductions, or excerpts of any such property whether in hard copy, electronic format, or otherwise.
31

(h)    Miscellaneous. Executive agrees that this Release specifies payment from the Company to himself or herself, the total of which meets or exceeds any and all funds due him or her by the Company, and that he or she will not seek to obtain any additional funds from the Company with the exception of non-reimbursed business expenses. This covenant does not preclude the Executive from seeking workers compensation, unemployment compensation, or benefit payments under the Company’s other employee benefit plans that could be due him or her.

(i)    Restrictive Covenants and Intellectual Property. Executive warrants that Executive has, and will continue to, comply fully with the restrictive covenants and other obligations set forth or incorporated by reference into Section 3.6 of the Plan.

(j)    THE COMPANY AND THE EXECUTIVE AGREE THAT THE SEVERANCE BENEFITS DESCRIBED IN THIS RELEASE AND THE PLAN ARE CONTINGENT UPON THE EXECUTIVE SIGNING THIS RELEASE. THE EXECUTIVE FURTHER UNDERSTANDS AND AGREES THAT IN SIGNING THIS RELEASE, EXECUTIVE IS RELEASING POTENTIAL LEGAL CLAIMS AGAINST THE COMPANY. THE EXECUTIVE UNDERSTANDS AND AGREES THAT IF HE OR SHE DECIDES NOT TO SIGN THIS RELEASE, OR IF HE OR SHE REVOKES THIS RELEASE, THAT HE OR SHE WILL IMMEDIATELY REFUND TO THE COMPANY ANY AND ALL SEVERANCE BENEFITS HE OR SHE MAY HAVE ALREADY RECEIVED.

(k)    The waiver contained in Paragraphs 2(a) through 2(e) above does not apply to any Claims with respect to:

(i)    Any claims under employee benefit plans (other than the Plan) subject to the Employee Retirement Income Security Act of 1974 (“ERISA”) in accordance with the terms of the applicable employee benefit plan,

(ii)    Any Claim under or based on a breach of this Release,

(iii)    Rights or Claims that may arise under the Age Discrimination in Employment Act after the date that Executive signs this Release,

(iv)    Any right to indemnification or directors’ and officers’ liability insurance coverage to which the Executive is otherwise entitled in accordance with the Company’s articles or by-laws.

EXECUTIVE ACKNOWLEDGES THAT HE OR SHE HAS READ AND IS VOLUNTARILY SIGNING THIS RELEASE. EXECUTIVE ALSO ACKNOWLEDGES THAT HE OR SHE IS HEREBY ADVISED TO CONSULT WITH AN ATTORNEY, HE OR SHE HAS BEEN GIVEN AT LEAST 30 DAYS TO CONSIDER THIS RELEASE BEFORE THE DEADLINE FOR SIGNING IT, AND HE OR SHE UNDERSTANDS THAT HE OR SHE MAY REVOKE THE RELEASE WITHIN SEVEN (7) DAYS (FOR MINNESOTA EXECUTIVES, 15 DAYS) AFTER SIGNING IT. IF NOT REVOKED WITHIN SUCH PERIOD, THIS RELEASE WILL BECOME EFFECTIVE ON THE

32

EIGHTH (8th) DAY (FOR MINNESOTA EXECUTIVES, SIXTEENTH (16TH) DAY) AFTER IT IS SIGNED BY EXECUTIVE.

BY SIGNING BELOW, BOTH THE COMPANY AND EXECUTIVE AGREE THAT THEY UNDERSTAND AND ACCEPT EACH PART OF THIS RELEASE.

ELEVANCE HEALTH, INC.

By:__________________________________

Print Name

Date:

___________________________________


EXECUTIVE

_____________________________________

Print Name

Date:

_____________________________________

33

EXHIBIT C
RESTRICTIVE COVENANTS AND INTELLECTUAL PROPERTY

Pursuant to Section 3.6 of the Plan and Paragraph 9 of the Employment Agreement, the provisions of this Exhibit C (including Appendix A hereto) apply to a Participant who has not yet accepted an Equity Award, and, upon acceptance of an Equity Award, these provisions shall be superseded by the restrictive covenants and intellectual property provisions applicable to the Participant under such Equity Award.

For purposes of this Exhibit C, “Company” shall mean Elevance Health, Inc. and its Subsidiaries and Affiliates. Participant acknowledges that Participant has the right to consult with counsel at Participant’s sole expense. As a condition of participating in the Plan and entering into the Employment Agreement, which Participant and the Company agree is fair and reasonable consideration, Participant agrees as follows, subject to any applicable provisions of Appendix A of this Exhibit C.

(a)    Confidentiality.

Participant recognizes that the Company derives substantial economic value from information created and used in its business which is not generally known by the public, including, but not limited to, plans, designs, concepts, computer programs, formulae, and equations; product fulfillment and supplier information; customer and supplier lists, and confidential business practices of the Company and any of its customers, vendors, business partners or suppliers; profit margins and the prices and discounts the Company obtains or has obtained or at which it sells or has sold or plans to sell its products or services (except for public pricing lists); manufacturing, assembling, labor and sales plans and costs; business and marketing plans, ideas, or strategies; confidential financial performance and projections; employee compensation; employee staffing and recruiting plans and employee personal information; and other confidential concepts and ideas related to the Company’s business (collectively, “Confidential Information”). Participant expressly acknowledges and agrees that by virtue of his/her employment with the Company, Participant will have access to and will use in the course of Participant’s duties certain Confidential Information and that Confidential Information constitutes trade secrets and confidential and proprietary business information of the Company, all of which is the exclusive property of the Company. For purposes of this Exhibit, Confidential Information includes, but is not limited to, information that constitutes a trade secret under applicable state or federal law. Confidential Information does not include information that Participant establishes by clear and convincing evidence is or may become known to Participant or to the public from sources outside the Company and through means other than a breach of Participant’s obligations under the Plan and the Employment Agreement.

Participant agrees that Participant will not for himself or herself or for any other person or entity, directly or indirectly, without the prior written consent of the Company, while employed by the Company and thereafter: (A) use Confidential Information for the benefit of any person or entity other than the Company or its affiliates; (B) remove, copy, duplicate or otherwise reproduce any document or tangible item embodying or pertaining to any of the Confidential Information, except as required to perform Participant’s duties for the Company or its affiliates; or (C) while
34

employed and thereafter, publish, release, disclose or deliver or otherwise make available to any third party any Confidential Information by any communication, including oral, documentary, electronic or magnetic information transmittal device or media. Upon Termination, Participant shall return all Confidential Information and all other property of the Company. This obligation of non-disclosure and non-use of information shall continue to exist for so long as such information remains Confidential Information.

(b)    Non-Competition.

During any period in which Participant is employed by the Company, and during a period of time after Participant’s Termination (the “Restriction Period”) which, unless otherwise limited by applicable state law, is (i) twenty-four (24) months for Executive Vice Presidents and the President & Chief Executive Officer, and (ii) the greater of the period of severance or twelve (12) months for all other Participants, Participant will not, without prior written consent of the Company, directly or through the direction or control of others, obtain a Competitive Position or perform a Restricted Activity in the Restricted Territory for a Competitor, as those terms are defined herein.

(i)    Competitive Position means any employment or performance of services with a Competitor (A) the same as or similar to the services that Participant performed for the Company in the last twenty-four (24) months of Participant’s employment with Company (the “Look Back Period”), or (B) in the performance of which Participant will likely use any Confidential Information of the Company.

(i)    Restricted Territory means any geographic area in which the Company does business and which Participant provided services in, had responsibility for, had a material presence or influence in, or had access to Confidential Information about, such business, within the Look Back Period.

(ii)    Restricted Activity means any activity for which Participant had responsibility for the Company or about which Participant had Confidential Information within the Look Back Period.

(iii)    Competitor means any entity or individual (other than the Company) engaged in any one or more of the following: management of network-based managed care plans and programs; administration of managed care services; provision of health insurance, long-term care insurance, dental, life, or disability insurance; administration of flexible spending accounts, COBRA continuation coverage, coordination of benefits, or subrogation services; or the provision, delivery, or administration of health benefit plans or health care services such as pharmacy benefits management (including Specialty pharmacy), value-based care delivery, behavioral health, palliative care, care for chronic and complex conditions, digital healthcare platforms, medical benefits management solutions, or health care research (including health economics and outcomes); or any other aspects of the business or products or services offered by the Company, as to which Participant had responsibilities or received Confidential Information about, during the Look Back Period.


35

(iv)    The restrictions contained in this subsection (b) shall not apply to attorneys who accept a Competitive Position that consists of practicing law.

(v)    If Participant receives an offer of a Competitive Position with a Competitor, as those terms are defined above, Participant shall notify the Company’s Chief Human Resources Officer, within five business days of receiving the offer and such notification shall include a detailed description of the job responsibilities and the identity of the Competitor. The description must be specific enough for the Company to determine whether Participant’s new opportunity constitutes a violation of this provision.

(c)    Non-Solicitation of Customers.

During any period in which Participant is employed by the Company, and during the Restriction Period after Participant’s Termination, Participant will not, either individually or as an employee, partner, consultant, independent contractor, owner, agent, or in any other capacity, directly or through the direction or control of others, for a Competitor of the Company as defined in subsection (b) above:

(i)    Solicit business from any client, account, or medical care provider of the Company that Participant had contact with, participated in contact with, had or shared responsibility for, or had access to Confidential Information about, during the Look Back Period; or

(ii)    Solicit business from any client, account, or medical care provider that the Company pursued, and Participant had contact with, responsibility for, or knowledge of Confidential Information about, by reason of Participant’s employment with the Company, during the Look Back Period.

For purposes of this paragraph (c), an individual policyholder in a plan maintained by the Company or by a client or account of the Company under which individual policies are issued, or a certificate holder in such plan under which group policies are issued, shall not be considered a client or account subject to this restriction solely by reason of being such a policyholder or certificate holder.

(d)    Non-Solicitation of Employees.

During any period in which Participant is employed by the Company, and during the Restriction Period after Participant’s Termination, Participant will not, either individually or as an employee, partner, independent contractor, owner, agent, or in any other capacity, directly or indirectly solicit, hire, attempt to solicit or hire, or participate in any attempt to solicit or hire, for any non-Company entity:

(i)    Any officer or employee of the Company whom the Participant knows to have access to or possession of Confidential Information that would give an unfair advantage to a Competitor;

36

(ii)    Any officer or employee of the Company who, on or at any time during the six (6) months immediately preceding the date of such solicitation or hire, held the position of Director or above with Company;

(iii)    Any officer or employee of the Company to whom Participant reported, or who reported to Participant, on or at any time during the six (6) months immediately preceding the dates of such solicitation or hire; or

(iv)    Any person who is or was an officer or employee of the Company during the six (6) months immediately preceding the date of such solicitation or hire, or whom the Participant was involved in recruiting while the Participant was employed by the Company.

(e)    Non-Disparagement.

Subject to the limitations in section (f) below, Participant agrees that he/she will not, nor will he/she cause or assist any other person to, make any statement to a third party or take any action which is intended to or would reasonably have the effect of disparaging or harming the Company or the business reputation of the Company’s directors, employees, officers, or managers, or make any verbal or written statement to any media outlet regarding the Company.

(f)    Limitations.

Nothing in this Exhibit prohibits Participant from (i) disclosing Workplace Conduct or the existence of a settlement involving Workplace Conduct that concerns conduct that Participant reasonably believes under state, federal, or common law to be illegal harassment, illegal retaliation, a wage & hour violation, or sexual assault, or that is recognized as against a clear mandate of public policy; (ii) disclosing Workplace Conduct that Participant has reason to believe is otherwise unlawful; or (iii) reporting possible violations of law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of any federal, state, or local law or regulation. “Workplace Conduct” means conduct occurring in the workplace, at work-related events coordinated by or through the Company, or between Employees, or between the Company and any Employee, off the workplace premises. Participant does not need the prior authorization of the Company to make any such reports or disclosures and Participant is not required to notify the Company that Participant has made such reports or disclosures. Disclosures protected by this section (f) may include a disclosure of trade secret information provided that it must comply with the restrictions in the Defend Trade Secrets Act of 2016 (DTSA). The DTSA provides that no individual will be held criminally or civilly liable under Federal or State trade secret law for the disclosure of a trade secret that: (i) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and made solely for the purpose of reporting or investigating a suspected violation of law; or, (ii) is made in a complaint or other document if such filing is under seal so that it is not made public. Also, an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order. If Participant is covered by Section 7 of the
37

National Labor Relations Act (NLRA) because Participant is not in a supervisor or management role, nothing in this Agreement shall prohibit Participant from using information Participant acquires regarding the wages, benefits, or other terms and conditions of employment at the Company for any purpose protected under the NLRA.

(g)    Assignment of Intellectual Property.

Participant agrees that he or she is expected to use his or her inventive and creative capacities for the benefit of the Company and to contribute, where possible, to the Company’s intellectual property in the ordinary course of employment.

(i)    “Inventions” mean any inventions, discoveries, improvements, designs, processes, machines, products, innovations, business methods or systems, know how, ideas or concepts, and related technologies or methodologies, whether or not shown or described in writing or reduced to practice and whether patentable or not. “Works” mean original works of authorship, including, but not limited to: literary works (including all written material), mask works, computer programs, formulas, tests, notes, data compilations, databases, artistic and graphic works (including designs, graphs, drawings, blueprints, and other works), recordings, models, photographs, slides, motion pictures, and audio visual works; whether copyrightable or not, and regardless of the form or manner in which documented or recorded. “Trademarks” mean any trademarks, service marks, trade dress or names, symbols, special wording, or devices used to identify a business or its business activities whether subject to trademark protection or not. The foregoing terms are collectively referred to herein as “Intellectual Property.”

(ii)    Participant assigns to the Company or its nominee Participant’s entire right, title and interest in and to all Inventions that are made, conceived, or reduced to practice by Participant, alone or jointly with others, during Participant’s employment with the Company (whether during working hours or not) that: (A) relate to the Company’s business or the Company’s actual or anticipated research or development; (B) involve the use or assistance of any tools, time, material, personnel, information, or facility of the Company; or (C) result from or relate to any work, services, or duties undertaken by Participant for the Company.

(iii)    Participant recognizes that all Works and Trademarks conceived, created, or reduced to practice by Participant, alone or jointly with others, during Participant’s employment shall to the fullest extent permissible by law be considered the Company’s sole and exclusive property and “works made for hire” as defined in the U.S. Copyright Laws for purposes of United States law and the law of any other country adhering to the “works made for hire” or similar notion or doctrine, and will be considered the Company’s property from the moment of creation or conception forward for all purposes without the need for any further action or agreement by Participant or the Company. If any such Works, Trademarks, or portions thereof shall not be legally qualified as a works made for hire in the United States or elsewhere or shall subsequently be held to not be a work made for hire or not the exclusive property of the Company, Participant hereby assigns to the Company all of Participant’s rights, title, and interest, past, present, and future, to such Works or Trademarks. Participant will not engage in any unauthorized publication or use of such Company Works or Trademarks, nor will Participant use same to compete with or otherwise cause damage to the business interests of the Company.

38

(iv)    It is the purpose and intent of this subsection (g) to convey to the Company all of the rights (inclusive of moral rights) and interests of every kind, that Participant may hold in Inventions, Works, Trademarks, and other intellectual property that are covered by clauses (g)(i) through (g)(iii) above (“Company Intellectual Property”), past, present, and future; and Participant waives any right that Participant may have to assert moral rights or other claims contrary to the foregoing understanding. It is understood that this means that in addition to the original work product (be it invention, plan, idea, know how, concept, development, discovery, process, method, or any other legally recognized item that can be legally owned), the Company exclusively owns all rights in any and all derivative works, copies, improvements, patents, registrations, claims, or other embodiments of ownership or control arising or resulting from an item of assigned Company Intellectual Property everywhere such may arise throughout the world. The decision whether or not to commercialize or market any Company Intellectual Property is within the Company's sole discretion and for the Company’s sole benefit and no royalty will be due to Participant as a result of the Company's efforts to commercialize or market any such invention. In the event that there is any Invention, Work, Trademark, or other form of intellectual property that is incorporated into any product or service of the Company that Participant retains any ownership of or rights in despite the assignments created by this Agreement, then Participant hereby grants to the Company and its assigns a nonexclusive, perpetual, irrevocable, fully paid-up, royalty-free, worldwide license to the use and control of any such item that is so incorporated and any derivatives thereof, including all rights to make, use, sell, reproduce, display, modify, or distribute the item and its derivatives. All assignments of rights provided for in this Agreement are understood to be fully completed and immediately effective and enforceable assignments by Participant of all intellectual property rights in Company Intellectual Property. When requested to do so by the Company, either during or subsequent to employment with the Company, Participant will (A) execute all documents requested by the Company to affirm or effect the vesting in the Company of the entire right, title and interest in and to the Company Intellectual Property at issue, and all patent, trademark, and/or copyright applications filed or issuing on such property; (B) execute all documents requested by the Company for filing and obtaining of patents, trademarks and/or copyrights; and (C) provide assistance that the Company reasonably requires to protect its right, title and interest in the Company Intellectual Property, including, but not limited to, providing declarations and testifying in administrative and legal proceedings with regard to Company Intellectual Property.

(v)    Power of Attorney: Participant hereby irrevocably appoints the Company as his or her agent and attorney in fact to execute any documents and take any action necessary for applications, registrations, or similar measures needed to secure the issuance of letters patent, copyright or trademark registration, or other legal establishment of the Company’s ownership and control rights in Company Intellectual Property in the event that Participant’s signature or other action is necessary and cannot be secured due to Participant’s physical or mental incapacity or for any other reason.

(vi)    Participant will make and maintain, and not destroy, notes and other records related to the conception, creation, discovery, and other development of Company Intellectual Property. These records shall be considered the exclusive property of the Company and are covered by clauses (g)(i) through (g)(v) above. During employment and for a period of one (1) year thereafter, Participant will promptly disclose to the Company (without revealing the trade secrets of any third party) any Intellectual Property that Participant creates, conceives, or contributes to, alone or with others, that involve, result from, relate to, or may reasonably be
39

anticipated to have some relationship to the line of business the Company is engaged in or its actual or anticipated research or development activity.

(vii)    Participant will not claim rights in, or control over, any Invention, Work, or Trademark as something excluded from section (g) because it was conceived or created prior to being employed by the Company (a “Prior Work”) unless such item is identified in reasonable detail in a separate writing, signed and submitted by Participant with the execution of the Employment Agreement. Participant will not incorporate any such Prior Work into any work or product of the Company without prior written authorization from the Company to do so; and, if such incorporation does occur, Participant grants the Company and its assigns a nonexclusive, perpetual, irrevocable, fully paid-up, royalty-free, worldwide license to the use and control of any such item that is so incorporated and any derivatives thereof, including all rights to make, use, sell, reproduce, display, modify, or distribute the item and its derivatives.

(viii)    The assignment provisions in this section (g) are limited to only those inventions that lawfully can be assigned by an employee to an employer. Some examples of state laws limiting the scope of assignable inventions are Delaware Code Title 19 Section 805; Kansas Statutes Section 44-130; Minnesota Statutes 13A Section 181.78; North Carolina General Statutes Article 10A, Chapter 66, Commerce and Business, Section 66-57.1; Utah Code Sections 34-39-l through 34-39-3, "Employment Inventions Act"; and Washington Rev. Code, Title 49 RCW: Labor Regulations, Chapter 49.44.140. NOTICE: By accepting this Agreement, Participant acknowledges that to the extent one of the foregoing laws applies, Participant’s assignment pursuant to this section (g) will not apply to an invention for which no equipment, supplies, facility, or trade secret information of the Company was used and which was developed entirely on Participant’s own time, unless: (A) the invention relates directly to the business of the Company or to the Company's actual or anticipated research or development; or (B) the invention results from any work performed by Participant for the Company. Similarly, to the extent California Labor Code Section 2870 or Illinois 765ILCS1060/1-3 "Participants Patent Act" controls, then the notice in the preceding sentence applies, absent the word “directly” in clause (A).

40

APPENDIX A

Alabama:
If Alabama law is deemed to apply, then the following applies to Participant: (a) Section 7(d) is rewritten as follows: “While employed and for a period of twelve (12) months from Termination, Participant will not participate in soliciting any Covered Employee of the Company who is in a Sensitive Position to leave the employment of the Company on behalf of (or for the benefit of) a Competitor nor will Participant knowingly assist a Competitor in efforts to hire a Covered Employee away from the Company. As used in this Section 7(d), a “Covered Employee” is an Employee with whom Participant worked, as to whom Participant had supervisory responsibilities, or regarding which Participant received Confidential Information during the Look Back Period. An Employee in a “Sensitive Position” refers to an Employee who is uniquely essential to the management, organization, or service of the business;” and (b) Section 7(c) is limited to prohibiting the solicitation of persons or entities who have a current business relationship with the Company.

Arizona:
If Arizona law is deemed to apply, then the following applies to Participant: (a) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret; and (b) the restrictions in Section 7(c) shall be limited to the Restricted Territory.

Arkansas, Connecticut, Montana, and South Carolina:
If Arkansas, Connecticut, Montana, or South Carolina law is deemed to apply, then the following applies to Participant: Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.

California:
If California law is deemed to apply, then the following applies to Participant: (a) the noncompetition restriction in Section 7(b) shall not apply; (b) the Employee non-solicitation restrictions in Section 7(d) shall not apply; and (c) Section 7(c) shall be limited to situations where Participant is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law). The preceding sentence supersedes any contradictory provision in any prior agreements between Participant and the Company regarding noncompetition or non-solicitation.

Colorado:
If Colorado law is deemed to apply, then the following applies to Participant:

(a)    Section 7(b) shall apply only if Participant earns Annualized Cash Compensation equivalent to or greater than the Threshold Amount for Highly Compensated Workers and to the extent that the conduct in violation of Section 7(b) is aided by Participant’s use or disclosure of the Company’s trade secrets.
(b)    Section 7(c) shall apply only if Participant earns Annualized Cash Compensation equivalent to or greater than sixty percent (60%) of the Threshold Amount for Highly Compensated Workers and to the extent that the conduct in violation of Section 7(c) is aided by Participant’s use or disclosure of the Company’s trade secrets.
(c)    Section 7(d) shall not apply.
(d)    “Annualized Cash Compensation” means: (1) the amount of gross salary or wage amount, the fee amount, or other compensation amount for the full year, if the worker was employed or engaged for a full year; or (2) the compensation that the worker would have earned, based on the worker’s gross salary or wage amount, fee, or other compensation if the worker was not employed or engaged for a full year. In determining whether a worker’s cash compensation exceeds the threshold amount, where the worker has been employed for less than a calendar year, the worker’s cash compensation exceeds the threshold amount if the worker would reasonably expect to earn more than the threshold amount during a calendar year of employment.

41

(e)    “Threshold Amount for Highly Compensated Workers” means the greater of the threshold amount for highly compensated workers as determined by the Division of Labor Standards and Statistics in the Department of Labor and Employment, as of August 10, 2022, or the date Participant accepts this Agreement.
(f)    Nothing contained in this Agreement shall be construed to prohibit Participant from disclosing information that:
(1)    arises from Participant’s general training, knowledge, skill, or experience, whether gained on the job or otherwise;
(2)    is readily ascertainable to the public; or (3) a worker otherwise has a right to disclose as legally protected conduct.
(g)    Participant acknowledges that Participant received notice of this Agreement (including, but not limited to, the provisions of Section 7: (1) before Participant accepted the Company’s offer of employment (if Participant is a new hire); or (2) at least fourteen (14) days before the earlier of (I) Participant’s acceptance of this Agreement, or (II) the effective date of any additional compensation or change in the terms or conditions of employment that provides consideration for the covenants in Section 7.
Georgia:
If Participant resides in Georgia and is subject to Georgia law, then Section 7(d) shall be limited to targeting for solicitation or hire Employees who are located within the Restricted Territory.

Illinois:
If Participant resides in Illinois and is subject to Illinois law, then:

(a)    The provisions of Section 7(c) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $45,000 per year in 2022-2026, $47,500 per year in 2027-2031, $50,000 per year in 2032-2036, and $52,500 beginning on January 1, 2037;

(b)    The provisions of Section 7(d) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $45,000 per year in 2022-2026, $47,500 per year in 2027-2031, $50,000 per year in 2032-2036, and $52,500 beginning on January 1, 2037;

(c)    The provisions of Section 7(b) shall apply only if Participant’s Earnings, as defined by the Illinois Freedom to Work Act, exceed $75,000 per year in 2022-2026, $80,000 per year in 2027-2031, $85,000 per year in 2032-2036, and $90,000 beginning on January 1, 2037;


(d)    The provisions of Section 7(b) shall not apply if Participant is covered by a collective bargaining agreement under the Illinois Public Relations Act;

(e)    Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret;

(f)    Participant acknowledges that Participant has been advised to consult with an attorney about this Agreement and has been given an opportunity to do so; and

(g)    If Participant is a new hire, Participant acknowledges that Participant has been provided a copy of this Agreement at least 14 calendar days before the commencement of employment. If Participant is an existing Employee, Participant acknowledges that Participant has been given at least 14 calendar days to review this Agreement.

Indiana:
If Participant resides in Indiana and is subject to Indiana law, then the restrictions on Participant under Section 7(d) shall apply only with respect to soliciting, hiring, attempting to solicit or hire, or participating in any attempt to solicit or hire individuals who themselves had access to Confidential Information in the prior six months.

Louisiana:
If Louisiana law is deemed to apply, then the following applies to Participant: (a) the “Restricted Territory” defined in Section 7 of the Agreement is understood to cover the following parishes in Louisiana and all counties outside Louisiana where Participant had responsibilities for the Company: Acadia, Allen, Ascension, Assumption, Avoyelles, Beauregard, Bienville, Bossier, Caddo, Calcasieu, Caldwell, Cameron, Catahoula, Claiborne, Concordia, DeSoto, East
42

Baton Rouge, East Carroll, East Feliciana, Evangeline, Franklin, Grant, Iberia, Iberville, Jackson, Jefferson, Jefferson Davis, LaSalle, Lafayette, Lafourche, Lincoln, Livingston, Madison, Morehouse, Natchitoches, Orleans, Ouachita, Plaquemines, Pointe Coupee, Rapides, Red River, Richland, Sabine, St. Bernard, St. Charles, St. Helena, St. James, St. John The Baptist, St. Landry, St. Martin, St. Mary, St. Tammany, Tangipahoa, Tensas, Terrebonne, Union, Vermilion, Vernon, Washington, Webster, West Baton Rouge, West Carroll, West Feliciana, Winn; and (b) the restrictions in Section 7(c) (as well as Section 7(b)) shall be limited to the foregoing parishes and counties.

Maine:
If Maine law is deemed to apply, then the following applies to Participant: (a) Participant acknowledges that if Participant is a new hire Participant received a copy of this Agreement prior to receiving a formal offer of employment from the Company and was given at least three business days to consider the Agreement before signing; (b) Section 7(b) will not take effect until one year of employment or a period of six months from the date the agreement is signed, whichever is later; and (c) Section 7(b) shall not apply if Participant earns at or below 400% of the federal poverty level.

Maryland:
If Maryland law is deemed to apply, then the following applies to Participant: Section 7(b) shall not apply if Participant earns equal to or less than $15/hour or $31,200 annually.

Massachusetts:
If Participant resides or works in Massachusetts for at least the thirty days preceding Participant’s Termination, then the Company will notify Participant within ten (10) business days of Participant’s Termination whether the Company decides to waive Section 7(b) or make these provisions enforceable by paying Participant garden leave as provided by the Massachusetts Noncompetition Agreement Act, G.L. c. 149, S. 24L. In addition, if Massachusetts law is deemed to apply, then the following applies to Participant:

(a)    Section 7(b) will not apply if Participant’s employment is terminated without “cause” or if Participant is terminated as part of a reduction in force. Participant further understands that for the limited purpose of the application of the non-competition clause in Section 7(b) of the Agreement, “cause” to terminate Participant’s employment exists if Participant has (i) committed, admitted committing, or plead guilty to a felony or crime involving moral turpitude, fraud, theft, misappropriation, or dishonesty, (ii) violated a material term of this Agreement or Company policy, (iii) engaged in insubordination, or failed or refused to perform assigned duties of Participant’s position despite reasonable opportunity to perform, (iv) failed to exercise reasonable care and diligence in the exercise of Participant’s duties for the Company, or (iv) engaged in conduct or omissions that Participant knew, or should have known (with the exercise of reasonable care), would cause, or be likely to cause, harm to the Company or its reputation in the business community;

(b)    Participant acknowledges that Participant has been advised to consult with an attorney about this Agreement and has been given an opportunity to do so;

(c)    the Restricted Period applicable to Section 7(b) shall be limited to a period of one year following Participant’s Termination (as well as while Participant is employed by the Company); however, if Participant breaches Section 7(b) of this Agreement, and also breaches Participant’s fiduciary duty to the Company and/or has unlawfully taken, physically or electronically, any Company records, then such Restricted Period shall be extended to a period of two
(2) years from Termination;

(d)    Participant acknowledges that (i) if Participant is being initially hired by the Company, that Participant received a copy of this Agreement prior to receiving a formal offer of employment from the Company or at least ten (10) business days before commencement of Participant’s employment by the Company, whichever came first; or (ii) if Participant was already employed by the Company at the time of signing this Agreement, that Participant was provided a copy hereof at least ten (10) business days before the effective date of this Agreement;

(e)    the tolling language Section 10(b) shall only apply to any breach of Section 7(c) and (d) (i.e., the tolling language shall not apply to Section 7(b)); and

(f)    Section 7(b) shall not apply to Participant following Termination if Participant is: classified as non-exempt under the FLSA; 18 years or younger; or an undergraduate or graduate student in an internship or other short-term employment relationship while enrolled in college or graduate school.

43

Minnesota:
If Minnesota law is deemed to apply, then the restrictions in Section 7(b) shall be limited to situations in which Participant is aided in his or her conduct by the use or disclosure of Confidential Information.

Nebraska:
If Nebraska law is deemed to apply, then the following applies to Participant: (a) Section 7(c) is limited to the solicitation of persons or entities with which Participant did business and had personal business-related contact during the Look Back Period; and (b) Section 7(b) is limited to restricting Participant from working for a Company client or account with whom the Participant did business and had personal business-related contact during the Look Back Period.

Nevada:
If Nevada law is deemed to apply, then the following applies to Participant: (a) Section 7 does not preclude Participant from providing services to any former client or customer of the Company if: (1) Participant did not solicit the former customer or client; (2) the customer or client voluntarily chose to leave and seek services from Participant; and (3) Participant is otherwise complying with the limitations in this Agreement as to time and scope of activity to be restrained; and (b) Section 7(b) does not apply if Participant is paid solely an hourly wage, exclusive of tips or gratuities.

New Hampshire:
If New Hampshire law is deemed to apply, then the following applies to Participant: (a) Section 7(b) does not apply if Participant earns an hourly rate less than or equal to 200 percent of the federal minimum wage; and (b) Participant acknowledges that Participant was given a copy of this Agreement prior to a change in job classification or the offer of employment.

New York:
If New York law is deemed to apply, then the following applies to Participant: Section 7(c) shall be modified to exclude those clients or customers who became a client or customer of the Company as a result of Participant’s independent contact and business development efforts with the customer or client prior to and independent from his/her employment with the Company.

North Carolina:
If North Carolina law is deemed to apply, then the following applies to Participant: (a) the Look Back Period shall be calculated looking back twenty-four (24) months from the date of enforcement and not from the date Participant’s employment ends; and (b) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.

North Dakota:
If North Dakota law is deemed to apply, then the following applies to Participant: (a) the noncompetition restriction in Section 7(b) shall not apply; and (b) Section 7(c) shall be limited to situations where Participant is aided in his or her conduct by the use or disclosure of the Company’s trade secrets (as defined by applicable law).

Oklahoma:
If Oklahoma law is deemed to apply, then the following applies to Participant: (i) Section 7(c) is limited to preclude only the direct solicitation of established customers of the Company for the purpose of doing any business that would compete with the Company’s business; and (ii) the noncompetition restrictions in Section 7(b) shall not apply.

Oregon:
If Oregon law is deemed to apply, then the following applies to Participant: the restrictions in Section 7(b) shall apply only if: (a) Participant is engaged in administrative, executive or professional work and performs predominantly intellectual, managerial, or creative tasks, exercises discretion and independent judgment and earns a salary or is otherwise exempt from Oregon's minimum wage and overtime laws; (b) the Company has a "protectable interest" (meaning, access to trade secrets or competitively sensitive confidential business or professional information); and (c) the total amount of Participant's annual gross salary and commission, calculated on an annual basis, at the time of Participant's Termination, exceeds $100,533 adjusted annually for inflation pursuant to the Consumer Price Index for
44

All Urban Consumers, West Region (All Items), as published by the Bureau of Labor Statistics of the United States Department of Labor immediately preceding the calendar year of Participant’s Termination. However, if Participant does not meet requirements of either (a) or (c) (or both), the Company may, on a case-by-case basis, decide to make Section 7(b) enforceable as to Participant (as allowed by Oregon law), by agreeing in writing to pay Participant, during the period of time Participant is restrained from competing, the greater of: (i) compensation equal to at least 50 percent of Participant’s annual gross base salary and commissions at the time of Termination; or (ii) fifty percent of $100,533 adjusted annually for inflation pursuant to the Consumer Price Index for All Urban Consumers, West Region (All Items), as published by the Bureau of Labor Statistics of the United States Department of Labor immediately preceding the calendar year of Participant’s Termination. If Participant is an existing Employee, Participant acknowledges that this Agreement was entered into upon a subsequent bona fide advancement of Participant by the Company; namely the Company is conferring upon Participant equity awards that, if accepted by Participant, will supplement Participant’s compensation.

Puerto Rico:
If Puerto Rico law is deemed to apply, then the following applies to Participant: (a) the Restricted Period and the Look Back Period in Section 7 shall be, in each case, only a period of twelve (12) months; (b) the Restricted Territory shall be limited to the territory of Puerto Rico; (c) the customer restriction in Section 7(c) shall be limited to clients, accounts, and medical care providers that were personally serviced by Participant during the Look Back Period and had an active business relationship with the Company within the last thirty (30) days prior to Participant’s Termination; and (d) the tolling provision in Section 10(b) shall not apply.

Rhode Island:
If Rhode Island law is deemed to apply, then Section 7(b) shall not apply to Participant following Termination if Participant is: classified as non-exempt under the FLSA; an undergraduate or graduate student in an internship or short-term employment relationship; 18 years of age or younger; or a low wage Participant (defined as earning less than 250% of the federal poverty level).

Utah:
If Utah law is deemed to apply, then the following applies to Participant: (a) the Restricted Period applicable to Section 7(b) shall be limited to a period of one year following Termination (as well as while Participant is employed by the Company).

Virginia:
If Virginia law is deemed to apply, then the following applies to Participant: (a) Section 7(b)-(d) shall not apply if Participant is a “low wage Participant.” A “low wage Participant” refers to a Participant whose average weekly earnings (calculated by dividing Participant's earnings during the period of 52 weeks immediately preceding Termination by 52, or if Participant worked fewer than 52 weeks, by the number of weeks that Participant was actually paid during the 52-week period) are less than the average weekly wage of the Commonwealth of Virginia as determined pursuant to subsection B of Virginia Code § 65.2-500. "Low-wage Participant" includes interns, students, apprentices, or trainees employed, with or without pay, at a trade or occupation in order to gain work or educational experience. "Low-wage Participant" also includes an individual who has independently contracted with another person to perform services independent of an employment relationship and who is compensated for such services by such person at an hourly rate that is less than the median hourly wage for the Commonwealth of Virginia for all occupations as reported, for the preceding year, by the Bureau of Labor Statistics of the U.S. Department of Labor. However, "low-wage Participant" does not include any Participant whose earnings are derived, in whole or in predominant part, from sales commissions, incentives, or bonuses paid to Participant by the Company; (b) Section 7 does not preclude Participant from providing services to any client or customer of the Company if Participant did not initiate contact with or solicit the former customer or client; and (c) Participant’s nondisclosure obligation in Section 7(a) shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret.

Washington (state):
If Participant resides in Washington at the time this Agreement is entered, Participant acknowledges that Participant was given at least ten (10) business days to consider this Agreement before accepting it.

In addition, if Washington law controls, then for so long as Washington law controls, the Agreement will be modified and applied as follows:

45

(a)    Section 7(b) shall apply following Termination only if Participant’s annualized earnings from the Company exceed
$100,000.00 per year (adjusted annually in accordance with Section 5 of Washington HP 1450), and Section 7(b) shall apply during employment only if Participant earns at least twice the Washington minimum hourly wage (subject to the common law duty of loyalty and the Company’s Code of Conduct);

(b)    for purposes of the application of the non-competition provision in Section 7(b), Participant understands that the non-competition provision will not be enforced against Participant if Participant is terminated from employment without “cause” or if Participant is laid off, unless the Company pays Participant during the Restricted Period an amount equal to Participant’s base salary at Termination less any compensation earned by Participant during the Restricted Period. Participant further understands that for the limited purpose of the application of the non-competition clause in Section 7(b) of the Agreement, “cause” to terminate Participant’s employment exists if Participant has (i) committed, admitted committing, or plead guilty to a felony or crime involving moral turpitude, fraud, theft, misappropriation, or dishonesty, (ii) violated a material term of this Agreement or Company policy, (iii) engaged in insubordination, or failed or refused to perform assigned duties of my position despite reasonable opportunity to perform, (iv) failed to exercise reasonable care and diligence in the exercise of Participant’s duties for the Company, or (iv) engaged in conduct or omissions that Participant knew, or should have known (with the exercise of reasonable care), would cause, or be likely to cause, harm to the Company or its reputation in the business community; and

(c)    Participant further acknowledges that if Participant is a new Employee, Participant has had advance notice of the terms of this Agreement prior to accepting the Company’s offer of employment.

Washington, D.C.:
Participant acknowledges that Participant was given a copy of Washington, D.C., Council Bill 24-256 (“Bill 24-256”) prior to or contemporaneously with accepting this Agreement.

If Participant is a “Covered Employee” as defined by Bill 24-256 and Participant is not a “Highly Compensated Employee,” as defined by Bill 24-256, the following applies to Participant: (1) Section 7(b) shall not apply; (2) “Confidential Information” shall, in all instances, be limited to information owned or possessed by the Company which is not available to the general public and which the Company has taken reasonable steps to ensure is protected from improper disclosure; (3) Participant is precluded, during Participant’s employment with the Company, from accepting money or a thing of value for performing work for a person other than the Company, where doing so can reasonably be concluded to result in (a) Participant’s disclosure or use of Confidential Information or “Proprietary employer information,” as defined by Bill 24-256; (b) a conflict with the Company’s established rules regarding conflicts of interest, or (c) impairment of the Company’s ability to comply with federal law, the law of the District of Columbia, or a contract or grant agreement.

If Participant is a “Covered Participant” as defined by Bill 24-256 and Participant is a “Highly Compensated Participant,” as defined by Bill 24-256, the following applies to Participant: (1) Participant acknowledges that Participant was given a copy of this Agreement at least 14 days before Participant commenced employment with the Company (if Participant is a new hire) or Participant was given a copy of this Agreement at least 14 days before Participant was required to accept this Agreement (if Participant is an existing Employee); (2) “Confidential Information” shall, in all instances, be limited to information owned or possessed by the Company which is not available to the general public and which the Company has taken reasonable steps to ensure is protected from improper disclosure; (3) the Restricted Period for purposes of the non-competition provision in Section 7(b) shall be limited to a period of twelve (12) months following Termination (and while Participant is employed by the Company); and (4) Participant is notified that The District of Columbia Ban on Non-Compete Agreements Amendment Act of 2020 limits the use of non-compete agreements. It allows employers to request non-compete agreements from “highly compensated employees” under certain conditions. The Company has determined that you are a highly compensated employee. For more information about the Ban on Non-Compete Agreements Amendment Act of 2020, contact the District of Columbia Department of Employment Services (DOES).

Wisconsin:
If Wisconsin law is deemed to apply, then the following applies to Participant: (a) Participant’s nondisclosure obligation in Section 7 shall extend for a period of three (3) years after Participant’s Termination as to Confidential Information that does not qualify for protection as a trade secret. Trade secret information shall be protected from disclosure as long as the information at issue continues to qualify as a trade secret; (b) the tolling provision in Section 10(b) shall not apply; and (c) Section 7(d) is rewritten as follows: “While employed and for a period of twelve (12) months following Termination, Participant will not participate in soliciting any “Covered Employee” of the Company
46

that is in a “Sensitive Position” to leave the employment of the Company on behalf of (or for the benefit of) a Competitor; nor will Participant knowingly assist a Competitor in efforts to hire a Covered Employee away from the Company. As used in this Section 7(d), a “Covered Employee” is an Employee with whom Participant worked, as to whom Participant had supervisory responsibilities, or regarding whom Participant received Confidential Information during the Look Back Period. A Participant in a “Sensitive Position” refers to an Employee who is in a management, supervisory, sales, research and development, or similar role where the Employee is provided Confidential Information or is involved in business dealings with the Company’s clients.”
47
 EX-31.1 6 exhibit311-20240331q12024.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gail K. Boudreaux, certify that:
1.I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
April 18, 2024 /s/ GAIL K. BOUDREAUX
 President and Chief Executive Officer


 EX-31.2 7 exhibit312-20240331q12024.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Mark B. Kaye, certify that:
1.I have reviewed this report on Form 10-Q of Elevance Health, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
April 18, 2024 /s/ MARK B. KAYE
      Executive Vice President and
     Chief Financial Officer


 EX-32.1 8 exhibit321-20240331q12024.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gail K. Boudreaux, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
April 18, 2024


 EX-32.2 9 exhibit322-20240331q12024.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Elevance Health, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark B. Kaye, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ MARK B. KAYE
Mark B. Kaye
Executive Vice President and Chief Financial Officer
April 18, 2024


 EX-101.SCH 10 elv-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Business Acquisitions and Divestitures link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Business Optimization Initiatives link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Medical Claims Payable link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Accumulated Other Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Shareholders' Earnings per Share link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Medical Claims Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Capital Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Shareholders' Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Business Acquisitions and Divestitures (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Business Optimization Initiatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Investments - Current and Long-Term Fixed Maturity Securities, Available-For-Sale (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Investments - Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Investments - Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Investments - Current Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Investments - Net Investment (Losses) and Gains (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Derivative Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Fair Value - Summary of Fair Value Measurements by Level (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Fair Value - Schedule of Estimated Fair Value by Level (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Medical Claims Payable - Reconciliation of Medical Claims Payable (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Medical Claims Payable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Medical Claims Payable - Reconciliation of Net Incurred Medical Claims to Benefit Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Medical Claims Payable - Reconciliation of the Claims Development to the Claims Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Capital Stock - Summary of Cash Dividend Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Capital Stock - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Capital Stock - Summary of Share Repurchases (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Capital Stock - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Capital Stock - Nonvested Restricted Stock Activity Including Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Capital Stock - Fair Values of Options Granted During the Period Estimated Using Weighted-Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Capital Stock - Schedule of Weighted-Average Fair Values Determined for the Periods (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Shareholders' Earnings per Share - Denominator for Basic and Diluted Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Shareholders' Earnings per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Segment Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Segment Information - Financial Data by Reportable Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Segment Information - Reconciliation of Reportable Segments Operating Revenues to Total Revenues Reported in the Consolidated Statements of Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Segment Information - Reconciliation of Income Before Income Tax Expense to Reportable Segments Operating Gain Included in the Consolidated Statements of Income (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 elv-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 elv-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 elv-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Proceeds from sales, maturities, calls or redemptions of fixed maturity securities Proceeds from Sale of Debt Securities, Available-for-Sale Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Insurance lines other than short duration Liability for Claims and Claims Adjustment Expense, Other Insurance Lines Liability for Claims and Claims Adjustment Expense, Other Insurance Lines Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Debt Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other invested assets Other Long-Term Investments Debt-to-capital ratio Debt Instrument, Debt-to-Capital Ratio Debt Instrument, Debt-to-Capital Ratio Revolving Credit Facility Revolving Credit Facility [Member] BioPlus Parent, LLC and Subsidiaries BioPlus Parent, LLC and Subsidiaries [Member] BioPlus Parent, LLC and Subsidiaries Schedule of Current and Long-Term Investments, Available-For-Sale Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Effect of foreign exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Deferred tax liabilities, net Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Senior Unsecured Notes Senior Unsecured Notes [Member] Senior Unsecured Notes [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Exercisable at end of period, Weighted-Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Mortgage-backed securities Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value Fixed maturity securities: Fixed Maturities [Member] Restatement Determination Date: Restatement Determination Date [Axis] Corporate securities Corporate Debt Securities [Member] Purchases of investments Payments to Acquire Investments Commitments and contingencies – Note 11 Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Long-term purchase commitment, amount Long-Term Purchase Commitment, Amount Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Capital Stock Equity [Text Block] Income Taxes Income Tax Disclosure [Text Block] Medical claims payable Gross medical claims payable, end of period Liability for Claims and Claims Adjustment Expense Equity securities: Equity Securities Fair value of investments in equity securities. Number of medical members served Number Of Medical Members Served Number of medical members served Quarterly dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Self-funded receivables Self-Funded Receivables, Net The carrying amount as of the balance sheet date due the entity from self-insured customers, net of the allowance for doubtful accounts. Total liabilities Financial Liabilities Fair Value Disclosure Revenue Recognition Revenue [Policy Text Block] Customer [Axis] Customer [Axis] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Current liabilities: Liabilities, Current [Abstract] Short-duration Insurance Contracts, Claim Year [Axis] Short-Duration Insurance Contracts, Accident Year [Axis] Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none Preferred Stock, Value, Issued Eliminations Intersegment Eliminations [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted- Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Proceeds originally received at time of divestiture Proceeds from Divestiture of Businesses Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Forfeited or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Derivative Instruments, Gain (Loss) by Hedging Relationship [Axis] Hedging Relationship [Axis] Number of counties in the Kansas City area the Company does not serve Number Of Counties In State Of Kansas Company Does Not Serve Number Of Counties In The State Of Kansas Company Does Not Serve Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level III Fair Value, Inputs, Level 3 [Member] Line of Credit Line of Credit [Member] Claims Development [Line Items] Claims Development [Line Items] Investment [Table] Schedule of Gain (Loss) on Securities [Table] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Amortized Cost Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract] Litigation Case [Axis] Litigation Case [Axis] Due after five years through ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Issuance of common stock under employee stock plans, net of related tax benefits Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol United States Government securities United States Government securities US Government Agencies Debt Securities [Member] Business Optimization Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted during the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net gain (loss) recognized in other comprehensive income, tax (expense) benefit Other Comprehensive Income (Loss), Tax Shareholders’ net income Shareholders' net income Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Due after one year through five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Gross medical claims payable, beginning of period Gross medical claims payable, end of period Short Duration Contract Liability For Claims Adjustment Expense The amount needed to reflect the estimated ultimate cost of settling short duration contract claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date for short duration. Commercial paper Commercial Paper Damages for Pharmacy Pricing Pharmacy pricing [Member] Pharmacy pricing [Member] Liabilities and equity Liabilities and Equity [Abstract] Fixed maturities, amortized cost, current Debt Securities, Available-for-Sale, Amortized Cost, Current Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Shareholders’ equity Equity, Attributable to Parent [Abstract] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Receivables, net Increase (Decrease) in Receivables Denominator for Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Receivables Receivable [Policy Text Block] Cost of products sold Cost of Goods and Services Sold Net incurred but not reported liabilities plus expected development on reported claims Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net Executive Category: Executive Category [Axis] Restricted Stock Shares and Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level I Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Reported Value Measurement Reported Value Measurement [Member] Goodwill Goodwill Statement, Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Major Types of Fixed Maturity Securities [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Investment Type [Axis] Investment Type [Axis] Current period medical claims Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year Measurement Basis [Axis] Measurement Basis [Axis] Reconciliation of Reportable Segments Operating Revenues to Total Revenues Reported in the Consolidated Statements of Income Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Investments [Domain] Investments [Domain] Prior periods medical claims Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years Accumulated Other Comprehensive (Loss) Income Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Dividends per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Foreign government securities Foreign Government Debt [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Net incurred medical claims: Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract] Schedule of Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] Restricted Stock Units Restricted Stock Units (RSUs) [Member] Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Senior revolving credit facility term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Accrued investment income receivable Accrued Investment Income Receivable Change in non-credit component of impairment losses on investments Change in non-credit component of impairment losses on investments net of tax Change in non-credit component of impairment losses on investments, net of tax effect. Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures Weighted Average Number of Shares Outstanding, Diluted, Adjustment Damages for Operational Breaches Operational [Member] Operational [Member] Net (losses) gains: Debt Securities, Available-for-Sale, Realized Gain (Loss) [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Due after ten years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 Income taxes payable Accrued Income Taxes, Current Total revenues Revenues Other receivables, allowance for doubtful accounts Allowance for Credit Loss, Receivable, Other, Current Commercial mortgage-backed securities Commercial Mortgage-Backed Securities [Member] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Net medical claims payable, end of period Liability for Unpaid Claims and Claims Adjustment Expense, Net Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Liability for employee termination costs Restructuring Reserve Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Dividends and dividend equivalents Dividends, Common Stock Total net payments Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Carelon Total Carelon Total [Member] Carelon Total Outstanding at end of period, Weighted-Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Summary of Cash Dividend Activity Dividends Declared [Table Text Block] Trading Arrangement: Trading Arrangement [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Commitments and Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Weighted-Average Fair Values Determined for the Periods Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Repurchase and retirement of common stock, including excise tax Stock Repurchased And Retired During Period, Value, Including Excise Tax Stock Repurchased And Retired During Period, Value, Including Excise Tax Allowance For Credit Losses Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Income taxes Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable Amortization of other intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Unearned income Unearned Premiums Recently Adopted Accounting Guidance and Recent Accounting Guidance Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Recognized loss on hedging derivatives Derivative, Loss on Derivative Average price per share (in dollars per share) Shares Acquired, Average Cost Per Share Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block] Class of Stock Disclosures [Abstract] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Business Optimization Initiatives and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Net medical claims payable, beginning of period Net medical claims payable, end of period Short duration contract liability for unpaid claims and adjustment expense, Net Short duration contract liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for short duration contract claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid short duration contract claims. Government sponsored securities US Government-sponsored Enterprises Debt Securities [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Increase in amount of stock authorized in the Stock Repurchase Program Increase In Stock Repurchase Program Authorization The amount of an increase authorized by an entity's Board of Directors to a previously authorized stock repurchase program. Changes in securities lending collateral Increase (Decrease) in Collateral Held under Securities Lending Estimated fair value, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Exchange traded funds Exchange Traded Funds [Member] Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Long-term debt Long-Term Debt Total assets Assets, Fair Value Disclosure Repurchase Agreements and Similar Transactions, Maturity Periods [Axis] Repurchase Agreements and Similar Transactions, Maturity Periods [Axis] Investment Income [Table] Investment Income [Table] Number of securities, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Operating expense Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $50 and $(85), respectively Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Employee Stock Option Employee Stock Option [Member] Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Investments Investment, Policy [Policy Text Block] Other, net Proceeds from (Payments for) Other Financing Activities Total shareholders’ comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Other invested assets Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI Depreciation and amortization Depreciation, Amortization and Accretion, Net Document Type Document Type Total expenses Benefits, Losses and Expenses Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned Securities Lending Transactions Ratio of Fair Value of Collateral Held To Securities On Loan Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions. Non-credit components of impairments on investments: AOCI, Non-Credit Components of Impairments on Investments, Including Portion Attributable to Noncontrolling Interest [Member] AOCI, Non-Credit Components of Impairments on Investments, Including Portion Attributable to Noncontrolling Interest CarelonRx CarelonRx Segment [Member] CarelonRx Segment [Member] Policy liabilities Increase (Decrease) in Insurance Liabilities Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Changes in bank overdrafts Increase (Decrease) in Outstanding Checks, Financing Activities Weighted- Average Option Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Expenses Benefits, Losses and Expenses [Abstract] Subsequent Event Subsequent Event [Member] Derivative [Table] Derivative [Table] Other current liabilities Other Liabilities, Current Cash Cash [Member] Income Statement [Abstract] Income Statement [Abstract] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Net investment income Net investment income Net Investment Income Title of 12(b) Security Title of 12(b) Security Business Optimization Initiatives [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive income (loss) before reclassifications, tax Other Comprehensive Income (Loss) before Reclassifications, Tax Gross losses Gross Losses From Other Investments Gross Losses From Other Investments Other comprehensive income attributable to noncontrolling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Income taxes receivable Income Taxes Receivable Operating Segments Operating Segments [Member] Nonvested at beginning of period (in dollars per share) Nonvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Other current assets Other Assets, Current Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Reconciliation of Medical Claims Payable Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number 2022 Short-Duration Insurance Contract, Accident Year 2022 [Member] Other comprehensive income attributable to noncontrolling interests, tax Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest Collateral received for securities loaned, at carrying value Deposits Received for Securities Loaned, at Carrying Value Other investments: Other Investments [Member] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Derivatives Derivative [Member] Measurement period adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Common equity securities Common Equity Securities [Member] Common Equity Securities [Member] Available-for-sale Securities Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Repurchase and retirement of common stock Payments for Repurchase of Common Stock Product revenue Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Investment [Line Items] Gain (Loss) on Securities [Line Items] Business Acquisitions and Divestitures Mergers, Acquisitions and Dispositions Disclosures [Text Block] Segments [Domain] Segments [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Other asset-backed securities Other Debt Obligations [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 5-Year Facility 5-Year Facility [Member] 5-Year Facility [Member] Short-duration Insurance Contracts, Claims Development [Table] Short-Duration Insurance Contracts, Claims Development [Table] Current assets: Assets, Current [Abstract] Prior periods redundancies Prior Year Claims and Claims Adjustment Expense Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Residential mortgage-backed securities Residential Mortgage-Backed Securities [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Change in net unrealized losses/gains on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Maturities, calls and redemptions from investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale PEO PEO [Member] Health Benefits Health Benefits Segment [Member] Health Benefits Segment Other receivables Other Receivables Proceeds from short-term borrowings Proceeds from Short-Term Debt Long-term investments: Long-Term Investments [Abstract] Reserves for future policy benefits Liability for Future Policy Benefit, before Reinsurance Notes Notes Payable Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Equity securities Equity Securities, FV-NI, Current Customer [Domain] Customer [Domain] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Quality improvement and other claims expense SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense Debt Instrument [Axis] Debt Instrument [Axis] Aggregate cost Stock Repurchased and Retired During Period, Value Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Exercisable at end of period, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Volatility factor Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Summary of Marketable Equity Securitites Investments in equity securities [Table Text Block] Investments in equity securities [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fixed maturities, amortized cost, noncurrent Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent Debt: Debt Disclosure [Abstract] Number of reportable segments Number of Reportable Segments Shareholders’ net income per share Earnings Per Share [Abstract] Earnings Per Share [Abstract] Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 232,544,717 and 233,071,088 Common Stock, Value, Issued Estimated fair value, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Due after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Operating revenue - affiliated Affiliated [Member] Affiliated [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Gain Contingency, Nature [Axis] Gain Contingencies, Nature [Axis] Schedule of Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position Schedule of Unrealized Loss on Investments [Table Text Block] Short-duration Insurance Contracts, Claim Year [Domain] Short-Duration Insurance Contracts, Accident Year [Domain] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total current assets Assets, Current Equity securities: Equity Securities [Member] All Individuals All Individuals [Member] Litigation Case [Domain] Litigation Case [Domain] Entity Filer Category Entity Filer Category Business Optimization Initiative Type [Axis] Restructuring Type [Axis] Summary of Share Repurchases Class of Treasury Stock [Table Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Statement [Table] Statement [Table] Restricted Stock Units - Contingent Restricted Stock Units - Contingent [Member] Restricted Stock Units - Contingent Current Fiscal Year End Date Current Fiscal Year End Date PEO Name PEO Name Reconciliation of Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Reconciliation of Net Incurred Medical Claims to Benefit Expense Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table Text Block] Tabular Disclosure For Reconciliation of Net Incurred Medical Claims to Benefit Expense. Granted (in dollars per share) Restricted stock awards granted during the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Equity Securities [Line Items] Marketable Securities [Line Items] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Fair Value, Nonrecurring Fair Value, Nonrecurring [Member] Fixed maturity securities (amortized cost of $30,427 and $30,446; allowance for credit losses of $4 and $4) Debt Securities, Available-for-Sale, Current Commercial paper Line of Credit, Current Organization Nature of Operations [Text Block] Other, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Fixed maturities, allowance for credit loss, current Debt Securities, Available-for-Sale, Allowance for Credit Loss, Current 2023 Short-Duration Insurance Contract, Accident Year 2023 [Member] Total shareholders’ equity Equity, Attributable to Parent Gross realized gains from sales Debt Securities, Available-for-Sale, Realized Gain Consolidation Items [Axis] Consolidation Items [Axis] Commercial Paper Commercial Paper [Member] Benefit expense Policyholder Benefits and Claims Incurred, Net Unearned income Increase (Decrease) in Deferred Revenue Premiums Premiums Earned, Net AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Weighted-average expected life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Anthem, Inc. v. Express Scripts, Inc. Anthem, Inc. v. Express Scripts, Inc. [Member] Anthem, Inc. v. Express Scripts, Inc. [Member] Income before income tax expense Income before income tax expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percentage of total assets at fair value Percentage of Total Assets Presented at Fair Value Percentage of Total Assets Presented at Fair Value States, municipalities and political subdivisions, tax-exempt US States and Political Subdivisions Debt Securities [Member] Business Optimization Initiatives Restructuring and Related Activities Disclosure [Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level II Fair Value, Inputs, Level 2 [Member] Current period Current Year Claims and Claims Adjustment Expense Future policy benefits: AOCI, Future Policy Benefits, Including Portion Attributable to Noncontrolling Interest [Member] AOCI, Future Policy Benefits, Including Portion Attributable to Noncontrolling Interest Other asset-backed securities Other Security Investments [Member] Entity Emerging Growth Company Entity Emerging Growth Company Securities lending collateral Securities Held as Collateral, at Fair Value Other intangible assets Intangible Assets, Net (Excluding Goodwill) Repurchase Agreements and Similar Transactions, Maturity Periods [Domain] Repurchase Agreements and Similar Transactions, Maturity Periods [Domain] Corporate & Other Corporate & Other Segment [Member] Corporate & Other Segment Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Finite-lived intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Document Fiscal Period Focus Document Fiscal Period Focus Dividends payable (in dollars per share) Dividends Payable, Amount Per Share Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Operating revenue - unaffiliated Unaffiliated [Member] Unaffiliated [Member] Securities lending transactions, initial collateral percentage value Securities Lending Transactions Initial Collateral Percentage Value Initial minimum percentage of cash and/or securities collateral accepted as compared to the value of securities on loan in a securities lending transaction. Title Trading Arrangement, Individual Title Outstanding at beginning of period (in dollars per share) Outstanding at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Change in net periodic pension and postretirement costs Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Fixed maturity securities (amortized cost of $902 and $890; allowance for credit losses of $0 and $0) Debt Securities, Available-for-Sale, Noncurrent Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Number of notices of appeal Number of Notices of Appeal Number of Notices of Appeal Shareholders' Earnings per Share Earnings Per Share [Text Block] Products and Services Product and Service [Axis] Estimated Fair Value Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract] Medical Claims Payable Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Equity Securities [Table] Marketable Securities [Table] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Derivatives - other assets Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement 2024 Short-Duration Insurance Contract, Accident Year 2024 [Member] Short-Duration Insurance Contract, Accident Year 2024 Investments [Abstract] Investments [Abstract] Property and equipment, net Property, Plant and Equipment, Net Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Cash Dividend per Share (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Other comprehensive (loss) income Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Foreign currency translation adjustments: Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Change in future policy benefits OCI, Liability for Future Policy Benefit, Gain (Loss), after Reclassification Adjustment and Tax (In millions, except share and per share data) Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Total net incurred medical claims Total net incurred medical claims Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims Due after ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Proceeds from long-term borrowings Proceeds from Issuance of Long-Term Debt BCBS Antitrust Litigation BCBS Antitrust Litigation [Member] BCBS Antitrust Litigation Fixed maturity securities: Available-for-Sale Securities, Debt Maturities [Abstract] Taxes paid through withholding of common stock under employee stock plans Payment, Tax Withholding, Share-Based Payment Arrangement Liabilities Liabilities [Abstract] Net income Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Other, net Payments for (Proceeds from) Other Investing Activities Retained Earnings Retained Earnings [Member] Schedule of Estimated Fair Value by Level Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet [Table Text Block] -- None. No documentation exists for this element. -- Current portion of long-term debt Long-Term Debt, Current Maturities Number of securities, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Reconciliation of Income Before Income Tax Expense to Reportable Segments Operating Gain Included in the Consolidated Statements of Income Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Total liabilities and equity Liabilities and Equity Cost or Amortized Cost Total fixed maturity securities Debt Securities, Available-for-Sale, Amortized Cost Other noncurrent assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Change in net unrealized gains/losses on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Basic (in dollars per share) Earnings Per Share, Basic Other policyholder liabilities Other Policyholder Funds Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Equity securities: Available-for-Sale Securities, Equity Securities [Abstract] Available-for-Sale Securities, Equity Securities Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Premium receivable, allowance for doubtful accounts Premium Receivable, Allowance for Credit Loss Arrangement Duration Trading Arrangement Duration Proceeds from sale of investments Proceeds from sale of equity and fixed maturity securities Proceeds from sale of equity and fixed maturity securities. Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Private equity securities Private Equity Funds [Member] Financial Data by Reportable Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Mortgage-backed securities Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost Ceded medical claims payable, end of period Liability for Claims and Claims Adjustment Expense, Ceded Medical Claims Payable Liability for Claims and Claims Adjustment Expense, Ceded Medical Claims Payable Impairment losses recognized in income Impairment (losses) reversals on investments Total impairment (losses) reversals on investments, before considering whether or not such amount is recognized in earnings or other comprehensive income. Charges or releases related to employee termination costs Restructuring Charges Self-funded receivables, allowance for doubtful accounts Self-funded Receivables, Allowance For Doubtful Accounts The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross self-funded receivable to net realizable value. Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Business Acquisitions [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Combinations [Abstract] Business Combinations [Abstract] Authorization remaining at the end of the period Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Estimated Fair Value Total fixed maturity securities Fixed maturity securities, available-for-sale: Debt Securities, Available-for-Sale Net payments attributable to: Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] Short-term borrowings Short-Term Debt Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Covenant, debt-to-capital ratio (not more than) Debt Instrument, Covenant, Debt-to-Capital Ratio Debt Instrument, Covenant, Debt-to-Capital Ratio Net gains (losses) on equity securities Equity Securities, FV-NI, Gain (Loss) Federal Home Loan Bank Advances Federal Home Loan Bank Advances [Member] Ceded medical claims payable, beginning of period Ceded medical claims payable, end of period Reinsurance Recoverable for Unpaid Claims and Claims Adjustments Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] Due in one year or less Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Paragon Healthcare, Inc. Paragon Healthcare, Inc. [Member] Paragon Healthcare, Inc. All Adjustments to Compensation All Adjustments to Compensation [Member] Reclassification from AOCI, current period, tax Reclassification from AOCI, Current Period, Tax Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Net losses on financial instruments Gain (Loss) on Investments Additional paid-in capital Additional Paid in Capital Due after five years through ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income taxes Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Business Optimization Plan [Axis] Restructuring Plan [Axis] Proceeds from issuance of common stock under employee stock plans Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Short-term borrowings from the FHLB Federal Home Loan Bank, Advances, Maturities Summary, Due in Next Rolling 12 Months Net losses on investments Investment Gains (Losses) Investment Gains (Losses) Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Surplus Notes Surplus Notes [Member] Surplus Notes [Member] Fair Value, Separate Account Investment [Table] Fair Value, Separate Account Investment [Table] Net losses on financial instruments Net losses on financial instruments Net losses (gains) on financial instruments Net (losses) gains on financial instruments Net (losses) gains on financial instruments Outstanding at end of period, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Issuance of common stock under employee stock plans, net of related tax benefits (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Other assets Increase (Decrease) in Other Operating Assets Convertible debenture repurchases, conversions and tax adjustments Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Unrealized gains (losses) recognized on equity securities still held at the end of the period Equity Securities, FV-NI, Unrealized Gain (Loss) Adjustment to Compensation, Amount Adjustment to Compensation Amount Carelon Services Carelon Services Segment [Member] Carelon Services Segment Employee Termination Employee Severance [Member] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Payments Payments for Restructuring Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Summary of Fair Value Measurements by Level Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Exercisable at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Corporate & Other Corporate and Other [Member] Repayments of long-term borrowings Repayments of Long-Term Debt Entity Central Index Key Entity Central Index Key Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Cash and cash equivalents Restricted Cash and Investments, Current Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax expense Income Tax Expense (Benefit) Gross gains Gains From Other Investments Gains From Other Investments Fair Value Fair Value Disclosures [Text Block] Fair value of collateral received at time of securities lending transactions Securities Loaned, Fair Value of Collateral Net cash flow hedges: Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Name Trading Arrangement, Individual Name Amounts reclassified from accumulated other comprehensive loss, net of tax benefit of $(33) and $(29), respectively Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Debt Instruments [Abstract] Debt Instruments [Abstract] Net (losses) gains on other investments Gain (Loss) on Sale of Other Investments Gross unrealized loss, 12 months or greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Product and service revenue Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] 2023-2024 Business Efficiency Program 2023-2024 Business Efficiency Program [Member] 2023-2024 Business Efficiency Program Amendment Flag Amendment Flag Service fees Service Fees [Member] Service Fees Total operating revenue Operating revenue Premiums Earned and Other Operating Revenue Premiums Earned and Other Operating Revenue Gross unrealized loss, less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Purchases of subsidiaries, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Liability for Claims and Claims Adjustment Expense [Abstract] Liability for Claims and Claims Adjustment Expense [Abstract] Due in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Credit Facility [Domain] Credit Facility [Domain] Repurchase and retirement of common stock, including excise tax (in shares) Shares repurchased (in shares) Stock Repurchased and Retired During Period, Shares Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Approximate amount of damages sought for breaches Loss Contingency, Damages Sought, Value Long-term debt, less current portion Long-Term Debt, Excluding Current Maturities Schedule of Net Investment (Losses) and Gains Gain (Loss) on Securities [Table Text Block] Denominator for diluted shareholders' earnings per share Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Other investments: Available-for-Sale Securities, Other Investments [Abstract] Available-for-Sale Securities, Other Investments Net realized losses from sales of fixed maturity securities Debt Securities, Available-for-Sale, Realized Gain (Loss) Gross realized losses from sales Debt Securities, Available-for-Sale, Realized Loss Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Gain Contingency, Nature [Domain] Gain Contingency, Nature [Domain] Net realized losses recognized on equity securities sold during the period Equity Securities, FV-NI, Realized Gain (Loss) Changes in securities lending payable Increase (Decrease) in Securities Lending Payable Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Equity in net losses of other invested assets Income (Loss) from Equity Method Investments Derivatives - other liabilities Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement Commitments and Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Number of states in which the Company is licensed to conduct insurance operations Number of States in which Entity Operates Cash flow hedges included in accumulated other comprehensive loss, net of tax AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Premium receivables Premiums Receivable, Net Category of Item Purchased [Axis] Category of Item Purchased [Axis] Pension and other postretirement benefits: Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Fair Value, Recurring Fair Value, Recurring [Member] Restructuring and Related Activities [Abstract] Overnight and Continuous Maturity Overnight [Member] Cash dividends Total Payments of Dividends Other noncurrent liabilities Other Liabilities, Noncurrent Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Cash Flow Hedging Cash Flow Hedging [Member] Payments Loss Contingency Accrual, Payments Segment Information Segment Reporting Disclosure [Text Block] Change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Denominator for basic shareholders' earnings per share - weighted-average shares Weighted Average Number of Shares Outstanding, Basic Debt Instrument [Line Items] Debt Instrument [Line Items] Fixed maturities, allowance for credit Loss, noncurrent Debt Securities, Available-for-Sale, Allowance for Credit Loss, Noncurrent Entity Current Reporting Status Entity Current Reporting Status Operating gain (loss) Reportable segments operating gain Operating Income (Loss) Technology Infrastructure and Related Management and Support Services Technology Infrastructure and Related Management and Support Services [Member] Technology Infrastructure and Related Management and Support Services AOCI Including Portion Attributable to Noncontrolling Interest AOCI Including Portion Attributable to Noncontrolling Interest [Member] Revenues Revenues [Abstract] Total operating revenue Operating Revenue Revenue from insurance services and products sold. Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Stock Options, Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Amounts outstanding Long-Term Line of Credit Recognized gain on hedging derivatives Derivative, Gain on Derivative Type of Business Optimization Initiative [Domain] Type of Restructuring [Domain] Noncontrolling Interests Noncontrolling Interest [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Noncontrolling Interest AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Noncontrolling Interest [Member] EX-101.PRE 14 elv-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 elv-20240331_g1.jpg ELEVANCE HEALTH LOGO begin 644 elv-20240331_g1.jpg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end XML 17 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
Apr. 10, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-16751  
Entity Registrant Name ELEVANCE HEALTH, INC.  
Entity Incorporation, State or Country Code IN  
Entity Tax Identification Number 35-2145715  
Entity Address, Address Line One 220 Virginia Avenue  
Entity Address, City or Town Indianapolis  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46204  
City Area Code 833  
Local Phone Number 401-1577  
Title of 12(b) Security Common Stock, $0.01 par value  
Trading Symbol ELV  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   232,417,867
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001156039  
Current Fiscal Year End Date --12-31  
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 6,226 $ 6,526
Fixed maturity securities (amortized cost of $30,427 and $30,446; allowance for credit losses of $4 and $4) 29,530 29,614
Equity securities 511 229
Premium receivables 8,931 7,902
Self-funded receivables 4,242 4,558
Other receivables 5,120 5,405
Other current assets 6,388 5,795
Total current assets 60,948 60,029
Long-term investments:    
Fixed maturity securities (amortized cost of $902 and $890; allowance for credit losses of $0 and $0) 880 876
Other invested assets 6,713 6,107
Property and equipment, net 4,451 4,359
Goodwill 25,947 25,317
Other intangible assets 10,710 10,273
Other noncurrent assets 2,245 1,967
Total assets 111,894 108,928
Current liabilities:    
Medical claims payable 16,459 16,111
Other policyholder liabilities 5,298 5,600
Unearned income 1,474 1,402
Accounts payable and accrued expenses 5,658 6,910
Short-term borrowings 1,575 225
Current portion of long-term debt 2,900 1,649
Other current liabilities 10,970 9,894
Total current liabilities 44,334 41,791
Long-term debt, less current portion 21,976 23,246
Reserves for future policy benefits 765 778
Deferred tax liabilities, net 2,201 1,970
Other noncurrent liabilities 1,908 1,738
Total liabilities 71,184 69,523
Commitments and contingencies – Note 11
Shareholders’ equity    
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none 0 0
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 232,544,717 and 233,071,088 2 2
Additional paid-in capital 8,883 8,868
Retained earnings 33,088 31,749
Accumulated other comprehensive loss (1,365) (1,313)
Total shareholders’ equity 40,608 39,306
Noncontrolling interests 102 99
Total equity 40,710 39,405
Total liabilities and equity $ 111,894 $ 108,928
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Fixed maturities, amortized cost, current $ 30,427 $ 30,446
Fixed maturities, allowance for credit loss, current 4 4
Fixed maturities, amortized cost, noncurrent 902 890
Fixed maturities, allowance for credit Loss, noncurrent $ 0 $ 0
Preferred stock, shares authorized (in shares) 100,000,000 100,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 900,000,000 900,000,000
Common stock, shares issued (in shares) 232,544,717 233,071,088
Common stock, shares outstanding (in shares) 232,544,717 233,071,088
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues    
Premiums $ 35,696 $ 35,868
Total operating revenue 42,273 41,898
Net investment income 465 387
Net losses on financial instruments (161) (113)
Total revenues 42,577 42,172
Expenses    
Benefit expense 30,546 30,786
Cost of products sold 3,825 3,481
Operating expense 4,886 4,800
Interest expense 265 251
Amortization of other intangible assets 116 235
Total expenses 39,638 39,553
Income before income tax expense 2,939 2,619
Income tax expense 690 615
Net income 2,249 2,004
Net income attributable to noncontrolling interests (3) (15)
Shareholders’ net income $ 2,246 $ 1,989
Shareholders’ net income per share    
Basic (in dollars per share) $ 9.65 $ 8.37
Diluted (in dollars per share) 9.59 8.30
Dividends per share (in dollars per share) $ 1.63 $ 1.48
Product revenue    
Revenues    
Product and service revenue $ 4,499 $ 4,022
Service fees    
Revenues    
Product and service revenue $ 2,078 $ 2,008
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net income $ 2,249 $ 2,004
Other comprehensive (loss) income, net of tax:    
Change in net unrealized losses/gains on investments (56) 427
Change in non-credit component of impairment losses on investments 0 (2)
Change in net unrealized gains/losses on cash flow hedges 2 11
Change in net periodic pension and postretirement costs 4 2
Change in future policy benefits (2) 2
Foreign currency translation adjustments 0 2
Other comprehensive (loss) income (52) 442
Net income attributable to noncontrolling interests (3) (15)
Other comprehensive income attributable to noncontrolling interests 0 (2)
Total shareholders’ comprehensive income $ 2,194 $ 2,429
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating activities    
Net income $ 2,249 $ 2,004
Adjustments to reconcile net income to net cash provided by operating activities:    
Net losses on financial instruments 161 113
Equity in net losses of other invested assets 27 30
Depreciation and amortization 331 462
Deferred income taxes 136 (255)
Share-based compensation 62 61
Changes in operating assets and liabilities:    
Receivables, net (282) (29)
Other invested assets (29) (15)
Other assets (1,104) (348)
Policy liabilities 31 306
Unearned income 72 3,282
Accounts payable and other liabilities (257) 18
Income taxes 581 839
Other, net 0 1
Net cash provided by operating activities 1,978 6,469
Investing activities    
Purchases of investments (6,103) (7,443)
Proceeds from sale of investments 4,898 2,489
Maturities, calls and redemptions from investments 535 3,533
Changes in securities lending collateral (212) 204
Purchases of subsidiaries, net of cash acquired (1,120) (1,638)
Purchases of property and equipment (279) (301)
Other, net (29) (28)
Net cash used in investing activities (2,310) (3,184)
Financing activities    
Proceeds from long-term borrowings 0 2,574
Repayments of long-term borrowings 0 (1,908)
Proceeds from short-term borrowings 1,350 325
Changes in securities lending payable 212 (205)
Changes in bank overdrafts (586) (291)
Repurchase and retirement of common stock (566) (622)
Cash dividends (379) (351)
Proceeds from issuance of common stock under employee stock plans 97 43
Taxes paid through withholding of common stock under employee stock plans (100) (98)
Other, net 4 2
Net cash used in financing activities 32 (531)
Effect of foreign exchange rates on cash and cash equivalents 0 1
Change in cash and cash equivalents (300) 2,755
Cash and cash equivalents at beginning of period 6,526 7,387
Cash and cash equivalents at end of period $ 6,226 $ 10,142
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2022   238.0        
Beginning balance at Dec. 31, 2022 $ 36,330 $ 2 $ 9,084 $ 29,647 $ (2,490) $ 87
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 2,004     1,989   15
Other comprehensive income (loss), net of tax $ 442       440 2
Repurchase and retirement of common stock, including excise tax (in shares) (1.3) (1.3)        
Repurchase and retirement of common stock, including excise tax $ (626)   (51) (575)    
Dividends and dividend equivalents (354)     (354)    
Issuance of common stock under employee stock plans, net of related tax benefits (in shares)   0.4        
Issuance of common stock under employee stock plans, net of related tax benefits 6   6 0    
Convertible debenture repurchases, conversions and tax adjustments (342)   (342)      
Ending balance (in shares) at Mar. 31, 2023   237.1        
Ending balance at Mar. 31, 2023 37,460 $ 2 8,697 30,707 (2,050) 104
Beginning balance (in shares) at Dec. 31, 2023   233.1        
Beginning balance at Dec. 31, 2023 39,405 $ 2 8,868 31,749 (1,313) 99
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 2,249     2,246   3
Other comprehensive income (loss), net of tax $ (52)       (52) 0
Repurchase and retirement of common stock, including excise tax (in shares) (1.1) (1.1)        
Repurchase and retirement of common stock, including excise tax $ (569)   (44) (525)    
Dividends and dividend equivalents (382)     (382)    
Issuance of common stock under employee stock plans, net of related tax benefits (in shares)   0.5        
Issuance of common stock under employee stock plans, net of related tax benefits 59   59 0    
Ending balance (in shares) at Mar. 31, 2024   232.5        
Ending balance at Mar. 31, 2024 $ 40,710 $ 2 $ 8,883 $ 33,088 $ (1,365) $ 102
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving over 46 million medical members through our affiliated health plans as of March 31, 2024. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also to unaffiliated health plans, including pharmacy services, dental, vision and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum HealthCare, Simply Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health, Carelon Behavioral Health and CareMore.
We have organized our brand portfolio into the following core go-to-market brands:
•Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;
•Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and
•Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation. For additional discussion regarding our segments, including the changes made, see Note 15 “Segment Information” included in this Quarterly Report on Form 10-Q.
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation and Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”), unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three months ended March 31, 2024 and 2023 have been recorded. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2024, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2023 included in our 2023 Annual Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $499 and $294 at March 31, 2024 and December 31, 2023, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.
Mortgage loans on real estate are classified as held for investment and are reported at their amortized cost basis net of allowance under the caption “Other invested assets” in our consolidated balance sheets. Amortized cost is the amount at which the loan is originated, adjusted for accrued interest, amortization of premium, discount and net deferred fees or costs, collection of cash and write-offs.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $212 at each of March 31, 2024 and December 31, 2023.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $89 and $87 at March 31, 2024 and December 31, 2023, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables
are reported net of an allowance for doubtful accounts of $956 and $941 at March 31, 2024 and December 31, 2023, respectively.
Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at March 31, 2024 or December 31, 2023. For the three months ended March 31, 2024 and 2023, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 changed the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year to our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. The adoption did not have an overall material impact on our financial statements.
Recent Accounting Guidance Not Yet Adopted: In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Income Taxes (Topic 740) ("ASU 2023-09"). The amendments in ASU 2023-09 are intended to improve income tax disclosures, primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for our fiscal year beginning after December 15, 2024. The amendments are to be applied on a prospective basis, although retrospective adoption is permitted. We do not believe the adoption of ASU 2023-09 will have a material impact on our consolidated financial statements or disclosures.
In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our fiscal year beginning after December 15, 2023, and interim periods within our fiscal year beginning after December 15, 2024. The amendments are to be applied retrospectively to all prior periods presented in the financial statements, and upon transition, the significant segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. We are currently evaluating the effects the adoption of ASU 2023-07 will have on our consolidated financial statements and related disclosures.
In August 2023, the FASB issued Accounting Standards Update No. 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement (“ASU 2023-05”). ASU 2023-05 clarifies existing guidance to reduce diversity in practice and requires a joint venture to recognize and initially measure its assets and liabilities using a new basis of accounting, at fair value, upon formation. These amendments are effective prospectively for all joint venture formations with a formation date on or after January 1, 2025. We do not believe the adoption of ASU 2023-05 will have a material impact on our consolidated financial statements and disclosures.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2023 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations, cash flows or disclosures.
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Acquisitions and Divestitures
 3 Months Ended
Mar. 31, 2024
Business Combinations [Abstract]  
Business Acquisitions and Divestitures Business Acquisitions and Divestitures
Completed Acquisitions
On March 11, 2024, we completed our acquisition of Paragon Healthcare, Inc. (“Paragon”). Paragon, which operates as part of CarelonRx, provides infusion services and injectable therapies through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of March 31, 2024, the purchase price was allocated to the tangible and intangible net assets acquired based on management's initial estimates of their fair values, of which $553 has been allocated to finite-lived intangible assets and $635 to goodwill. The majority of the goodwill is not deductible for income tax purposes. As of March 31, 2024, the initial accounting for the acquisition has not been finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of March 31, 2024, the purchase price was allocated to the tangible and intangible net assets acquired based on management’s estimates of their fair values, of which $820 has been allocated to finite-lived intangible assets and $893 to goodwill. Measurement period adjustments during the three months ended March 31, 2024 were $(5). The majority of goodwill is not deductible for income tax purposes. As of March 31, 2024, the initial accounting for the acquisition was finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
Divestiture
On April 1, 2024, we completed the sale of our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard entered into a product distribution partnership. The related net assets held for sale and results of operations for the life and disability businesses to be divested as of and for the three months ending March 31, 2024 were not material.
Pending Acquisitions
On December 31, 2023, we entered into an agreement to acquire Centers Plan for Healthy Living LLC and Centers for Specialty Care Group IPA, LLC (“Centers”). Centers is a managed long-term care plan that serves New York state Medicaid and dually-eligible Medicaid/Medicare members, enabling adults with long-term care needs and disabilities to live safely and independently in their own home. This acquisition aligns with our strategic plan to grow the Health Benefits segment and leverage industry-leading expertise while serving Medicaid and dually eligible populations. The acquisition is expected to close in the third quarter of 2024 and is subject to standard closing conditions and customary approvals.
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition is subject to closing conditions and approvals.
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Optimization Initiatives
 3 Months Ended
Mar. 31, 2024
Restructuring and Related Activities [Abstract]  
Business Optimization Initiatives Business Optimization Initiatives
During the third quarter of 2023, based on a strategic review of our operations, assets and investments, management implemented the “2023-2024 Business Efficiency Program” to enhance operating efficiency, refine the focus of our investments and optimize our physical footprint. The 2023-2024 Business Efficiency Program includes the write-off of certain information technology assets and contract exit costs, a reduction in staff including the relocation of certain job functions, and the impairment of assets associated with the closure or partial closure of data centers and offices. The 2023-2024 Business Efficiency Program is expected to be substantially complete by the end of the third quarter of 2024. Cash outlays associated with this program, which primarily relate to the personnel-related costs, are expected to be paid through 2024.
The ending balances related to the total liabilities for employee termination costs under the 2023-2024 Business Efficiency Program at March 31, 2024 and December 31, 2023 were $150 and $191, respectively, and were recorded in the Corporate & Other reportable segment. During the quarter ended March 31, 2024 there were no charges or releases related to employee termination costs under the 2023-2024 Business Efficiency Program, and payments were $41.
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments
 3 Months Ended
Mar. 31, 2024
Investments [Abstract]  
Investments Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.
A summary of current and long-term fixed maturity securities, available-for-sale, at March 31, 2024 and December 31, 2023 is as follows:
Cost or
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Allowance
For Credit
Losses		Estimated
Fair Value
 
March 31, 2024
Fixed maturity securities:
United States Government securities$1,858 $6 $(73)$— $1,791 
Government sponsored securities127 — (4)— 123 
Foreign government securities73 — (1)— 72 
States, municipalities and political subdivisions, tax-exempt3,722 55 (150)— 3,627 
Corporate securities16,099 256 (575)(2)15,778 
Residential mortgage-backed securities4,204 27 (302)— 3,929 
Commercial mortgage-backed securities1,971 12 (89)(2)1,892 
Other asset-backed securities3,275 28 (105)— 3,198 
Total fixed maturity securities$31,329 $384 $(1,299)$(4)$30,410 
December 31, 2023
Fixed maturity securities:
United States Government securities$1,873 $25 $(54)$— $1,844 
Government sponsored securities112 1 (3)— 110 
Foreign government securities5 1 (2)— 4 
States, municipalities and political subdivisions, tax-exempt3,985 69 (152)— 3,902 
Corporate securities14,838 322 (580)(2)14,578 
Residential mortgage-backed securities4,071 40 (279)— 3,832 
Commercial mortgage-backed securities2,174 13 (138)(2)2,047 
Other asset-backed securities4,278 25 (130)— 4,173 
Total fixed maturity securities$31,336 $496 $(1,338)$(4)$30,490 
Other asset-backed securities primarily consists of collateralized loan obligations and other debt securities.
For fixed maturity securities in an unrealized loss position at March 31, 2024 and December 31, 2023, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss		Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss
March 31, 2024
Fixed maturity securities:
United States Government securities46 $1,188 $(29)48$306 $(44)
Government sponsored securities4 40 — 3951 (4)
Foreign government securities
5 10 — 24 (1)
States, municipalities and political subdivisions, tax-exempt231 449 (4)1,0011,656 (146)
Corporate securities906 2,324 (31)2,4225,775 (544)
Residential mortgage-backed securities239 1,026 (14)1,6311,958 (288)
Commercial mortgage-backed securities84 364 (6)4151,059 (83)
Other asset-backed securities126 454 (16)4141,288 (89)
Total fixed maturity securities1,641 $5,855 $(100)5,972$12,097 $(1,199)
December 31, 2023
Fixed maturity securities:
United States Government securities35 $552 $(9)44 $370 $(45)
Government sponsored securities— — — 4052 (3)
Foreign government securities
— — — 24 (2)
States, municipalities and political subdivisions, tax-exempt203354 (2)1,0341,811 (150)
Corporate securities389608 (15)2,6246,871 (565)
Residential mortgage-backed securities
183438 (5)1,6202,075 (274)
Commercial mortgage-backed securities
112353 (6)5341,317 (132)
Other asset-backed securities110394 (18)7612,342 (112)
Total fixed maturity securities1,032 $2,699 $(55)6,659$14,842 $(1,283)
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of March 31, 2024, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions.
Allowances for credit losses have been recorded in the amount of $4 at both March 31, 2024 and December 31, 2023, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest.
The amortized cost and fair value of fixed maturity securities at March 31, 2024, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost		Estimated
Fair Value
Due in one year or less$369 $365 
Due after one year through five years6,038 5,900 
Due after five years through ten years11,099 10,864 
Due after ten years7,648 7,460 
Mortgage-backed securities6,175 5,821 
Total fixed maturity securities$31,329 $30,410 
During the three months ended March 31, 2024 and 2023, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $5,401 and $5,410, respectively.
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at March 31, 2024 and December 31, 2023 is as follows:
 March 31, 2024December 31, 2023
Equity securities:
Exchange traded funds$382 $106 
Common equity securities52 45 
Private equity securities77 78 
Total$511 $229 
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments is reported on a one or three month lag due to the timing of when we receive financial information from the companies.
On April 12, 2024, we entered into an agreement to partner with Clayton, Dubilier & Rice (“CD&R”) to accelerate innovation in care delivery across multiple regions in the United States by bringing together through a new company, (“NewCo”), certain care delivery and enablement assets of Carelon Management Services Inc., a Carelon Health business (“CMSI Assets”), and two CD&R portfolio businesses, apree health and Millennium Physician Group. Our investment in NewCo will be through a combination of cash, an existing equity investment in apree health, and the contribution of CMSI Assets. We will account for our initial minority ownership interest in NewCo as an equity method investment. Further, in connection with our equity investment, each party will have certain rights and obligations, including certain put, call, and purchase price true-up options, for which the estimated value will be determinable at the time of the incremental investments. The contribution of CMSI Assets and businesses to be contributed by CD&R to NewCo are subject to standard closing conditions and customary approvals.
Investment (Losses) and Gains
Net investment (losses) and gains for the three months ended March 31, 2024 and 2023 are as follows:
Three Months Ended 
 March 31
20242023
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales$22 $10 
Gross realized losses from sales(159)(115)
Impairment losses recognized in income
(2)(7)
Net realized losses from sales of fixed maturity securities(139)(112)
Equity securities:
Unrealized gains (losses) recognized on equity securities still held at the end of the period
2 (1)
Net realized losses recognized on equity securities sold during the period
— (1)
Net gains (losses) on equity securities2 (2)
Other investments:
Gross gains16 27 
Gross losses(20)(1)
Impairment losses recognized in income(25)(3)
Net (losses) gains on other investments
(29)23 
Net losses on investments$(166)$(91)
Accrued Investment Income
At March 31, 2024 and December 31, 2023, accrued investment income totaled $294 and $301, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.
Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,592 and $2,380 at March 31, 2024 and December 31, 2023, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of March 31, 2024 and December 31, 2023. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.
At March 31, 2024 and December 31, 2023, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,351 and $2,255, respectively, of United States Government securities for $241 and $99, respectively, and of residential mortgage-backed securities for $0 and $26, respectively.
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Derivative Financial Instruments
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $209 and $211 at March 31, 2024 and December 31, 2023, respectively.
During the three months ended March 31, 2024, we recognized gains of $11 and losses of $6, respectively, on non-hedging derivatives. During the three months ended March 31, 2023, we recognized gains of $12 and losses of $34 on non-hedging derivatives, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 7, “Fair Value,” included in this Quarterly Report on Form 10-Q.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. These assets and liabilities are classified into one of three levels of hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 7 “Fair Value,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K.
A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at March 31, 2024 and December 31, 2023 is as follows:
Level ILevel IILevel IIITotal
March 31, 2024
Assets:
Cash equivalents$1,155$—$—$1,155
Fixed maturity securities, available-for-sale:
United States Government securities—1,791—1,791
Government sponsored securities—123—123
Foreign government securities—72—72
States, municipalities and political subdivisions, tax-exempt—3,627—3,627
Corporate securities—15,7265215,778
Residential mortgage-backed securities—3,914153,929
Commercial mortgage-backed securities—1,881111,892
Other asset-backed securities—2,4787203,198
Total fixed maturity securities, available-for-sale—29,61279830,410
Equity securities:
Exchange traded funds382——382
Common equity securities1537—52
Private equity securities——7777
Total equity securities3973777511
Other invested assets - common equity securities102——102
Securities lending collateral—2,594—2,594
Derivatives - other assets—2—2
Total assets$1,654$32,245$875$34,774
Percentage of total assets at fair value
5%93%2%100%
Liabilities:
Derivatives - other liabilities$—$(61)$—$(61)
Total liabilities$—$(61)$—$(61)
December 31, 2023
Assets:
Cash equivalents$2,210$—$—$2,210
Fixed maturity securities, available-for-sale:
United States Government securities—1,844—1,844
Government sponsored securities—110—110
Foreign government securities—4—4
States, municipalities and political subdivisions, tax-exempt—3,902—3,902
Corporate securities—14,5324614,578
Residential mortgage-backed securities—3,83023,832
Commercial mortgage-backed securities—2,047—2,047
Other asset-backed securities—3,6345394,173
Total fixed maturity securities, available-for-sale—29,90358730,490
Equity securities:
Exchange traded funds106——106
Common equity securities1233—45
Private equity securities——7878
Total equity securities1183378229
Other invested assets - common equity securities111——111
Securities lending collateral—2,382—2,382
Derivatives - other assets—10—10
Total assets$2,439$32,328$665$35,432
Percentage of total assets at fair value
7%91%2%100%
Liabilities:
Derivatives - other liabilities$—$(40)$—$(40)
Total liabilities$—$(40)$—$(40)
There were no individually material transfers into or out of Level III during the three months ended March 31, 2024 or 2023. There were no adjustments to quoted market prices obtained from the pricing services during the three months ended March 31, 2024 or 2023.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition of Paragon in the first quarter of 2024 and the acquisition of BioPlus in the first quarter of 2023. The net assets acquired in our acquisitions of Paragon and BioPlus and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of tangible assets acquired and liabilities assumed were recorded at their carrying values as of the acquisition date, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Paragon and BioPlus were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Also in 2023, we entered into a shareholder’s agreement which included certain put and call options on our minority interest ownership of Liberty Dental. The resulting net put option liability was recorded at its fair value measured at the date of acquisition using Level III inputs with an election not to mark the derivative to market. Other than the assets acquired and liabilities assumed in our acquisitions of Paragon and BioPlus and the net put option on Liberty Dental, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three months ended March 31, 2024 or 2023.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.
Non-financial instruments such as property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.
See Note 7 “Fair Value,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K for details on the methods and assumptions used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets.
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at March 31, 2024 and December 31, 2023 is as follows:
 Carrying
Value		Estimated Fair Value
 Level ILevel IILevel IIITotal
March 31, 2024
Assets:
Other invested assets$6,611 $— $— $6,580 $6,580 
Liabilities:
Debt:
Short-term borrowings225 — 225 — 225 
Commercial paper
1,350 — 1,350 — 1,350 
Notes24,876 — 23,046 — 23,046 
December 31, 2023
Assets:
Other invested assets$5,996 $— $— $5,972 $5,972 
Liabilities:
Debt:
Short-term borrowings225 — 225 — 225 
Notes24,895 — 23,569 — 23,569 
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
During the three months ended March 31, 2024 and 2023, we recognized income tax expense of $690 and $615, respectively, which represent an effective income tax rate of 23.5% for both periods.
Income taxes payable totaled $38 at March 31, 2024 and income taxes receivable totaled $543 at December 31, 2023. We recognize the income tax payable as a liability under the caption “Other current liabilities” and the income tax receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims Payable
 3 Months Ended
Mar. 31, 2024
Liability for Claims and Claims Adjustment Expense [Abstract]  
Medical Claims Payable Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the three months ended March 31, 2024 and 2023 is as follows:
20242023
Gross medical claims payable, beginning of period$15,865 $15,348 
Ceded medical claims payable, beginning of period(7)(6)
Net medical claims payable, beginning of period15,858 15,342 
Net incurred medical claims:
Current period30,708 30,751 
Prior periods redundancies(1,205)(1,068)
Total net incurred medical claims29,503 29,683 
Net payments attributable to:
Current period medical claims19,580 19,948 
Prior periods medical claims9,606 9,593 
Total net payments29,186 29,541 
Net medical claims payable, end of period16,175 15,484 
Ceded medical claims payable, end of period8 7 
Gross medical claims payable, end of period$16,183 $15,491 
At March 31, 2024, the total of net incurred but not reported liabilities plus expected development on reported claims was $724, $4,323 and $11,128 for the claim years 2022 and prior, 2023 and 2024, respectively.
The favorable development recognized in the three months ended March 31, 2024 resulted from faster than expected development of completion factors from the latter part of 2023 as well as trend factors in late 2023 developing more favorably than originally expected. The favorable development recognized in the three months ended March 31, 2023 resulted primarily from trend factors in late 2022 developing more favorably than expected and favorable development in the completion factors resulting from the latter part of 2022 developing faster than expected.
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:
20242023
Total net incurred medical claims$29,503 $29,683 
Quality improvement and other claims expense1,043 1,103 
Benefit expense$30,546 $30,786 
The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of March 31, 2024 is as follows:
Total
Net medical claims payable, end of period$16,175 
Ceded medical claims payable, end of period8 
Insurance lines other than short duration276 
Gross medical claims payable, end of period$16,459 
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Debt Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At March 31, 2024 and December 31, 2023, we had $24,851 and $24,870, respectively, outstanding under these notes.
We have an unsecured surplus note with an outstanding principal balance of $25 at both March 31, 2024 and December 31, 2023.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of March 31, 2024, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.4%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of March 31, 2024, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at any time during the three months ended March 31, 2024 or the year ended December 31, 2023.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. At March 31, 2024 and December 31, 2023, we had $1,350 and $0, respectively, outstanding under this program. Beginning June 30, 2023, we have reclassified our commercial paper balances from long-term debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $225 of outstanding short-term borrowings from the FHLBs at each of March 31, 2024 and December 31, 2023.
All debt is a direct obligation of Elevance Health, Inc., except for the surplus note and the FHLBs borrowings.
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Litigation and Regulatory Proceedings
We are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or probable or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible or probable loss or range of losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings.
With respect to the cases described below, we contest liability and/or the amount of damages in each matter, and we believe we have meritorious defenses. We do not believe the outcome of any known pending or threatened legal actions or proceedings will, in the aggregate, have a material impact on our financial position. However, unanticipated outcomes do
sometimes occur, which could result in liabilities in excess of our accruals and could have a material adverse effect on our consolidated financial position or results of operations.
In addition to the lawsuits described below, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings (“government actions”). These government actions include routine and special inquiries by and disclosures to state insurance departments, state attorneys general, U.S. Regulatory Agencies, the U.S. Attorney General and subcommittees of the U.S. Congress. Such government actions could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these government actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.
In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.
In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the opt-out deadline.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In compliance with the Subscriber Settlement Agreement, we paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by us of $596, which was accrued in 2020.
Four notices of appeal of the Final Approval Order were heard by a panel of the United States Court of Appeals for the Eleventh Circuit in September 2023 (the “Eleventh Circuit”), and the Eleventh Circuit affirmed the Court’s Final Approval Order approving the Subscriber Settlement Agreement in October 2023. Petitions for rehearing were filed by certain appellants in November 2023 and December 2023 and were denied in January 2024. As a result, the Eleventh Circuit issued a mandate terminating the jurisdiction of the Eleventh Circuit in February 2024. In March 2024, Home Depot, one of the appellants, filed a petition for certiorari to the United States Supreme Court. On the respondents' request, the United States Supreme Court granted an extension to respond until May 2024. In the event that all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, determining that Ohio v. American Express Co. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the provider groups’ boycott claims are subject to the rule of reason. In December 2023, the Court denied defendants’ motion for summary judgment on providers’ damage claims as time-barred and speculative and provider plaintiffs’ motion for partial summary judgment on the defendants’ single entity defense due to the existence of genuine issues of material fact. In January 2024, the Court issued orders (i) denying defendants’ motion for summary judgment on (a) all claims by certain hospital providers and (b) any claims based on the Blue system's rules other than exclusive serviced areas or BlueCard and (ii) denying provider plaintiffs’ motion for partial summary judgment on defendants’ common law trademark claims. Provider plaintiffs’ motion for class certification, filed in October 2020, remains pending. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group, Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.) (“Alaska Air”); JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-GMB (N.D. Ala.) (“Jet Blue”); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.) (dismissed without prejudice in June 2023); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.); Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.) (“VHS”). In February 2023, the Court denied the defendants’ motion to dismiss based on a statute of limitations defense in Alaska Air and Jet Blue. In September 2023, the California court presiding over the VHS case, upheld its prior order granting in part defendants’ motion to strike based on the statute of limitations. We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.
Express Scripts, Inc. PBM Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit sought to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms (the “Pricing Claim”); (ii) was required to provide competitive benchmark pricing to us through the term of the ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.
Express Scripts disputed our contractual claims and it sought declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claimed that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q were (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which the District Court denied in March 2023. In November 2023, the District Court issued a final judgment ending the lawsuit in the District Court after the parties settled and stipulated to dismiss the only remaining claim that had not been disposed of by the court order or stipulation. In December 2023, we filed a notice of appeal with the United States Court of Appeal for the Second Circuit (the “Second Circuit”), regarding the Pricing Claim. In February 2024, the Second Circuit ordered the parties to participate in mediation. The mediation occurred in March 2024 and was unsuccessful. The ultimate outcome of this appeal cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, we filed an answer. In March 2023, discovery commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert discovery to be completed by February 2025. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. Our remaining commitment under this agreement at March 31, 2024 is approximately $432. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.
We formed CarelonRx, to market and offer pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own, starting in the second quarter of 2019. The comprehensive pharmacy services portfolio includes all core pharmacy services, such as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database and member services. CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C. (“CVS”), which is a subsidiary of CVS Health Corporation, pursuant to an agreement, that is set to terminate on December 31, 2025. Beginning in the first quarter of 2024, CarelonRx is assuming responsibility for pharmacy mail order front-end intake and member services from CVS.
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Capital Stock
 3 Months Ended
Mar. 31, 2024
Class of Stock Disclosures [Abstract]  
Capital Stock Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of our cash dividend activity for the three months ended March 31, 2024 and 2023 is as follows: 
Declaration DateRecord DatePayment Date
Cash
Dividend
per Share
Total
Three Months Ended March 31, 2024
January 23, 2024March 8, 2024March 22, 2024$1.63$379 
Three Months Ended March 31, 2023
January 24, 2023March 10, 2023March 24, 2023$1.48$351 
On April 16, 2024, our Audit Committee declared a second quarter 2024 dividend to shareholders of $1.63 per share, payable on June 25, 2024 to shareholders of record at the close of business on June 10, 2024.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.
A summary of common stock repurchases for the three months ended March 31, 2024 and 2023 is as follows:
Three Months Ended March 31
 20242023
Shares repurchased1.1 1.3 
Average price per share$492.76 $476.66 
Aggregate cost$566 $622 
Authorization remaining at the end of the period$3,633 $6,254 
For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt,” included in this Quarterly Report on Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K.
Stock Incentive Plans
A summary of stock option activity for the three months ended March 31, 2024 is as follows:
Number of
Shares		Weighted-
Average
Option Price
per Share		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at January 1, 20243.0 $327.14 
Granted0.5 499.11 
Exercised(0.3)288.95 
Forfeited or expired— 431.01 
Outstanding at March 31, 20243.2 356.58 6.44$521 
Exercisable at March 31, 20242.2 297.24 5.23$482 
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the three months ended March 31, 2024 is as follows:
Restricted
Stock Shares
and Units		Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 20241.1 $423.94 
Granted0.6 499.00 
Vested(0.6)352.33 
Forfeited— 456.61 
Nonvested at March 31, 20241.1 475.31 
During the three months ended March 31, 2024, we granted approximately 0.3 restricted stock units that are contingent upon us achieving earnings targets over the three-year period from 2024 to 2026. These grants have been included in the activity shown above but will be subject to adjustment at the end of 2026 based on results in the three-year period.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K.
The following weighted-average assumptions were used to estimate the fair values of options granted during the three months ended March 31, 2024 and 2023:
Three Months Ended March 31
20242023
Risk-free interest rate4.28 %3.95 %
Volatility factor28.00 %29.00 %
Quarterly dividend yield0.327 %0.316 %
Weighted-average expected life (years)4.404.40
The following weighted-average fair values per option or share were determined for the three months ended March 31, 2024 and 2023: 
Three Months Ended March 31
20242023
Options granted during the period$134.53 $127.14 
Restricted stock awards granted during the period499.00 469.31 
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accumulated Other Comprehensive (Loss) Income
 3 Months Ended
Mar. 31, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income
A reconciliation of the components of accumulated other comprehensive (loss) income at March 31, 2024 and 2023 is as follows:
Three Months Ended 
 March 31
20242023
Net unrealized investment (losses) gains:
Beginning of period balance$(632)$(1,755)
Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $50 and $(85), respectively
(162)337 
Amounts reclassified from accumulated other comprehensive loss, net of tax benefit of $(33) and $(29), respectively
106 90 
Other comprehensive (loss) income
(56)427 
Other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0, respectively
— (2)
End of period balance(688)(1,330)
Non-credit components of impairments on investments:
Beginning of period balance(3)(3)
Other comprehensive loss, net of tax benefit of $0 and $1, respectively
— (2)
End of period balance(3)(5)
Net cash flow hedges:
Beginning of period balance(211)(229)
Other comprehensive income, net of tax (expense) benefit of $(1) and $8, respectively
2 11 
End of period balance(209)(218)
Pension and other postretirement benefits:
Beginning of period balance(459)(499)
Other comprehensive income, net of tax expense of $(1) and $(1), respectively
4 2 
End of period balance(455)(497)
Future policy benefits:
Beginning of period balance10 13 
Other comprehensive (loss) income, net of tax expense of $0 and $0, respectively
(2)2 
End of period balance8 15 
Foreign currency translation adjustments:
Beginning of period balance(18)(17)
Other comprehensive income, net of tax expense of $0 and $0, respectively
— 2 
End of period balance(18)(15)
Total:
Total beginning of period accumulated other comprehensive loss(1,313)(2,490)
Total other comprehensive (loss) income, net of tax benefit (expense) of $15, and $(106), respectively
(52)442 
Total other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0 respectively
— (2)
Total end of period accumulated other comprehensive loss$(1,365)$(2,050)
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Earnings per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Shareholders' Earnings per Share Shareholders' Earnings per Share
The denominator for basic and diluted shareholders' earnings per share for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023
Denominator for basic shareholders' earnings per share – weighted-average shares
232.7 237.5 
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures
1.5 2.2 
Denominator for diluted shareholders' earnings per share
234.2 239.7 
During the three months ended March 31, 2024 and 2023, weighted-average shares related to certain stock options of 0.6 and 0.4 respectively, were excluded from the denominator for diluted shareholders' earnings per share because the stock options were anti-dilutive.
During the three months ended March 31, 2024, we issued approximately 0.6 restricted stock units under our stock incentive plans, 0.3 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2024 through 2026. During the three months ended March 31, 2023, we issued approximately 0.6 restricted stock units under our stock incentive plans, 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2023 through 2025. The contingent restricted stock units have been excluded from the denominators for diluted shareholders' earnings per share and will be included only if and when the contingency is met.
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Segment Information Segment Information
We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. During the fourth quarter of 2023, we moved our Carelon Global Solutions international businesses from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation.
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid and FEHB program members. Our Health Benefits segment also includes our National Government Services business. The Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental, vision and supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy services business. CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy services portfolio, which includes all core pharmacy services, such as home delivery and specialty
pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug
database and member services.
Our Carelon Services segment integrates physical, behavioral, social and pharmacy services to deliver whole health affordably through creating value by offering market-competitive services, powered by analytics. Carelon Services offers a broad array of healthcare related services and capabilities to internal and external customers including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services and subrogation services, as well as health and wellness programs. At the end of 2023, Carelon Services integrated Carelon Global Solutions into the Carelon family of offerings. The companies under Carelon Global Solutions have been providing services related to data management, information technology and business operations since 2019 and were previously included within our Corporate & Other segment.
Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an operating segment, as well as corporate expenses not allocated to our other reportable segments.
We define operating revenues to include premium income, product revenue and service fees. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating expense.
Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, in addition to certain administrative and other services provided by our international businesses, which are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.
Financial data by reportable segment for the three months ended March 31, 2024 and 2023 is as follows:
Carelon
Health
Benefits		CarelonRxCarelon
Services		TotalCorporate
& Other		EliminationsTotal
Three Months Ended March 31, 2024
Premiums$35,382 $— $408 $408 $— $(94)$35,696 
Product revenue— 4,499 — 4,499 — — 4,499 
Service fees1,876 1 197 198 4 — 2,078 
Operating revenue - unaffiliated37,258 4,500 605 5,105 4 (94)42,273 
Operating revenue - affiliated— 3,567 3,404 6,971 123 (7,094)— 
Operating revenue - total$37,258 $8,067 $4,009 $12,076 $127 $(7,188)$42,273 
Operating gain (loss)$2,287 $523 $290 $813 $(84)$— $3,016 
Three Months Ended March 31, 2023
Premiums$35,534 $— $410 $410 $— $(76)$35,868 
Product revenue— 4,022 — 4,022 — — 4,022 
Service fees1,746 — 208 208 54 — 2,008 
Operating revenue - unaffiliated37,280 4,022 618 4,640 54 (76)41,898 
Operating revenue - affiliated— 4,002 2,842 6,844 37 (6,881)— 
Operating revenue - total$37,280 $8,024 $3,460 $11,484 $91 $(6,957)$41,898 
Operating gain (loss)
$2,149 $512 $229 $741 $(59)$— $2,831 
For segment reporting, we present all capitated risk arrangements on a gross basis; therefore, eliminations also include adjustments for unaffiliated capitated risk arrangements that are recognized on a net basis under GAAP, as well as affiliated eliminations.
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023
Reportable segments’ operating revenue$42,273 $41,898 
Net investment income465 387 
Net losses on financial instruments(161)(113)
Total revenues$42,577 $42,172 
A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023
Income before income tax expense$2,939 $2,619 
Net investment income(465)(387)
Net losses on financial instruments161 113 
Interest expense265 251 
Amortization of other intangible assets116 235 
Reportable segments’ operating gain$3,016 $2,831 
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Shareholders' net income $ 2,246 $ 1,989
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation and Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”), unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three months ended March 31, 2024 and 2023 have been recorded. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2024, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2023 included in our 2023 Annual Report on Form 10-K.
Foreign Currency
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements.
Investments
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.
Mortgage loans on real estate are classified as held for investment and are reported at their amortized cost basis net of allowance under the caption “Other invested assets” in our consolidated balance sheets. Amortized cost is the amount at which the loan is originated, adjusted for accrued interest, amortization of premium, discount and net deferred fees or costs, collection of cash and write-offs.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
Receivables
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $212 at each of March 31, 2024 and December 31, 2023.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $89 and $87 at March 31, 2024 and December 31, 2023, respectively.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables
are reported net of an allowance for doubtful accounts of $956 and $941 at March 31, 2024 and December 31, 2023, respectively.
Revenue Recognition
Revenue Recognition: For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at March 31, 2024 or December 31, 2023. For the three months ended March 31, 2024 and 2023, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Recently Adopted Accounting Guidance and Recent Accounting Guidance Not Yet Adopted
Recently Adopted Accounting Guidance: In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 changed the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year to our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. The adoption did not have an overall material impact on our financial statements.
Recent Accounting Guidance Not Yet Adopted: In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Income Taxes (Topic 740) ("ASU 2023-09"). The amendments in ASU 2023-09 are intended to improve income tax disclosures, primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for our fiscal year beginning after December 15, 2024. The amendments are to be applied on a prospective basis, although retrospective adoption is permitted. We do not believe the adoption of ASU 2023-09 will have a material impact on our consolidated financial statements or disclosures.
In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our fiscal year beginning after December 15, 2023, and interim periods within our fiscal year beginning after December 15, 2024. The amendments are to be applied retrospectively to all prior periods presented in the financial statements, and upon transition, the significant segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. We are currently evaluating the effects the adoption of ASU 2023-07 will have on our consolidated financial statements and related disclosures.
In August 2023, the FASB issued Accounting Standards Update No. 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement (“ASU 2023-05”). ASU 2023-05 clarifies existing guidance to reduce diversity in practice and requires a joint venture to recognize and initially measure its assets and liabilities using a new basis of accounting, at fair value, upon formation. These amendments are effective prospectively for all joint venture formations with a formation date on or after January 1, 2025. We do not believe the adoption of ASU 2023-05 will have a material impact on our consolidated financial statements and disclosures.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2023 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations, cash flows or disclosures.
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments (Tables)
 3 Months Ended
Mar. 31, 2024
Investments [Abstract]  
Schedule of Current and Long-Term Investments, Available-For-Sale
A summary of current and long-term fixed maturity securities, available-for-sale, at March 31, 2024 and December 31, 2023 is as follows:
Cost or
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Allowance
For Credit
Losses		Estimated
Fair Value
 
March 31, 2024
Fixed maturity securities:
United States Government securities$1,858 $6 $(73)$— $1,791 
Government sponsored securities127 — (4)— 123 
Foreign government securities73 — (1)— 72 
States, municipalities and political subdivisions, tax-exempt3,722 55 (150)— 3,627 
Corporate securities16,099 256 (575)(2)15,778 
Residential mortgage-backed securities4,204 27 (302)— 3,929 
Commercial mortgage-backed securities1,971 12 (89)(2)1,892 
Other asset-backed securities3,275 28 (105)— 3,198 
Total fixed maturity securities$31,329 $384 $(1,299)$(4)$30,410 
December 31, 2023
Fixed maturity securities:
United States Government securities$1,873 $25 $(54)$— $1,844 
Government sponsored securities112 1 (3)— 110 
Foreign government securities5 1 (2)— 4 
States, municipalities and political subdivisions, tax-exempt3,985 69 (152)— 3,902 
Corporate securities14,838 322 (580)(2)14,578 
Residential mortgage-backed securities4,071 40 (279)— 3,832 
Commercial mortgage-backed securities2,174 13 (138)(2)2,047 
Other asset-backed securities4,278 25 (130)— 4,173 
Total fixed maturity securities$31,336 $496 $(1,338)$(4)$30,490 
Schedule of Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position
For fixed maturity securities in an unrealized loss position at March 31, 2024 and December 31, 2023, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position: 
 Less than 12 Months12 Months or Greater
(Securities are whole amounts)Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss		Number of
Securities		Estimated
Fair Value		Gross
Unrealized
Loss
March 31, 2024
Fixed maturity securities:
United States Government securities46 $1,188 $(29)48$306 $(44)
Government sponsored securities4 40 — 3951 (4)
Foreign government securities
5 10 — 24 (1)
States, municipalities and political subdivisions, tax-exempt231 449 (4)1,0011,656 (146)
Corporate securities906 2,324 (31)2,4225,775 (544)
Residential mortgage-backed securities239 1,026 (14)1,6311,958 (288)
Commercial mortgage-backed securities84 364 (6)4151,059 (83)
Other asset-backed securities126 454 (16)4141,288 (89)
Total fixed maturity securities1,641 $5,855 $(100)5,972$12,097 $(1,199)
December 31, 2023
Fixed maturity securities:
United States Government securities35 $552 $(9)44 $370 $(45)
Government sponsored securities— — — 4052 (3)
Foreign government securities
— — — 24 (2)
States, municipalities and political subdivisions, tax-exempt203354 (2)1,0341,811 (150)
Corporate securities389608 (15)2,6246,871 (565)
Residential mortgage-backed securities
183438 (5)1,6202,075 (274)
Commercial mortgage-backed securities
112353 (6)5341,317 (132)
Other asset-backed securities110394 (18)7612,342 (112)
Total fixed maturity securities1,032 $2,699 $(55)6,659$14,842 $(1,283)
Schedule of Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity
The amortized cost and fair value of fixed maturity securities at March 31, 2024, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost		Estimated
Fair Value
Due in one year or less$369 $365 
Due after one year through five years6,038 5,900 
Due after five years through ten years11,099 10,864 
Due after ten years7,648 7,460 
Mortgage-backed securities6,175 5,821 
Total fixed maturity securities$31,329 $30,410 
Summary of Marketable Equity Securitites
A summary of marketable equity securities at March 31, 2024 and December 31, 2023 is as follows:
 March 31, 2024December 31, 2023
Equity securities:
Exchange traded funds$382 $106 
Common equity securities52 45 
Private equity securities77 78 
Total$511 $229 
Schedule of Net Investment (Losses) and Gains
Net investment (losses) and gains for the three months ended March 31, 2024 and 2023 are as follows:
Three Months Ended 
 March 31
20242023
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales$22 $10 
Gross realized losses from sales(159)(115)
Impairment losses recognized in income
(2)(7)
Net realized losses from sales of fixed maturity securities(139)(112)
Equity securities:
Unrealized gains (losses) recognized on equity securities still held at the end of the period
2 (1)
Net realized losses recognized on equity securities sold during the period
— (1)
Net gains (losses) on equity securities2 (2)
Other investments:
Gross gains16 27 
Gross losses(20)(1)
Impairment losses recognized in income(25)(3)
Net (losses) gains on other investments
(29)23 
Net losses on investments$(166)$(91)
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Summary of Fair Value Measurements by Level
A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at March 31, 2024 and December 31, 2023 is as follows:
Level ILevel IILevel IIITotal
March 31, 2024
Assets:
Cash equivalents$1,155$—$—$1,155
Fixed maturity securities, available-for-sale:
United States Government securities—1,791—1,791
Government sponsored securities—123—123
Foreign government securities—72—72
States, municipalities and political subdivisions, tax-exempt—3,627—3,627
Corporate securities—15,7265215,778
Residential mortgage-backed securities—3,914153,929
Commercial mortgage-backed securities—1,881111,892
Other asset-backed securities—2,4787203,198
Total fixed maturity securities, available-for-sale—29,61279830,410
Equity securities:
Exchange traded funds382——382
Common equity securities1537—52
Private equity securities——7777
Total equity securities3973777511
Other invested assets - common equity securities102——102
Securities lending collateral—2,594—2,594
Derivatives - other assets—2—2
Total assets$1,654$32,245$875$34,774
Percentage of total assets at fair value
5%93%2%100%
Liabilities:
Derivatives - other liabilities$—$(61)$—$(61)
Total liabilities$—$(61)$—$(61)
December 31, 2023
Assets:
Cash equivalents$2,210$—$—$2,210
Fixed maturity securities, available-for-sale:
United States Government securities—1,844—1,844
Government sponsored securities—110—110
Foreign government securities—4—4
States, municipalities and political subdivisions, tax-exempt—3,902—3,902
Corporate securities—14,5324614,578
Residential mortgage-backed securities—3,83023,832
Commercial mortgage-backed securities—2,047—2,047
Other asset-backed securities—3,6345394,173
Total fixed maturity securities, available-for-sale—29,90358730,490
Equity securities:
Exchange traded funds106——106
Common equity securities1233—45
Private equity securities——7878
Total equity securities1183378229
Other invested assets - common equity securities111——111
Securities lending collateral—2,382—2,382
Derivatives - other assets—10—10
Total assets$2,439$32,328$665$35,432
Percentage of total assets at fair value
7%91%2%100%
Liabilities:
Derivatives - other liabilities$—$(40)$—$(40)
Total liabilities$—$(40)$—$(40)
Schedule of Estimated Fair Value by Level
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at March 31, 2024 and December 31, 2023 is as follows:
 Carrying
Value		Estimated Fair Value
 Level ILevel IILevel IIITotal
March 31, 2024
Assets:
Other invested assets$6,611 $— $— $6,580 $6,580 
Liabilities:
Debt:
Short-term borrowings225 — 225 — 225 
Commercial paper
1,350 — 1,350 — 1,350 
Notes24,876 — 23,046 — 23,046 
December 31, 2023
Assets:
Other invested assets$5,996 $— $— $5,972 $5,972 
Liabilities:
Debt:
Short-term borrowings225 — 225 — 225 
Notes24,895 — 23,569 — 23,569 
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims Payable (Tables)
 3 Months Ended
Mar. 31, 2024
Liability for Claims and Claims Adjustment Expense [Abstract]  
Reconciliation of Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the three months ended March 31, 2024 and 2023 is as follows:
20242023
Gross medical claims payable, beginning of period$15,865 $15,348 
Ceded medical claims payable, beginning of period(7)(6)
Net medical claims payable, beginning of period15,858 15,342 
Net incurred medical claims:
Current period30,708 30,751 
Prior periods redundancies(1,205)(1,068)
Total net incurred medical claims29,503 29,683 
Net payments attributable to:
Current period medical claims19,580 19,948 
Prior periods medical claims9,606 9,593 
Total net payments29,186 29,541 
Net medical claims payable, end of period16,175 15,484 
Ceded medical claims payable, end of period8 7 
Gross medical claims payable, end of period$16,183 $15,491 
Reconciliation of Net Incurred Medical Claims to Benefit Expense
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:
20242023
Total net incurred medical claims$29,503 $29,683 
Quality improvement and other claims expense1,043 1,103 
Benefit expense$30,546 $30,786 
Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable
The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of March 31, 2024 is as follows:
Total
Net medical claims payable, end of period$16,175 
Ceded medical claims payable, end of period8 
Insurance lines other than short duration276 
Gross medical claims payable, end of period$16,459 
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Capital Stock (Tables)
 3 Months Ended
Mar. 31, 2024
Class of Stock Disclosures [Abstract]  
Summary of Cash Dividend Activity
A summary of our cash dividend activity for the three months ended March 31, 2024 and 2023 is as follows: 
Declaration DateRecord DatePayment Date
Cash
Dividend
per Share
Total
Three Months Ended March 31, 2024
January 23, 2024March 8, 2024March 22, 2024$1.63$379 
Three Months Ended March 31, 2023
January 24, 2023March 10, 2023March 24, 2023$1.48$351 
Summary of Share Repurchases
A summary of common stock repurchases for the three months ended March 31, 2024 and 2023 is as follows:
Three Months Ended March 31
 20242023
Shares repurchased1.1 1.3 
Average price per share$492.76 $476.66 
Aggregate cost$566 $622 
Authorization remaining at the end of the period$3,633 $6,254 
Summary of Stock Option Activity
A summary of stock option activity for the three months ended March 31, 2024 is as follows:
Number of
Shares		Weighted-
Average
Option Price
per Share		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at January 1, 20243.0 $327.14 
Granted0.5 499.11 
Exercised(0.3)288.95 
Forfeited or expired— 431.01 
Outstanding at March 31, 20243.2 356.58 6.44$521 
Exercisable at March 31, 20242.2 297.24 5.23$482 
Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the three months ended March 31, 2024 is as follows:
Restricted
Stock Shares
and Units		Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 20241.1 $423.94 
Granted0.6 499.00 
Vested(0.6)352.33 
Forfeited— 456.61 
Nonvested at March 31, 20241.1 475.31 
Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods
The following weighted-average assumptions were used to estimate the fair values of options granted during the three months ended March 31, 2024 and 2023:
Three Months Ended March 31
20242023
Risk-free interest rate4.28 %3.95 %
Volatility factor28.00 %29.00 %
Quarterly dividend yield0.327 %0.316 %
Weighted-average expected life (years)4.404.40
Schedule of Weighted-Average Fair Values Determined for the Periods
The following weighted-average fair values per option or share were determined for the three months ended March 31, 2024 and 2023: 
Three Months Ended March 31
20242023
Options granted during the period$134.53 $127.14 
Restricted stock awards granted during the period499.00 469.31 
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accumulated Other Comprehensive (Loss) Income (Tables)
 3 Months Ended
Mar. 31, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Reconciliation of Components of Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive (loss) income at March 31, 2024 and 2023 is as follows:
Three Months Ended 
 March 31
20242023
Net unrealized investment (losses) gains:
Beginning of period balance$(632)$(1,755)
Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $50 and $(85), respectively
(162)337 
Amounts reclassified from accumulated other comprehensive loss, net of tax benefit of $(33) and $(29), respectively
106 90 
Other comprehensive (loss) income
(56)427 
Other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0, respectively
— (2)
End of period balance(688)(1,330)
Non-credit components of impairments on investments:
Beginning of period balance(3)(3)
Other comprehensive loss, net of tax benefit of $0 and $1, respectively
— (2)
End of period balance(3)(5)
Net cash flow hedges:
Beginning of period balance(211)(229)
Other comprehensive income, net of tax (expense) benefit of $(1) and $8, respectively
2 11 
End of period balance(209)(218)
Pension and other postretirement benefits:
Beginning of period balance(459)(499)
Other comprehensive income, net of tax expense of $(1) and $(1), respectively
4 2 
End of period balance(455)(497)
Future policy benefits:
Beginning of period balance10 13 
Other comprehensive (loss) income, net of tax expense of $0 and $0, respectively
(2)2 
End of period balance8 15 
Foreign currency translation adjustments:
Beginning of period balance(18)(17)
Other comprehensive income, net of tax expense of $0 and $0, respectively
— 2 
End of period balance(18)(15)
Total:
Total beginning of period accumulated other comprehensive loss(1,313)(2,490)
Total other comprehensive (loss) income, net of tax benefit (expense) of $15, and $(106), respectively
(52)442 
Total other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0 respectively
— (2)
Total end of period accumulated other comprehensive loss$(1,365)$(2,050)
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Earnings per Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Denominator for Basic and Diluted Earnings Per Share
The denominator for basic and diluted shareholders' earnings per share for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023
Denominator for basic shareholders' earnings per share – weighted-average shares
232.7 237.5 
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures
1.5 2.2 
Denominator for diluted shareholders' earnings per share
234.2 239.7 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Financial Data by Reportable Segment
Financial data by reportable segment for the three months ended March 31, 2024 and 2023 is as follows:
Carelon
Health
Benefits		CarelonRxCarelon
Services		TotalCorporate
& Other		EliminationsTotal
Three Months Ended March 31, 2024
Premiums$35,382 $— $408 $408 $— $(94)$35,696 
Product revenue— 4,499 — 4,499 — — 4,499 
Service fees1,876 1 197 198 4 — 2,078 
Operating revenue - unaffiliated37,258 4,500 605 5,105 4 (94)42,273 
Operating revenue - affiliated— 3,567 3,404 6,971 123 (7,094)— 
Operating revenue - total$37,258 $8,067 $4,009 $12,076 $127 $(7,188)$42,273 
Operating gain (loss)$2,287 $523 $290 $813 $(84)$— $3,016 
Three Months Ended March 31, 2023
Premiums$35,534 $— $410 $410 $— $(76)$35,868 
Product revenue— 4,022 — 4,022 — — 4,022 
Service fees1,746 — 208 208 54 — 2,008 
Operating revenue - unaffiliated37,280 4,022 618 4,640 54 (76)41,898 
Operating revenue - affiliated— 4,002 2,842 6,844 37 (6,881)— 
Operating revenue - total$37,280 $8,024 $3,460 $11,484 $91 $(6,957)$41,898 
Operating gain (loss)
$2,149 $512 $229 $741 $(59)$— $2,831 
Reconciliation of Reportable Segments Operating Revenues to Total Revenues Reported in the Consolidated Statements of Income
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023
Reportable segments’ operating revenue$42,273 $41,898 
Net investment income465 387 
Net losses on financial instruments(161)(113)
Total revenues$42,577 $42,172 
Reconciliation of Income Before Income Tax Expense to Reportable Segments Operating Gain Included in the Consolidated Statements of Income
A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:
 Three Months Ended 
 March 31
 20242023
Income before income tax expense$2,939 $2,619 
Net investment income(465)(387)
Net losses on financial instruments161 113 
Interest expense265 251 
Amortization of other intangible assets116 235 
Reportable segments’ operating gain$3,016 $2,831 
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization (Details)
individual in Millions
 3 Months Ended
Mar. 31, 2024
individual
state
segment
county
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of medical members served | individual 46
Number of counties in the Kansas City area the Company does not serve | county 30
Number of states in which the Company is licensed to conduct insurance operations | state 50
Number of reportable segments | segment 4
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation and Significant Accounting Policies (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Accounting Policies [Abstract]    
Cash and cash equivalents $ 499 $ 294
Securities lending transactions, initial collateral percentage value 102.00%  
Premium receivable, allowance for doubtful accounts $ 212 212
Self-funded receivables, allowance for doubtful accounts 89 87
Other receivables, allowance for doubtful accounts $ 956 $ 941
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Acquisitions and Divestitures (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Business Acquisition [Line Items]    
Goodwill $ 25,947 $ 25,317
Paragon Healthcare, Inc.    
Business Acquisition [Line Items]    
Finite-lived intangible assets acquired 553  
Goodwill 635  
BioPlus Parent, LLC and Subsidiaries    
Business Acquisition [Line Items]    
Finite-lived intangible assets acquired 820  
Goodwill 893  
Measurement period adjustments $ (5)  
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Business Optimization Initiatives (Details) - 2023-2024 Business Efficiency Program - Employee Termination - Corporate & Other - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Business Optimization Initiatives [Line Items]    
Liability for employee termination costs $ 150 $ 191
Charges or releases related to employee termination costs 0  
Payments $ 41  
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments - Current and Long-Term Fixed Maturity Securities, Available-For-Sale (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost $ 31,329 $ 31,336
Gross Unrealized Gains 384 496
Gross Unrealized Losses (1,299) (1,338)
Allowance For Credit Losses (4) (4)
Estimated Fair Value 30,410 30,490
United States Government securities    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 1,858 1,873
Gross Unrealized Gains 6 25
Gross Unrealized Losses (73) (54)
Allowance For Credit Losses 0 0
Estimated Fair Value 1,791 1,844
Government sponsored securities    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 127 112
Gross Unrealized Gains 0 1
Gross Unrealized Losses (4) (3)
Allowance For Credit Losses 0 0
Estimated Fair Value 123 110
Foreign government securities    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 73 5
Gross Unrealized Gains 0 1
Gross Unrealized Losses (1) (2)
Allowance For Credit Losses 0 0
Estimated Fair Value 72 4
States, municipalities and political subdivisions, tax-exempt    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 3,722 3,985
Gross Unrealized Gains 55 69
Gross Unrealized Losses (150) (152)
Allowance For Credit Losses 0 0
Estimated Fair Value 3,627 3,902
Corporate securities    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 16,099 14,838
Gross Unrealized Gains 256 322
Gross Unrealized Losses (575) (580)
Allowance For Credit Losses (2) (2)
Estimated Fair Value 15,778 14,578
Residential mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 4,204 4,071
Gross Unrealized Gains 27 40
Gross Unrealized Losses (302) (279)
Allowance For Credit Losses 0 0
Estimated Fair Value 3,929 3,832
Commercial mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 1,971 2,174
Gross Unrealized Gains 12 13
Gross Unrealized Losses (89) (138)
Allowance For Credit Losses (2) (2)
Estimated Fair Value 1,892 2,047
Other asset-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Cost or Amortized Cost 3,275 4,278
Gross Unrealized Gains 28 25
Gross Unrealized Losses (105) (130)
Allowance For Credit Losses 0 0
Estimated Fair Value $ 3,198 $ 4,173
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments - Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position (Details)
$ in Millions
Mar. 31, 2024
USD ($)
security
Dec. 31, 2023
USD ($)
security
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | security 1,641 1,032,000,000
Estimated fair value, less than 12 months $ 5,855 $ 2,699
Gross unrealized loss, less than 12 months $ (100) $ (55)
Number of securities, 12 months or greater | security 5,972 6,659,000,000
Estimated fair value, 12 months or greater $ 12,097 $ 14,842
Gross unrealized loss, 12 months or greater $ (1,199) $ (1,283)
United States Government securities    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | security 46 35,000,000
Estimated fair value, less than 12 months $ 1,188 $ 552
Gross unrealized loss, less than 12 months $ (29) $ (9)
Number of securities, 12 months or greater | security 48 44,000,000
Estimated fair value, 12 months or greater $ 306 $ 370
Gross unrealized loss, 12 months or greater $ (44) $ (45)
Government sponsored securities    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | security 4 0
Estimated fair value, less than 12 months $ 40 $ 0
Gross unrealized loss, less than 12 months $ 0 $ 0
Number of securities, 12 months or greater | security 39 40,000,000
Estimated fair value, 12 months or greater $ 51 $ 52
Gross unrealized loss, 12 months or greater $ (4) $ (3)
Foreign government securities    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | security 5 0
Estimated fair value, less than 12 months $ 10 $ 0
Gross unrealized loss, less than 12 months $ 0 $ 0
Number of securities, 12 months or greater | security 2 2,000,000
Estimated fair value, 12 months or greater $ 4 $ 4
Gross unrealized loss, 12 months or greater $ (1) $ (2)
States, municipalities and political subdivisions, tax-exempt    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | security 231 203,000,000
Estimated fair value, less than 12 months $ 449 $ 354
Gross unrealized loss, less than 12 months $ (4) $ (2)
Number of securities, 12 months or greater | security 1,001 1,034,000,000
Estimated fair value, 12 months or greater $ 1,656 $ 1,811
Gross unrealized loss, 12 months or greater $ (146) $ (150)
Corporate securities    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | security 906 389,000,000
Estimated fair value, less than 12 months $ 2,324 $ 608
Gross unrealized loss, less than 12 months $ (31) $ (15)
Number of securities, 12 months or greater | security 2,422 2,624,000,000
Estimated fair value, 12 months or greater $ 5,775 $ 6,871
Gross unrealized loss, 12 months or greater $ (544) $ (565)
Residential mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | security 239 183,000,000
Estimated fair value, less than 12 months $ 1,026 $ 438
Gross unrealized loss, less than 12 months $ (14) $ (5)
Number of securities, 12 months or greater | security 1,631 1,620,000,000
Estimated fair value, 12 months or greater $ 1,958 $ 2,075
Gross unrealized loss, 12 months or greater $ (288) $ (274)
Commercial mortgage-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | security 84 112,000,000
Estimated fair value, less than 12 months $ 364 $ 353
Gross unrealized loss, less than 12 months $ (6) $ (6)
Number of securities, 12 months or greater | security 415 534,000,000
Estimated fair value, 12 months or greater $ 1,059 $ 1,317
Gross unrealized loss, 12 months or greater $ (83) $ (132)
Other asset-backed securities    
Debt Securities, Available-for-sale [Line Items]    
Number of securities, less than 12 months | security 126 110,000,000
Estimated fair value, less than 12 months $ 454 $ 394
Gross unrealized loss, less than 12 months $ (16) $ (18)
Number of securities, 12 months or greater | security 414 761,000,000
Estimated fair value, 12 months or greater $ 1,288 $ 2,342
Gross unrealized loss, 12 months or greater $ (89) $ (112)
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Schedule of Investments [Line Items]      
Allowance for credit losses $ 4   $ 4
Proceeds from sales, maturities, calls or redemptions of fixed maturity securities 5,401 $ 5,410  
Accrued investment income receivable 294   301
Fair value of collateral received at time of securities lending transactions $ 2,592   $ 2,380
Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned 102.00%   102.00%
United States Government securities      
Schedule of Investments [Line Items]      
Allowance for credit losses $ 0   $ 0
Residential mortgage-backed securities      
Schedule of Investments [Line Items]      
Allowance for credit losses 0   0
States, municipalities and political subdivisions, tax-exempt      
Schedule of Investments [Line Items]      
Allowance for credit losses 0   0
Overnight and Continuous | Cash      
Schedule of Investments [Line Items]      
Collateral received for securities loaned, at carrying value 2,351   2,255
Overnight and Continuous | United States Government securities      
Schedule of Investments [Line Items]      
Collateral received for securities loaned, at carrying value 241   99
Overnight and Continuous | Residential mortgage-backed securities      
Schedule of Investments [Line Items]      
Collateral received for securities loaned, at carrying value $ 0   $ 26
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments - Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Amortized Cost    
Due in one year or less $ 369  
Due after one year through five years 6,038  
Due after five years through ten years 11,099  
Due after ten years 7,648  
Mortgage-backed securities 6,175  
Total fixed maturity securities 31,329 $ 31,336
Estimated Fair Value    
Due in one year or less 365  
Due after one year through five years 5,900  
Due after five years through ten years 10,864  
Due after ten years 7,460  
Mortgage-backed securities 5,821  
Total fixed maturity securities $ 30,410 $ 30,490
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments - Current Equity Securities (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Equity Securities [Line Items]    
Equity securities $ 511 $ 229
Exchange traded funds    
Equity Securities [Line Items]    
Equity securities 382 106
Common equity securities    
Equity Securities [Line Items]    
Equity securities 52 45
Private equity securities    
Equity Securities [Line Items]    
Equity securities $ 77 $ 78
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Investments - Net Investment (Losses) and Gains (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Other investments:    
Net losses on investments $ (166) $ (91)
Fixed maturity securities:    
Fixed maturity securities:    
Gross realized gains from sales 22 10
Gross realized losses from sales (159) (115)
Impairment losses recognized in income (2) (7)
Net realized losses from sales of fixed maturity securities (139) (112)
Equity securities:    
Equity securities:    
Unrealized gains (losses) recognized on equity securities still held at the end of the period 2 (1)
Net realized losses recognized on equity securities sold during the period 0 (1)
Net gains (losses) on equity securities 2 (2)
Other investments:    
Fixed maturity securities:    
Impairment losses recognized in income (25) (3)
Other investments:    
Gross gains 16 27
Gross losses (20) (1)
Net (losses) gains on other investments $ (29) $ 23
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Derivative Financial Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Derivative [Line Items]      
Recognized gain on hedging derivatives $ 11 $ 12  
Recognized loss on hedging derivatives 6 $ 34  
Cash Flow Hedging      
Derivative [Line Items]      
Cash flow hedges included in accumulated other comprehensive loss, net of tax $ (209)   $ (211)
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value - Summary of Fair Value Measurements by Level (Details)
$ in Millions
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
(In millions, except share and per share data)    
Cash equivalents $ 1,155 $ 2,210
Fixed maturity securities, available-for-sale: 30,410 30,490
Other invested assets 6,713 6,107
Securities lending collateral 2,594 2,382
Total assets $ 34,774 $ 35,432
Percentage of total assets at fair value 1 1
Liabilities    
Total liabilities $ (61) $ (40)
United States Government securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 1,791 1,844
Government sponsored securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 123 110
Foreign government securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 72 4
States, municipalities and political subdivisions, tax-exempt    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 3,627 3,902
Corporate securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 15,778 14,578
Residential mortgage-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 3,929 3,832
Commercial mortgage-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 1,892 2,047
Other asset-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 3,198 4,173
Equity securities:    
(In millions, except share and per share data)    
Equity securities: 511 229
Equity securities: | Exchange traded funds    
(In millions, except share and per share data)    
Equity securities: 382 106
Equity securities: | Common equity securities    
(In millions, except share and per share data)    
Equity securities: 52 45
Equity securities: | Private equity securities    
(In millions, except share and per share data)    
Equity securities: 77 78
Other investments: | Common equity securities    
(In millions, except share and per share data)    
Other invested assets 102 111
Derivatives    
(In millions, except share and per share data)    
Derivatives - other assets 2 10
Liabilities    
Derivatives - other liabilities (61) (40)
Level I    
(In millions, except share and per share data)    
Cash equivalents 1,155 2,210
Fixed maturity securities, available-for-sale: 0 0
Securities lending collateral 0 0
Total assets $ 1,654 $ 2,439
Percentage of total assets at fair value 0.05 0.07
Liabilities    
Total liabilities $ 0 $ 0
Level I | United States Government securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level I | Government sponsored securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level I | Foreign government securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level I | States, municipalities and political subdivisions, tax-exempt    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level I | Corporate securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level I | Residential mortgage-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level I | Commercial mortgage-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level I | Other asset-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level I | Equity securities:    
(In millions, except share and per share data)    
Equity securities: 397 118
Level I | Equity securities: | Exchange traded funds    
(In millions, except share and per share data)    
Equity securities: 382 106
Level I | Equity securities: | Common equity securities    
(In millions, except share and per share data)    
Equity securities: 15 12
Level I | Equity securities: | Private equity securities    
(In millions, except share and per share data)    
Equity securities: 0 0
Level I | Other investments: | Common equity securities    
(In millions, except share and per share data)    
Other invested assets 102 111
Level I | Derivatives    
(In millions, except share and per share data)    
Derivatives - other assets 0 0
Liabilities    
Derivatives - other liabilities 0 0
Level II    
(In millions, except share and per share data)    
Cash equivalents 0 0
Fixed maturity securities, available-for-sale: 29,612 29,903
Securities lending collateral 2,594 2,382
Total assets $ 32,245 $ 32,328
Percentage of total assets at fair value 0.93 0.91
Liabilities    
Total liabilities $ (61) $ (40)
Level II | United States Government securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 1,791 1,844
Level II | Government sponsored securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 123 110
Level II | Foreign government securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 72 4
Level II | States, municipalities and political subdivisions, tax-exempt    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 3,627 3,902
Level II | Corporate securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 15,726 14,532
Level II | Residential mortgage-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 3,914 3,830
Level II | Commercial mortgage-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 1,881 2,047
Level II | Other asset-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 2,478 3,634
Level II | Equity securities:    
(In millions, except share and per share data)    
Equity securities: 37 33
Level II | Equity securities: | Exchange traded funds    
(In millions, except share and per share data)    
Equity securities: 0 0
Level II | Equity securities: | Common equity securities    
(In millions, except share and per share data)    
Equity securities: 37 33
Level II | Equity securities: | Private equity securities    
(In millions, except share and per share data)    
Equity securities: 0 0
Level II | Other investments: | Common equity securities    
(In millions, except share and per share data)    
Other invested assets 0 0
Level II | Derivatives    
(In millions, except share and per share data)    
Derivatives - other assets 2 10
Liabilities    
Derivatives - other liabilities (61) (40)
Level III    
(In millions, except share and per share data)    
Cash equivalents 0 0
Fixed maturity securities, available-for-sale: 798 587
Securities lending collateral 0 0
Total assets $ 875 $ 665
Percentage of total assets at fair value 0.02 0.02
Liabilities    
Total liabilities $ 0 $ 0
Level III | United States Government securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level III | Government sponsored securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level III | Foreign government securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level III | States, municipalities and political subdivisions, tax-exempt    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 0 0
Level III | Corporate securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 52 46
Level III | Residential mortgage-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 15 2
Level III | Commercial mortgage-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 11 0
Level III | Other asset-backed securities    
(In millions, except share and per share data)    
Fixed maturity securities, available-for-sale: 720 539
Level III | Equity securities:    
(In millions, except share and per share data)    
Equity securities: 77 78
Level III | Equity securities: | Exchange traded funds    
(In millions, except share and per share data)    
Equity securities: 0 0
Level III | Equity securities: | Common equity securities    
(In millions, except share and per share data)    
Equity securities: 0 0
Level III | Equity securities: | Private equity securities    
(In millions, except share and per share data)    
Equity securities: 77 78
Level III | Other investments: | Common equity securities    
(In millions, except share and per share data)    
Other invested assets 0 0
Level III | Derivatives    
(In millions, except share and per share data)    
Derivatives - other assets 0 0
Liabilities    
Derivatives - other liabilities $ 0 $ 0
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value - Schedule of Estimated Fair Value by Level (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
(In millions, except share and per share data)    
Other invested assets $ 6,713 $ 6,107
Debt:    
Short-term borrowings 1,575 225
Estimate of Fair Value Measurement    
Debt:    
Short-term borrowings 225  
Commercial paper 1,350  
Fair Value, Nonrecurring | Reported Value Measurement    
(In millions, except share and per share data)    
Other invested assets 6,611 5,996
Debt:    
Short-term borrowings 225 225
Commercial paper 1,350  
Notes 24,876 24,895
Fair Value, Recurring | Estimate of Fair Value Measurement    
(In millions, except share and per share data)    
Other invested assets 6,580 5,972
Debt:    
Short-term borrowings   225
Notes 23,046 23,569
Fair Value, Recurring | Level I | Estimate of Fair Value Measurement    
(In millions, except share and per share data)    
Other invested assets 0 0
Debt:    
Short-term borrowings 0 0
Commercial paper 0  
Notes 0 0
Fair Value, Recurring | Level II | Estimate of Fair Value Measurement    
(In millions, except share and per share data)    
Other invested assets 0 0
Debt:    
Short-term borrowings 225 225
Commercial paper 1,350  
Notes 23,046 23,569
Fair Value, Recurring | Level III | Estimate of Fair Value Measurement    
(In millions, except share and per share data)    
Other invested assets 6,580 5,972
Debt:    
Short-term borrowings 0 0
Commercial paper 0  
Notes $ 0 $ 0
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Income Tax Disclosure [Abstract]      
Income taxes payable $ 38    
Income tax expense $ 690 $ 615  
Effective income tax rate 23.50% 23.50%  
Income taxes receivable     $ 543
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims Payable - Reconciliation of Medical Claims Payable (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]    
Gross medical claims payable, beginning of period $ 15,865 $ 15,348
Ceded medical claims payable, beginning of period (7) (6)
Net medical claims payable, beginning of period 15,858 15,342
Net incurred medical claims:    
Current period 30,708 30,751
Prior periods redundancies (1,205) (1,068)
Total net incurred medical claims 29,503 29,683
Net payments attributable to:    
Current period medical claims 19,580 19,948
Prior periods medical claims 9,606 9,593
Total net payments 29,186 29,541
Net medical claims payable, end of period 16,175 15,484
Ceded medical claims payable, end of period 8 7
Gross medical claims payable, end of period $ 16,183 $ 15,491
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims Payable - Narrative (Details)
$ in Millions
Mar. 31, 2024
USD ($)
2022  
Claims Development [Line Items]  
Net incurred but not reported liabilities plus expected development on reported claims $ 724
2023  
Claims Development [Line Items]  
Net incurred but not reported liabilities plus expected development on reported claims 4,323
2024  
Claims Development [Line Items]  
Net incurred but not reported liabilities plus expected development on reported claims $ 11,128
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims Payable - Reconciliation of Net Incurred Medical Claims to Benefit Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Liability for Claims and Claims Adjustment Expense [Abstract]    
Total net incurred medical claims $ 29,503 $ 29,683
Quality improvement and other claims expense 1,043 1,103
Benefit expense $ 30,546 $ 30,786
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Medical Claims Payable - Reconciliation of the Claims Development to the Claims Liability (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Liability for Claims and Claims Adjustment Expense [Abstract]    
Net medical claims payable, end of period $ 16,175  
Ceded medical claims payable, end of period 8  
Insurance lines other than short duration 276  
Gross medical claims payable, end of period $ 16,459 $ 16,111
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Debt (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Commercial Paper    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 4,000  
Commercial paper 1,350 $ 0
Surplus Notes    
Debt Instrument [Line Items]    
Long-term debt 25 25
Federal Home Loan Bank Advances    
Debt Instrument [Line Items]    
Short-term borrowings from the FHLB 225 225
Senior Notes | Senior Unsecured Notes    
Debt Instrument [Line Items]    
Long-term debt $ 24,851 24,870
Line of Credit | 5-Year Facility | Revolving Credit Facility    
Debt Instrument [Line Items]    
Senior revolving credit facility term 5 years  
Maximum borrowing capacity $ 4,000  
Covenant, debt-to-capital ratio (not more than) 0.60  
Debt-to-capital ratio 0.394  
Amounts outstanding $ 0 $ 0
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Details)
$ in Millions
 1 Months Ended 3 Months Ended
Sep. 30, 2022
USD ($)
appeal
Mar. 31, 2016
USD ($)
Mar. 31, 2024
USD ($)
Commitments and Contingencies [Line Items]      
Payments $ 506    
Number of notices of appeal | appeal 4    
Technology Infrastructure and Related Management and Support Services      
Commitments and Contingencies [Line Items]      
Long-term purchase commitment, amount     $ 432
Anthem, Inc. v. Express Scripts, Inc.      
Commitments and Contingencies [Line Items]      
Proceeds originally received at time of divestiture   $ 4,675  
Anthem, Inc. v. Express Scripts, Inc. | Damages for Pharmacy Pricing      
Commitments and Contingencies [Line Items]      
Approximate amount of damages sought for breaches   14,800  
Anthem, Inc. v. Express Scripts, Inc. | Damages for Operational Breaches      
Commitments and Contingencies [Line Items]      
Approximate amount of damages sought for breaches   $ 158  
BCBS Antitrust Litigation      
Commitments and Contingencies [Line Items]      
Payments $ 596    
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Capital Stock - Summary of Cash Dividend Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 22, 2024
Mar. 24, 2023
Mar. 31, 2024
Mar. 31, 2023
Class of Stock Disclosures [Abstract]        
Cash Dividend per Share (in dollars per share) $ 1.63 $ 1.48    
Total     $ 379 $ 351
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Capital Stock - Narrative (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Apr. 16, 2024
Jan. 24, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Increase in amount of stock authorized in the Stock Repurchase Program     $ 5,000
Grants (in shares) 0.6    
Restricted Stock Units      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Grants (in shares) 0.3    
Subsequent Event      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Dividends payable (in dollars per share)   $ 1.63  
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Capital Stock - Summary of Share Repurchases (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Class of Stock Disclosures [Abstract]    
Shares repurchased (in shares) 1.1 1.3
Average price per share (in dollars per share) $ 492.76 $ 476.66
Aggregate cost $ 566 $ 622
Authorization remaining at the end of the period $ 3,633 $ 6,254
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Capital Stock - Summary of Stock Option Activity (Details)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
USD ($)
$ / shares
shares
Number of Shares  
Outstanding at beginning of period (in shares) | shares 3.0
Granted (in shares) | shares 0.5
Exercised (in shares) | shares (0.3)
Forfeited or expired (in shares) | shares 0.0
Outstanding at end of period (in shares) | shares 3.2
Weighted- Average Option Price per Share  
Outstanding at beginning of period (in dollars per share) | $ / shares $ 327.14
Granted (in dollars per share) | $ / shares 499.11
Exercised (in dollars per share) | $ / shares 288.95
Forfeited or expired (in dollars per share) | $ / shares 431.01
Outstanding at end of period (in dollars per share) | $ / shares $ 356.58
Stock Options, Additional Disclosures  
Exercisable at end of period (in shares) | shares 2.2
Exercisable at end of period (in dollars per share) | $ / shares $ 297.24
Outstanding at end of period, Weighted-Average Remaining Contractual Life 6 years 5 months 8 days
Exercisable at end of period, Weighted-Average Remaining Contractual Life 5 years 2 months 23 days
Outstanding at end of period, Aggregate Intrinsic Value | $ $ 521
Exercisable at end of period, Aggregate Intrinsic Value | $ $ 482
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Capital Stock - Nonvested Restricted Stock Activity Including Restricted Stock Units (Details) - $ / shares
shares in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Restricted Stock Shares and Units    
Nonvested at beginning of period (in shares) 1.1  
Grants (in shares) 0.6  
Vested (in shares) (0.6)  
Forfeited (in shares) 0.0  
Nonvested at end of period (in shares) 1.1  
Weighted- Average Grant Date Fair Value per Share    
Nonvested at beginning of period (in dollars per share) $ 423.94  
Granted (in dollars per share) 499.00 $ 469.31
Vested (in dollars per share) 352.33  
Forfeited (in dollars per share) 456.61  
Nonvested at end of period (in dollars per share) $ 475.31  
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Capital Stock - Fair Values of Options Granted During the Period Estimated Using Weighted-Average Assumptions (Details)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Class of Stock Disclosures [Abstract]    
Risk-free interest rate 4.28% 3.95%
Volatility factor 28.00% 29.00%
Quarterly dividend yield 0.327% 0.316%
Weighted-average expected life (years) 4 years 4 months 24 days 4 years 4 months 24 days
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Capital Stock - Schedule of Weighted-Average Fair Values Determined for the Periods (Details) - $ / shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Class of Stock Disclosures [Abstract]    
Options granted during the period (in dollars per share) $ 134.53 $ 127.14
Restricted stock awards granted during the period (in dollars per share) $ 499.00 $ 469.31
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance $ 39,405 $ 36,330
Other comprehensive income (loss), net of tax (52) 442
Other comprehensive income attributable to noncontrolling interests 0 (2)
Ending balance 40,710 37,460
AOCI Including Portion Attributable to Noncontrolling Interest    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (1,313) (2,490)
Ending balance (1,365) (2,050)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (632) (1,755)
Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $50 and $(85), respectively (162) 337
Amounts reclassified from accumulated other comprehensive loss, net of tax benefit of $(33) and $(29), respectively 106 90
Other comprehensive income (loss), net of tax (56) 427
Ending balance (688) (1,330)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Noncontrolling Interest    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Other comprehensive income attributable to noncontrolling interests 0 (2)
Non-credit components of impairments on investments:    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (3) (3)
Other comprehensive income (loss), net of tax 0 (2)
Ending balance (3) (5)
Net cash flow hedges:    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (211) (229)
Other comprehensive income (loss), net of tax 2 11
Ending balance (209) (218)
Pension and other postretirement benefits:    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (459) (499)
Other comprehensive income (loss), net of tax 4 2
Ending balance (455) (497)
Future policy benefits:    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance 10 13
Other comprehensive income (loss), net of tax (2) 2
Ending balance 8 15
Foreign currency translation adjustments:    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Beginning balance (18) (17)
Other comprehensive income (loss), net of tax 0 2
Ending balance $ (18) $ (15)
XML 77 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Parenthetical) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other comprehensive income attributable to noncontrolling interests, tax $ 0 $ 0
Net gain (loss) recognized in other comprehensive income, tax (expense) benefit 15 (106)
Other comprehensive income attributable to noncontrolling interests 0 (2)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other comprehensive income (loss) before reclassifications, tax 50 (85)
Reclassification from AOCI, current period, tax 33 29
Non-credit components of impairments on investments:    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Net gain (loss) recognized in other comprehensive income, tax (expense) benefit 0 1
Net cash flow hedges:    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Net gain (loss) recognized in other comprehensive income, tax (expense) benefit (1) 8
Pension and other postretirement benefits:    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Net gain (loss) recognized in other comprehensive income, tax (expense) benefit (1) (1)
Future policy benefits:    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Net gain (loss) recognized in other comprehensive income, tax (expense) benefit 0 0
Foreign currency translation adjustments:    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Net gain (loss) recognized in other comprehensive income, tax (expense) benefit 0 0
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Noncontrolling Interest    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Other comprehensive income attributable to noncontrolling interests, tax 0 0
Other comprehensive income attributable to noncontrolling interests $ 0 $ (2)
XML 78 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Earnings per Share - Denominator for Basic and Diluted Earnings per Share (Details) - shares
shares in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Denominator for basic shareholders' earnings per share - weighted-average shares 232.7 237.5
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures 1.5 2.2
Denominator for diluted shareholders' earnings per share 234.2 239.7
XML 79 R63.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Shareholders' Earnings per Share - Narrative (Details) - shares
shares in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Employee Stock Option    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares (in shares) 0.6 0.4
Restricted Stock Units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares (in shares) 0.6 0.6
Restricted Stock Units - Contingent    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares (in shares) 0.3 0.2
XML 80 R64.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information - Narrative (Details)
 3 Months Ended
Mar. 31, 2024
segment
Segment Reporting [Abstract]  
Number of reportable segments 4
XML 81 R65.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information - Financial Data by Reportable Segment (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting Information [Line Items]    
Premiums $ 35,696 $ 35,868
Operating revenue 42,273 41,898
Operating gain (loss) 3,016 2,831
Product revenue    
Segment Reporting Information [Line Items]    
Product and service revenue 4,499 4,022
Service fees    
Segment Reporting Information [Line Items]    
Product and service revenue 2,078 2,008
Eliminations    
Segment Reporting Information [Line Items]    
Premiums (94) (76)
Operating revenue (7,188) (6,957)
Operating gain (loss) 0 0
Eliminations | Product revenue    
Segment Reporting Information [Line Items]    
Product and service revenue 0 0
Eliminations | Service fees    
Segment Reporting Information [Line Items]    
Product and service revenue 0 0
Health Benefits | Operating Segments    
Segment Reporting Information [Line Items]    
Premiums 35,382 35,534
Operating revenue 37,258 37,280
Operating gain (loss) 2,287 2,149
Health Benefits | Operating Segments | Product revenue    
Segment Reporting Information [Line Items]    
Product and service revenue 0 0
Health Benefits | Operating Segments | Service fees    
Segment Reporting Information [Line Items]    
Product and service revenue 1,876 1,746
Carelon Total | Operating Segments    
Segment Reporting Information [Line Items]    
Premiums 408 410
Operating revenue 12,076 11,484
Operating gain (loss) 813 741
Carelon Total | Operating Segments | Product revenue    
Segment Reporting Information [Line Items]    
Product and service revenue 4,499 4,022
Carelon Total | Operating Segments | Service fees    
Segment Reporting Information [Line Items]    
Product and service revenue 198 208
CarelonRx | Operating Segments    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating revenue 8,067 8,024
Operating gain (loss) 523 512
CarelonRx | Operating Segments | Product revenue    
Segment Reporting Information [Line Items]    
Product and service revenue 4,499 4,022
CarelonRx | Operating Segments | Service fees    
Segment Reporting Information [Line Items]    
Product and service revenue 1 0
Carelon Services | Operating Segments    
Segment Reporting Information [Line Items]    
Premiums 408 410
Operating revenue 4,009 3,460
Operating gain (loss) 290 229
Carelon Services | Operating Segments | Product revenue    
Segment Reporting Information [Line Items]    
Product and service revenue 0 0
Carelon Services | Operating Segments | Service fees    
Segment Reporting Information [Line Items]    
Product and service revenue 197 208
Corporate & Other | Operating Segments    
Segment Reporting Information [Line Items]    
Premiums 0 0
Operating revenue 127 91
Operating gain (loss) (84) (59)
Corporate & Other | Operating Segments | Product revenue    
Segment Reporting Information [Line Items]    
Product and service revenue 0 0
Corporate & Other | Operating Segments | Service fees    
Segment Reporting Information [Line Items]    
Product and service revenue 4 54
Operating revenue - unaffiliated    
Segment Reporting Information [Line Items]    
Operating revenue 42,273 41,898
Operating revenue - unaffiliated | Eliminations    
Segment Reporting Information [Line Items]    
Operating revenue (94) (76)
Operating revenue - unaffiliated | Health Benefits | Operating Segments    
Segment Reporting Information [Line Items]    
Operating revenue 37,258 37,280
Operating revenue - unaffiliated | Carelon Total | Operating Segments    
Segment Reporting Information [Line Items]    
Operating revenue 5,105 4,640
Operating revenue - unaffiliated | CarelonRx | Operating Segments    
Segment Reporting Information [Line Items]    
Operating revenue 4,500 4,022
Operating revenue - unaffiliated | Carelon Services | Operating Segments    
Segment Reporting Information [Line Items]    
Operating revenue 605 618
Operating revenue - unaffiliated | Corporate & Other | Operating Segments    
Segment Reporting Information [Line Items]    
Operating revenue 4 54
Operating revenue - affiliated | Eliminations    
Segment Reporting Information [Line Items]    
Operating revenue (7,094) (6,881)
Operating revenue - affiliated | Health Benefits | Eliminations    
Segment Reporting Information [Line Items]    
Operating revenue 0 0
Operating revenue - affiliated | Carelon Total | Eliminations    
Segment Reporting Information [Line Items]    
Operating revenue 6,971 6,844
Operating revenue - affiliated | CarelonRx | Eliminations    
Segment Reporting Information [Line Items]    
Operating revenue 3,567 4,002
Operating revenue - affiliated | Carelon Services | Eliminations    
Segment Reporting Information [Line Items]    
Operating revenue 3,404 2,842
Operating revenue - affiliated | Corporate & Other | Eliminations    
Segment Reporting Information [Line Items]    
Operating revenue $ 123 $ 37
XML 82 R66.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information - Reconciliation of Reportable Segments Operating Revenues to Total Revenues Reported in the Consolidated Statements of Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting [Abstract]    
Total operating revenue $ 42,273 $ 41,898
Net investment income 465 387
Net losses on financial instruments (161) (113)
Total revenues $ 42,577 $ 42,172
XML 83 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information - Reconciliation of Income Before Income Tax Expense to Reportable Segments Operating Gain Included in the Consolidated Statements of Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Segment Reporting [Abstract]    
Income before income tax expense $ 2,939 $ 2,619
Net investment income (465) (387)
Net losses (gains) on financial instruments 161 113
Interest expense 265 251
Amortization of other intangible assets 116 235
Reportable segments operating gain $ 3,016 $ 2,831
EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 333 336 1 false 75 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://www.elevancehealth.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Consolidated Balance Sheets Sheet http://www.elevancehealth.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statements of Income Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome Consolidated Statements of Income Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Cash Flows Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Changes in Equity Sheet http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity Consolidated Statements of Changes in Equity Statements 7 false false R8.htm 0000008 - Disclosure - Organization Sheet http://www.elevancehealth.com/role/Organization Organization Notes 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Business Acquisitions and Divestitures Sheet http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestitures Business Acquisitions and Divestitures Notes 10 false false R11.htm 0000011 - Disclosure - Business Optimization Initiatives Sheet http://www.elevancehealth.com/role/BusinessOptimizationInitiatives Business Optimization Initiatives Notes 11 false false R12.htm 0000012 - Disclosure - Investments Sheet http://www.elevancehealth.com/role/Investments Investments Notes 12 false false R13.htm 0000013 - Disclosure - Derivative Financial Instruments Sheet http://www.elevancehealth.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 13 false false R14.htm 0000014 - Disclosure - Fair Value Sheet http://www.elevancehealth.com/role/FairValue Fair Value Notes 14 false false R15.htm 0000015 - Disclosure - Income Taxes Sheet http://www.elevancehealth.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 0000016 - Disclosure - Medical Claims Payable Sheet http://www.elevancehealth.com/role/MedicalClaimsPayable Medical Claims Payable Notes 16 false false R17.htm 0000017 - Disclosure - Debt Sheet http://www.elevancehealth.com/role/Debt Debt Notes 17 false false R18.htm 0000018 - Disclosure - Commitments and Contingencies Sheet http://www.elevancehealth.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 0000019 - Disclosure - Capital Stock Sheet http://www.elevancehealth.com/role/CapitalStock Capital Stock Notes 19 false false R20.htm 0000020 - Disclosure - Accumulated Other Comprehensive (Loss) Income Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncome Accumulated Other Comprehensive (Loss) Income Notes 20 false false R21.htm 0000021 - Disclosure - Shareholders' Earnings per Share Sheet http://www.elevancehealth.com/role/ShareholdersEarningsperShare Shareholders' Earnings per Share Notes 21 false false R22.htm 0000022 - Disclosure - Segment Information Sheet http://www.elevancehealth.com/role/SegmentInformation Segment Information Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPolicies 25 false false R26.htm 9954472 - Disclosure - Investments (Tables) Sheet http://www.elevancehealth.com/role/InvestmentsTables Investments (Tables) Tables http://www.elevancehealth.com/role/Investments 26 false false R27.htm 9954473 - Disclosure - Fair Value (Tables) Sheet http://www.elevancehealth.com/role/FairValueTables Fair Value (Tables) Tables http://www.elevancehealth.com/role/FairValue 27 false false R28.htm 9954474 - Disclosure - Medical Claims Payable (Tables) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableTables Medical Claims Payable (Tables) Tables http://www.elevancehealth.com/role/MedicalClaimsPayable 28 false false R29.htm 9954475 - Disclosure - Capital Stock (Tables) Sheet http://www.elevancehealth.com/role/CapitalStockTables Capital Stock (Tables) Tables http://www.elevancehealth.com/role/CapitalStock 29 false false R30.htm 9954476 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeTables Accumulated Other Comprehensive (Loss) Income (Tables) Tables http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncome 30 false false R31.htm 9954477 - Disclosure - Shareholders' Earnings per Share (Tables) Sheet http://www.elevancehealth.com/role/ShareholdersEarningsperShareTables Shareholders' Earnings per Share (Tables) Tables http://www.elevancehealth.com/role/ShareholdersEarningsperShare 31 false false R32.htm 9954478 - Disclosure - Segment Information (Tables) Sheet http://www.elevancehealth.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.elevancehealth.com/role/SegmentInformation 32 false false R33.htm 9954479 - Disclosure - Organization (Details) Sheet http://www.elevancehealth.com/role/OrganizationDetails Organization (Details) Details http://www.elevancehealth.com/role/Organization 33 false false R34.htm 9954480 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details) Sheet http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails Basis of Presentation and Significant Accounting Policies (Details) Details http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies 34 false false R35.htm 9954481 - Disclosure - Business Acquisitions and Divestitures (Details) Sheet http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails Business Acquisitions and Divestitures (Details) Details http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestitures 35 false false R36.htm 9954482 - Disclosure - Business Optimization Initiatives (Details) Sheet http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails Business Optimization Initiatives (Details) Details http://www.elevancehealth.com/role/BusinessOptimizationInitiatives 36 false false R37.htm 9954483 - Disclosure - Investments - Current and Long-Term Fixed Maturity Securities, Available-For-Sale (Details) Sheet http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails Investments - Current and Long-Term Fixed Maturity Securities, Available-For-Sale (Details) Details 37 false false R38.htm 9954484 - Disclosure - Investments - Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position (Details) Sheet http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails Investments - Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position (Details) Details 38 false false R39.htm 9954485 - Disclosure - Investments - Narrative (Details) Sheet http://www.elevancehealth.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 39 false false R40.htm 9954486 - Disclosure - Investments - Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity (Details) Sheet http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails Investments - Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity (Details) Details 40 false false R41.htm 9954487 - Disclosure - Investments - Current Equity Securities (Details) Sheet http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails Investments - Current Equity Securities (Details) Details 41 false false R42.htm 9954488 - Disclosure - Investments - Net Investment (Losses) and Gains (Details) Sheet http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails Investments - Net Investment (Losses) and Gains (Details) Details 42 false false R43.htm 9954489 - Disclosure - Derivative Financial Instruments (Details) Sheet http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails Derivative Financial Instruments (Details) Details http://www.elevancehealth.com/role/DerivativeFinancialInstruments 43 false false R44.htm 9954490 - Disclosure - Fair Value - Summary of Fair Value Measurements by Level (Details) Sheet http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails Fair Value - Summary of Fair Value Measurements by Level (Details) Details 44 false false R45.htm 9954491 - Disclosure - Fair Value - Schedule of Estimated Fair Value by Level (Details) Sheet http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails Fair Value - Schedule of Estimated Fair Value by Level (Details) Details 45 false false R46.htm 9954492 - Disclosure - Income Taxes (Details) Sheet http://www.elevancehealth.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.elevancehealth.com/role/IncomeTaxes 46 false false R47.htm 9954493 - Disclosure - Medical Claims Payable - Reconciliation of Medical Claims Payable (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails Medical Claims Payable - Reconciliation of Medical Claims Payable (Details) Details 47 false false R48.htm 9954494 - Disclosure - Medical Claims Payable - Narrative (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails Medical Claims Payable - Narrative (Details) Details 48 false false R49.htm 9954495 - Disclosure - Medical Claims Payable - Reconciliation of Net Incurred Medical Claims to Benefit Expense (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails Medical Claims Payable - Reconciliation of Net Incurred Medical Claims to Benefit Expense (Details) Details 49 false false R50.htm 9954496 - Disclosure - Medical Claims Payable - Reconciliation of the Claims Development to the Claims Liability (Details) Sheet http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails Medical Claims Payable - Reconciliation of the Claims Development to the Claims Liability (Details) Details 50 false false R51.htm 9954497 - Disclosure - Debt (Details) Sheet http://www.elevancehealth.com/role/DebtDetails Debt (Details) Details http://www.elevancehealth.com/role/Debt 51 false false R52.htm 9954498 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.elevancehealth.com/role/CommitmentsandContingencies 52 false false R53.htm 9954499 - Disclosure - Capital Stock - Summary of Cash Dividend Activity (Details) Sheet http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails Capital Stock - Summary of Cash Dividend Activity (Details) Details 53 false false R54.htm 9954500 - Disclosure - Capital Stock - Narrative (Details) Sheet http://www.elevancehealth.com/role/CapitalStockNarrativeDetails Capital Stock - Narrative (Details) Details 54 false false R55.htm 9954501 - Disclosure - Capital Stock - Summary of Share Repurchases (Details) Sheet http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails Capital Stock - Summary of Share Repurchases (Details) Details 55 false false R56.htm 9954502 - Disclosure - Capital Stock - Summary of Stock Option Activity (Details) Sheet http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails Capital Stock - Summary of Stock Option Activity (Details) Details 56 false false R57.htm 9954503 - Disclosure - Capital Stock - Nonvested Restricted Stock Activity Including Restricted Stock Units (Details) Sheet http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails Capital Stock - Nonvested Restricted Stock Activity Including Restricted Stock Units (Details) Details 57 false false R58.htm 9954504 - Disclosure - Capital Stock - Fair Values of Options Granted During the Period Estimated Using Weighted-Average Assumptions (Details) Sheet http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringthePeriodEstimatedUsingWeightedAverageAssumptionsDetails Capital Stock - Fair Values of Options Granted During the Period Estimated Using Weighted-Average Assumptions (Details) Details 58 false false R59.htm 9954505 - Disclosure - Capital Stock - Schedule of Weighted-Average Fair Values Determined for the Periods (Details) Sheet http://www.elevancehealth.com/role/CapitalStockScheduleofWeightedAverageFairValuesDeterminedforthePeriodsDetails Capital Stock - Schedule of Weighted-Average Fair Values Determined for the Periods (Details) Details 59 false false R60.htm 9954506 - Disclosure - Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Details) Details http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeTables 60 false false R61.htm 9954507 - Disclosure - Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Parenthetical) (Details) Sheet http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Parenthetical) (Details) Details http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeTables 61 false false R62.htm 9954508 - Disclosure - Shareholders' Earnings per Share - Denominator for Basic and Diluted Earnings per Share (Details) Sheet http://www.elevancehealth.com/role/ShareholdersEarningsperShareDenominatorforBasicandDilutedEarningsperShareDetails Shareholders' Earnings per Share - Denominator for Basic and Diluted Earnings per Share (Details) Details 62 false false R63.htm 9954509 - Disclosure - Shareholders' Earnings per Share - Narrative (Details) Sheet http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails Shareholders' Earnings per Share - Narrative (Details) Details 63 false false R64.htm 9954510 - Disclosure - Segment Information - Narrative (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails Segment Information - Narrative (Details) Details 64 false false R65.htm 9954511 - Disclosure - Segment Information - Financial Data by Reportable Segment (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails Segment Information - Financial Data by Reportable Segment (Details) Details 65 false false R66.htm 9954512 - Disclosure - Segment Information - Reconciliation of Reportable Segments Operating Revenues to Total Revenues Reported in the Consolidated Statements of Income (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationReconciliationofReportableSegmentsOperatingRevenuestoTotalRevenuesReportedintheConsolidatedStatementsofIncomeDetails Segment Information - Reconciliation of Reportable Segments Operating Revenues to Total Revenues Reported in the Consolidated Statements of Income (Details) Details 66 false false R67.htm 9954513 - Disclosure - Segment Information - Reconciliation of Income Before Income Tax Expense to Reportable Segments Operating Gain Included in the Consolidated Statements of Income (Details) Sheet http://www.elevancehealth.com/role/SegmentInformationReconciliationofIncomeBeforeIncomeTaxExpensetoReportableSegmentsOperatingGainIncludedintheConsolidatedStatementsofIncomeDetails Segment Information - Reconciliation of Income Before Income Tax Expense to Reportable Segments Operating Gain Included in the Consolidated Statements of Income (Details) Details 67 false false All Reports Book All Reports elv-20240331.htm elv-20240331.xsd elv-20240331_cal.xml elv-20240331_def.xml elv-20240331_lab.xml elv-20240331_pre.xml elv-20240331_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "elv-20240331.htm": { "nsprefix": "elv", "nsuri": "http://www.elevancehealth.com/20240331", "dts": { "inline": { "local": [ "elv-20240331.htm" ] }, "schema": { "local": [ "elv-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "elv-20240331_cal.xml" ] }, "definitionLink": { "local": [ "elv-20240331_def.xml" ] }, "labelLink": { "local": [ "elv-20240331_lab.xml" ] }, "presentationLink": { "local": [ "elv-20240331_pre.xml" ] } }, "keyStandard": 307, "keyCustom": 29, "axisStandard": 25, "axisCustom": 0, "memberStandard": 51, "memberCustom": 24, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 333, "entityCount": 1, "segmentCount": 75, "elementCount": 632, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1021, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.elevancehealth.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "longName": "0000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "longName": "0000004 - Statement - Consolidated Statements of Income", "shortName": "Consolidated Statements of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R5": { "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "longName": "0000005 - Statement - Consolidated Statements of Comprehensive Income", "shortName": "Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R6": { "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows", "longName": "0000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R7": { "role": "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity", "longName": "0000007 - Statement - Consolidated Statements of Changes in Equity", "shortName": "Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.elevancehealth.com/role/Organization", "longName": "0000008 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPolicies", "longName": "0000009 - Disclosure - Basis of Presentation and Significant Accounting Policies", "shortName": "Basis of Presentation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestitures", "longName": "0000010 - Disclosure - Business Acquisitions and Divestitures", "shortName": "Business Acquisitions and Divestitures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.elevancehealth.com/role/BusinessOptimizationInitiatives", "longName": "0000011 - Disclosure - Business Optimization Initiatives", "shortName": "Business Optimization Initiatives", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.elevancehealth.com/role/Investments", "longName": "0000012 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstruments", "longName": "0000013 - Disclosure - Derivative Financial Instruments", "shortName": "Derivative Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.elevancehealth.com/role/FairValue", "longName": "0000014 - Disclosure - Fair Value", "shortName": "Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.elevancehealth.com/role/IncomeTaxes", "longName": "0000015 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.elevancehealth.com/role/MedicalClaimsPayable", "longName": "0000016 - Disclosure - Medical Claims Payable", "shortName": "Medical Claims Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.elevancehealth.com/role/Debt", "longName": "0000017 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.elevancehealth.com/role/CommitmentsandContingencies", "longName": "0000018 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.elevancehealth.com/role/CapitalStock", "longName": "0000019 - Disclosure - Capital Stock", "shortName": "Capital Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncome", "longName": "0000020 - Disclosure - Accumulated Other Comprehensive (Loss) Income", "shortName": "Accumulated Other Comprehensive (Loss) Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.elevancehealth.com/role/ShareholdersEarningsperShare", "longName": "0000021 - Disclosure - Shareholders' Earnings per Share", "shortName": "Shareholders' Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.elevancehealth.com/role/SegmentInformation", "longName": "0000022 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.elevancehealth.com/role/InvestmentsTables", "longName": "9954472 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.elevancehealth.com/role/FairValueTables", "longName": "9954473 - Disclosure - Fair Value (Tables)", "shortName": "Fair Value (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableTables", "longName": "9954474 - Disclosure - Medical Claims Payable (Tables)", "shortName": "Medical Claims Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.elevancehealth.com/role/CapitalStockTables", "longName": "9954475 - Disclosure - Capital Stock (Tables)", "shortName": "Capital Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DividendsDeclaredTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeTables", "longName": "9954476 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)", "shortName": "Accumulated Other Comprehensive (Loss) Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.elevancehealth.com/role/ShareholdersEarningsperShareTables", "longName": "9954477 - Disclosure - Shareholders' Earnings per Share (Tables)", "shortName": "Shareholders' Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.elevancehealth.com/role/SegmentInformationTables", "longName": "9954478 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.elevancehealth.com/role/OrganizationDetails", "longName": "9954479 - Disclosure - Organization (Details)", "shortName": "Organization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "elv:NumberOfMedicalMembersServed", "unitRef": "individual", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "elv:NumberOfMedicalMembersServed", "unitRef": "individual", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "longName": "9954480 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashAndInvestmentsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashAndInvestmentsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails", "longName": "9954481 - Disclosure - Business Acquisitions and Divestitures (Details)", "shortName": "Business Acquisitions and Divestitures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-42", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R36": { "role": "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails", "longName": "9954482 - Disclosure - Business Optimization Initiatives (Details)", "shortName": "Business Optimization Initiatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-45", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-45", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "longName": "9954483 - Disclosure - Investments - Current and Long-Term Fixed Maturity Securities, Available-For-Sale (Details)", "shortName": "Investments - Current and Long-Term Fixed Maturity Securities, Available-For-Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R38": { "role": "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "longName": "9954484 - Disclosure - Investments - Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position (Details)", "shortName": "Investments - Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "unitRef": "security", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "unitRef": "security", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "longName": "9954485 - Disclosure - Investments - Narrative (Details)", "shortName": "Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R40": { "role": "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails", "longName": "9954486 - Disclosure - Investments - Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity (Details)", "shortName": "Investments - Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails", "longName": "9954487 - Disclosure - Investments - Current Equity Securities (Details)", "shortName": "Investments - Current Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-64", "name": "us-gaap:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "elv:InvestmentsinequitysecuritiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R42": { "role": "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails", "longName": "9954488 - Disclosure - Investments - Net Investment (Losses) and Gains (Details)", "shortName": "Investments - Net Investment (Losses) and Gains (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "elv:InvestmentGainsLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "elv:InvestmentGainsLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails", "longName": "9954489 - Disclosure - Derivative Financial Instruments (Details)", "shortName": "Derivative Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeGainOnDerivative", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeGainOnDerivative", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "longName": "9954490 - Disclosure - Fair Value - Summary of Fair Value Measurements by Level (Details)", "shortName": "Fair Value - Summary of Fair Value Measurements by Level (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "longName": "9954491 - Disclosure - Fair Value - Schedule of Estimated Fair Value by Level (Details)", "shortName": "Fair Value - Schedule of Estimated Fair Value by Level (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherLongTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-193", "name": "us-gaap:ShortTermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "elv:CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R46": { "role": "http://www.elevancehealth.com/role/IncomeTaxesDetails", "longName": "9954492 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedIncomeTaxesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedIncomeTaxesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails", "longName": "9954493 - Disclosure - Medical Claims Payable - Reconciliation of Medical Claims Payable (Details)", "shortName": "Medical Claims Payable - Reconciliation of Medical Claims Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "elv:ShortDurationContractLiabilityForClaimsAdjustmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails", "longName": "9954494 - Disclosure - Medical Claims Payable - Narrative (Details)", "shortName": "Medical Claims Payable - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-199", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-199", "name": "us-gaap:ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails", "longName": "9954495 - Disclosure - Medical Claims Payable - Reconciliation of Net Incurred Medical Claims to Benefit Expense (Details)", "shortName": "Medical Claims Payable - Reconciliation of Net Incurred Medical Claims to Benefit Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementaryInsuranceInformationOtherOperatingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "elv:ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R50": { "role": "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails", "longName": "9954496 - Disclosure - Medical Claims Payable - Reconciliation of the Claims Development to the Claims Liability (Details)", "shortName": "Medical Claims Payable - Reconciliation of the Claims Development to the Claims Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.elevancehealth.com/role/DebtDetails", "longName": "9954497 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-209", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-209", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails", "longName": "9954498 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-213", "name": "us-gaap:LossContingencyAccrualPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "us-gaap:LossContingencyAccrualPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails", "longName": "9954499 - Disclosure - Capital Stock - Summary of Cash Dividend Activity (Details)", "shortName": "Capital Stock - Summary of Cash Dividend Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-220", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-220", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "longName": "9954500 - Disclosure - Capital Stock - Narrative (Details)", "shortName": "Capital Stock - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-223", "name": "elv:IncreaseInStockRepurchaseProgramAuthorization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-223", "name": "elv:IncreaseInStockRepurchaseProgramAuthorization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "longName": "9954501 - Disclosure - Capital Stock - Summary of Share Repurchases (Details)", "shortName": "Capital Stock - Summary of Share Repurchases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R56": { "role": "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails", "longName": "9954502 - Disclosure - Capital Stock - Summary of Stock Option Activity (Details)", "shortName": "Capital Stock - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails", "longName": "9954503 - Disclosure - Capital Stock - Nonvested Restricted Stock Activity Including Restricted Stock Units (Details)", "shortName": "Capital Stock - Nonvested Restricted Stock Activity Including Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringthePeriodEstimatedUsingWeightedAverageAssumptionsDetails", "longName": "9954504 - Disclosure - Capital Stock - Fair Values of Options Granted During the Period Estimated Using Weighted-Average Assumptions (Details)", "shortName": "Capital Stock - Fair Values of Options Granted During the Period Estimated Using Weighted-Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.elevancehealth.com/role/CapitalStockScheduleofWeightedAverageFairValuesDeterminedforthePeriodsDetails", "longName": "9954505 - Disclosure - Capital Stock - Schedule of Weighted-Average Fair Values Determined for the Periods (Details)", "shortName": "Capital Stock - Schedule of Weighted-Average Fair Values Determined for the Periods (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "longName": "9954506 - Disclosure - Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Details)", "shortName": "Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-263", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R61": { "role": "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails", "longName": "9954507 - Disclosure - Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Parenthetical) (Details)", "shortName": "Accumulated Other Comprehensive (Loss) Income - Reconciliation of the Components of Accumulated Other Comprehensive Loss (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.elevancehealth.com/role/ShareholdersEarningsperShareDenominatorforBasicandDilutedEarningsperShareDetails", "longName": "9954508 - Disclosure - Shareholders' Earnings per Share - Denominator for Basic and Diluted Earnings per Share (Details)", "shortName": "Shareholders' Earnings per Share - Denominator for Basic and Diluted Earnings per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails", "longName": "9954509 - Disclosure - Shareholders' Earnings per Share - Narrative (Details)", "shortName": "Shareholders' Earnings per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-267", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-267", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails", "longName": "9954510 - Disclosure - Segment Information - Narrative (Details)", "shortName": "Segment Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails", "longName": "9954511 - Disclosure - Segment Information - Financial Data by Reportable Segment (Details)", "shortName": "Segment Information - Financial Data by Reportable Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-277", "name": "us-gaap:PremiumsEarnedNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "unique": true } }, "R66": { "role": "http://www.elevancehealth.com/role/SegmentInformationReconciliationofReportableSegmentsOperatingRevenuestoTotalRevenuesReportedintheConsolidatedStatementsofIncomeDetails", "longName": "9954512 - Disclosure - Segment Information - Reconciliation of Reportable Segments Operating Revenues to Total Revenues Reported in the Consolidated Statements of Income (Details)", "shortName": "Segment Information - Reconciliation of Reportable Segments Operating Revenues to Total Revenues Reported in the Consolidated Statements of Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "elv:OperatingRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "elv:OperatingRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.elevancehealth.com/role/SegmentInformationReconciliationofIncomeBeforeIncomeTaxExpensetoReportableSegmentsOperatingGainIncludedintheConsolidatedStatementsofIncomeDetails", "longName": "9954513 - Disclosure - Segment Information - Reconciliation of Income Before Income Tax Expense to Reportable Segments Operating Gain Included in the Consolidated Statements of Income (Details)", "shortName": "Segment Information - Reconciliation of Income Before Income Tax Expense to Reportable Segments Operating Gain Included in the Consolidated Statements of Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "elv-20240331.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "elv_A20232024BusinessEfficiencyProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "A20232024BusinessEfficiencyProgramMember", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023-2024 Business Efficiency Program", "label": "2023-2024 Business Efficiency Program [Member]", "documentation": "2023-2024 Business Efficiency Program" } } }, "auth_ref": [] }, "elv_A5YearFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "A5YearFacilityMember", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5-Year Facility", "label": "5-Year Facility [Member]", "documentation": "5-Year Facility [Member]" } } }, "auth_ref": [] }, "elv_AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future policy benefits:", "label": "AOCI, Future Policy Benefits, Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "AOCI, Future Policy Benefits, Including Portion Attributable to Noncontrolling Interest" } } }, "auth_ref": [] }, "elv_AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-credit components of impairments on investments:", "label": "AOCI, Non-Credit Components of Impairments on Investments, Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "AOCI, Non-Credit Components of Impairments on Investments, Including Portion Attributable to Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r117", "r162" ] }, "us-gaap_AccruedInvestmentIncomeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedInvestmentIncomeReceivable", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued investment income receivable", "label": "Accrued Investment Income Receivable", "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments." } } }, "auth_ref": [ "r158", "r603", "r936" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and other postretirement benefits:", "label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r5", "r18", "r45", "r938", "r939", "r940" ] }, "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments:", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r4", "r18", "r45", "r224", "r939", "r940" ] }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash flow hedges:", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest." } } }, "auth_ref": [ "r217", "r224", "r503", "r939", "r940" ] }, "us-gaap_AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Noncontrolling Interest", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Noncontrolling Interest [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to noncontrolling interest." } } }, "auth_ref": [ "r212", "r213", "r214", "r217", "r938", "r939", "r940" ] }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Including Noncontrolling Interest [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest." } } }, "auth_ref": [ "r212", "r213", "r214", "r217", "r224", "r939", "r940" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r225", "r535", "r537", "r538", "r539", "r540", "r541" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r44", "r45", "r126", "r206", "r599", "r648", "r649" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r224", "r225", "r535", "r537", "r538", "r539", "r540", "r541" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r18", "r45", "r509", "r512", "r545", "r643", "r644", "r938", "r939", "r940", "r950", "r951", "r952" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r884" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r120", "r829", "r1023" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r475", "r476", "r477", "r661", "r950", "r951", "r952", "r1000", "r1025" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r890" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r890" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r890" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r890" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Convertible debenture repurchases, conversions and tax adjustments", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments", "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "elv_AffiliatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "AffiliatedMember", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating revenue - affiliated", "label": "Affiliated [Member]", "documentation": "Affiliated [Member]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r855", "r866", "r876", "r901" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r858", "r869", "r879", "r904" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r890" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r897" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r862", "r870", "r880", "r897", "r905", "r909", "r917" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r915" ] }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables, allowance for doubtful accounts", "label": "Allowance for Credit Loss, Receivable, Other, Current", "documentation": "Amount of allowance for credit loss on receivable, classified as other and current." } } }, "auth_ref": [ "r205" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationofIncomeBeforeIncomeTaxExpensetoReportableSegmentsOperatingGainIncludedintheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of other intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r13", "r69", "r71" ] }, "elv_AnthemInc.v.ExpressScriptsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "AnthemInc.v.ExpressScriptsInc.Member", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anthem, Inc. v. Express Scripts, Inc.", "label": "Anthem, Inc. v. Express Scripts, Inc. [Member]", "documentation": "Anthem, Inc. v. Express Scripts, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Antidilutive shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r266" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r18", "r45", "r938", "r939", "r940" ] }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges included in accumulated other comprehensive loss, net of tax", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r216" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r159", "r201", "r240", "r275", "r290", "r296", "r340", "r385", "r386", "r388", "r389", "r390", "r392", "r394", "r396", "r397", "r499", "r504", "r532", "r593", "r689", "r829", "r846", "r994", "r995", "r1005" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(In millions, except share and per share data)", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r195", "r208", "r240", "r340", "r385", "r386", "r388", "r389", "r390", "r392", "r394", "r396", "r397", "r499", "r504", "r532", "r829", "r994", "r995", "r1005" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r103" ] }, "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodDomain", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]", "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Domain]", "documentation": "Maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats." } } }, "auth_ref": [ "r243", "r562" ] }, "us-gaap_AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsSoldUnderAgreementsToRepurchaseMaturityPeriodsAxis", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]", "label": "Repurchase Agreements and Similar Transactions, Maturity Periods [Axis]", "documentation": "Information by maturity period remaining for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements. Element name and standard label in Maturity [numeric lower end] to [numeric higher end] [date measure] [Member] or Maturity Greater Than [low end numeric value] [date measure] [Member] or Maturity Less Than [high end numeric value] [date measure] [Member] formats." } } }, "auth_ref": [ "r243", "r562" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r312" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r313" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost or Amortized Cost", "totalLabel": "Total fixed maturity securities", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r309", "r348", "r592" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed maturity securities:", "label": "Available-for-Sale Securities, Debt Maturities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r969" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r318", "r588" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r968" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r317", "r587" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due after ten years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r970" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due after ten years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r319", "r589" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r967" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r316", "r586" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Mortgage-backed securities", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping." } } }, "auth_ref": [ "r965", "r966" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Mortgage-backed securities", "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping." } } }, "auth_ref": [ "r315", "r585", "r965" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAmortizedCostandFairValueofFixedMaturitySecuritiesByContractualMaturityDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair\u00a0Value", "totalLabel": "Total fixed maturity securities", "verboseLabel": "Fixed maturity securities, available-for-sale:", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r310", "r348", "r580", "r961" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed maturity securities (amortized cost of $30,427 and $30,446; allowance for credit losses of $4 and $4)", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r306", "r348" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed maturity securities (amortized cost of $902 and $890; allowance for credit losses of $0 and $0)", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r198", "r306", "r348" ] }, "elv_AvailableForSaleSecuritiesEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "AvailableForSaleSecuritiesEquitySecuritiesAbstract", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities:", "label": "Available-for-Sale Securities, Equity Securities [Abstract]", "documentation": "Available-for-Sale Securities, Equity Securities" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossAbstract", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (losses) gains:", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss) [Abstract]" } } }, "auth_ref": [] }, "elv_AvailableForSaleSecuritiesOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "AvailableForSaleSecuritiesOtherInvestmentsAbstract", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments:", "label": "Available-for-Sale Securities, Other Investments [Abstract]", "documentation": "Available-for-Sale Securities, Other Investments" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r912" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r913" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r908" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r908" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r908" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r908" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r908" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r908" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r911" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r910" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r909" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r909" ] }, "elv_BCBSAntitrustLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "BCBSAntitrustLitigationMember", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BCBS Antitrust Litigation", "label": "BCBS Antitrust Litigation [Member]", "documentation": "BCBS Antitrust Litigation" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r140" ] }, "us-gaap_BenefitsLossesAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BenefitsLossesAndExpenses", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total expenses", "label": "Benefits, Losses and Expenses", "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs." } } }, "auth_ref": [ "r172" ] }, "us-gaap_BenefitsLossesAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BenefitsLossesAndExpensesAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses", "label": "Benefits, Losses and Expenses [Abstract]" } } }, "auth_ref": [] }, "elv_BioPlusParentLLCAndSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "BioPlusParentLLCAndSubsidiariesMember", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BioPlus Parent, LLC and Subsidiaries", "label": "BioPlus Parent, LLC and Subsidiaries [Member]", "documentation": "BioPlus Parent, LLC and Subsidiaries" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r497", "r825", "r826" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r83", "r84", "r497", "r825", "r826" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r497" ] }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement period adjustments", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete." } } }, "auth_ref": [ "r87" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r85", "r86" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations [Abstract]", "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "elv_CarelonRxSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "CarelonRxSegmentMember", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CarelonRx", "label": "CarelonRx Segment [Member]", "documentation": "CarelonRx Segment [Member]" } } }, "auth_ref": [] }, "elv_CarelonServicesSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "CarelonServicesSegmentMember", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carelon Services", "label": "Carelon Services Segment [Member]", "documentation": "Carelon Services Segment" } } }, "auth_ref": [] }, "elv_CarelonTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "CarelonTotalMember", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carelon Total", "label": "Carelon Total [Member]", "documentation": "Carelon Total" } } }, "auth_ref": [] }, "elv_CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "CarryingAndFairValuesByLevelOfFinancialInstrumentsNotRecordedAtFairValueOnConsolidatedBalanceSheetTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/FairValueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Fair Value by Level", "label": "Carrying And Fair Values By Level Of Financial Instruments Not Recorded At Fair Value On Consolidated Balance Sheet [Table Text Block]", "documentation": "-- None. No documentation exists for this element. --" } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reported Value Measurement", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r104", "r105" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r54", "r197", "r805" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r56" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r54", "r137", "r237" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r137" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashMember", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": [ "r197" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r888" ] }, "elv_Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Change in non-credit component of impairment losses on investments", "label": "Change in non-credit component of impairment losses on investments net of tax", "documentation": "Change in non-credit component of impairment losses on investments, net of tax effect." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClaimsDevelopmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClaimsDevelopmentLineItems", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Claims Development [Line Items]", "label": "Claims Development [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Class of Stock Disclosures [Abstract]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r889" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r889" ] }, "us-gaap_CommercialMortgageBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialMortgageBackedSecuritiesMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial mortgage-backed securities", "label": "Commercial Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by commercial real estate mortgage loans." } } }, "auth_ref": [ "r966", "r972", "r973", "r997" ] }, "us-gaap_CommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaper", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper", "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days." } } }, "auth_ref": [ "r114", "r160", "r1010" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r144", "r837", "r838", "r839", "r840" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies \u2013 Note 11", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r41", "r110", "r596", "r675" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r142", "r379", "r380", "r801", "r987" ] }, "elv_CommonEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "CommonEquitySecuritiesMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common equity securities", "label": "Common Equity Securities [Member]", "documentation": "Common Equity Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash Dividend per Share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r148" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Dividends per share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r148" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r833", "r834", "r835", "r837", "r838", "r839", "r840", "r950", "r951", "r1000", "r1022", "r1025" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r119" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r119", "r676" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r119" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r19", "r119", "r676", "r695", "r1025", "r1026" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value $0.01, shares authorized \u2013 900,000,000; shares issued and outstanding \u2013 232,544,717 and 233,071,088", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r119", "r598", "r829" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r894" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r893" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r895" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r892" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r46", "r221", "r223", "r230", "r582", "r614" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r125", "r229", "r581", "r610" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r244", "r277", "r288", "r289", "r290", "r291", "r292", "r294", "r298", "r385", "r386", "r387", "r388", "r390", "r391", "r393", "r395", "r396", "r994", "r995" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r244", "r277", "r288", "r289", "r290", "r291", "r292", "r294", "r298", "r385", "r386", "r387", "r388", "r390", "r391", "r393", "r395", "r396", "r994", "r995" ] }, "us-gaap_CorporateAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateAndOtherMember", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate & Other", "label": "Corporate and Other [Member]", "documentation": "Component of an entity that provides financial and operational oversight and administrative support for other segments and other segments not separately reported due to size or nature of business activities. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r954" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r822", "r824", "r1021" ] }, "elv_CorporateOtherSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "CorporateOtherSegmentMember", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate & Other", "label": "Corporate & Other Segment [Member]", "documentation": "Corporate & Other Segment" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r130", "r578" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt:", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.elevancehealth.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r143", "r238", "r398", "r404", "r405", "r406", "r407", "r408", "r409", "r414", "r421", "r422", "r424" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r31", "r116", "r117", "r161", "r163", "r244", "r399", "r400", "r401", "r402", "r403", "r405", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r544", "r815", "r816", "r817", "r818", "r819", "r947" ] }, "elv_DebtInstrumentCovenantDebtToCapitalRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "DebtInstrumentCovenantDebtToCapitalRatio", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant, debt-to-capital ratio (not more than)", "label": "Debt Instrument, Covenant, Debt-to-Capital Ratio", "documentation": "Debt Instrument, Covenant, Debt-to-Capital Ratio" } } }, "auth_ref": [] }, "elv_DebtInstrumentDebtToCapitalRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "DebtInstrumentDebtToCapitalRatio", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt-to-capital ratio", "label": "Debt Instrument, Debt-to-Capital Ratio", "documentation": "Debt Instrument, Debt-to-Capital Ratio" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r244", "r399", "r400", "r401", "r402", "r403", "r405", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r544", "r815", "r816", "r817", "r818", "r819", "r947" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r39", "r244", "r399", "r400", "r401", "r402", "r403", "r405", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r544", "r815", "r816", "r817", "r818", "r819", "r947" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r39", "r73", "r74", "r106", "r107", "r109", "r111", "r146", "r147", "r244", "r399", "r400", "r401", "r402", "r403", "r405", "r410", "r411", "r412", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r544", "r815", "r816", "r817", "r818", "r819", "r947" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior revolving credit facility term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentsAbstract", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instruments [Abstract]", "label": "Debt Instruments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Allowance For Credit Losses", "terseLabel": "Allowance for credit losses", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r311", "r348", "r353", "r354" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed maturities, allowance for credit loss, current", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r348" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNoncurrent", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed maturities, allowance for credit Loss, noncurrent", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Noncurrent", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r348" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed maturities, amortized cost, current", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r348", "r964" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed maturities, amortized cost, noncurrent", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r348", "r964" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated fair value, 12 months or greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r179", "r350", "r813" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross unrealized loss, 12 months or greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r179", "r350" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities, 12 months or greater", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r983" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated fair value, less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r179", "r350", "r813" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross unrealized loss, less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r179", "r350" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities, less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r983" ] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross realized gains from sales", "label": "Debt Securities, Available-for-Sale, Realized Gain", "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r338" ] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net realized losses from sales of fixed maturity securities", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r974" ] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross realized losses from sales", "label": "Debt Securities, Available-for-Sale, Realized Loss", "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r338" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale Securities", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r13", "r151", "r184", "r490", "r491", "r949" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities, net", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r479", "r480", "r595" ] }, "us-gaap_DepositsReceivedForSecuritiesLoanedAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsReceivedForSecuritiesLoanedAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collateral received for securities loaned, at carrying value", "label": "Deposits Received for Securities Loaned, at Carrying Value", "documentation": "Amount of obligation to return cash received as collateral for security loaned to another party." } } }, "auth_ref": [ "r176" ] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Amortization and Accretion, Net", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives - other assets", "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset." } } }, "auth_ref": [ "r209", "r770", "r771", "r807" ] }, "us-gaap_DerivativeGainOnDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainOnDerivative", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized gain on hedging derivatives", "label": "Derivative, Gain on Derivative", "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r506" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Financial Instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r155", "r507", "r514" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r20", "r97", "r99" ] }, "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Derivatives - other liabilities", "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset." } } }, "auth_ref": [ "r209", "r770", "r771", "r807" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r514" ] }, "us-gaap_DerivativeLossOnDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLossOnDerivative", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized loss on hedging derivatives", "label": "Derivative, Loss on Derivative", "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r506" ] }, "us-gaap_DerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "label": "Derivative [Member]", "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)." } } }, "auth_ref": [ "r156" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r20", "r92", "r93", "r94", "r96", "r98", "r99", "r100", "r101", "r102", "r514" ] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends and dividend equivalents", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r9", "r148" ] }, "us-gaap_DividendsDeclaredTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsDeclaredTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Cash Dividend Activity", "label": "Dividends Declared [Table Text Block]", "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends." } } }, "auth_ref": [] }, "us-gaap_DividendsPayableAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableAmountPerShare", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable (in dollars per share)", "label": "Dividends Payable, Amount Per Share", "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date." } } }, "auth_ref": [ "r57" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r850" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r883" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Shareholders\u2019 net income per share", "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r231", "r250", "r251", "r252", "r253", "r254", "r259", "r261", "r263", "r264", "r265", "r269", "r517", "r518", "r583", "r615", "r810" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r231", "r250", "r251", "r252", "r253", "r254", "r261", "r263", "r264", "r265", "r269", "r517", "r518", "r583", "r615", "r810" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Earnings per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r258", "r266", "r267", "r268" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r534" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r482" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Termination", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r848" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r848" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r848" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r922" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r848" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r848" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r848" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r848" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r19", "r191", "r224", "r225", "r226", "r245", "r246", "r247", "r249", "r255", "r257", "r270", "r341", "r342", "r440", "r475", "r476", "r477", "r486", "r487", "r508", "r509", "r510", "r511", "r512", "r513", "r516", "r535", "r537", "r538", "r539", "r540", "r541", "r545", "r643", "r644", "r645", "r661", "r716" ] }, "elv_EquitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "EquitySecurities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities:", "label": "Equity Securities", "documentation": "Fair value of investments in equity securities." } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r202", "r529", "r806" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gains (losses) on equity securities", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r619", "r978" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net realized losses recognized on equity securities sold during the period", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r617", "r978" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) recognized on equity securities still held at the end of the period", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r618", "r978" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities:", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r66", "r841", "r842", "r843", "r1027" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r891" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r855", "r866", "r876", "r901" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r852", "r863", "r873", "r898" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate of Fair Value Measurement", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r412", "r531", "r816", "r817" ] }, "us-gaap_ExchangeTradedFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExchangeTradedFundsMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange traded funds", "label": "Exchange Traded Funds [Member]", "documentation": "Investment that follows an index, commodity or basket of assets that trades similar to a stock on an exchange." } } }, "auth_ref": [ "r997", "r1001" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r897" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r520", "r521", "r525" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r520", "r521", "r525" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r412", "r443", "r444", "r445", "r446", "r447", "r448", "r521", "r550", "r551", "r552", "r816", "r817", "r822", "r823", "r824" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r29", "r103", "r412", "r816", "r817" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r520", "r521", "r522", "r523", "r526" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.elevancehealth.com/role/FairValue" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r519" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level I", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r412", "r443", "r448", "r521", "r550", "r822", "r823", "r824" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level II", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r412", "r443", "r448", "r521", "r551", "r816", "r817", "r822", "r823", "r824" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a0III", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r412", "r443", "r444", "r445", "r446", "r447", "r448", "r521", "r552", "r816", "r817", "r822", "r823", "r824" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r412", "r443", "r444", "r445", "r446", "r447", "r448", "r550", "r551", "r552", "r816", "r817", "r822", "r823", "r824" ] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Nonrecurring", "label": "Fair Value, Nonrecurring [Member]", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } }, "auth_ref": [ "r520", "r521", "r522", "r523", "r524", "r526" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r519", "r526" ] }, "us-gaap_FederalHomeLoanBankAdvancesMaturitiesSummaryDueInNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalHomeLoanBankAdvancesMaturitiesSummaryDueInNextRollingTwelveMonths", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Short-term borrowings from the FHLB", "label": "Federal Home Loan Bank, Advances, Maturities Summary, Due in Next Rolling 12 Months", "documentation": "Amount of advances from Federal Home Loan Bank (FHLBank) maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date." } } }, "auth_ref": [] }, "us-gaap_FederalHomeLoanBankAdvancesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalHomeLoanBankAdvancesMember", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal Home Loan Bank Advances", "label": "Federal Home Loan Bank Advances [Member]", "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans." } } }, "auth_ref": [ "r166" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r343", "r344", "r345", "r346", "r347", "r349", "r351", "r352", "r423", "r438", "r514", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r611", "r813", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r974", "r975", "r976", "r977" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total liabilities", "label": "Financial Liabilities Fair Value Disclosure", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [] }, "us-gaap_FixedMaturitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FixedMaturitiesMember", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed maturity securities:", "label": "Fixed Maturities [Member]", "documentation": "This element provides types of investments that may be contained within the fixed maturity category which are securities having a stated final repayment date. Examples of items within this category may include bonds, including convertibles and bonds with warrants, and redeemable preferred stocks." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r533" ] }, "us-gaap_ForeignGovernmentDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignGovernmentDebtMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign government securities", "label": "Foreign Government Debt [Member]", "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity." } } }, "auth_ref": [ "r963", "r971" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r859", "r870", "r880", "r905" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r859", "r870", "r880", "r905" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r859", "r870", "r880", "r905" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r859", "r870", "r880", "r905" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r859", "r870", "r880", "r905" ] }, "us-gaap_GainContingenciesByNatureAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainContingenciesByNatureAxis", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain Contingency, Nature [Axis]", "label": "Gain Contingencies, Nature [Axis]", "documentation": "Information by nature of gain contingency." } } }, "auth_ref": [ "r993" ] }, "us-gaap_GainContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainContingencyNatureDomain", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain Contingency, Nature [Domain]", "label": "Gain Contingency, Nature [Domain]", "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization." } } }, "auth_ref": [ "r993" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Net losses on financial instruments", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r133", "r923" ] }, "us-gaap_GainLossOnInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestmentsTextBlock", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Investment (Losses) and Gains", "label": "Gain (Loss) on Securities [Table Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": [ "r941", "r942" ] }, "us-gaap_GainLossOnSaleOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfOtherInvestments", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (losses) gains on other investments", "label": "Gain (Loss) on Sale of Other Investments", "documentation": "Amount of gain (loss) included in earnings for investments classified as other." } } }, "auth_ref": [ "r13" ] }, "elv_GainsFromOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "GainsFromOtherInvestments", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross gains", "label": "Gains From Other Investments", "documentation": "Gains From Other Investments" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails", "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r199", "r355", "r579", "r814", "r829", "r984", "r985" ] }, "elv_GrossLossesFromOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "GrossLossesFromOtherInvestments", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross losses", "label": "Gross Losses From Other Investments", "documentation": "Gross Losses From Other Investments" } } }, "auth_ref": [] }, "elv_HealthBenefitsSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "HealthBenefitsSegmentMember", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Health Benefits", "label": "Health Benefits Segment [Member]", "documentation": "Health Benefits Segment" } } }, "auth_ref": [] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.elevancehealth.com/role/DerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r20" ] }, "elv_Impairmentlossesreversalsoninvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "Impairmentlossesreversalsoninvestments", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment losses recognized in income", "label": "Impairment (losses) reversals on investments", "documentation": "Total impairment (losses) reversals on investments, before considering whether or not such amount is recognized in earnings or other comprehensive income." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationofIncomeBeforeIncomeTaxExpensetoReportableSegmentsOperatingGainIncludedintheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income tax expense", "terseLabel": "Income before income tax expense", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r127", "r168", "r275", "r289", "r295", "r298", "r584", "r606", "r812" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in net losses of other invested assets", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r13", "r128", "r167", "r282", "r339", "r605" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r241", "r478", "r483", "r484", "r485", "r488", "r492", "r495", "r496", "r658" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r181", "r185", "r256", "r257", "r283", "r481", "r489", "r620" ] }, "us-gaap_IncomeTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReceivable", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes receivable", "label": "Income Taxes Receivable", "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable." } } }, "auth_ref": [ "r936" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and other liabilities", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other." } } }, "auth_ref": [ "r946" ] }, "us-gaap_IncreaseDecreaseInCollateralHeldUnderSecuritiesLending": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInCollateralHeldUnderSecuritiesLending", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in securities lending collateral", "label": "Increase (Decrease) in Collateral Held under Securities Lending", "documentation": "The increase (decrease) during the period in the carrying amount of assets, which may include but are not limited to cash and investments, received as collateral pertaining to securities loaned to a counterparty to the transaction. Includes the change during the period in any unrealized gain or loss on such investments." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Unearned income", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r802" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable", "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes." } } }, "auth_ref": [ "r946" ] }, "us-gaap_IncreaseDecreaseInInsuranceLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInsuranceLiabilities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Policy liabilities", "label": "Increase (Decrease) in Insurance Liabilities", "documentation": "The increase (decrease) in insurance liability balances during the period." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInOutstandingChecksFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOutstandingChecksFinancingActivities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in bank overdrafts", "label": "Increase (Decrease) in Outstanding Checks, Financing Activities", "documentation": "The change in cash during the period due to the net increase or decrease in outstanding checks, the liability that represents checks that have been issued but that have not cleared. The entity may classify these cash flows as financing or operating activities." } } }, "auth_ref": [ "r14", "r55" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Receivables, net", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInSecuritiesLendingPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInSecuritiesLendingPayable", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in securities lending payable", "label": "Increase (Decrease) in Securities Lending Payable", "documentation": "The increase (decrease) during the period in the carrying amount of the liability pertaining to obligations to return collateral that the entity received when it loaned securities to the counterparty to the transaction." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTradingSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTradingSecurities", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other invested assets", "label": "Increase (Decrease) in Debt Securities, Trading, and Equity Securities, FV-NI", "documentation": "Amount of increase (decrease) of investment in debt and equity securities, measured at fair value with changes in fair value recognized in net income." } } }, "auth_ref": [ "r12", "r53" ] }, "elv_IncreaseInStockRepurchaseProgramAuthorization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "IncreaseInStockRepurchaseProgramAuthorization", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in amount of stock authorized in the Stock Repurchase Program", "label": "Increase In Stock Repurchase Program Authorization", "documentation": "The amount of an increase authorized by an entity's Board of Directors to a previously authorized stock repurchase program." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r862", "r870", "r880", "r897", "r905", "r909", "r917" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r915" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r851", "r921" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r851", "r921" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r851", "r921" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r68", "r70" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationofIncomeBeforeIncomeTaxExpensetoReportableSegmentsOperatingGainIncludedintheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r108", "r170", "r227", "r279", "r543", "r700", "r844", "r1024" ] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntersegmentEliminationMember", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eliminations", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r277", "r288", "r289", "r290", "r291", "r292", "r294", "r298" ] }, "elv_InvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "InvestmentGainsLosses", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net losses on investments", "label": "Investment Gains (Losses)", "documentation": "Investment Gains (Losses)" } } }, "auth_ref": [] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r616", "r651", "r652", "r653", "r654", "r741", "r743" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r663", "r664", "r665", "r666", "r667", "r721", "r730", "r745", "r753", "r766", "r772", "r773", "r789", "r793", "r794", "r795", "r796", "r835" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r663", "r664", "r665", "r666", "r667", "r721", "r730", "r745", "r753", "r766", "r772", "r773", "r789", "r793", "r794", "r795", "r796", "r835" ] }, "us-gaap_InvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments [Abstract]", "label": "Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amortized Cost and Fair Value of Fixed Maturity Securities, By Contractual Maturity", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.elevancehealth.com/role/Investments" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r157", "r171", "r177", "r190", "r304", "r307", "r527", "r528" ] }, "elv_InvestmentsinequitysecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "InvestmentsinequitysecuritiesTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Marketable Equity Securitites", "label": "Investments in equity securities [Table Text Block]", "documentation": "Investments in equity securities [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r36", "r240", "r340", "r385", "r386", "r388", "r389", "r390", "r392", "r394", "r396", "r397", "r500", "r504", "r505", "r532", "r674", "r811", "r846", "r994", "r1005", "r1006" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r124", "r165", "r602", "r829", "r948", "r979", "r1002" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r38", "r196", "r240", "r340", "r385", "r386", "r388", "r389", "r390", "r392", "r394", "r396", "r397", "r500", "r504", "r505", "r532", "r829", "r994", "r1005", "r1006" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Medical claims payable", "terseLabel": "Gross medical claims payable, end of period", "label": "Liability for Claims and Claims Adjustment Expense", "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date." } } }, "auth_ref": [ "r112", "r175" ] }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseAbstract", "lang": { "en-us": { "role": { "terseLabel": "Liability for Claims and Claims Adjustment Expense [Abstract]", "label": "Liability for Claims and Claims Adjustment Expense [Abstract]" } } }, "auth_ref": [] }, "elv_LiabilityForClaimsAndClaimsAdjustmentExpenseCededMedicalClaimsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseCededMedicalClaimsPayable", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ceded medical claims payable, end of period", "label": "Liability for Claims and Claims Adjustment Expense, Ceded Medical Claims Payable", "documentation": "Liability for Claims and Claims Adjustment Expense, Ceded Medical Claims Payable" } } }, "auth_ref": [] }, "elv_LiabilityForClaimsAndClaimsAdjustmentExpenseOtherInsuranceLines": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseOtherInsuranceLines", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance lines other than short duration", "label": "Liability for Claims and Claims Adjustment Expense, Other Insurance Lines", "documentation": "Liability for Claims and Claims Adjustment Expense, Other Insurance Lines" } } }, "auth_ref": [] }, "us-gaap_LiabilityForFuturePolicyBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefits", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves for future policy benefits", "label": "Liability for Future Policy Benefit, before Reinsurance", "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract." } } }, "auth_ref": [ "r641", "r642", "r646", "r831", "r1009" ] }, "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayable" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Claims Payable", "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]", "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments." } } }, "auth_ref": [ "r638" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net payments attributable to:", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails": { "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current period medical claims", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs." } } }, "auth_ref": [ "r24" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails": { "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior periods medical claims", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years", "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs." } } }, "auth_ref": [ "r24" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net incurred medical claims", "terseLabel": "Total net incurred medical claims", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process." } } }, "auth_ref": [ "r174" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net incurred medical claims:", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationoftheClaimsDevelopmenttotheClaimsLiabilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net medical claims payable, end of period", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net", "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims." } } }, "auth_ref": [ "r112", "r175", "r1009" ] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r31", "r163", "r1011" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r33" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r116", "r161" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r31", "r163", "r411", "r425", "r816", "r817", "r1011" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r203" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, less current portion", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r204" ] }, "us-gaap_LongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestmentsAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments:", "label": "Long-Term Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term purchase commitment, amount", "label": "Long-Term Purchase Commitment, Amount", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Category of Item Purchased [Axis]", "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r39" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r39", "r72" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r381", "r382", "r383", "r384", "r989", "r990" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r381", "r382", "r383", "r384", "r989", "r990" ] }, "us-gaap_LossContingencyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualPayments", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments", "label": "Loss Contingency Accrual, Payments", "documentation": "Amount of cash outflow reducing loss contingency liability." } } }, "auth_ref": [ "r988" ] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Approximate amount of damages sought for breaches", "label": "Loss Contingency, Damages Sought, Value", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": [ "r988", "r989", "r990" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r303", "r821", "r996", "r1017", "r1020" ] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesLineItems", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities [Line Items]", "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTable", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities [Table]", "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MaturityOvernightMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaturityOvernightMember", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Overnight and Continuous", "label": "Maturity Overnight [Member]", "documentation": "Maturity period of the day after the reporting date for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements." } } }, "auth_ref": [ "r242" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r889" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r889" ] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestitures" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisitions and Divestitures", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r113", "r152" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r43", "r164", "r240", "r340", "r385", "r388", "r389", "r390", "r396", "r397", "r532", "r601", "r678" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r908" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r916" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r303", "r821", "r996", "r1017", "r1020" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r890" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.elevancehealth.com/role/Organization" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r183", "r189" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r236" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r236" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r137", "r138", "r139" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Shareholders\u2019 net income", "terseLabel": "Shareholders' net income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r129", "r139", "r169", "r194", "r219", "r222", "r226", "r240", "r248", "r250", "r251", "r252", "r253", "r256", "r257", "r262", "r275", "r289", "r295", "r298", "r340", "r385", "r386", "r388", "r389", "r390", "r392", "r394", "r396", "r397", "r518", "r532", "r609", "r697", "r714", "r715", "r812", "r844", "r994" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r91", "r154", "r219", "r222", "r256", "r257", "r608", "r940" ] }, "us-gaap_NetInvestmentIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentIncome", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationofIncomeBeforeIncomeTaxExpensetoReportableSegmentsOperatingGainIncludedintheConsolidatedStatementsofIncomeDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationofReportableSegmentsOperatingRevenuestoTotalRevenuesReportedintheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net investment income", "negatedTerseLabel": "Net investment income", "label": "Net Investment Income", "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments." } } }, "auth_ref": [ "r182", "r612", "r613", "r701", "r844" ] }, "elv_NetLossesGainsOnFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "NetLossesGainsOnFinancialInstruments", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.elevancehealth.com/role/SegmentInformationReconciliationofIncomeBeforeIncomeTaxExpensetoReportableSegmentsOperatingGainIncludedintheConsolidatedStatementsofIncomeDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationofReportableSegmentsOperatingRevenuestoTotalRevenuesReportedintheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net losses on financial instruments", "terseLabel": "Net losses on financial instruments", "negatedTerseLabel": "Net losses (gains) on financial instruments", "label": "Net (losses) gains on financial instruments", "documentation": "Net (losses) gains on financial instruments" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Guidance and Recent Accounting Guidance Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r889" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r859", "r870", "r880", "r897", "r905" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r887" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r886" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r897" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r916" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r916" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r88", "r440", "r950", "r951", "r952", "r1025" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes", "label": "Notes Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r31", "r163", "r1011" ] }, "elv_NumberOfCountiesInStateOfKansasCompanyDoesNotServe": { "xbrltype": "integerItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "NumberOfCountiesInStateOfKansasCompanyDoesNotServe", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of counties in the Kansas City area the Company does not serve", "label": "Number Of Counties In State Of Kansas Company Does Not Serve", "documentation": "Number Of Counties In The State Of Kansas Company Does Not Serve" } } }, "auth_ref": [] }, "elv_NumberOfMedicalMembersServed": { "xbrltype": "decimalItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "NumberOfMedicalMembersServed", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of medical members served", "label": "Number Of Medical Members Served", "documentation": "Number of medical members served" } } }, "auth_ref": [] }, "elv_NumberOfNoticesOfAppeal": { "xbrltype": "integerItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "NumberOfNoticesOfAppeal", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of notices of appeal", "label": "Number of Notices of Appeal", "documentation": "Number of Notices of Appeal" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails", "http://www.elevancehealth.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r955" ] }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfStatesInWhichEntityOperates", "presentation": [ "http://www.elevancehealth.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states in which the Company is licensed to conduct insurance operations", "label": "Number of States in which Entity Operates", "documentation": "The number of states the entity operates in as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in future policy benefits", "label": "OCI, Liability for Future Policy Benefit, Gain (Loss), after Reclassification Adjustment and Tax", "documentation": "Amount, after tax and reclassification adjustment, of unrealized gain (loss) from (increase) decrease in liability for future policy benefit from change in discount rate." } } }, "auth_ref": [ "r215", "r216" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails", "http://www.elevancehealth.com/role/SegmentInformationReconciliationofIncomeBeforeIncomeTaxExpensetoReportableSegmentsOperatingGainIncludedintheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating gain (loss)", "terseLabel": "Reportable segments operating gain", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r275", "r289", "r295", "r298", "r812" ] }, "elv_OperatingRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "OperatingRevenue", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationReconciliationofReportableSegmentsOperatingRevenuestoTotalRevenuesReportedintheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total operating revenue", "label": "Operating Revenue", "documentation": "Revenue from insurance services and products sold." } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r288", "r289", "r290", "r291", "r292", "r298" ] }, "elv_OperationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "OperationalMember", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Damages for Operational Breaches", "label": "Operational [Member]", "documentation": "Operational [Member]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAggregatedInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAggregatedInvestmentsMember", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other asset-backed securities", "label": "Other Security Investments [Member]", "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests." } } }, "auth_ref": [ "r664", "r665", "r752" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r207", "r829" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r200" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in net unrealized losses/gains on investments", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r212", "r213", "r216" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $50 and $(85), respectively", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r30", "r45", "r225", "r535", "r538", "r541", "r938" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications, tax", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r7", "r224", "r610" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in net unrealized gains/losses on cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r211", "r216" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive (loss) income", "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r19", "r30", "r220", "r223", "r229", "r535", "r536", "r541", "r581", "r610", "r938", "r939" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income, net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other comprehensive income attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r10", "r17", "r153", "r220", "r223" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in net periodic pension and postretirement costs", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r6", "r126" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) recognized in other comprehensive income, tax (expense) benefit", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r7", "r224", "r229", "r481", "r493", "r494", "r535", "r539", "r541", "r581", "r610" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income attributable to noncontrolling interests, tax", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r10", "r17", "r153" ] }, "us-gaap_OtherDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDebtSecuritiesMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other asset-backed securities", "label": "Other Debt Obligations [Member]", "documentation": "Investments in debt securities classified as other." } } }, "auth_ref": [ "r982", "r997", "r1001" ] }, "us-gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInvestmentsMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other investments:", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other investments." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r37", "r829" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r40" ] }, "us-gaap_OtherLongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermInvestments", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 }, "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails", "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other invested assets", "label": "Other Long-Term Investments", "documentation": "Amount of long-term investments classified as other." } } }, "auth_ref": [ "r591", "r935" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r889" ] }, "us-gaap_OtherPolicyholderFunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPolicyholderFunds", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other policyholder liabilities", "label": "Other Policyholder Funds", "documentation": "Amount due to policyholders for funds held that are returnable under the terms of insurance contracts, classified as other." } } }, "auth_ref": [ "r594" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r205", "r684" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r857", "r868", "r878", "r903" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r860", "r871", "r881", "r906" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r860", "r871", "r881", "r906" ] }, "elv_ParagonHealthcareInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "ParagonHealthcareInc.Member", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paragon Healthcare, Inc.", "label": "Paragon Healthcare, Inc. [Member]", "documentation": "Paragon Healthcare, Inc." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r885" ] }, "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForLossesAndLossAdjustmentExpense", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net payments", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid", "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process." } } }, "auth_ref": [ "r11", "r24" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r924", "r943" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase and retirement of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r51" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r369", "r945" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofCashDividendActivityDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends", "terseLabel": "Total", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r51" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Taxes paid through withholding of common stock under employee stock plans", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r234" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of subsidiaries, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r49" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r135" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r136" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r888" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r888" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r887" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r897" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r890" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r886" ] }, "elv_PercentageOfTotalAssetsPresentedAtFairValue": { "xbrltype": "pureItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "PercentageOfTotalAssetsPresentedAtFairValue", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of total assets at fair value", "label": "Percentage of Total Assets Presented at Fair Value", "documentation": "Percentage of Total Assets Presented at Fair Value" } } }, "auth_ref": [] }, "elv_PharmacypricingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "PharmacypricingMember", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Damages for Pharmacy Pricing", "label": "Pharmacy pricing [Member]", "documentation": "Pharmacy pricing [Member]" } } }, "auth_ref": [] }, "us-gaap_PolicyholderBenefitsAndClaimsIncurredNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyholderBenefitsAndClaimsIncurredNet", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefit expense", "label": "Policyholder Benefits and Claims Incurred, Net", "documentation": "Amount, after effects of policies assumed or ceded, of expense related to the provision for policy benefits and costs incurred." } } }, "auth_ref": [ "r1016" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r530" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r118", "r676" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r118", "r427" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r118", "r676", "r695", "r1025", "r1026" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, without par value, shares authorized \u2013 100,000,000; shares issued and outstanding \u2013 none", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r118", "r597", "r829" ] }, "elv_PremiumsEarnedAndOtherOperatingRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "PremiumsEarnedAndOtherOperatingRevenue", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating revenue", "terseLabel": "Operating revenue", "label": "Premiums Earned and Other Operating Revenue", "documentation": "Premiums Earned and Other Operating Revenue" } } }, "auth_ref": [] }, "us-gaap_PremiumsEarnedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PremiumsEarnedNet", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "elv_PremiumsEarnedAndOtherOperatingRevenue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Premiums", "label": "Premiums Earned, Net", "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned." } } }, "auth_ref": [ "r187", "r188", "r636", "r650" ] }, "us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PremiumsReceivableAllowanceForDoubtfulAccounts", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Premium receivable, allowance for doubtful accounts", "label": "Premium Receivable, Allowance for Credit Loss", "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value." } } }, "auth_ref": [ "r926", "r957", "r980", "r981", "r1015" ] }, "us-gaap_PremiumsReceivableAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PremiumsReceivableAtCarryingValue", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Premium receivables", "label": "Premiums Receivable, Net", "documentation": "The carrying amount as of the balance sheet date due the entity from (a) agents and insureds, (b) uncollected premiums and (c) others, net of the allowance for doubtful accounts." } } }, "auth_ref": [ "r1012", "r1013", "r1014" ] }, "us-gaap_PrivateEquityFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivateEquityFundsMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private equity securities", "label": "Private Equity Funds [Member]", "documentation": "Investments held in private equity funds." } } }, "auth_ref": [ "r997" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds originally received at time of divestiture", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from long-term borrowings", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r50", "r655" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities, calls and redemptions from investments", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r232", "r233", "r962" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r925", "r944" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales, maturities, calls or redemptions of fixed maturity securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r47", "r232", "r305", "r338" ] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from short-term borrowings", "label": "Proceeds from Short-Term Debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r50" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock under employee stock plans", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r8", "r23" ] }, "elv_Proceedsfromsaleofequityandfixedmaturitysecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "Proceedsfromsaleofequityandfixedmaturitysecurities", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of investments", "label": "Proceeds from sale of equity and fixed maturity securities", "documentation": "Proceeds from sale of equity and fixed maturity securities." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r820" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and Services", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r300", "r578", "r632", "r633", "r634", "r635", "r636", "r637", "r804", "r820", "r830", "r927", "r991", "r992", "r996", "r1017" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r300", "r578", "r632", "r633", "r634", "r635", "r636", "r637", "r804", "r820", "r830", "r927", "r991", "r992", "r996", "r1017" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows", "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r194", "r219", "r222", "r235", "r240", "r248", "r256", "r257", "r275", "r289", "r295", "r298", "r340", "r385", "r386", "r388", "r389", "r390", "r392", "r394", "r396", "r397", "r498", "r501", "r502", "r518", "r532", "r584", "r607", "r660", "r697", "r714", "r715", "r812", "r827", "r828", "r845", "r940", "r994" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r15", "r590", "r604", "r829" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r885" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r885" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables", "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r956", "r958", "r959", "r960" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive loss, net of tax benefit of $(33) and $(29), respectively", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r30", "r45", "r225", "r535", "r540", "r541", "r938" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodTax", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification from AOCI, current period, tax", "label": "Reclassification from AOCI, Current Period, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r7", "r218", "r224", "r610" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Reconciliation of Income Before Income Tax Expense to Reportable Segments Operating Gain Included in the Consolidated Statements of Income", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r63", "r64" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Reconciliation of Reportable Segments Operating Revenues to Total Revenues Reported in the Consolidated Statements of Income", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r62", "r64" ] }, "elv_ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "ReconciliationofNetIncurredMedicalClaimstoBenefitExpenseTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Net Incurred Medical Claims to Benefit Expense", "label": "Reconciliation of Net Incurred Medical Claims to Benefit Expense [Table Text Block]", "documentation": "Tabular Disclosure For Reconciliation of Net Incurred Medical Claims to Benefit Expense." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r852", "r863", "r873", "r898" ] }, "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Ceded medical claims payable, beginning of period", "periodEndLabel": "Ceded medical claims payable, end of period", "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments", "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer." } } }, "auth_ref": [ "r112", "r175", "r1008", "r1018", "r1019" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of long-term borrowings", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r52", "r656" ] }, "us-gaap_ResidentialMortgageBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResidentialMortgageBackedSecuritiesMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Residential mortgage-backed securities", "label": "Residential Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by residential real estate mortgage loans." } } }, "auth_ref": [ "r963", "r966", "r971", "r972", "r973", "r997" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r853", "r864", "r874", "r899" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r854", "r865", "r875", "r900" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r861", "r872", "r882", "r907" ] }, "us-gaap_RestrictedCashAndInvestmentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndInvestmentsCurrent", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Restricted Cash and Investments, Current", "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal." } } }, "auth_ref": [ "r799", "r800", "r937" ] }, "elv_RestrictedStockUnitsContingentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "RestrictedStockUnitsContingentMember", "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units - Contingent", "label": "Restricted Stock Units - Contingent [Member]", "documentation": "Restricted Stock Units - Contingent" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiatives" ], "lang": { "en-us": { "role": { "terseLabel": "Business Optimization Initiatives", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r366", "r367", "r369", "r372", "r378" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges or releases related to employee termination costs", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r13", "r373", "r375", "r986" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Optimization Initiative Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r368", "r369", "r375", "r376" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Optimization Initiatives [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r375", "r376", "r377" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Optimization Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Optimization Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for employee termination costs", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r369", "r374" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r121", "r148", "r600", "r647", "r649", "r657", "r677", "r829" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r191", "r245", "r246", "r247", "r249", "r255", "r257", "r341", "r342", "r475", "r476", "r477", "r486", "r487", "r508", "r510", "r511", "r513", "r516", "r643", "r645", "r661", "r1025" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "elv_PremiumsEarnedAndOtherOperatingRevenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and service revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r276", "r277", "r288", "r293", "r294", "r300", "r302", "r303", "r441", "r442", "r578" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r698", "r803", "r808" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationReconciliationofReportableSegmentsOperatingRevenuestoTotalRevenuesReportedintheConsolidatedStatementsofIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r228", "r240", "r276", "r277", "r288", "r293", "r294", "r300", "r302", "r303", "r340", "r385", "r386", "r388", "r389", "r390", "r392", "r394", "r396", "r397", "r532", "r584", "r994" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r916" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r916" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Components of Accumulated Other Comprehensive Loss", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r45", "r1003", "r1004" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Current and Long-Term Investments, Available-For-Sale", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.elevancehealth.com/role/BusinessAcquisitionsandDivestituresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisitions [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r83", "r84", "r497" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator for Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r953" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r82" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/FairValueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Value Measurements by Level", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r520", "r521" ] }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Separate Account Investment [Table]", "label": "Fair Value, Separate Account Investment [Table]", "documentation": "Disclosure of information about fair value of asset supporting separate account." } } }, "auth_ref": [ "r180", "r832", "r1021" ] }, "us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementReportedAmountsSummaryLineItems", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment [Line Items]", "label": "Gain (Loss) on Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r941", "r942", "r974" ] }, "us-gaap_ScheduleOfGainLossOnInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGainLossOnInvestmentsTable", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNetInvestmentLossesandGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment [Table]", "label": "Schedule of Gain (Loss) on Securities [Table]", "documentation": "Disclosure of information about realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": [ "r941", "r942", "r974" ] }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Income [Table]", "label": "Investment Income [Table]", "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments." } } }, "auth_ref": [ "r132", "r134", "r611" ] }, "us-gaap_ScheduleOfInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInvestmentsLineItems", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Line Items]", "label": "Schedule of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r742", "r744", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792" ] }, "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Medical Claims Payable", "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]", "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims." } } }, "auth_ref": [ "r173" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Optimization Initiatives and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r375", "r376", "r377" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r59", "r60", "r61", "r67" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Data by Reportable Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r59", "r60", "r61", "r67" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r21", "r22", "r80" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted During the Periods", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r150" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Nonvested Restricted Stock Activity Including Restricted Stock Units", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfTreasuryStockByClassTextBlock", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Share Repurchases", "label": "Class of Treasury Stock [Table Text Block]", "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r75", "r76", "r77", "r78" ] }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Aggregate Fair Value and Gross Unrealized Loss of Fixed Maturity Securities in an Unrealized Loss Position", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value)." } } }, "auth_ref": [ "r178" ] }, "us-gaap_SecuritiesHeldAsCollateralAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuritiesHeldAsCollateralAtFairValue", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Securities lending collateral", "label": "Securities Held as Collateral, at Fair Value", "documentation": "The carrying amount (fair value) as of the balance sheet date of securities held that had been pledged by counterparties under financing and lending arrangements, pursuant to which the entity has the right by agreement or custom to sell or re-pledge such securities." } } }, "auth_ref": [ "r65" ] }, "elv_SecuritiesLendingTransactionsInitialCollateralPercentageValue": { "xbrltype": "percentItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "SecuritiesLendingTransactionsInitialCollateralPercentageValue", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities lending transactions, initial collateral percentage value", "label": "Securities Lending Transactions Initial Collateral Percentage Value", "documentation": "Initial minimum percentage of cash and/or securities collateral accepted as compared to the value of securities on loan in a securities lending transaction." } } }, "auth_ref": [] }, "elv_SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan": { "xbrltype": "percentItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities lending transactions ratio of fair value of collateral held to fair value of securities loaned", "label": "Securities Lending Transactions Ratio of Fair Value of Collateral Held To Securities On Loan", "documentation": "Ratio of fair value of collateral held to fair value of securities loaned in securities lending transactions." } } }, "auth_ref": [] }, "us-gaap_SecuritiesLoanedFairValueOfCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuritiesLoanedFairValueOfCollateral", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of collateral received at time of securities lending transactions", "label": "Securities Loaned, Fair Value of Collateral", "documentation": "Fair value of the securities pledged as collateral against securities loaned." } } }, "auth_ref": [ "r210" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r847" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r849" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails", "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r272", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r303", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r371", "r377", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r814", "r927", "r1017" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r271", "r272", "r273", "r274", "r275", "r287", "r292", "r296", "r297", "r298", "r299", "r300", "r301", "r303" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "elv_SelfFundedReceivablesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "SelfFundedReceivablesNet", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Self-funded receivables", "label": "Self-Funded Receivables, Net", "documentation": "The carrying amount as of the balance sheet date due the entity from self-insured customers, net of the allowance for doubtful accounts." } } }, "auth_ref": [] }, "elv_SelffundedReceivablesAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "SelffundedReceivablesAllowanceForDoubtfulAccounts", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Self-funded receivables, allowance for doubtful accounts", "label": "Self-funded Receivables, Allowance For Doubtful Accounts", "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross self-funded receivable to net realizable value." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_BenefitsLossesAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expense", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r131" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "elv_SeniorUnsecuredNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "SeniorUnsecuredNotesMember", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Notes", "label": "Senior Unsecured Notes [Member]", "documentation": "Senior Unsecured Notes [Member]" } } }, "auth_ref": [] }, "elv_ServiceFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "ServiceFeesMember", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome", "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service fees", "label": "Service Fees [Member]", "documentation": "Service Fees" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r465" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r465" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grants (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r463" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails", "http://www.elevancehealth.com/role/CapitalStockScheduleofWeightedAverageFairValuesDeterminedforthePeriodsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in dollars per share)", "terseLabel": "Restricted stock awards granted during the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r463" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in shares)", "periodEndLabel": "Nonvested at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r460", "r461" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock\u00a0Shares and Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Nonvested at beginning of period (in dollars per share)", "periodEndLabel": "Nonvested at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r460", "r461" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Grant\u00a0Date Fair\u00a0Value per\u00a0Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r464" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNonvestedRestrictedStockActivityIncludingRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r464" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringthePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r472" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringthePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility factor", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r471" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringthePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r473" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, Additional Disclosures", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r454" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r454" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited or expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r998" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Forfeited or expired (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r998" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r999" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockScheduleofWeightedAverageFairValuesDeterminedforthePeriodsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted during the period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r466" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted-Average Fair Values Determined for the Periods", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year." } } }, "auth_ref": [ "r81" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at end of period, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r79" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in shares)", "periodEndLabel": "Outstanding at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r452", "r453" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in dollars per share)", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r452", "r453" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Option\u00a0Price per\u00a0Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercisable at end of period, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r469" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails", "http://www.elevancehealth.com/role/ShareholdersEarningsperShareNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r457" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r456" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockFairValuesofOptionsGrantedDuringthePeriodEstimatedUsingWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average expected life (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r470" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at end of period, Weighted-Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r79" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding at end of period, Weighted-Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r149" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "elv_ShortDurationContractLiabilityForClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "ShortDurationContractLiabilityForClaimsAdjustmentExpense", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Gross medical claims payable, beginning of period", "periodEndLabel": "Gross medical claims payable, end of period", "label": "Short Duration Contract Liability For Claims Adjustment Expense", "documentation": "The amount needed to reflect the estimated ultimate cost of settling short duration contract claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date for short duration." } } }, "auth_ref": [] }, "us-gaap_ShortDurationInsuranceContractAccidentYear2022Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortDurationInsuranceContractAccidentYear2022Member", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022", "label": "Short-Duration Insurance Contract, Accident Year 2022 [Member]", "documentation": "Accident year 2022 in which covered event occurs under terms of short-duration insurance contract." } } }, "auth_ref": [ "r640" ] }, "us-gaap_ShortDurationInsuranceContractAccidentYear2023Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortDurationInsuranceContractAccidentYear2023Member", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Short-Duration Insurance Contract, Accident Year 2023 [Member]", "documentation": "Accident year 2023 in which covered event occurs under terms of short-duration insurance contract." } } }, "auth_ref": [ "r640" ] }, "elv_ShortDurationInsuranceContractAccidentYear2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "ShortDurationInsuranceContractAccidentYear2024Member", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Short-Duration Insurance Contract, Accident Year 2024 [Member]", "documentation": "Short-Duration Insurance Contract, Accident Year 2024" } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/FairValueScheduleofEstimatedFairValuebyLevelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term borrowings", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r115", "r161", "r829", "r1010" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortdurationInsuranceContractsAccidentYearAxis", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-duration Insurance Contracts, Claim Year [Axis]", "label": "Short-Duration Insurance Contracts, Accident Year [Axis]", "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortdurationInsuranceContractsAccidentYearDomain", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-duration Insurance Contracts, Claim Year [Domain]", "label": "Short-Duration Insurance Contracts, Accident Year [Domain]", "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-duration Insurance Contracts, Claims Development [Table]", "label": "Short-Duration Insurance Contracts, Claims Development [Table]", "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortdurationInsuranceContractsIncurredButNotReportedIbnrClaimsLiabilityNet", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net incurred but not reported liabilities plus expected development on reported claims", "label": "Short-Duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net", "documentation": "Undiscounted amount, after reinsurance, of incurred-but-not-reported (IBNR) liabilities plus expected development on reported claims, for claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Short Duration Medical Claims Payable to the Consolidated Medical Claims Payable", "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]", "documentation": "Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts." } } }, "auth_ref": [ "r26" ] }, "elv_ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Net medical claims payable, beginning of period", "periodEndLabel": "Net medical claims payable, end of period", "label": "Short duration contract liability for unpaid claims and adjustment expense, Net", "documentation": "Short duration contract liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for short duration contract claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid short duration contract claims." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails", "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r193", "r272", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r303", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r371", "r377", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r814", "r927", "r1017" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossParentheticalDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement, Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r19", "r42", "r191", "r224", "r225", "r226", "r245", "r246", "r247", "r249", "r255", "r257", "r270", "r341", "r342", "r440", "r475", "r476", "r477", "r486", "r487", "r508", "r509", "r510", "r511", "r512", "r513", "r516", "r535", "r537", "r538", "r539", "r540", "r541", "r545", "r643", "r644", "r645", "r661", "r716" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r245", "r246", "r247", "r270", "r578", "r651", "r662", "r668", "r669", "r670", "r671", "r672", "r673", "r676", "r679", "r680", "r681", "r682", "r683", "r685", "r686", "r687", "r688", "r690", "r691", "r692", "r693", "r694", "r696", "r698", "r699", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r716", "r836" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.elevancehealth.com/role/ConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r245", "r246", "r247", "r270", "r578", "r651", "r662", "r668", "r669", "r670", "r671", "r672", "r673", "r676", "r679", "r680", "r681", "r682", "r683", "r685", "r686", "r687", "r688", "r690", "r691", "r692", "r693", "r694", "r696", "r698", "r699", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r716", "r836" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r856", "r867", "r877", "r902" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock plans, net of related tax benefits (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r19", "r118", "r119", "r148" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r19", "r118", "r119", "r148", "r457" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock plans, net of related tax benefits", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r19", "r42", "r148" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorization remaining at the end of the period", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails", "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase and retirement of common stock, including excise tax (in shares)", "terseLabel": "Shares repurchased (in shares)", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r19", "r118", "r119", "r148" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate cost", "label": "Stock Repurchased and Retired During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r19", "r118", "r119", "r148" ] }, "elv_StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "StockRepurchasedAndRetiredDuringPeriodValueIncludingExciseTax", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase and retirement of common stock, including excise tax", "label": "Stock Repurchased And Retired During Period, Value, Including Excise Tax", "documentation": "Stock Repurchased And Retired During Period, Value, Including Excise Tax" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r119", "r122", "r123", "r141", "r678", "r695", "r717", "r718", "r829", "r846", "r948", "r979", "r1002", "r1025" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/AccumulatedOtherComprehensiveLossIncomeReconciliationoftheComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets", "http://www.elevancehealth.com/role/ConsolidatedStatementsofChangesinEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r88", "r89", "r90", "r191", "r192", "r225", "r245", "r246", "r247", "r249", "r255", "r341", "r342", "r440", "r475", "r476", "r477", "r486", "r487", "r508", "r509", "r510", "r511", "r512", "r513", "r516", "r535", "r537", "r541", "r545", "r644", "r645", "r659", "r678", "r695", "r717", "r718", "r797", "r845", "r948", "r979", "r1002", "r1025" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.elevancehealth.com/role/CapitalStock" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r145", "r239", "r426", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r515", "r719", "r720", "r798" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r542", "r546" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r542", "r546" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r542", "r546" ] }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current period", "label": "Current Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs." } } }, "auth_ref": [ "r639" ] }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense", "crdr": "debit", "calculation": { "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails": { "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofMedicalClaimsPayableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prior periods redundancies", "label": "Prior Year Claims and Claims Adjustment Expense", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs." } } }, "auth_ref": [ "r639" ] }, "us-gaap_SupplementaryInsuranceInformationOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementaryInsuranceInformationOtherOperatingExpense", "crdr": "debit", "presentation": [ "http://www.elevancehealth.com/role/MedicalClaimsPayableReconciliationofNetIncurredMedicalClaimstoBenefitExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quality improvement and other claims expense", "label": "SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense", "documentation": "Amount of operating expense classified as other, disclosed in supplementary insurance information." } } }, "auth_ref": [ "r630" ] }, "elv_SurplusNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "SurplusNotesMember", "presentation": [ "http://www.elevancehealth.com/role/DebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surplus Notes", "label": "Surplus Notes [Member]", "documentation": "Surplus Notes [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r896" ] }, "elv_TechnologyInfrastructureAndRelatedManagementAndSupportServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "TechnologyInfrastructureAndRelatedManagementAndSupportServicesMember", "presentation": [ "http://www.elevancehealth.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology Infrastructure and Related Management and Support Services", "label": "Technology Infrastructure and Related Management and Support Services [Member]", "documentation": "Technology Infrastructure and Related Management and Support Services" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r888" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r895" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r915" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r917" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.elevancehealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentEquitySecuritiesDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "verboseLabel": "Major Types of Fixed Maturity Securities [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r423", "r438", "r514", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r611", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r974", "r975", "r976", "r977" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r918" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r919" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r917" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r917" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r920" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r918" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.elevancehealth.com/role/CapitalStockSummaryofShareRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average price per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r75" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.elevancehealth.com/role/BusinessOptimizationInitiativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Business Optimization Initiative [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r368", "r369", "r375", "r376" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States Government securities", "verboseLabel": "United States Government securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r809", "r822", "r1007" ] }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government sponsored securities", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)." } } }, "auth_ref": [ "r997", "r1007" ] }, "us-gaap_USStatesAndPoliticalSubdivisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USStatesAndPoliticalSubdivisionsMember", "presentation": [ "http://www.elevancehealth.com/role/FairValueSummaryofFairValueMeasurementsbyLevelDetails", "http://www.elevancehealth.com/role/InvestmentsAggregateFairValueandGrossUnrealizedLossofFixedMaturitySecuritiesinanUnrealizedLossPositionDetails", "http://www.elevancehealth.com/role/InvestmentsCurrentandLongTermFixedMaturitySecuritiesAvailableForSaleDetails", "http://www.elevancehealth.com/role/InvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "States, municipalities and political subdivisions, tax-exempt", "label": "US States and Political Subdivisions Debt Securities [Member]", "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments." } } }, "auth_ref": [ "r822", "r1021" ] }, "elv_UnaffiliatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.elevancehealth.com/20240331", "localname": "UnaffiliatedMember", "presentation": [ "http://www.elevancehealth.com/role/SegmentInformationFinancialDatabyReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating revenue - unaffiliated", "label": "Unaffiliated [Member]", "documentation": "Unaffiliated [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r914" ] }, "us-gaap_UnearnedPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnearnedPremiums", "crdr": "credit", "calculation": { "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Unearned income", "label": "Unearned Premiums", "documentation": "Carrying amount of premiums written on insurance contracts that have not been earned as of the balance sheet date." } } }, "auth_ref": [ "r186" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.elevancehealth.com/role/ShareholdersEarningsperShareDenominatorforBasicandDilutedEarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShareDenominatorforBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities \u2013 employee stock options, nonvested restricted stock awards and convertible debentures", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r953" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.elevancehealth.com/role/ShareholdersEarningsperShareDenominatorforBasicandDilutedEarningsperShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShareDenominatorforBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Denominator for diluted shareholders' earnings per share", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r260", "r265" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.elevancehealth.com/role/ShareholdersEarningsperShareDenominatorforBasicandDilutedEarningsperShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.elevancehealth.com/role/ShareholdersEarningsperShareDenominatorforBasicandDilutedEarningsperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator for basic shareholders' earnings per share - weighted-average shares", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r259", "r265" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i),(j),(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i-k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "80", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4C" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4D" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4E" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-8" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-5" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-4A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.13(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04.5,6,7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "944", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479808/944-20-55-15" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "220", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(13)(a)(2))", "SubTopic": "210", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(1))", "SubTopic": "220", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(c))", "SubTopic": "220", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-12" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//420/tableOfContent" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-11" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//944-40/tableOfContent" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29E" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480078/944-80-55-17" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r923": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-5" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479616/944-310-45-6" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" } } } ZIP 91 0001156039-24-000066-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001156039-24-000066-xbrl.zip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�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end XML 93 elv-20240331_htm.xml IDEA: XBRL DOCUMENT 0001156039 2024-01-01 2024-03-31 0001156039 2024-04-10 0001156039 2024-03-31 0001156039 2023-12-31 0001156039 2023-01-01 2023-03-31 0001156039 us-gaap:ProductMember 2024-01-01 2024-03-31 0001156039 us-gaap:ProductMember 2023-01-01 2023-03-31 0001156039 elv:ServiceFeesMember 2024-01-01 2024-03-31 0001156039 elv:ServiceFeesMember 2023-01-01 2023-03-31 0001156039 2022-12-31 0001156039 2023-03-31 0001156039 us-gaap:CommonStockMember 2023-12-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001156039 us-gaap:RetainedEarningsMember 2023-12-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001156039 us-gaap:NoncontrollingInterestMember 2023-12-31 0001156039 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001156039 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001156039 us-gaap:CommonStockMember 2024-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001156039 us-gaap:RetainedEarningsMember 2024-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2024-03-31 0001156039 us-gaap:CommonStockMember 2022-12-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001156039 us-gaap:RetainedEarningsMember 2022-12-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001156039 us-gaap:NoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001156039 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001156039 us-gaap:CommonStockMember 2023-03-31 0001156039 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001156039 us-gaap:RetainedEarningsMember 2023-03-31 0001156039 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001156039 us-gaap:NoncontrollingInterestMember 2023-03-31 0001156039 elv:ParagonHealthcareInc.Member 2024-03-31 0001156039 elv:BioPlusParentLLCAndSubsidiariesMember 2024-03-31 0001156039 elv:BioPlusParentLLCAndSubsidiariesMember 2024-01-01 2024-03-31 0001156039 us-gaap:EmployeeSeveranceMember elv:A20232024BusinessEfficiencyProgramMember elv:CorporateOtherSegmentMember 2024-03-31 0001156039 us-gaap:EmployeeSeveranceMember elv:A20232024BusinessEfficiencyProgramMember elv:CorporateOtherSegmentMember 2023-12-31 0001156039 us-gaap:EmployeeSeveranceMember elv:A20232024BusinessEfficiencyProgramMember elv:CorporateOtherSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:ForeignGovernmentDebtMember 2024-03-31 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-03-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember 2024-03-31 0001156039 us-gaap:OtherAggregatedInvestmentsMember 2024-03-31 0001156039 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:ForeignGovernmentDebtMember 2023-12-31 0001156039 us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001156039 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0001156039 us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0001156039 us-gaap:OtherAggregatedInvestmentsMember 2023-12-31 0001156039 us-gaap:ExchangeTradedFundsMember 2024-03-31 0001156039 us-gaap:ExchangeTradedFundsMember 2023-12-31 0001156039 elv:CommonEquitySecuritiesMember 2024-03-31 0001156039 elv:CommonEquitySecuritiesMember 2023-12-31 0001156039 us-gaap:PrivateEquityFundsMember 2024-03-31 0001156039 us-gaap:PrivateEquityFundsMember 2023-12-31 0001156039 us-gaap:FixedMaturitiesMember 2024-01-01 2024-03-31 0001156039 us-gaap:FixedMaturitiesMember 2023-01-01 2023-03-31 0001156039 us-gaap:EquitySecuritiesMember 2024-01-01 2024-03-31 0001156039 us-gaap:EquitySecuritiesMember 2023-01-01 2023-03-31 0001156039 us-gaap:OtherInvestmentsMember 2024-01-01 2024-03-31 0001156039 us-gaap:OtherInvestmentsMember 2023-01-01 2023-03-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:CashMember 2024-03-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:CashMember 2023-12-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0001156039 us-gaap:MaturityOvernightMember us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0001156039 us-gaap:CashFlowHedgingMember 2024-03-31 0001156039 us-gaap:CashFlowHedgingMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialMortgageBackedSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialMortgageBackedSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialMortgageBackedSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:OtherDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:OtherDebtSecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:EquitySecuritiesMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2024-03-31 0001156039 elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2024-03-31 0001156039 us-gaap:DerivativeMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignGovernmentDebtMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignGovernmentDebtMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignGovernmentDebtMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:USStatesAndPoliticalSubdivisionsMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ResidentialMortgageBackedSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:CommercialMortgageBackedSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:OtherDebtSecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:ExchangeTradedFundsMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 elv:CommonEquitySecuritiesMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:PrivateEquityFundsMember us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:EquitySecuritiesMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2023-12-31 0001156039 elv:CommonEquitySecuritiesMember us-gaap:OtherInvestmentsMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeMember 2023-12-31 0001156039 us-gaap:DerivativeMember 2023-12-31 0001156039 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001156039 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001156039 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-03-31 0001156039 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsNonrecurringMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001156039 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001156039 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2022Member 2024-03-31 0001156039 us-gaap:ShortDurationInsuranceContractAccidentYear2023Member 2024-03-31 0001156039 elv:ShortDurationInsuranceContractAccidentYear2024Member 2024-03-31 0001156039 elv:SeniorUnsecuredNotesMember us-gaap:SeniorNotesMember 2024-03-31 0001156039 elv:SeniorUnsecuredNotesMember us-gaap:SeniorNotesMember 2023-12-31 0001156039 elv:SurplusNotesMember 2024-03-31 0001156039 elv:SurplusNotesMember 2023-12-31 0001156039 us-gaap:RevolvingCreditFacilityMember elv:A5YearFacilityMember us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001156039 us-gaap:RevolvingCreditFacilityMember elv:A5YearFacilityMember us-gaap:LineOfCreditMember 2024-03-31 0001156039 us-gaap:RevolvingCreditFacilityMember elv:A5YearFacilityMember us-gaap:LineOfCreditMember 2023-12-31 0001156039 us-gaap:CommercialPaperMember 2024-03-31 0001156039 us-gaap:CommercialPaperMember 2023-12-31 0001156039 us-gaap:FederalHomeLoanBankAdvancesMember 2024-03-31 0001156039 us-gaap:FederalHomeLoanBankAdvancesMember 2023-12-31 0001156039 2022-09-01 2022-09-30 0001156039 elv:BCBSAntitrustLitigationMember 2022-09-01 2022-09-30 0001156039 2022-09-30 0001156039 elv:AnthemInc.v.ExpressScriptsInc.Member elv:PharmacypricingMember 2016-03-01 2016-03-31 0001156039 elv:AnthemInc.v.ExpressScriptsInc.Member elv:OperationalMember 2016-03-01 2016-03-31 0001156039 elv:AnthemInc.v.ExpressScriptsInc.Member 2016-03-01 2016-03-31 0001156039 elv:TechnologyInfrastructureAndRelatedManagementAndSupportServicesMember 2024-01-01 2024-03-31 0001156039 2024-03-22 2024-03-22 0001156039 2023-03-24 2023-03-24 0001156039 us-gaap:SubsequentEventMember 2024-04-16 0001156039 2023-01-24 0001156039 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001156039 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001156039 elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001156039 elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001156039 elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001156039 elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0001156039 elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001156039 elv:AOCINonCreditComponentsOfImpairmentsOnInvestmentsIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-12-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-01-01 2024-03-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-01-01 2023-03-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-03-31 0001156039 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-03-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001156039 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001156039 elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001156039 elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001156039 elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001156039 elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0001156039 elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001156039 elv:AOCIFuturePolicyBenefitsIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-01-01 2023-03-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001156039 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001156039 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001156039 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2022-12-31 0001156039 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001156039 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0001156039 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001156039 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001156039 elv:RestrictedStockUnitsContingentMember 2024-01-01 2024-03-31 0001156039 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001156039 elv:RestrictedStockUnitsContingentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:HealthBenefitsSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:CarelonRxSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:CarelonServicesSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:CarelonTotalMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:CorporateAndOtherMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember elv:HealthBenefitsSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember elv:CarelonRxSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember elv:CarelonServicesSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember elv:CarelonTotalMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember us-gaap:CorporateAndOtherMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember elv:HealthBenefitsSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember elv:CarelonRxSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember elv:CarelonServicesSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember elv:CarelonTotalMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember us-gaap:CorporateAndOtherMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:ServiceFeesMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember elv:HealthBenefitsSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember elv:CarelonRxSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember elv:CarelonServicesSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember elv:CarelonTotalMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember us-gaap:CorporateAndOtherMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:UnaffiliatedMember 2024-01-01 2024-03-31 0001156039 elv:UnaffiliatedMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember elv:HealthBenefitsSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember elv:CarelonRxSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember elv:CarelonServicesSegmentMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember elv:CarelonTotalMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember us-gaap:CorporateAndOtherMember 2024-01-01 2024-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember 2024-01-01 2024-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:HealthBenefitsSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:CarelonRxSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:CarelonServicesSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:CarelonTotalMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:CorporateAndOtherMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember elv:HealthBenefitsSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember elv:CarelonRxSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember elv:CarelonServicesSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember elv:CarelonTotalMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember us-gaap:ProductMember us-gaap:CorporateAndOtherMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember us-gaap:ProductMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember elv:HealthBenefitsSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember elv:CarelonRxSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember elv:CarelonServicesSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember elv:CarelonTotalMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:ServiceFeesMember us-gaap:CorporateAndOtherMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:ServiceFeesMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember elv:HealthBenefitsSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember elv:CarelonRxSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember elv:CarelonServicesSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember elv:CarelonTotalMember 2023-01-01 2023-03-31 0001156039 us-gaap:OperatingSegmentsMember elv:UnaffiliatedMember us-gaap:CorporateAndOtherMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:UnaffiliatedMember 2023-01-01 2023-03-31 0001156039 elv:UnaffiliatedMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember elv:HealthBenefitsSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember elv:CarelonRxSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember elv:CarelonServicesSegmentMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember elv:CarelonTotalMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember us-gaap:CorporateAndOtherMember 2023-01-01 2023-03-31 0001156039 us-gaap:IntersegmentEliminationMember elv:AffiliatedMember 2023-01-01 2023-03-31 shares iso4217:USD iso4217:USD shares elv:individual elv:county elv:state elv:segment pure elv:security elv:appeal false 2024 Q1 0001156039 --12-31 10-Q true 2024-03-31 false 001-16751 ELEVANCE HEALTH, INC. IN 35-2145715 220 Virginia Avenue Indianapolis IN 46204 833 401-1577 Common Stock, $0.01 par value ELV NYSE Yes Yes Large Accelerated Filer false false false 232417867 6226000000 6526000000 30427000000 30446000000 4000000 4000000 29530000000 29614000000 511000000 229000000 8931000000 7902000000 4242000000 4558000000 5120000000 5405000000 6388000000 5795000000 60948000000 60029000000 902000000 890000000 0 0 880000000 876000000 6713000000 6107000000 4451000000 4359000000 25947000000 25317000000 10710000000 10273000000 2245000000 1967000000 111894000000 108928000000 16459000000 16111000000 5298000000 5600000000 1474000000 1402000000 5658000000 6910000000 1575000000 225000000 2900000000 1649000000 10970000000 9894000000 44334000000 41791000000 21976000000 23246000000 765000000 778000000 2201000000 1970000000 1908000000 1738000000 71184000000 69523000000 100000000 100000000 0 0 0 0 0 0 0.01 0.01 900000000 900000000 232544717 232544717 233071088 233071088 2000000 2000000 8883000000 8868000000 33088000000 31749000000 -1365000000 -1313000000 40608000000 39306000000 102000000 99000000 40710000000 39405000000 111894000000 108928000000 35696000000 35868000000 4499000000 4022000000 2078000000 2008000000 42273000000 41898000000 465000000 387000000 -161000000 -113000000 42577000000 42172000000 30546000000 30786000000 3825000000 3481000000 4886000000 4800000000 265000000 251000000 116000000 235000000 39638000000 39553000000 2939000000 2619000000 690000000 615000000 2249000000 2004000000 3000000 15000000 2246000000 1989000000 9.65 8.37 9.59 8.30 1.63 1.48 2249000000 2004000000 -56000000 427000000 0 -2000000 2000000 11000000 -4000000 -2000000 -2000000 2000000 0 2000000 -52000000 442000000 3000000 15000000 0 2000000 2194000000 2429000000 2249000000 2004000000 -161000000 -113000000 -27000000 -30000000 331000000 462000000 136000000 -255000000 62000000 61000000 282000000 29000000 29000000 15000000 1104000000 348000000 31000000 306000000 72000000 3282000000 -257000000 18000000 581000000 839000000 0 -1000000 1978000000 6469000000 6103000000 7443000000 4898000000 2489000000 535000000 3533000000 212000000 -204000000 1120000000 1638000000 279000000 301000000 29000000 28000000 -2310000000 -3184000000 0 2574000000 0 1908000000 1350000000 325000000 212000000 -205000000 -586000000 -291000000 566000000 622000000 379000000 351000000 97000000 43000000 100000000 98000000 4000000 2000000 32000000 -531000000 0 1000000 -300000000 2755000000 6526000000 7387000000 6226000000 10142000000 233100000 2000000 8868000000 31749000000 -1313000000 99000000 39405000000 2246000000 3000000 2249000000 -52000000 0 -52000000 1100000 44000000 525000000 569000000 382000000 382000000 500000 59000000 0 59000000 232500000 2000000 8883000000 33088000000 -1365000000 102000000 40710000000 238000000.0 2000000 9084000000 29647000000 -2490000000 87000000 36330000000 1989000000 15000000 2004000000 440000000 2000000 442000000 1300000 51000000 575000000 626000000 354000000 354000000 400000 6000000 0 6000000 342000000 342000000 237100000 2000000 8697000000 30707000000 -2050000000 104000000 37460000000 Organization<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico unless the context otherwise requires.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in terms of medical membership, serving over 46 million medical members through our affiliated health plans as of March 31, 2024. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal Health Products &amp; Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also to unaffiliated health plans, including pharmacy services, dental, vision and supplemental health insurance benefits, as well as integrated health services. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum HealthCare, Simply Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health, Carelon Behavioral Health and CareMore. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have organized our brand portfolio into the following core go-to-market brands:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed plans;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Carelon — this brand brings together our healthcare-related brands and capabilities, including our CarelonRx and Carelon Services businesses, under a single brand name. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate &amp; Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international business from the Corporate &amp; Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation. For additional discussion regarding our segments, including the changes made, see Note 15 “Segment Information” included in this Quarterly Report on Form 10-Q.</span></div> 46000000 30 50 4 Basis of Presentation and Significant Accounting Policies<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”), unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three months ended March 31, 2024 and 2023 have been recorded. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2024, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2023 included in our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $499 and $294 at March 31, 2024 and December 31, 2023, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The changes in fair value of our marketable equity securities are recognized in our results of operations within net losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortgage loans on real estate are classified as held for investment and are reported at their amortized cost basis net of allowance under the caption “Other invested assets” in our consolidated balance sheets. Amortized cost is the amount at which the loan is originated, adjusted for accrued interest, amortization of premium, discount and net deferred fees or costs, collection of cash and write-offs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $212 at each of March 31, 2024 and December 31, 2023. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $89 and $87 at March 31, 2024 and December 31, 2023, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are reported net of an allowance for doubtful accounts of $956 and $941 at March 31, 2024 and December 31, 2023, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at March 31, 2024 or December 31, 2023. For the three months ended March 31, 2024 and 2023, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Services—Insurance (Topic 944): Effective Date and Early Application </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-11”). The amendments in ASU 2020-11 changed the effective date and early application of Accounting Standards Update No. 2018-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year to our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. The adoption did not have an overall material impact on our financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2023-09"). The amendments in ASU 2023-09 are intended to improve income tax disclosures, primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for our fiscal year beginning after December 15, 2024. The amendments are to be applied on a prospective basis, although retrospective adoption is permitted. We do not believe the adoption of ASU 2023-09 will have a material impact on our consolidated financial statements or disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2023-07”). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our fiscal year beginning after December 15, 2023, and interim periods within our fiscal year beginning after December 15, 2024. The amendments are to be applied retrospectively to all prior periods presented in the financial statements, and upon transition, the significant segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. We are currently evaluating the effects the adoption of ASU 2023-07 will have on our consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the FASB issued Accounting Standards Update No. 2023-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2023-05”). ASU 2023-05 clarifies existing guidance to reduce diversity in practice and requires a joint venture to recognize and initially measure its assets and liabilities using a new basis of accounting, at fair value, upon formation. These amendments are effective prospectively for all joint venture formations with a formation date on or after January 1, 2025. We do not believe the adoption of ASU 2023-05 will have a material impact on our consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2023 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations, cash flows or disclosures.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”), unless the information contained in those disclosures materially changed or is required by GAAP. In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three months ended March 31, 2024 and 2023 have been recorded. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2024, or any other period. The seasonal nature of portions of our health care and related benefits business, as well as competitive and other market conditions, may cause full-year results to differ from estimates based upon our interim results of operations. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2023 included in our 2023 Annual Report on Form 10-K.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents: </span>We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. 499000000 294000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The changes in fair value of our marketable equity securities are recognized in our results of operations within net losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations and are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mortgage loans on real estate are classified as held for investment and are reported at their amortized cost basis net of allowance under the caption “Other invested assets” in our consolidated balance sheets. Amortized cost is the amount at which the loan is originated, adjusted for accrued interest, amortization of premium, discount and net deferred fees or costs, collection of cash and write-offs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” on our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.</span></div> 1.02 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium receivables include the uncollected amounts from employer risk-based groups, individuals and government programs for insurance services. Premium receivables are reported net of an allowance for doubtful accounts of $212 at each of March 31, 2024 and December 31, 2023. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers for administrative services. Self-funded receivables are reported net of an allowance for doubtful accounts of $89 and $87 at March 31, 2024 and December 31, 2023, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income and other miscellaneous amounts due to us. These receivables </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are reported net of an allowance for doubtful accounts of $956 and $941 at March 31, 2024 and December 31, 2023, respectively.</span></div> 212000000 212000000 89000000 87000000 956000000 941000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at March 31, 2024 or December 31, 2023. For the three months ended March 31, 2024 and 2023, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at March 31, 2024 or December 31, 2023. For the three months ended March 31, 2024 and 2023, revenue recognized from performance obligations related to prior periods, such as changes in transaction price, were not material. For contracts that have an original, expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Services—Insurance (Topic 944): Effective Date and Early Application </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2020-11”). The amendments in ASU 2020-11 changed the effective date and early application of Accounting Standards Update No. 2018-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year to our interim and annual reporting periods beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. The adoption did not have an overall material impact on our financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2023-09"). The amendments in ASU 2023-09 are intended to improve income tax disclosures, primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for our fiscal year beginning after December 15, 2024. The amendments are to be applied on a prospective basis, although retrospective adoption is permitted. We do not believe the adoption of ASU 2023-09 will have a material impact on our consolidated financial statements or disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2023-07”). The amendments in ASU 2023-07 are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our fiscal year beginning after December 15, 2023, and interim periods within our fiscal year beginning after December 15, 2024. The amendments are to be applied retrospectively to all prior periods presented in the financial statements, and upon transition, the significant segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. We are currently evaluating the effects the adoption of ASU 2023-07 will have on our consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the FASB issued Accounting Standards Update No. 2023-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2023-05”). ASU 2023-05 clarifies existing guidance to reduce diversity in practice and requires a joint venture to recognize and initially measure its assets and liabilities using a new basis of accounting, at fair value, upon formation. These amendments are effective prospectively for all joint venture formations with a formation date on or after January 1, 2025. We do not believe the adoption of ASU 2023-05 will have a material impact on our consolidated financial statements and disclosures.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other new accounting pronouncements that were issued or became effective since the issuance of our 2023 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations, cash flows or disclosures.</span></div> Business Acquisitions and Divestitures<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Completed Acquisitions </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2024, we completed our acquisition of Paragon Healthcare, Inc. (“Paragon”). Paragon, which operates as part of CarelonRx, provides infusion services and injectable therapies through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of March 31, 2024, the purchase price was allocated to the tangible and intangible net assets acquired based on management's initial estimates of their fair values, of which $553 has been allocated to finite-lived intangible assets and $635 to goodwill. The majority of the goodwill is not deductible for income tax purposes. As of March 31, 2024, the initial accounting for the acquisition has not been finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. As of March 31, 2024, the purchase price was allocated to the tangible and intangible net assets acquired based on management’s estimates of their fair values, of which $820 has been allocated to finite-lived intangible assets and $893 to goodwill. Measurement period adjustments during the three months ended March 31, 2024 were $(5). The majority of goodwill is not deductible for income tax purposes. As of March 31, 2024, the initial accounting for the acquisition was finalized. The proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2024, we completed the sale of our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard entered into a product distribution partnership. The related net assets held for sale and results of operations for the life and disability businesses to be divested as of and for the three months ending March 31, 2024 were not material.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pending Acquisitions</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2023, we entered into an agreement to acquire Centers Plan for Healthy Living LLC and Centers for Specialty Care Group IPA, LLC (“Centers”). Centers is a managed long-term care plan that serves New York state Medicaid and dually-eligible Medicaid/Medicare members, enabling adults with long-term care needs and disabilities to live safely and independently in their own home. This acquisition aligns with our strategic plan to grow the Health Benefits segment and leverage industry-leading expertise while serving Medicaid and dually eligible populations. The acquisition is expected to close in the third quarter of 2024 and is subject to standard closing conditions and customary approvals.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service &amp; Indemnity Company, d/b/a Blue Cross and Blue Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. The acquisition is subject to closing conditions and approvals.</span></div> 553000000 635000000 820000000 893000000 -5000000 Business Optimization Initiatives <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2023, based on a strategic review of our operations, assets and investments, management implemented the “2023-2024 Business Efficiency Program” to enhance operating efficiency, refine the focus of our investments and optimize our physical footprint. The 2023-2024 Business Efficiency Program includes the write-off of certain information technology assets and contract exit costs, a reduction in staff including the relocation of certain job functions, and the impairment of assets associated with the closure or partial closure of data centers and offices. The 2023-2024 Business Efficiency Program is expected to be substantially complete by the end of the third quarter of 2024. Cash outlays associated with this program, which primarily relate to the personnel-related costs, are expected to be paid through 2024.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ending balances related to the total liabilities for employee termination costs under the 2023-2024 Business Efficiency Program at March 31, 2024 and December 31, 2023 were $150 and $191, respectively, and were recorded in the Corporate &amp; Other reportable segment. During the quarter ended March 31, 2024 there were no charges or releases related to employee termination costs under the 2023-2024 Business Efficiency Program, and payments were $41.</span></div> 150000000 191000000 0 41000000 Investments <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fixed Maturity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses for credit losses on investments may be recorded in future periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current and long-term fixed maturity securities, available-for-sale, at March 31, 2024 and December 31, 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost or <br/>Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance <br/>For Credit <br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,336 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,490 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other asset-backed securities primarily consists of collateralized loan obligations and other debt securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fixed maturity securities in an unrealized loss position at March 31, 2024 and December 31, 2023, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Securities are whole amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,659</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,283)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses on our securities shown in the table above have not been recognized into income because, as of March 31, 2024, we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their maturity or anticipated recovery. The declines in fair values are largely due to increasing interest rates driven by the higher rate of inflation and other market conditions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances for credit losses have been recorded in the amount of $4 at both March 31, 2024 and December 31, 2023, for declines in fair value due to unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of fixed maturity securities at March 31, 2024, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,329 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,410 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of $5,401 and $5,410, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of marketable equity securities at March 31, 2024 and December 31, 2023 is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:68.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Invested Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments is reported on a one or three month lag due to the timing of when we receive financial information from the companies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2024, we entered into an agreement to partner with Clayton, Dubilier &amp; Rice (“CD&amp;R”) to accelerate innovation in care delivery across multiple regions in the United States by bringing together through a new company, (“NewCo”), certain care delivery and enablement assets of Carelon Management Services Inc., a Carelon Health business (“CMSI Assets”), and two CD&amp;R portfolio businesses, apree health and Millennium Physician Group. Our investment in NewCo will be through a combination of cash, an existing equity investment in apree health, and the contribution of CMSI Assets. We will account for our initial minority ownership interest in NewCo as an equity method investment. Further, in connection with our equity investment, each party will have certain rights and obligations, including certain put, call, and purchase price true-up options, for which the estimated value will be determinable at the time of the incremental investments. The contribution of CMSI Assets and businesses to be contributed by CD&amp;R to NewCo are subject to standard closing conditions and customary approvals.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment (Losses) and Gains</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment (losses) and gains for the three months ended March 31, 2024 and 2023 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.359%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains from sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses from sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized losses from sales of fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized on equity securities still held at the end of the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized losses recognized on equity securities sold during the period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) on equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on other investments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Investment Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024 and December 31, 2023, accrued investment income totaled $294 and $301, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Lending Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to $2,592 and $2,380 at March 31, 2024 and December 31, 2023, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of March 31, 2024 and December 31, 2023. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024 and December 31, 2023, the remaining contractual maturity of our securities lending agreements included overnight and continuous transactions of cash for $2,351 and $2,255, respectively, of United States Government securities for $241 and $99, respectively,</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and of residential mortgage-backed securities for $0 and $26, respectively.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of current and long-term fixed maturity securities, available-for-sale, at March 31, 2024 and December 31, 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost or <br/>Amortized <br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance <br/>For Credit <br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,299)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,578 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,071 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,336 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,490 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1858000000 6000000 73000000 0 1791000000 127000000 0 4000000 0 123000000 73000000 0 1000000 0 72000000 3722000000 55000000 150000000 0 3627000000 16099000000 256000000 575000000 2000000 15778000000 4204000000 27000000 302000000 0 3929000000 1971000000 12000000 89000000 2000000 1892000000 3275000000 28000000 105000000 0 3198000000 31329000000 384000000 1299000000 4000000 30410000000 1873000000 25000000 54000000 0 1844000000 112000000 1000000 3000000 0 110000000 5000000 1000000 2000000 0 4000000 3985000000 69000000 152000000 0 3902000000 14838000000 322000000 580000000 2000000 14578000000 4071000000 40000000 279000000 0 3832000000 2174000000 13000000 138000000 2000000 2047000000 4278000000 25000000 130000000 0 4173000000 31336000000 496000000 1338000000 4000000 30490000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fixed maturity securities in an unrealized loss position at March 31, 2024 and December 31, 2023, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Securities are whole amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,775 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,659</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,842 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,283)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 46 1188000000 29000000 48 306000000 44000000 4 40000000 0 39 51000000 4000000 5 10000000 0 2 4000000 1000000 231 449000000 4000000 1001 1656000000 146000000 906 2324000000 31000000 2422 5775000000 544000000 239 1026000000 14000000 1631 1958000000 288000000 84 364000000 6000000 415 1059000000 83000000 126 454000000 16000000 414 1288000000 89000000 1641 5855000000 100000000 5972 12097000000 1199000000 35000000 552000000 9000000 44000000 370000000 45000000 0 0 0 40000000 52000000 3000000 0 0 0 2000000 4000000 2000000 203000000 354000000 2000000 1034000000 1811000000 150000000 389000000 608000000 15000000 2624000000 6871000000 565000000 183000000 438000000 5000000 1620000000 2075000000 274000000 112000000 353000000 6000000 534000000 1317000000 132000000 110000000 394000000 18000000 761000000 2342000000 112000000 1032000000 2699000000 55000000 6659000000 14842000000 1283000000 4000000 4000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of fixed maturity securities at March 31, 2024, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,038 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,329 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,410 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 369000000 365000000 6038000000 5900000000 11099000000 10864000000 7648000000 7460000000 6175000000 5821000000 31329000000 30410000000 5401000000 5410000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of marketable equity securities at March 31, 2024 and December 31, 2023 is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:68.302%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 382000000 106000000 52000000 45000000 77000000 78000000 511000000 229000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment (losses) and gains for the three months ended March 31, 2024 and 2023 are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.359%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized gains from sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross realized losses from sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized losses from sales of fixed maturity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) recognized on equity securities still held at the end of the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized losses recognized on equity securities sold during the period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) on equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment losses recognized in income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (losses) gains on other investments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 22000000 10000000 -159000000 -115000000 2000000 7000000 -139000000 -112000000 2000000 -1000000 0 -1000000 2000000 -2000000 16000000 27000000 20000000 1000000 25000000 3000000 -29000000 23000000 -166000000 -91000000 294000000 301000000 2592000000 2380000000 1.02 1.02 2351000000 2255000000 241000000 99000000 0 26000000 Derivative Financial Instruments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” “Other noncurrent assets,” “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $209 and $211 at March 31, 2024 and December 31, 2023, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized gains of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $11 and losses of $6,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> respectively, on non-hedging derivatives. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized gains of $12 and losses of $34 on non-hedging derivatives, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information relating to the fair value of our derivative assets and liabilities, see Note 7, “Fair Value,” included in this Quarterly Report on Form 10-Q.</span></div> -209000000 -211000000 11000000 6000000 12000000 34000000 Fair Value <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. These assets and liabilities are classified into one of three levels of hierarchy defined by GAAP. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 7 “Fair Value,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at March 31, 2024 and December 31, 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,726</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,778</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,612</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,410</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,245</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,774</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of total assets at fair value</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,210</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,532</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,578</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,634</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,173</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,903</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,490</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,328</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,432</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of total assets at fair value</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no individually material transfers into or out of Level III during the three months ended March 31, 2024 or 2023. There were no adjustments to quoted market prices obtained from the pricing services during the three months ended March 31, 2024 or 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition of Paragon in the first quarter of 2024 and the acquisition of BioPlus in the first quarter of 2023. The net assets acquired in our acquisitions of Paragon and BioPlus and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of tangible assets acquired and liabilities assumed were recorded at their carrying values as of the acquisition date, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of Paragon and BioPlus were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Also in 2023, we entered into a shareholder’s agreement which included certain put and call options on our minority interest ownership of Liberty Dental. The resulting net put option liability was recorded at its fair value measured at the date of acquisition using Level III inputs with an election not to mark the derivative to market. Other than the assets acquired and liabilities assumed in our acquisitions of Paragon and BioPlus and the net put option on Liberty Dental, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three months ended March 31, 2024 or 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-financial instruments such as property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and liabilities are not listed in the table below.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 7 “Fair Value,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K for details on the methods and assumptions used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at March 31, 2024 and December 31, 2023 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at March 31, 2024 and December 31, 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,791</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,726</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,778</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,198</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,612</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,410</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594</span></td><td colspan="3" style="background-color:#ffffff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 7pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,245</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,774</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of total assets at fair value</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,210</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed maturity securities, available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government sponsored securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, municipalities and political subdivisions, tax-exempt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,902</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,532</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,578</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,634</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,173</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fixed maturity securities, available-for-sale</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,903</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,490</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange traded funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets - common equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities lending collateral</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,382</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,328</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,432</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of total assets at fair value</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives - other liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td></tr></table></div> 1155000000 0 0 1155000000 0 1791000000 0 1791000000 0 123000000 0 123000000 0 72000000 0 72000000 0 3627000000 0 3627000000 0 15726000000 52000000 15778000000 0 3914000000 15000000 3929000000 0 1881000000 11000000 1892000000 0 2478000000 720000000 3198000000 0 29612000000 798000000 30410000000 382000000 0 0 382000000 15000000 37000000 0 52000000 0 0 77000000 77000000 397000000 37000000 77000000 511000000 102000000 0 0 102000000 0 2594000000 0 2594000000 0 2000000 0 2000000 1654000000 32245000000 875000000 34774000000 0.05 0.93 0.02 1 0 61000000 0 61000000 0 61000000 0 61000000 2210000000 0 0 2210000000 0 1844000000 0 1844000000 0 110000000 0 110000000 0 4000000 0 4000000 0 3902000000 0 3902000000 0 14532000000 46000000 14578000000 0 3830000000 2000000 3832000000 0 2047000000 0 2047000000 0 3634000000 539000000 4173000000 0 29903000000 587000000 30490000000 106000000 0 0 106000000 12000000 33000000 0 45000000 0 0 78000000 78000000 118000000 33000000 78000000 229000000 111000000 0 0 111000000 0 2382000000 0 2382000000 0 10000000 0 10000000 2439000000 32328000000 665000000 35432000000 0.07 0.91 0.02 1 0 40000000 0 40000000 0 40000000 0 40000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at March 31, 2024 and December 31, 2023 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level II</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level III</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other invested assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6611000000 0 0 6580000000 6580000000 225000000 0 225000000 0 225000000 1350000000 0 1350000000 0 1350000000 24876000000 0 23046000000 0 23046000000 5996000000 0 0 5972000000 5972000000 225000000 0 225000000 0 225000000 24895000000 0 23569000000 0 23569000000 Income Taxes<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023, we recognized income tax expense of $690 an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $615, respectively, which represent an effective income tax rate of 23.5% for both periods.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable totaled $38 at March 31, 2024 and income taxes receivable totaled $543 at December 31, 2023. We recognize the income tax payable as a liability under the caption “Other current liabilities” and the income tax receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.</span></div> 690000000 615000000 0.235 0.235 38000000 543000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Claims Payable</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable for the three months ended March 31, 2024 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,751 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods redundancies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods medical claims</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,484 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,183 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2024, the total of net incurred but not reported liabilities plus expected development on reported claims was $724, $4,323 and $11,128 for the claim years 2022 and prior, 2023 and 2024, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable development recognized in the three months ended March 31, 2024 resulted from faster than expected development of completion factors from the latter part of 2023 as well as trend factors in late 2023 developing more favorably than originally expected. The favorable development recognized in the three months ended March 31, 2023 resulted primarily from trend factors in late 2022 developing more favorably than expected and favorable development in the completion factors resulting from the latter part of 2022 developing faster than expected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,546 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of March 31, 2024 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,459 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending balances for medical claims payable for the three months ended March 31, 2024 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,348 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net incurred medical claims:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,751 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods redundancies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net payments attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period medical claims</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods medical claims</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,541 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,484 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,183 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,491 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 15865000000 15348000000 7000000 6000000 15858000000 15342000000 30708000000 30751000000 -1205000000 -1068000000 29503000000 29683000000 19580000000 19948000000 9606000000 9593000000 29186000000 29541000000 16175000000 15484000000 8000000 7000000 16183000000 15491000000 724000000 4323000000 11128000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net incurred medical claims</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,503 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality improvement and other claims expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,546 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.379%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 29503000000 29683000000 1043000000 1103000000 30546000000 30786000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of March 31, 2024 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net medical claims payable, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ceded medical claims payable, end of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross medical claims payable, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,459 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 16175000000 8000000 276000000 16459000000 Debt<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally issue senior unsecured notes for long-term borrowing purposes. At March 31, 2024 and December 31, 2023, we had $24,851 and $24,870, respectively, outstanding under these notes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an unsecured surplus note with an outstanding principal balance of $25 at both March 31, 2024 and December 31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. As of March 31, 2024, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.4%. We do not believe the restrictions contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of March 31, 2024, we were in compliance with all of our debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at any time during the three months ended March 31, 2024 or the year ended December 31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. At March 31, 2024 and December 31, 2023, we had $1,350 and $0, respectively, outstanding under this program. Beginning June 30, 2023, we have reclassified our commercial paper balances from long-term debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $225 of outstanding short-term borrowings from the FHLBs at each of March 31, 2024 and December 31, 2023.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All debt is a direct obligation of Elevance Health, Inc., except for the surplus note and the FHLBs borrowings.</span></div> 24851000000 24870000000 25000000 25000000 P5Y P5Y 4000000000 P5Y 0.60 P5Y P5Y 0.394 P5Y P5Y 0 0 P5Y 4000000000 1350000000 0 225000000 225000000 Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Proceedings </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or probable or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible or probable loss or range of losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the cases described below, we contest liability and/or the amount of damages in each matter, and we believe we have meritorious defenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe the outcome of any known pending or threatened legal actions or proceedings will, in the aggregate, have a material impact on our financial position. However, unanticipated outcomes do </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sometimes occur, which could result in liabilities in excess of our accruals and could have a material adverse effect on our consolidated financial position or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the lawsuits described below, we are also involved in other pending and threatened litigation of the character incidental to our business and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings (“government actions”). These government actions include routine and special inquiries by and disclosures to state insurance departments, state attorneys general, U.S. Regulatory Agencies, the U.S. Attorney General and subcommittees of the U.S. Congress. Such government actions could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these government actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blue Cross Blue Shield Antitrust Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Blue Cross Blue Shield Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the opt-out deadline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In compliance with the Subscriber Settlement Agreement, we paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by us of $596, which was accrued in 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four notices of appeal of the Final Approval Order were heard by a panel of the United States Court of Appeals for the Eleventh Circuit in September 2023 (the “Eleventh Circuit”), and the Eleventh Circuit affirmed the Court’s Final Approval Order approving the Subscriber Settlement Agreement in October 2023. Petitions for rehearing were filed by certain appellants in November 2023 and December 2023 and were denied in January 2024. As a result, the Eleventh Circuit issued a mandate terminating the jurisdiction of the Eleventh Circuit in February 2024. In March 2024, Home Depot, one of the appellants, filed a petition for certiorari to the United States Supreme Court. On the respondents' request, the United States Supreme Court granted an extension to respond until May 2024. In the event that all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review applicable to the providers’ claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants’ motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs’ motion for partial summary judgment, determining that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio v. American Express Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the “national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) denying the provider plaintiffs’ motion for partial summary judgment on the standard of review, reaffirming its prior holding that the provider groups’ boycott claims are subject to the rule of reason. In December 2023, the Court denied defendants’ motion for summary judgment on providers’ damage claims as time-barred and speculative and provider plaintiffs’ motion for partial summary judgment on the defendants’ single entity defense due to the existence of genuine issues of material fact. In January 2024, the Court issued orders (i) denying defendants’ motion for summary judgment on (a) all claims by certain hospital providers and (b) any claims based on the Blue system's rules other than exclusive serviced areas or BlueCard and (ii) denying provider plaintiffs’ motion for partial summary judgment on defendants’ common law trademark claims. Provider plaintiffs’ motion for class certification, filed in October 2020, remains pending. We intend to continue to vigorously defend the provider litigation, which we believe is without merit; however, its ultimate outcome cannot be presently determined.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alaska Air Group, Inc., et al. v. Anthem, Inc., et al.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No. 2:21-cv-01209-AMM (N.D. Ala.) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(“Alaska Air”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JetBlue Airways Corp., et al. v. Anthem, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00558-GMB (N.D. Ala.) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(“Jet Blue”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00265-RDP (N.D. Ala.) (dismissed without prejudice in June 2023); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bed Bath &amp; Beyond Inc. v. Anthem, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-01256-SGC (N.D. Ala.);</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Hoover, et al. v. Blue Cross Blue Shield Association, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 2:22-cv-00261-RDP (N.D. Ala.); and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VHS Liquidating Trust v. Blue Cross of California, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. RG21106600 (Cal. Super.) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(“VHS”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In February 2023, the Court denied the defendants’ motion to dismiss based on a statute of limitations defense in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alaska Air </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jet Blue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2023, the California court presiding over the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">case, upheld its prior order granting in part defendants’ motion to strike based on the statute of limitations.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Express Scripts, Inc. PBM Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anthem, Inc. v. Express Scripts, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit sought to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms (the “Pricing Claim”); (ii) was required to provide competitive benchmark pricing to us through the term of the ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Express Scripts disputed our contractual claims and it sought declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claimed that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts’ only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q were (i) our operational breach claim based on Express Scripts’ prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging our remaining operational breach claims, which the District Court denied in March 2023. In November 2023, the District Court issued a final judgment ending the lawsuit in the District Court after the parties settled and stipulated to dismiss the only remaining claim that had not been disposed of by the court order or stipulation. In December 2023, we filed a notice of appeal with the United States Court of Appeal for the Second Circuit (the “Second Circuit”), regarding the Pricing Claim. In February 2024, the Second Circuit ordered the parties to participate in mediation. The mediation occurred in March 2024 and was unsuccessful. The ultimate outcome of this appeal cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Risk Adjustment Litigation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of New York (the “New York District Court”) in a case captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States v. Anthem, Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, we filed an answer. In March 2023, discovery commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by June 2024 and expert discovery to be completed by February 2025. We intend to continue to vigorously defend this suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. Our remaining commitment under this agreement at March 31, 2024 is approximately $432. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formed CarelonRx, to market and offer pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own, starting in the second quarter of 2019. The comprehensive pharmacy services portfolio includes all core pharmacy services, such as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database and member services. CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C. (“CVS”), which is a subsidiary of CVS Health Corporation, pursuant to an agreement, that is set to terminate on December 31, 2025. Beginning in the first quarter of 2024, CarelonRx is assuming responsibility for pharmacy mail order front-end intake and member services from CVS.</span></div> 506000000 596000000 4 14800000000 158000000 4675000000 432000000 Capital Stock<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Capital – Dividends and Stock Repurchase Program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash dividend activity for the three months ended March 31, 2024 and 2023 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:34.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Record Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Payment Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 23, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 24, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2024, our Audit Committee declared a second quarter 2024 dividend to shareholders of $1.63 per share, payable on June 25, 2024 to shareholders of record at the close of business on June 10, 2024.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock repurchases for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorization remaining at the end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt,” included in this Quarterly Report on Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the three months ended March 31, 2024 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:44.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Option Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the three months ended March 31, 2024 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Shares<br/>and Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at January 1, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, we granted approximately 0.3 restricted stock units that are contingent upon us achieving earnings targets over the three-year period from 2024 to 2026. These grants have been included in the activity shown above but will be subject to adjustment at the end of 2026 based on results in the three-year period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, 2023 included in Part II, Item 8 of our 2023 Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to estimate the fair values of options granted during the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average fair values per option or share were determined for the three months ended March 31, 2024 and 2023:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.53 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards granted during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash dividend activity for the three months ended March 31, 2024 and 2023 is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:34.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Declaration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Record Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Payment Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 23, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 24, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1.63 379000000 1.48 351000000 1.63 5000000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of common stock repurchases for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorization remaining at the end of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1100000 1300000 492.76 476.66 566000000 622000000 3633000000 6254000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the three months ended March 31, 2024 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:44.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Option Price<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.01 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3000000.0 327.14 500000 499.11 300000 288.95 0 431.01 3200000 356.58 P6Y5M8D 521000000 2200000 297.24 P5Y2M23D 482000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the three months ended March 31, 2024 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock Shares<br/>and Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at January 1, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456.61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475.31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1100000 423.94 600000 499.00 600000 352.33 0 456.61 1100000 475.31 300000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used to estimate the fair values of options granted during the three months ended March 31, 2024 and 2023:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quarterly dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40</span></td></tr></table></div> 0.0428 0.0395 0.2800 0.2900 0.00327 0.00316 P4Y4M24D P4Y4M24D <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average fair values per option or share were determined for the three months ended March 31, 2024 and 2023:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.53 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards granted during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 134.53 127.14 499.00 469.31 Accumulated Other Comprehensive (Loss) Income <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the components of accumulated other comprehensive (loss) income at March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.959%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized investment (losses) gains:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $50 and $(85), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss, net of tax benefit of $(33) and $(29), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-credit components of impairments on investments:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax benefit of $0 and $1, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (expense) benefit of $(1) and $8, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $(1) and $(1), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Future policy benefits:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax expense of $0 and $0, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $0 and $0, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total beginning of period accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax benefit (expense) of $15, and $(106), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0 respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total end of period accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,365)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,050)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the components of accumulated other comprehensive (loss) income at March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.959%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized investment (losses) gains:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications, net of tax benefit (expense) of $50 and $(85), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss, net of tax benefit of $(33) and $(29), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,330)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-credit components of impairments on investments:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax benefit of $0 and $1, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flow hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax (expense) benefit of $(1) and $8, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and other postretirement benefits:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $(1) and $(1), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Future policy benefits:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax expense of $0 and $0, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax expense of $0 and $0, respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">End of period balance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total beginning of period accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax benefit (expense) of $15, and $(106), respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to noncontrolling interests, net of tax benefit of $0 and $0 respectively</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total end of period accumulated other comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,365)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,050)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -632000000 -1755000000 50000000 -85000000 -162000000 337000000 33000000 29000000 -106000000 -90000000 -56000000 427000000 0 0 0 2000000 -688000000 -1330000000 -3000000 -3000000 0 1000000 0 -2000000 -3000000 -5000000 -211000000 -229000000 -1000000 8000000 2000000 11000000 -209000000 -218000000 -459000000 -499000000 -1000000 -1000000 4000000 2000000 -455000000 -497000000 10000000 13000000 0 0 -2000000 2000000 8000000 15000000 -18000000 -17000000 0 0 0 2000000 -18000000 -15000000 -1313000000 -2490000000 15000000 -106000000 -52000000 442000000 0 0 0 2000000 -1365000000 -2050000000 Shareholders' Earnings per Share<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denominator for basic and diluted shareholders' earnings per share for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic shareholders' earnings per share – weighted-average shares</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted shareholders' earnings per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, weighted-average shares related to certain stock options of 0.6 and 0.4 respectively, were excluded from the denominator for diluted shareholders' earnings per share because the stock options were anti-dilutive.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, we issued approximately 0.6 restricted stock units under our stock incentive plans, 0.3 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2024 through 2026. During the three months ended March 31, 2023, we issued approximately 0.6 restricted stock units under our stock incentive plans, 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three-year period of 2023 through 2025. The contingent restricted stock units have been excluded from the denominators for diluted shareholders' earnings per share and will be included only if and when the contingency is met.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The denominator for basic and diluted shareholders' earnings per share for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic shareholders' earnings per share – weighted-average shares</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for diluted shareholders' earnings per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 232700000 237500000 1500000 2200000 234200000 239700000 600000 400000 600000 300000 600000 200000 Segment Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate &amp; Other. During the fourth quarter of 2023, we moved our Carelon Global Solutions international businesses from the Corporate &amp; Other reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-based, BlueCard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Medicare, Medicaid and FEHB program members. Our Health Benefits segment also includes our National Government Services business. The Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and provides a variety of specialty and other insurance products and services such as stop loss, dental, vision and supplemental health insurance benefits.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our CarelonRx segment includes our pharmacy services business. CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy services portfolio, which includes all core pharmacy services, such as home delivery and specialty</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">database and member services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Carelon Services segment integrates physical, behavioral, social and pharmacy services to deliver whole health affordably through creating value by offering market-competitive services, powered by analytics. Carelon Services offers a broad array of healthcare related services and capabilities to internal and external customers including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services and subrogation services, as well as health and wellness programs. At the end of 2023, Carelon Services integrated Carelon Global Solutions into the Carelon family of offerings. The companies under Carelon Global Solutions have been providing services related to data management, information technology and business operations since 2019 and were previously included within our Corporate &amp; Other segment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Corporate &amp; Other segment includes our businesses that do not individually meet the quantitative threshold for an operating segment, as well as corporate expenses not allocated to our other reportable segments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define operating revenues to include premium income, product revenue and service fees. Operating revenues are derived from premiums and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and operating expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, in addition to certain administrative and other services provided by our international businesses, which are recorded at cost or management’s estimate of fair market value. These affiliated revenues are eliminated in consolidation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health <br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon <br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate <br/>&amp; Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,188)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For segment reporting, we present all capitated risk arrangements on a gross basis; therefore, eliminations also include adjustments for unaffiliated capitated risk arrangements that are recognized on a net basis under GAAP, as well as affiliated eliminations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,577 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,172 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating gain</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 4 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial data by reportable segment for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health <br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CarelonRx</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carelon <br/>Services</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate <br/>&amp; Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,382 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,971 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,188)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - unaffiliated</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - affiliated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,881)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating revenue - total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating gain (loss)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 35382000000 0 408000000 408000000 0 -94000000 35696000000 0 4499000000 0 4499000000 0 0 4499000000 1876000000 1000000 197000000 198000000 4000000 0 2078000000 37258000000 4500000000 605000000 5105000000 4000000 -94000000 42273000000 0 3567000000 3404000000 6971000000 123000000 -7094000000 37258000000 8067000000 4009000000 12076000000 127000000 -7188000000 42273000000 2287000000 523000000 290000000 813000000 -84000000 0 3016000000 35534000000 0 410000000 410000000 0 -76000000 35868000000 0 4022000000 0 4022000000 0 0 4022000000 1746000000 0 208000000 208000000 54000000 0 2008000000 37280000000 4022000000 618000000 4640000000 54000000 -76000000 41898000000 0 4002000000 2842000000 6844000000 37000000 -6881000000 37280000000 8024000000 3460000000 11484000000 91000000 -6957000000 41898000000 2149000000 512000000 229000000 741000000 -59000000 0 2831000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,273 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on financial instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,577 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,172 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 42273000000 41898000000 465000000 387000000 -161000000 -113000000 42577000000 42172000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended <br/> March 31</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net losses on financial instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of other intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reportable segments’ operating gain</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2939000000 2619000000 465000000 387000000 -161000000 -113000000 265000000 251000000 116000000 235000000 3016000000 2831000000 false false false false